
<html lang="en"     class="pb-page"  data-request-id="2f61734b-1cf5-4f67-ab38-4801ac767e9d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.8b01610;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-9"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="A Survey of the Structures of US FDA Approved Combination Drugs" /></meta><meta name="dc.Creator" content="Pradipta  Das" /></meta><meta name="dc.Creator" content="Michael D.  Delost" /></meta><meta name="dc.Creator" content="Munaum H.  Qureshi" /></meta><meta name="dc.Creator" content="David T.  Smith" /></meta><meta name="dc.Creator" content="Jon T.  Njardarson" /></meta><meta name="dc.Description" content="Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In..." /></meta><meta name="Description" content="Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01610" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01610" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01610" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01610" /></link>
        
    
    

<title>A Survey of the Structures of US FDA Approved Combination Drugs | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01610" /></meta><meta property="og:title" content="A Survey of the Structures of US FDA Approved Combination Drugs" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0001.jpeg" /></meta><meta property="og:description" content="Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In this Perspective, we report the first comprehensive compilation and analysis of US FDA approved combination drugs, from the first approval in 1943 through 2018. Our database contains 419 combination drugs, which are represented by 328 unique small molecule structures. Breakdown of these drugs according to disease category, structure, combination composition, and year of approval is presented as well as the top 24 most commonly used small molecule combination drug components. For frequently used small molecule components, we present “relationship diagrams” to aid in the visualization of the many drug combinations these structures are part of. The main body contains 10 disease-focused sections wherein every small molecule component utilized as part of a combination for each disease category is displayed." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01610"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01610">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-31/acsodf.2021.6.issue-31/20210810/acsodf.2021.6.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-31/ancham.2021.93.issue-31/20210810/ancham.2021.93.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-31/bichaw.2021.60.issue-31/20210810/bichaw.2021.60.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-15/cmatex.2021.33.issue-15/20210810/cmatex.2021.33.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-8/estlcu.2021.8.issue-8/20210810/estlcu.2021.8.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-8/jceda8.2021.98.issue-8/20210810/jceda8.2021.98.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-8/jctcce.2021.17.issue-8/20210810/jctcce.2021.17.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-31/langd5.2021.37.issue-31/20210810/langd5.2021.37.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-15/mamobx.2021.54.issue-15/20210810/mamobx.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01610&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01610&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01610&amp;href=/doi/10.1021/acs.jmedchem.8b01610" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4265-4311</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01530" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b02004" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Survey of the Structures of US FDA Approved Combination Drugs</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Pradipta Das</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pradipta Das</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pradipta++Das">Pradipta Das</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael D. Delost</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael D. Delost</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Delost">Michael D. Delost</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Munaum H. Qureshi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Munaum H. Qureshi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Munaum+H.++Qureshi">Munaum H. Qureshi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David T. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David T. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+T.++Smith">David T. Smith</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jon T. Njardarson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon T. Njardarson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (520) 626-0754. E-mail: <a href="/cdn-cgi/l/email-protection#b9d7d3d8cbddd8cbcaf9dcd4d8d0d597d8cbd0c3d6d7d897dcddcc"><span class="__cf_email__" data-cfemail="cca2a6adbea8adbebf8ca9a1ada5a0e2adbea5b6a3a2ade2a9a8b9">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon+T.++Njardarson">Jon T. Njardarson</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2268-1479" title="Orcid link">http://orcid.org/0000-0003-2268-1479</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01610&amp;href=/doi/10.1021%2Facs.jmedchem.8b01610" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4265–4311</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 16, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 October 2018</li><li><span class="item_label"><b>Published</b> online</span>16 November 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01610" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01610</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4265%26pageCount%3D47%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPradipta%2BDas%252C%2BMichael%2BD.%2BDelost%252C%2BMunaum%2BH.%2BQureshi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D9%26contentID%3Dacs.jmedchem.8b01610%26title%3DA%2BSurvey%2Bof%2Bthe%2BStructures%2Bof%2BUS%2BFDA%2BApproved%2BCombination%2BDrugs%26numPages%3D47%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4311%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01610"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8034</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">61</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01610" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Survey of the Structures of US FDA Approved Combination Drugs&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Pradipta&quot;,&quot;last_name&quot;:&quot;Das&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Delost&quot;},{&quot;first_name&quot;:&quot;Munaum&quot;,&quot;last_name&quot;:&quot;H. Qureshi&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;T. Smith&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;T. Njardarson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4265-4311&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01610&quot;},&quot;abstract&quot;:&quot;Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In this Perspective, we report the first comprehensive compilation and analysis of US FDA approved combination drugs, from the first approval in 1943 through 2018. Our database contains 419 combination drugs, which are represented by 328 unique small molecule structures. Breakdown of these drugs according to disease category, structure, combination composition, and year of approval is presented as well as the top 24 most commonly used small molecule combination drug components. For frequently used small molecule components, we present “relationship diagrams” to aid in the visualization of the many drug combinations these structures are part of. The main body contains 10 disease-focused sections wherein every small molecule component utilized as part of a combination for each disease category is displayed.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01610&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01610" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01610&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01610" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01610&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01610" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01610&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01610&amp;href=/doi/10.1021/acs.jmedchem.8b01610" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01610" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01610" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (15 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26pmid%3D30444362%26genre%3Darticle%26aulast%3DDas%26date%3D2019%26atitle%3DA%2BSurvey%2Bof%2Bthe%2BStructures%2Bof%2BUS%2BFDA%2BApproved%2BCombination%2BDrugs%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D9%26spage%3D4265%26epage%3D4311%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292276" title="Small molecules">Small molecules</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/jmcmar.2019.62.issue-9/20190509/jmcmar.2019.62.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In this Perspective, we report the first comprehensive compilation and analysis of US FDA approved combination drugs, from the first approval in 1943 through 2018. Our database contains 419 combination drugs, which are represented by 328 unique small molecule structures. Breakdown of these drugs according to disease category, structure, combination composition, and year of approval is presented as well as the top 24 most commonly used small molecule combination drug components. For frequently used small molecule components, we present “relationship diagrams” to aid in the visualization of the many drug combinations these structures are part of. The main body contains 10 disease-focused sections wherein every small molecule component utilized as part of a combination for each disease category is displayed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our ongoing quest to create new educational and research content using the graphical language of organic chemistry,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> we have compiled for this Perspective a comprehensive list of US FDA approved combination drugs (1940 to September 2018). Surprisingly, our survey of the literature revealed that the small molecule structural composition of this important category of drugs has previously not been presented or analyzed. A summary of the composition of this combination drug collection is graphically depicted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The collection contains a total of 419 FDA approved combination drugs, out of which 367 are structurally unique combinations. These 367 combinations are represented by only 328 small molecules. Analysis of this important small molecule data set reveals high representation of aromatic moieties (78%) and nitrogen heterocycles (58%) and the majority of structures (53%) contain at least one asymmetric stereocenter. Oxygen heterocycles are less represented (19%) than their nitrogen heterocyclic counterparts. Beyond the four common atoms of life (C, H, N, and O), this collection has rich representation of small molecules containing sulfur atoms (19%), almost twice that of fluorine atoms (10%).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Graphical breakdown of US FDA approved small molecule combination drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> presents the distribution of the 419 US FDA approved combination drugs<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> as a function of the decade when they were approved and the disease category they belong to, which is represented by the color-coded portion of each bar. Cancer chemotherapy combinations are not included in the introductory figures as a disease category. Although chemotherapy agents are FDA approved as monotherapies and widely used in combination regimens, only a few are approved as combination therapies. However, an extended discussion of the landscape of cancer combinations, past, present, and future, appear at the end of this review. What is evident from this graphical representation is that this category of pharmaceuticals has been growing steadily since the first combination drugs were approved. The highest growth rate occurred between the 1940s and 1950s (375%); the lowest growth rate occurred between the 1960s and 1970s (9%). A possible explanation for the initial surge of combination drug approvals followed by a slowed rate can be the FDAs new stringent criteria and approval guidelines in 1971. In the 1950s and 1960s, there was controversy surrounding drug manufacturers and the FDA promoting antibiotic combinations despite a lack of strong evidence supporting that combinations were superior to each drug separately. As of 1971, strong evidence is needed to show that a combination drug offers a therapeutic benefit compared to each individual drug entity.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In 1943, Hycodan (homatropine + hydrocodone) became the earliest combination to be approved. However, it has since been discontinued. The next combination drug that was approved in 1948, Cafergot (ergotamine + caffeine), is still on the market. The most recent approved drug included in our survey, Delstrigo (doravirine + lamivudine + tenofovir disoproxil fumarate), was approved in 2018 to treat HIV-1 infection for adults. In the 1940s, only two disease categories (nervous and respiratory systems) were represented by the four combination drugs approved. The 1990s marked the first decade that treatments for all 10 disease categories (excluding cancer) were represented. Both nervous and respiratory system combinations have appeared in every decade. In the current decade (2010–2018), there is a major increase in the number of anti-infective combination drugs being approved and a large increase in respiratory system, endocrine system, and genito-urinary and sex hormone drug combinations. Approval of cardiovascular drugs is in sharp decline during the current decade.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Number of combination drugs approved by decade.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">US FDA approved combination drugs are composed of two or more small molecules with individual International Nonproprietary Names (INNs). The detailed breakdown of these three categories is illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, which reveals that combination drugs with two small molecules represent the clear majority (81%), followed by combination drugs containing three (16%) and four (3%) INNs, respectively. Combinations with two INNs are quite evenly distributed between all 10 disease categories with drugs treating nervous system (17%, salmon) and cardiovascular (17%, blue) conditions leading the way followed by anti-infective (12%, orange) and respiratory system (12%, green) drugs. Least represented in this category, and not represented in other categories, are combination drugs used to address musculo-skeletal (3%, gray) type conditions. Combinations composed of three small molecules are represented by eight disease categories, of which the majority are prescribed for anti-infective (40%, orange) or nervous system (24%, salmon) conditions. There are only 11 combination drugs containing four small molecules, out of which six (55%, orange) are anti-infective agents. Closer inspection of these complex combinations reveals that infective diseases such as hepatitis C and human immunodeficiency virus-1 (HIV-1) are typically treated with more drug components. Furthermore, half of the anti-infective combinations containing three or four small molecules have been approved within the past decade. This signifies that ongoing research dedicated to the treatment of serious infections such as hepatitis C and HIV-1 has continued to be a priority.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Frequency and disease distribution of combination drugs with 2, 3, and 4 small molecule components</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A closer look at the relative impact 75 years (1943–2018) of combination drugs has had on disease categories is presented in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Combination drugs approved to alleviate symptoms associated with nervous system (19%, salmon) or anti-infective (18%, orange) conditions are the most highly represented disease categories followed by cardiovascular drugs (15%, blue). These three disease categories, which correspond to 52% of all approved combination drugs, are the areas of medicine where combination drugs have had the most success to date. The fourth and fifth ranked disease categories in terms of the number of combination drugs are the respiratory system (11%, green) and genito-urinary and sex hormone (9%, yellow) categories. About the same number of combination drugs (5–7%) have been approved for sensory organ (light blue), alimentary tract and metabolism (dark green), endocrine system (purple), and dermatological (brown) conditions.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Distribution of US FDA approved combination drugs according to disease category.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the same INNs are represented multiple times in many combination drugs, the distribution of the INNs is far from even. Some molecules punch above their weight and appear in a high amount of US FDA approved drug combinations. To aid in visualizing this privileged class of small molecules, we have created a top 24 list ranked according to the number of combinations these drugs appear in (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Although these 24 small molecules represent only 7% of the total number of unique small molecules approved, they remarkably are found in 76% of the combination drugs. From a structural standpoint, these heavy hitters are interesting as well. For example, the majority (62%) of these structures are chiral, while 66% contain at least one aromatic ring. Nitrogen heterocycles are significantly represented (38%) and appear in almost twice as many of these prevalent structures than oxygen heterocycles (21%). Four (16%) of these 24 compounds, including the most abundant (hydrochlorothiazide), are decorated with at least one sulfur atom while only one (no. 15, emtricitabine) is substituted with a fluorine atom. Natural products (neomycin, polymyxin B, codeine, caffeine, and hydrocortisone) and natural product derivatives play a significant role among these top structures, with 16 (58%) belonging to this category, including six steroids and two opioids. The primary differences between the structural diversity of the top 24 compared to all the combination drug components are more chiral structures (62% vs 53%) and less representation of nitrogen heterocycles (38% vs 57%) and fluorine substituents (1% vs 9%). A possible explanation for lower percentages of fluorine substituents in the top 24 could be the lack of efficient fluorination methods available during the time these pharmaceuticals were developed. The development of scalable fluorination methods (especially late-development fluorination methods) continues to be pursued.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The top five combination drug components are hydrochlorothiazide, neomycin, pseudoephedrine, aspirin, and polymyxin B, which appear in 35, 24, 23, 20, and 19 combination drugs, respectively, which overall is an astonishing 121 (29%) total number of combinations. Almost all hydrochlorothiazide-containing combinations are used to treat cardiovascular conditions, while neomycin and polymyxin, which are anti-infectives, also target infections in sensory organ and dermatological areas.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Top 24 most frequently utilized small molecule combination drug components.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To better aid in visualizing some of these top 24 privileged small molecules and their respective combination drug partners, we have created several structure-based “relationship diagrams” which include information about disease categories as well as the names of associated combinations.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Hydrochlorothiazide Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hydrochlorothiazide, a member of the thiazide family of diuretics first approved in 1958, is used both alone as well as in combination with various cardiovascular drugs to treat hypertension and heart failure.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> HCTZ and HCT are both used as an abbreviation for hydrochlorothiazide; HCTZ is used when the compound itself is abbreviated, and HCT is used when hydrochlorothiazide is present in a combination drug. The combination structure relationship diagrams for hydrochlorothiazide are presented in <a data-tab="pane-pcw-Figures" href="#fig6A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6A" id="" class=" internalNav">6A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6B" id="" class=" internalNav">6B</a></a>. Thirty-three unique drug combinations with hydrochlorothiazide have been approved, with the majority being indicated for cardiovascular treatment. Twenty-nine (88%) of the combinations contain two components total; the remaining four (12%) contain three components total. Overall, 11 structural classes and two disease categories (cardiovascular and endocrine) are represented. Hydrochlorothiazide has been combined with beta blockers (propranolol, pindolol, labetalol, metoprolol, and bisoprolol and timolol), angiotensin-converting enzyme (ACE) inhibitors (captopril, moexipril, enalapril, benazepril, quinapril, fosinopril, and lisinopril), angiotensin-II receptor antagonists (eprosartan, losartan, irbesartan, valsartan, candesartan, telmisartan, and olmesartan), a renin inhibitor (aliskiren), a calcium channel blocker (amlodipine), natural products (reserpine and deserpidine), other diuretics (amiloride, spironolactone, and triamterene), as well as various other antihypertensive drugs (guanethidine and hydralazine). ACE inhibitors were discovered after John Vane showed that the venom of the Brazilian viper, <i>Bothrops jararaca</i>, inhibited ACE in dog lungs. The first ACE inhibitor, captopril, was launched in 1981.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Three years later, captopril went on to become the first ACE inhibitor to be used in combination with HCTZ. Aliskiren, the first and only renin inhibitor, was approved 109 years after renin was first discovered in 1898. Even after aliskiren was discovered in 1993, it took 14 years to finally be approved. This was because after Ciba and Sandoz merged to form Novartis in 1996, valsartan, not aliskiren, was chosen to be developed. In 1999, former Ciba employees founded Speedel to continue developing aliskiren. In 2003, after successful phase I clinical trials and improved process chemistry, aliskiren was licensed back to Novartis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Aldoril (methyldopa + hydrochlorothiazide), approved in 1962 but later discontinued, was the first hydrochlorothiazide combination to be approved. The other component, methyldopa, was used as an α-2 adrenergic receptor agonist. In 1965, Dyazide (triamterene + hydrochlorothiazide) became the earliest combination to contain an additional diuretic (triamterene). In 2010, Tribenzor (olmesartan + amlodipine + hydrochlorothiazide) and Amturnide (aliskiren + hydrochlorothiazide + amlopidine) became the latest HCTZ combinations to be approved. There are various rationales for combining thiazides, especially HCTZ with other agents. It has been shown that combining HCTZ with another antihypertensive agent with a different mechanism of action can increase blood pressure responses.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Although thiazides are cost-effective as well as extremely effective, taking them as a full dose monotherapy regimen can often lead to undesirable side effects, which ultimately leads to patients no longer willing to take the drug. Therefore, combining a diuretic with another mechanistically distinct antihypertensive agent lowers the dose of diuretic given which reduces undesirable side effects. Furthermore, the other drug added can reduce side effects of HCTZ. For example, ACE inhibitors can help negate the oxidation activity of HCTZ as well as its propensity to lower potassium serum levels.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig6A" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0007.jpeg" id="GRAPHIC-d7e265-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6A. Combination structure relationship diagram for hydrochlorothiazide containing two INNs</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig6A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6B" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0008.jpeg" id="GRAPHIC-d7e272-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6B. Combination structure relationship diagram for hydrochlorothiazide containing three INNs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig6B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Pseudoephedrine Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pseudoephedrine, a substituted phenethylamine, is used as a nasal decongestant both by itself as well as in combinations.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Pseudoephedrine is part of 23 unique combinations, highlighted in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, belonging to six structural and two disease categories (respiratory and nervous system), respectively. Majority of these combinations (74%) contain an antihistamine component, whose structural cores are in most cases a 1,1-diaryl 1,1-dialkylamine motif. Pseudoephedrine + antihistamines has been shown to be an effective combination in treating seasonal allergic rhinitis (SAR) through complementary mechanisms. Pseudoephedrine can treat nasal congestion associated with SAR but has no effects on histamine. Antihistamines can treat SAR but are ineffective as nasal decongestants.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Earliest such antihistamine cores were substituted with short linear terminating tertiary amines, while later ones contained heterocyclic trialkylamine groups (piperidine, pyrrolidine, or piperazine), with the two aryl rings being connected by a more rigid 1,1-ethylene linker. First-generation antihistamines (brompheniramine, chlorpheniramine, dexbrompheniramine, clemastine, and triprolidine) suffered from sedation side effects because of their ability to penetrate the blood–brain barrier.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Second-generation antihistamines, such as acrivastine, cetirizine, and fexofenadine, have limited blood–brain barrier permeability as a result of their hydrophilic carboxylic acid groups, which minimizes the risk of unwanted sedation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Loratadine, which contains an additional rigid seven-membered ring, is also a second-generation antihistamine with limited potential for sedation. Loratadine contains a carbamate which is metabolized in vivo to the amine. Levocetirizine (an enantiomer of cetirizine) and desloratadine (a metabolite of loratadine) are referred to as third-generation antihistamines. Pseudoephedrine combinations with nonsteroidal anti-inflammatory drugs (NSAIDs) help control pain and inflammation. Advil C.S. and Aleve C.S., which partner pseudoephedrine with ibuprofen and naproxen, respectively, were approved in 1989 and 1999 and serve as examples of this combination. A triple combination (advil A.S.) was approved in 2004, which added chlorpheniramine as the third component with ibuprofen. Morphinan members codeine, hydrocodone, and dextromethorphan (DM) act as antitussive cough suppressants, while guaifenesin acts as an expectorant in various combinations. In 1950, Chlor-trimeton (pseudoephedrine + chlorpheniramine) became the first pseudoephedrine-containing combination to be approved. However, Chlor-trimeton has since been discontinued. Thirty-four years later, Triacin-C (codeine + pseudoephedrine + triprolidine) became the first pseudoephedrine combination to contain a morphinan member (codeine). In 2015, Hycofenix (pseudoephedrine + guaifenesin + hydrocodone) became the latest pseudoephedrine combination to be approved. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, many well-known drugs such as Allegra D, Mucinex D, Aleve C.S, Advil A.S., Zyrtec-D, and Claritin D contain pseudoephedrine as one of the drug components.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Combination structure relationship diagram for pseudoephedrine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Acetaminophen Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acetaminophen, originally released in 1953, is an analgesic used to treat pain and fever conditions.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> It has been approved as a component of 15 combination drugs, all of which are used to treat pain. Several structural classes (as indicated by color) are represented in the structure relationship diagram (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), including natural products (codeine and its derivatives, caffeine, and pseudoephedrine), 1,1-diaryl antihistamines, aspirin, and a barbiturate (butalbital). About half (53%) of the combinations are composed of two components, 40% contain three components, and only one is approved with four components, Fioricet w/cod (acetaminophen + caffeine + butalbital + codeine). Members of the opiate family are the most commonly partnered class (67%). Caffeine, a natural product stimulant seen in four combinations, enhances acetaminophen’s analgesic effects as well as absorption.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Furthermore, it has been shown that caffeine and aspirin in combination with acetaminophen is more efficacious and has a faster onset of action compared to ibuprofen in the treatment of migraines.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A faster onset of action as well as a longer duration with tramadol and acetaminophen combination (compared to the individual drugs) has led to its effective use in the management of postoperative pain.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Morphinan members (codeine, hydrocodone, oxycodone, and dihydrocodeine) as well as other opioids (tramadol, pentazocine, and dextropropoxyphene) are used as additional analgesics. Clemastine and dexbrompheniramine, both first-generation antihistamines, as well as pseudoephedrine, a nasal decongestant, are seen in a few combinations. Approved in 1958, Synalgos-DC-A (dihydrocodeine + acetaminophen + caffeine) became the first acetaminophen-containing combination drug available. However, it has since been discontinued along with others. Twenty-six years later, butalbital, a barbiturate, was approved in combination with caffeine (fioricet). It is now seen in three combinations with acetaminophen. Percocet, originally approved in 1999, contains oxycodone as the additional component. Although widely used, acetaminophen is among the most dangerous and controversial drugs in the world, with a history of false assumptions and errors when initially developed. As of 2011, acetaminophen dosage is limited to 325 mg in all combination drugs. This is because acetaminophen is metabolized to a highly electrophilic species <i>N</i>-acetyl-<i>p</i>-benzoquinone imine (NAPQI), which is a major source of toxicity that can cause acute liver failure (ALF), kidney damage, and impaired fetal development.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Interestingly, research suggests that combination analgesics may induce rebound headaches while losing initial antiheadache activity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Vicodin, (acetaminophen + hydrocodone), first available in 1983, is used as a narcotic and an analgesic.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Combination structure relationship diagram for acetaminophen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Aspirin Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) first introduced in 1899 by Bayer.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Aspirin is indicated both by itself as well as in combination with other drugs as a pain reliever and for anti-inflammatory purposes. However, aspirin also possesses antiplatelet blood thinning properties; this allows it to be used for treatment of various cardiovascular issues in combination with other drugs.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The combination structure relationship diagram for aspirin is shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>. Aspirin has been approved as part of 20 combinations, out of which 19 are structurally unique. Eighteen (90%) of these combinations are approved for nervous system conditions, with Aggrenox and Yosprala being approved for cardiovascular conditions, respectively. Aspirin combinations have been approved continuously since the 1950s, with two to four new combinations approved each decade until the present. Aspirin has been combined with diverse families of structures such as opioids (oxycodone, codeine, dihydrocodeine, propoxyphene, and pentazocine), a stimulant (caffeine), muscle relaxants of the carbamate class (carisoprodol, methocarbamol, and meprobamate), an analgesic (acetaminophen), a vasodilator (dipyridamole), a proton pump inhibitor (omeprazole), an antihistamine (orphenadrine), and a statin (pravastatin). In 1950, Percodan (oxycodone + aspirin) became the first combination drug containing aspirin to be approved. Synalgos-DC (dihydrocodeine + aspirin + caffeine), Fiorinal w/cod (aspirin + butalbital + codeine), Soma w/cod (codeine + carisoprodol + aspirin), and Excedrin (aspirin + acetaminophen + caffeine), approved in 1983, 1990, 1996, and 2003, respectively, are used as pain relievers especially for headaches. Aggrenox (aspirin + dipyridamole), approved in 1999, helps reduce the risk of stroke in patients with past blood clotting issues. In 2016, Yosprala (aspirin + omeprazole) became the most recent aspirin combination to be approved. Yosprala is a platelet aggregation inhibitor used to prevent cardiovascular events in patients at risk of aspirin-induced gastric ulcers.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> It is worth noting that close to half (45%) of these aspirin combinations have been discontinued.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Combination structure relationship diagram for aspirin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Metformin Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Metformin, the structure relationship diagram of which can be found in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, is an antidiabetic drug indicated for treatment of type 2 diabetes by suppressing liver glucose production.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> First discovered in 1922, metformin traces its roots from <i>Galega officinalis</i>, a plant rich in guanidine shown to lower blood glucose. Along with other guanidine derivatives (biguanides), metformin had a renaissance in the 1940s during a search for antimalarial agents. Although pursued as a treatment for diabetes in 1957, metformin was less potent then phenformin and buformin and therefore received less interest. However, after phenformin and buformin were discontinued in the 1970s due to increased risk of lactic acidosis, metformin finally received some traction and was introduced to the United States market in 1995.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Furthermore, metformin’s prominence in combination drugs in the treatment of type II diabetes is likely the result of a positive impact on cardiovascular health. Death from cardiovascular disease continues to be a major concern for type 2 diabetes patients.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Metformin has been approved as a component of 14 unique combination drugs, out of which four (actoplus MET, avandamet, metaglip, and segluromet) have been approved for additional disease categories. A total of five unique structural classes and two disease categories (endocrine and metabolism) are represented. All these combinations partner metformin with one other small molecule component. In 1999, Amaryl (glimepiride + metformin), became the first metformin-containing combination drug to be approved. In 2017, Segluromet (ertugliflozin + metformin), was the latest metformin-containing combination to be approved. The other structural component of every combination is from a different class of antidiabetic drugs in all cases. Four major classes of antidiabetic drugs have been combined with metformin: the gliptins, glitazones, sulfonylureas, and gliflozins.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The glitazones (pioglitazone and rosiglitazone), recognizable by their thiazolidinedione heterocycle, are seen in two formulations. The gliptins (sitagliptin, saxagliptin, linagliptin, and alogliptin) as a class are dipeptidyl-peptidase (DPP)-4 inhibitors; they are seen in four combinations with sitagliptin, being the first to be approved as a combination with metformin. Members from the sulfonylurea family (glimepiride, glipizide, and glyburide) are found in three combinations, while the gliflozin family (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), which contain a characteristic pyranose, is represented in four combinations. Finally, the meglitinides (repaglinide) appear in a single metformin combination. Improved glycemic control as well as reductions in pills taken and undesirable side effects are among the beneficial reasons cited for metformin combinations.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> For example, weight gain is associated with sulfonylureas and glitazones.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The addition of metformin can help minimize this weight gain as a result of its ability to increase glucagon-like peptide-1 levels.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Combination structure relationship diagram for metformin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Ethinyl Estradiol Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23686" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23686" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Contraceptive pills have been on the market for over half a century. It is estimated that over 100 million women are on some regimen of hormonal medication. In the early 1950s, Carl Djerassi synthesized the first oral contraceptive, norethindrone, a progestin. Less than a decade later, Enovid (norethynodrel + mestranol) became the first contraceptive combination pill to be approved by the FDA.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The combination structure relationship diagram for ethinyl estradiol is depicted in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>. Ethinyl estradiol, originally approved in 1943, has been approved as component of 15 combinations, of which 11 are structurally unique. All of these combinations belong to endocrine and genito-urinary and sex hormone disease categories. Ethinyl estradiol is an estrogen used in birth control as an oral contraceptive.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Ethinyl estradiol is a synthetic derivative of estradiol, with the only difference between the two being an ethynyl substitution at C17 in the former. This substitution at C17 from the native estrogen secondary alcohol to a tertiary propargylic alcohol is critical as it increases the bioavailability of the drug by slowing the metabolic oxidation of the hydroxyl group at C17 to a ketone. As a result, ethinyl estradiol is several-hundred times more potent in comparison to estradiol.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Synthetic progestogens are used in conjunction with ethinyl estradiol in all combinations. Beyaz (ethinyl estradiol + drospirenone + levomelate) is the only approved ethinyl estradiol combination with more than two small molecule components. Beyaz contains levomefolate, which is the biologically active form of vitamin B9 (folate). Majority of synthetic progestogens also contain an ethynyl substitution at C17, with exception of drospirenone (a component of beyaz and yasmin), which is substituted with a γ-spirolactone at the C17 junction. These combinations are used as oral contraceptives for birth control. In 1970, demulen (ethinyl estradiol + ethynodiol diacetate) became the earliest ethinyl estradiol combination to be approved by the US FDA. Xulane (ethinyl estradiol + norelgestromin) is the most recent (2014) ethinyl estradiol combination to receive approval.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Combination structure relationship diagram for ethinyl estradiol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Lamivudine Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lamivudine, approved as a monotherapy in 1995, has been used in a variety of combinations for treatment and prevention of HIV-1/AIDS. Lamivudine is an analogue of cytidine with a 1,3-oxathiolane in place of a furanose ring. Like other nucleotide analogues, lamivudine is a nucleoside reverse transcriptase inhibitor which functions by inhibiting both HIV reverse transcriptase. However, in addition, lamivudine is also an inhibitor of hepatitis B virus polymerase.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> As depicted in the combination structure relationship diagram in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, these 14 unique combinations are all anti-infective agents, which are represented by six chemical structure categories including peptidomimetic HIV-1 protease inhibitors (atazanavir and ritonavir), nucleosides, as well as other structural diversity. It should be noted that ritonavir is currently used as a pharmacokinetic enhancer to help increase the bioavailability of protease inhibitors. This is because ritonavir is a cytochrome P450 (CYP450) 3A4 inhibitor.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Because of the large structures of the many small molecule components of combination drugs including Lamivudine, an alternative, more compact relationship diagram is presented. In the interest of providing compact, informative diagrams, this format will be repeated as necessary through the remainder of the paper. In 1997, Combivir (lamivudine + zidovudine) became the first lamivudine combination drug to be approved. Zidovudine, also a nucleoside reverse transcriptase inhibitor, is particularly intriguing for the presence of a rare azido (N<sub>3</sub>) functional group. Zidovudine, at one time recommended as a first line treatment for HIV-1, has limited beneficial effects when given as a monotherapy due to HIV-1 resistance. A strategy to combat this obstacle of drug resistance is combinational therapy with two or more antiretroviral agents. One such fruitful combination with zidovudine is lamivudine. Zidovudine and lamivudine have been shown to possess a synergetic relationship in vitro. Resistance to one of the drugs sensitizes the reverse transcriptase activity of the other. One such example is viruses with a mutation at codon 184 of the HIV-polymerase gene are resistant to lamivudine but not zidovudine.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In 2018, Symfi Lo (lamivudine + efavirenz + tenofovir disoproxil) and Delstrigo (doravirine + lamivudine + tenofovir disoproxil fumarate) became the latest lamivudine combinations to be approved for treatment of HIV-1. To date, lamivudine has been combined with HIV protease inhibitors (ritonavir, atazanavir), HIV integrase strand transfer inhibitors (dolutegravir and raltegravir), other nucleoside analogue reverse-transcriptase inhibitors (abacavir, stavudine, and zidovudine), non-nucleoside reverse transcriptase inhibitor (efavirenz, nevirapine, and doravirine), as well as a nucleotide reverse transcriptase inhibitor (tenofovir disoproxil). In the interest of finding effective cost-effective drug reduction strategies, there continues to be contemporary research investigating the role of utilizing a pharmacokinetic (PK) booster such as ritonavir in combination with a dual therapy such as lamivudine + atazanavir.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Combination structure relationship diagram for Lamivudine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Emtricitabine Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Emtricitabine, an analogue of cytidine and an antiretroviral drug of the reverse-transcriptase inhibitor class, is used for both the prevention and treatment of HIV-1.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> A fluorine atom at C5 and an oxathiolane in place of a dihydroxyfuran distinguishes this drug structurally from cytidine. A single fluorine atom distinguishes emtricitabine from lamivudine. Emtricitabine has both a higher bioavailability (93% vs 86%) as well as serum half-life (10 h vs 5–7 h) compared to lamivudine.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> It has been approved as a component of nine combination drugs to combat HIV-1, which are displayed in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. Interestingly, these nine combinations are only represented by eight unique chemical partners which have been combined as combinations of two (22%), three (56%), or four (22%) components, respectively. Overall, six unique structural classes of drugs and one disease category (anti-infective) are represented. Either tenofovir alafenamide or tenofovir disoproxil, both reverse transcriptase inhibitor adenine analogues, are seen in every combination. Integrase inhibitors (elvitegravir and bictegravir), which function by preventing integrase from delivering viral genome information to the DNA of the host cell, appear in three combinations.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> Cobicistat, a pharmacokinetic enhancer that functions by inhibiting CYP450 (CYP3A) enzymes, is a component of two combinations.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Non-nucleoside reverse transcriptase inhibitors (efavirenz, rilpivirine, and nevirapine) turn up in four combinations. Emtricitabine combinations are relatively recent, with Truvada (emtricitabine + tenofovir disoproxil) becoming the first combination to be approved in 2004. In the last 14 years, eight additional emtricitabine combinations have been approved. Biktarvy (emtricitabine + tenofovir alafenamide + bictegravir), which treats chronic HIV-1 infection in patients who have no current antiretroviral treatment program, was the latest emtricitabine combination drug to be approved in 2018.</div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Combination structure relationship diagram for Emtricitabine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Amlodipine Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Amlodipine is a long-acting third-generation dihydropyridine (DHP) calcium channel blocker originally approved in 1981 to treat hypertension and angina.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Amlodipine contains a 1,4-DHP central core, which is characteristic of many other calcium channel blockers. The central DHP cores are synthesized using the classic Hantzsch reaction, known since 1882. Like all other DHP blockers, a phenyl substituent at C4 is crucial for antagonist activity. The structure relationship diagram for amlodipine’s 10 US FDA approved combinations is presented in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>. These combinations are represented by five structural classes and all are approved to treat cardiovascular conditions. For example, caduet combines amlodipine with atorvastatin, a member of the statin family, to reduce cardiovascular events. Amlodipine is also seen in combinations with ACE inhibitors (benazepril and perindopril), angiotensin-II receptor antagonists (olmesartan, valsartan, and telmisartan), a diuretic (hydrochlorothiazide), and a renin inhibitor (aliskiren). In 1995, Lotrel (amlodipine + benzapril) became the first amlodipine-containing combination to be approved. In 2010, the latest year when amplodipine combinations were approved, Tekamlo (aliskiren + amlodipine), Amturnide (aliskiren + hydrochlorothiazide + amlodipine), and Tribenzor (olmesartan medoxomil + hydrochlorothiazide + amlodipine) were approved. Olmesartan medoxomil is a prodrug of olmesartan; the 1,3-dioxol-2-one moiety enhances the bioavailability of the parent drug as it is metabolized to the free acid in vivo.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Benazepril and perindopril are also ester prodrugs, metabolized in the liver to benazeprilat and perindoprilatin, respectively.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Combination structure relationship diagram for Amlodipine</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Neomycin Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Neomycin, an aminoglycoside discovered in 1949, is used as an antibiotic in combination with a variety of other structures.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Neomycin is effective against most Gram-negative bacteria, and although it is active against staphylococci, it is not effective against all Gram-positive bacteria. Thus, to attain a broader spectrum of antibacterial activity, some neomycin combinations contain additional antibiotics which are more effective against Gram-positive bacteria. Neomycin’s combination structure relationship diagram is depicted in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>. A total of 24 combinations containing neomycin have been approved, out of which 19 are structurally unique. All but two (lidocaine and thonzonium) of neomycin’s combination partners are either steroid derivatives or natural product macrocyclic peptides. The primary indications for these combinations is anti-infective; however, some of these combinations target sensory organ and/or dermatological areas.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The majority (58%) of neomycin-containing combinations drugs were approved in the 1960s. Polymyxin B, a lipopeptide macrolactam antibiotic effective against Gram-negative bacterial infections, is neomycin’s most frequent combination partner and is found in a total of 11 (46%) combinations.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The polymyxin b + neomycin combinations were designed to be full spectrum antibiotics effective against both Gram-negative and Gram-positive bacteria; polymyxin b is only effective against Gram-negative bacteria. Bacitracin, which appears in five combinations, is a cyclic peptide isolated in 1945 solely effective against Gram-positive bacteria.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Bacitracin combined with neomycin is effective against both Gram-positive and Gram-negative bacteria.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Gramicidin, which is part of one combination (Neosporin) approved for two disease categories, is a cyclic peptide isolated in 1939 as a mixture of three compounds. Gramicidin is an antibiotic mostly effective against Gram-positive and select Gram-negative.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Colistin, an antibiotic produced from <i>Paenibacillus polymyxa</i>, is a polymyxin polypeptide antibiotic effective against most Gram-negative bacteria.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The steroidal components (hydrocortisone, dexamethasone, fluocinolone acetonide, prednisolone acetate, methylprednisolone, triamcinolone acetonide, and flurandrenolide) of these combinations act as anti-inflammatory agents. Lidocaine, a local anesthetic, and thonzonium bromide, a surfactant, are seen in one and two combinations, respectively. The primary indication for these combinations is anti-infective, with the additional agents added to relieve inflammation. In 1957, cortisporin, which is a mixture of the four components, hydrocortisone, neomycin, polymyxin b, and bacitracin, was the earliest neomycin-containing combination drug to be approved. Cortisporin is used to treat swimmer’s ear, an infection of the outer ear. It is still currently available. In 1987, Neosporin G.U. (neomycin + polymyxin B) became the most recent neomycin combination to be approved as antibiotic cream to treat infections. Neosporin continues to be a popular household item. The majority of neomycin combinations were approved in the 1960s (a total of 14). Maxitrol (dexamethasone + neomycin + polymyxin b), approved in 1963, is used as an ophthalmic antibacterial agent. Dexamethasone, the steroid component, controls the inflammation. Neo-Synalar (fluocinolone acetonide + neomycin), approved in 1963, combines an anti-infective with a steroid. Neomycin acts as the anti-infective against bacteria such as <i>Staphylococcus aureus</i>; fluocinolone acetonide is added to treat mild to moderate dermatitis while additionally reducing itching and inflammation.</div><figure id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0019.jpeg" id="GRAPHIC-d7e534-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Combination structure relationship diagram for neomycin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Introduction to Disease Categories</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24820" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24820" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the following 10 sections, we present all the structures approved as part of US FDA combinations. To make this extensive small molecule data set more accessible, we have chosen to break it down according to the disease category for which these small molecule structures were approved as combination drug components. We concluded that this organizational strategy would be most attractive and useful to researchers interested in chemical architectures that have made it all the way to approval for any given disease category. To better aid the reader, structures that share common cores are graphically summarized as one structure with colored circles employed to highlight differences. This display approach reveals that many drugs are quite similar too each other, which is especially evident for steroids, morphinan members, and antibiotics.</div><div class="NLM_p">Furthermore, we have separated the small molecule structures within each disease category into two components: primary or secondary. “Primary” components, labeled in a pink color, indicate that these drugs directly treat a medical condition associated with the disease category. “Secondary” components, labeled in blue, indicate that these drugs are added to the primary component as additives to control side effects or because they are primary components for treating a different disease category but target regions of the body associated with the secondary disease category. For example, urinary and respiratory infections are treated with antibiotics, which are anti-infectives. Therefore, these antibiotics appear as primary components in the anti-infective disease category; however, these drugs also appear as secondary components in the genito-urinary and respiratory disease categories because they also target urinary and respiratory regions of the body.</div><div id="sec11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Anti-Infectives</h3><div class="NLM_p">US FDA approved anti-infective drug combination components are displayed in <a data-tab="pane-pcw-Figures" href="#fig16A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16A" id="" class=" internalNav">16A</a></a>, <a data-tab="pane-pcw-Figures" href="#fig16B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16B" id="" class=" internalNav">16B</a></a>, <a data-tab="pane-pcw-Figures" href="#fig17A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17A" id="" class=" internalNav">17A</a></a>, and <a data-tab="pane-pcw-Figures" href="#fig17B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17B" id="" class=" internalNav">17B</a></a>. We have broken the discussion of these 79 molecules, which make up 74 approved combinations, into two sections. The first section is focused on antivirals (<a data-tab="pane-pcw-Figures" href="#fig16A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16A" id="" class=" internalNav">16A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig16B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16B" id="" class=" internalNav">16B</a></a>), while the second section is dedicated to coverage of antibiotics and miscellaneous anti-infective (<a data-tab="pane-pcw-Figures" href="#fig17A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17A" id="" class=" internalNav">17A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig17B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17B" id="" class=" internalNav">17B</a></a>. These combinations are utilized in a variety of ways, such as broad-spectrum antibiotics, antivirals against HIV-1 and hepatitis C, tuberculosis, and topical steroid and nonsteroidal anti-infectives. Remarkable structural diversity is represented in this second largest of the combination drug families, including natural product antibiotics, β-lactams, nucleoside derivatives, and antiviral peptides.</div><figure id="fig16A" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 16A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0020.jpeg" id="GRAPHIC-d7e587-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16A. Anti-infective (anti-HIV) approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig16A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig16B" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 16B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0021.jpeg" id="GRAPHIC-d7e594-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16B. Anti-infective (antiviral) approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig16B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec11_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Section 1 (Antivirals)</h4><div class="NLM_p">The heavy hitters in this category are the nucleoside drugs lamivudine, emtricitabine, and tenofovir disoproxil, which are all in the list of top 24 drugs, having been approved as part of 15, nine, and nine anti-infective combinations, respectively. These three drugs are all components of combinations used to treat HIV-1/AIDS. Lamivudine and emtricitabine are differentiated by a single point of substitution on the nucleobase (H vs F). Other classes of antivirals are almost exclusively seen in combinations with lamivudine or emtricitabine and are all indicated for treatment of HIV-1. One such family, the integrase inhibitors (INIs) (-tegravir), are a relatively new family of antivirals seen in antiviral combinations. The INIs are recognizable by a pyridin-4(1<i>H</i>)-one or related heterocycle as well as various less-common heterocycles such as oxadiazole, 1,3-oxazepane, and 1,3-oxazinane. A more comprehensive discussion on specific antiviral drug classes, seen in combinations for HIV-1 treatment, were previously discussed in the lamivudine and emtricitabine sections above.</div><div class="NLM_p last">A myriad of combinations to treat hepatitis C have been approved. Three protease inhibitors (NS5A, NS5B, and NS3/4A) in the hepatitis C virus are targeted in seven unique combinations. In 2014, Harvoni (ledipasvir + sofosbuvir) and Viekira Pak (dasabuvir + ombitasvir + paritaprevir + ritonavir) became the earliest hepatitis C combinations to be approved. Structurally, many of the antiviral families share common recognizable motifs. NS5A inhibitors (-asvir) contain a central heterocycle or aromatic that is heavily flanked on both sides by nitrogen heterocycles (usually imidazoles) and peptide components. These inhibitors are quite large, with two members being centrally symmetrical (ombitasvir and pibrentastvir). NS3/4A protease inhibitors (-previr) are strikingly similarly looking macrolactams decorated with two or three cyclopropane rings, and a highly decorated hydroxy-pyrrolidine. In addition, 75% contain a quinoxaline heterocycle. Both NS5B inhibitors (-buvir) contain an uracil nucleotide.</div></div><div id="sec11_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Section 2 (Antibiotics and Various Anti-infectives)</h4><div class="NLM_p">The most notable members of this category are polymyxin B, neomycin, hydrocortisone acetate, and hydrocortisone, all of which appear in the top 24, having been approved as parts of 10, seven, five, and four combination drugs, respectively. Sulfonamides (sulfacetamide and sulfisoxazole acetyl), natural products (gentamicin, tobramycin, polymyxin B, oxytetracycline, and erythromycin), a folate synthesis inhibitor (trimethoprim), and a fluoroquinolone (ciprofloxacin) represent the diverse types of antibiotic families seen in anti-infective combinations (<a data-tab="pane-pcw-Figures" href="#fig17A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17A" id="" class=" internalNav">17A</a></a>). Corticosteroids are frequently used in combinations with anti-infectives as secondary components in controlling inflammation. In 1953, chloromycetin hydrocortisone (chloramphenicol + hydrocortisone acetate) became the earliest anti-infective combination to be approved (<a data-tab="pane-pcw-Figures" href="#fig17B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17B" id="" class=" internalNav">17B</a></a>). Bactrim (trimethoprim + sulfamethoxazole), approved in 1973, is utilized as a broad-spectrum antibiotic. Trimethoprim, a trisubstituted pyrimidine, has been used as an antibiotic, usually against bladder infections. Sulfamethoxazole, an isoxazole sulfonamide, is utilized as a broad-spectrum antibiotic and to treat bladder infections, bronchitis, and prostatitis. Bactrim is a historically significant combination drug, as it was the first combination to be approved under the FDA’s new stringent guidelines which required evidence that a combination offered “a therapeutic advantage over each of the components administered separately”.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The carbapenems, penams, oxapenams cephalosporins, and all other members of the β-lactam family are usually combined with β-lactamase inhibitors to help extend their activity and prevent degradation. In 1985, Primaxin (imipenem + cilastatin)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> became the earliest combination to contain a β-lactam antibiotic and a β-lactamase inhibitor. Cilastatin is a renal dehydropeptidase inhibitor which helps prevent host modification of β-lactam antibiotics.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Unasyn (ampicillin + sulbactam), Zosyn (piperacillin + tazobactam), Augmentin (amoxicillin + clavulanate), and Augmentin XR (amoxicillin + clavulanate) approved in 1986, 1993, 1996, and 2002, respectively, are broad-spectrum β-lactam antibiotics effective against a variety of bacterial infections. Common respiratory infections, such as bronchitis, pneumonia, and sinusitis, are treated using a β-lactam antibiotic and β-lactamase inhibitors. Rifamate (isoniazid + rifampin) and Rifater (isoniazid + pyrazinamide + rifampin), approved in 1975 and 1994, respectively, are both indicated for pulmonary tuberculosis. Rifampin is a member of the rifamycin family of antibiotics. Peroxidative activation of isoniazid by mycobacterial enzyme KatG generates a reactive species which then covalently binds to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) (both nucleic acid and lipid enzyme inhibitors).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Recently, non-β-lactam β-lactamase inhibitors (avibactam and vaborbactam) have been used in conjunction with a β-lactam as broad-spectrum antibiotics.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> Urinary tract infections are treated with a cephalosporin β-lactams (ceftolozane or ceftazidime) in combination with a β-lactamase inhibitors (avibactam or tazobactam). Avibactam is unique among these structures as it does not contain a β-lactam. In fact, it is a founding member of the diazabicyclooctanes (DBOs), a new class of non-β-lactam β-lactamase inhibitors effective against class A and C β-lactamases. The hypothesis that DBOs could be potential β-lactam mimics was proposed by chemists at Hoechst Marion Roussel (HMR) in the mid-1990s. HMR eventually merged with Rhone-Poulenc and Sanofi to form Sanofi-Aventis. When Sanofi-Aventis decided to drop their anti-infective program, the DBO project was inherited by a spin-off company, Novexel. Progress finally was made after Novexel was acquired by AstraZeneca; avibactam was released shortly after. DBOs have yet to reach their potential, as lengthy syntheses are required to produce these unique compounds.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Unlike traditional β-lactamase inhibitors whose mechanism of action is through irreversible covalent inhibition, avibactam operates as a reversible covalent inhibitor. This reversible covalent inhibition aids in protecting avibactam’s β-lactam combination partners from hydrolysis.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Vaborbactam contains a structurally unique oxaborinanol heterocycle. Boron-containing drugs are an emerging class of pharmaceuticals. Boron possesses unique properties that can be exploited in tuning a drug’s mechanism of action to target specific diseases.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> For example, boronic acids are also unique in that they can function as transition state analogues with serine residues as result of their ability to reversibly form covalent bonds with alcohols. This allows them to be effective inhibitors of serine carbapenemase. This is precisely why vaborbactam is thought to be a strong inhibitor of various β-lactamases.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Synercid (quinupristin + dalfopristin), approved in 1999, is used to treat bacterial infections resistant to other antibiotics such as vancomycin. Both quinupristin and dalfopristin are pristinamycin derivatives of the streptogramin antibiotic class. This combination treats <i>Enterococcus faecium</i> previously resistant to vancomycin and <i>Staphylococcus</i>.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Pyocidin (polymyxin B + hydrocortisone) and Otovel (ciprofloxacine + fluocinolone acetonide) were both approved in 2016 for the treatment of acute otitis media. One hydroxyquinoline member (clioquinol) appears in combination with Nystatin (nystaform). Clioquinol is structurally notable as it contains two different halogen atoms (chlorine and iodine). The hydroxyquinoline family is thought to possess diverse bioactivity (antineurodegenerative, anticancer, antifungal, antioxidative, antimicrobial, antidiabetic, etc.) as a result of their ability to chelate metals such as Zn, Fe, and Cu.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><figure id="fig17A" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 17A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0022.jpeg" id="GRAPHIC-d7e656-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17A. Anti-infective (nonviral) approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig17A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig17B" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 17B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0023.jpeg" id="GRAPHIC-d7e663-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17B. Anti-infective (nonviral) approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig17B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Alimentary Tract and Metabolism</h3><div class="NLM_p">All 52 structures, which are part of 31 US FDA approved alimentary tract and metabolism combinations, are presented in <a data-tab="pane-pcw-Figures" href="#fig18A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18A" id="" class=" internalNav">18A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig18B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18B" id="" class=" internalNav">18B</a></a>. Metformin is the only drug in this category that is in the list of top 24 most commonly utilized combination drug components. Out of 31 combination drugs approved for treatment of alimentary tract and metabolism related conditions, six include metformin as a contributing INN. Metformin was first partnered with pioglitazone in 2000, followed by rosiglitazone, alogliptin, empagliflozin, ertugliflozin, and most recently glipizide in 2008. In 1960, Lomotil (diphenoxylate + atropine) was approved as an antidiarrheal, making it one of the earliest alimentary tract combinations to be approved. Diphenoxylate, an opioid member of the phenyl piperidine class, acts as the antidiarrheal. Atropine, an anticholinergic, is included in this combination to discourage overdose with an opioid. If too much Lomotil is taken, atropine will cause undesirable side effects such as nausea.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The prazole proton pump inhibitors (esomeprazole, omeprazole, and lansoprazole), recognizable by their benzimidazole core, are parts of combinations with common NSAIDs to treat arthritis and cardiovascular events in patients at risk of gastric ulcers. Prazoles have also been combined with natural product antibiotics and penams to treat gastric ulcers caused by <i>Helicobacter pylori</i>. In 1999, Prevpac (lansoprazole + amoxicillin + clarithromycin) became the first approved combination drug containing a prazole. Famotidine, an H<sub>2</sub> antagonist recognizable by its thiazole, thioether, and guanidine, as well as Misoprostol (a prostaglandin analogue) appear in combinations with NSAIDs as well to treat gastric ulcers. Ammonul (sodium phenylacetate + sodium benzoate), approved in 1960, is indicated for acute hyperammonemia and encephalopathy associated with deficient urea cycles. This combination helps patients eliminate nitrogen through an alternate mechanism.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Contrave (bupropion + naltrexone), approved in 2014, is used for weight loss.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Bupropion, a substituted cathinone antidepressant of the norepinephrine–dopamine reuptake inhibitor (NDRI) family, and naltrexone, an oxymorphone analogue which manages opioid dependence, help the brain regulate appetite. Lonsurf (trifluridine + tipiracil), approved in 2015, is a combination used to treat metastatic colorectal cancer. Its components are trifluridine, a nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor. Four major classes of antidiabetic drugs are components of alimentary tract and metabolism combinations: the gliptins, glitazones, sulfonylureas, and gliflozins.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Duetact (pioglitazone + glimepiride), Oseni (alogliptin + pioglitazone), Glyxambi (empagliflozin + linagliptin), Steglujan (ertugliflozin + sitagliptin), and Qtern (dapagliflozin + saxagliptin), approved in 2006, 2013, 2015, 2017, and 2017, respectively, also treat type 2 diabetes. Because the pathogenesis of type 2 diabetes is usually caused by multiple defects, combining two antidiabetic drugs with distinct mechanisms of actions has been shown to be an effective route to treating type 2 diabetes. For example, the thiazolidinediones (TZDs), such as pioglitazone, facilitate the uptake of peripheral glucose while (DPP)-4 inhibitors such as alogliptin enhance insulin secretion from the pancreas. These complementary modes of action can lead to a more efficacious treatment for the patient.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><figure id="fig18A" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 18A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0024.jpeg" id="GRAPHIC-d7e699-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18A. All alimentary tract and metabolism approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig18A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18B" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 18B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0025.jpeg" id="GRAPHIC-d7e706-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18B. All alimentary tract and metabolism approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig18B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Cardiovascular</h3><div class="NLM_p">The 57 molecular components of all 64 US FDA-approved cardiovascular drug combinations are depicted in <a data-tab="pane-pcw-Figures" href="#fig19A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19A" id="" class=" internalNav">19A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig19B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19B" id="" class=" internalNav">19B</a></a>. These drugs are primarily used to treat hypertension and high cholesterol. Cardiovascular combinations are the third most frequent disease category, with cardiovascular combination drugs having been continuously approved since the 1950s to the present day. This category contains hydrochlorothiazide, which is the most commonly combined drug component found in 35 combinations, of which 33 are used to treat cardiovascular conditions. Amlodipine is the second most frequently partnered cardiovascular component, appearing in 10 approved cardiovascular combinations. Approved in 1958, Diupres-250 (reserpine + chlorothiazide) is the first cardiovascular combination to be approved. Enduronyl (deserpidine + methyclothiazide) and Dralserp (hydralazine + reserpine), approved in 1961 and 1977, respectively, are examples of reserpine type family compounds used to treat hypertension. Reserpine is a natural product alkaloid with antipsychotic and antihypertensive properties. It has a structure identical in most respects to deserpidine, with the exception of a methoxy ether group present on the indole ring of reserpine. There has been much debate over why hydrochlorothiazide has been preferred over chlorthalidone both in monotherapy as well as combination drugs. Although hydrochlorothiazide is seen in most combinations, chlorthalidone, a thiazide-like diuretic, possesses a very similar pharmacological profile, with some concluding chlorthalidone is superior.<a onclick="showRef(event, 'ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72">(70−72)</a> Despite this, chlorthalidone is only seen in six combinations: Regroton (chlorthalidone + reserpine), Kerledex (chlorthalidone + betaxolol), Lopressidone (chlorthalidone +metoprolol), Tenoretic (atenolol + chlorthalidone), Clorpres (clonidine + chlorthalidone), and Edarbyclor (chlorthalidone + azilsartan + medoxomil). One intriguing explanation for hydrochlorothiazide’s preference over chlorthalidone is because hydrochlorothiazide’s abbreviation (HCT when used in a combination drug) lends itself for easier prescription writing over chlorthalidone.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Amiloride is unique in that it is structurally distinct from other diuretics as it contains a pyrazine-carbonyl-guanidine. Unlike the thiazides which interfere with the Na–Cl antiporter, amiloride is a epithelial sodium channel blocker.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The angiotensin II receptor antagonists (sartan family) are heavily represented in this catagory. This family is easily recognizable as most members contain characteristic tetrazole, biphenyl-methyl, and imidazole pharmacophores. Tetrazoles can function as carboxylate group bioisosteres.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In 1995, Hyzaar (losartan + hydrochlorothiazide) became the first combination containing a sartan member to be approved. Various beta blockers are also seen in combinations with cardiovascular drugs and diuretics. These members contain a characteristic aminopropanol component attached to an aromatic group. Three generations of beta blockers exist. The first generations were nonselective and predominately ortho-substituted on their aromatic ring. However, the selectivity of beta-blockers was not realized until para-substituted aromatics displayed β<sub>1</sub> selectivity. In 1979, Inderide (propranolol + hydrochlorothiazide) became the earliest combination to contain a beta-blocker to be approved. In 2016, Byvalson (nebivolol + valsartan) became the most recently approved beta-blocker combination. Nebivolol, a third-generation beta-blocker, is structurally a dimer which is unique for this family. Verapamil is the sole representative of the phenylalkylamine family of calcium channel blockers. It was among the earliest compounds identified to block Ca<sup>2+</sup> in the early 1960s.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Verapamil also has the distinction of being the only calcium channel blocker to be indicated for all three variants of angina (vasospastic, chronic stable, and unstable).<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> In 1996, verapamil was approved as a combination (tarka) with the ACE inhibitor trandolapril to treat hypertension. The DHP family of calcium channel blockers (amlodipine and felodipine) are also represented in antihypertensive combinations. In 1999, Aggrenox (aspirin + dipyridamole) was approved to combat stroke. Dipyridamole, a platelet inhibitor, contains an intriguing fused dipyrimidine heterocycle. Dicurin Procaine (procaine + merethoxylline + theophylline) combines a procaine (local anesthetic) with theophylline (xanthine bronchodilator) and is used as a diuretic. Theophylline, along with natural methylxanthines, was once used as a diuretic before more potent diuretics became available.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Mercurial diuretics, such as merethoxylline, were once very commonly used. They have widely been replaced by safer diuretic alternatives such as thiazides. Procaine limits the discomfort of merethoxylline when it is injected into the tissues.</div><figure id="fig19A" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 19A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0026.jpeg" id="GRAPHIC-d7e754-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19A. All cardiovascular approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig19A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig19B" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 19B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0027.jpeg" id="GRAPHIC-d7e761-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19B. All cardiovascular approved antihypertensive and secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig19B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Dermatological</h3><div class="NLM_p">All 24 combination components of the 21 US FDA approved dermatological combination drugs are shown in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>. Survey of these structures quickly reveals that natural products and their derivatives play a major role (78%). Most prominent among those are steroids (30%), with representation also from complex macrocycles, carbohydrates, vitamin derivatives, and other natural motifs. Most notable among these structures is neomycin, the no. 2 ranked compound seen in combinations, which has been approved as part of 11 dermatological combinations. Neomycin is frequently seen in combinations with corticosteroids. This is because patients diagnosed with atopic dermatitis are often predisposed to secondary bacterial infections. The atopic dermatitis is treated with fluocinolone acetonide as the primary indication which also controls inflammation; neomycin is added as the antibacterial agent.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Polymyxin B, hydrocortisone, and hydrocortisone acetate, all of which are in the list of top 24 combination drug components, have been approved for three, three, and two dermatological drug combinations, respectively. Indications range from acne, athlete’s foot, melisma, and plaque psoriasis. In 1954, Achromycin (procaine + tetracycline) became the earliest dermatological combination to be approved. Tetracyclines have been used by dermatologists to treat acne vulgaris for decades.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Epifoam (hydrocortisone + pramoxine), approved in 1979, is used as an antipruritic. Pramoxine, a synthetic morpholine-containing topical anesthetic, prevents the itching, while hydrocortisone, a naturally occurring steroid, acts as an anti-inflammatory agent. Lotrisone (clotrimazole + betamethasone), approved in 1984, is a topical antifungal agent used to treat conditions such as athlete’s foot and ringworm. Clotrimazole, a synthetic imidazole of the azole antimycotic family, acts as the antifungal component,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> while betamethasone, a synthetic steroid, controls the inflammation. Benzamycin (erythromycin + benzoyl peroxide), Duac (benzoyl peroxide + clindamycin), Ziana (clindamycin + tretinoin), and Epiduo (adapalene + benzoyl peroxide), approved in 2000, 2002, 2006, and 2008, respectively, are approved to treat acne. Benzoyl peroxide has been used to reduce <i>Propionibacterium acnes</i> as well as inflammation associated caused by acne for decades. Contrary to most antibiotics, benzoyl peroxide is directly toxic to <i>P. acnes</i>, therefore no drug related resistance is seen. In addition, benzoyl peroxide helps prevent the emergence of erythromycin and clindamycin resistant <i>P. acnes</i> strains when used in combination.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Tri-Luma (fluocinolone acetonide + hydroquinone + tretinoin), approved in 2002, is a skin bleaching agent used to treat melisma. Fluocinolone acetonide (a corticosteroid) acts as an anti-inflammatory agent, tretinoin, (a retinoid) acts as a skin exfoliant, and hydroquinone acts as a melanin synthesis inhibitor, lightening the skin by inhibiting melanin.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Taclonex (calcipotriol + betamethasone dipropionate), approved in 2008, is indicated for treatment of plaque psoriasis. Calcipotriol, a vitamin D3 analogue, helps slow the growth of skin cells, while betamethasone dipropionate, a corticosteroid, controls the inflammation.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Adapalene, a vitamin A derivative (retinoid) indicated for treatment of acne, contains an adamantane. The route of administration of dermatological combinations are primarily topical and cutaneous, as most are formulated as creams, gels, or aerosols.</div><figure id="fig20" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0028.jpeg" id="GRAPHIC-d7e799-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. All dermatological approved combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Endocrine System</h3><div class="NLM_p">All 29 endocrine system combination structure components are shown in <a data-tab="pane-pcw-Figures" href="#fig21A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21A" id="" class=" internalNav">21A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig21B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21B" id="" class=" internalNav">21B</a></a>. A total of 26 combinations are used to treat conditions such as type 2 diabetes and menopause. Most commonly utilized among these structures is metformin, which is a component of 12 approved endocrine system combinations. Other top 24 structures which have been approved for this disease category are ethinyl estradiol, conjugated estrogens, and hydrochlorothiazide, approved for three, three, and two, combinations, respectively. Steroids play a significant role as components, as do antidiabetic and cardiovascular drug families. In 1995, Prempro and Premphase (conjugated estrogens + medroxyprogesterone) became the earliest combination to be approved. Four major classes of antidiabetic drugs appear in endocrine system combinations: the gliptins, glitazones, sulfonylureas, and gliflozins. In a truly unique combination, Qsymia (phentermine + topirimate), approved in 2012, is used for weight loss. Topirimate’s unique structure consists of three oxygen heterocycles. Topirimate is also interesting therapeutically because it is generally used as an anticonvulsant, however, it also possesses weight loss side effects. The role of phentermine, a substituted amphetamine, in this combination is to help suppress appetite. Prempro and Premphase (conjugated estrogens + medroxyprogesterone) and Duavee (bazedoxifene + conjugated estrogens), approved in 1995 and 2013, respectively, are used to treat menopause symptoms as well as postmenopausal osteoporosis.</div><figure id="fig21A" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 21A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0029.jpeg" id="GRAPHIC-d7e819-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21A. All endocrine system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig21A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig21B" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 21B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0030.jpeg" id="GRAPHIC-d7e826-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21B. All endocrine system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig21B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Genito-Urinary and Sex Hormones</h3><div class="NLM_p">The 45 genito-urinary and sex hormone drug combination components are displayed in <a data-tab="pane-pcw-Figures" href="#fig22A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22A" id="" class=" internalNav">22A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig22B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22B" id="" class=" internalNav">22B</a></a>. A total of 38 unique US FDA approved combinations are used as oral contraceptives, as hormone therapy to treat menopause symptoms, and antibiotics to treat urinary tract infections. Steroid structures do not only represent the majority of all small molecule structures (53%), but they are also the three most utilized components with ethinyl estradiol, conjugated estrogens, and norethindrone acetate, appearing in 12, four, and four genito-urinary and sex hormone combinations, respectively. Closer examination reveals four common substitution locations with progestins and three substitution locations with estrogens, wherein all structural differences occur among its members. In second place, in terms of combination, component frequency are β-lactams (12%). In 1957, PMB 200 (conjugated estrogens + meprobamate) became the first combination to be approved. Lupaneta pack (norethindrone acetate + leuprolide acetate), approved in 2012, treats pain caused by endometriosis. Leuprolide acetate is a synthetic gonadotropin releasing hormone nonapeptide analogue. Jalyn (dutasteride + tamsulosin), approved in 2010, treats benign prostatic hyperplasia (BPH) in males. Dutasteride, a 5α-reductase inhibitor, treats the enlarged prostate by inhibiting the formation of dihydrotestosterone (DHT) from testosterone.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Tamsulosin, an α-1 blocker, relaxes bladder neck muscles in the prostate to make it easier to both urinate and pass kidney stones.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Various progestin and estrogen derivative combinations are used as oral contraceptives as well as to treat menopausal symptoms.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Diclegis (doxylamine + pyridoxine), reapproved in 2013, treats morning sickness during pregnancy. Doxylamine, a first-generation antihistamine, is employed with pyridoxine, vitamin B<sub>6</sub>. Diclegis was originally marketed under the name Bendectin. Bendectin was originally approved in 1956 with an additional component, dicyclomine.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> However, dicyclomine was removed from the original formulation due to lack of efficacy.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> In 1983, after various controversial lawsuits against Bendectin without any scientific evidence to support, the manufacture decided to discontinue the drug. The lawsuits alleged a variety of birth defects such as congenital defects. One lawsuit alleged that Bendectin caused unilateral fetal limb reduction, although that is biologically implausible. Shortly after its discontinuation, the impact was immediately noticeable as the number of women admitted to hospitals for vomiting doubled.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><figure id="fig22A" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 22A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0031.jpeg" id="GRAPHIC-d7e861-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22A. All genito-urinary and sex hormones system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig22A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig22B" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 22B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0032.jpeg" id="GRAPHIC-d7e868-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22B. All genito-urinary and sex hormones system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig22B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Musculo-Skeletal</h3><div class="NLM_p">The 18 musculo-skeletal combination component structures are shown in <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>. These 18 structures appear in 10 unique combinations. Natural products and their derivatives play a prominent role in this disease category. Steroids are the major structural family (22%), which also happens to contain the only components (conjugated estrogens and norethindrone acetate) that are in the top 24 and approved for more than one combination (two each). Other notable members include morphinans, NSAIDS, and various antacids. Many combinations in this family are used to treat gout, a type of arthritis, which is caused by elevated levels of uric acid in the blood. In 1976, colprobenecid (probenecid + colchicine) became the earliest combination to be approved. Probenecid helps facilitate uric acid secretion while its partner colchicine, a natural product, is a non-NSAID anti-inflammatory agent used to control inflammatory arthritis in patients with gout. Another interesting combination that treats hyperuricemia associated with gout involves Lesinurad, a URAT1 inhibitor in conjunction with allopurinol, a member of the xanthine family.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Lesinurad is unique structurally, as it contains a triazole, a bromine atom (rare in pharmaceuticals), as well as a cyclopropane which are being seen more frequently. URAT1 is a protein responsible for reabsorbing uric acid in the kidneys. Allopurinol functions by inhibiting xanthine oxidase, an enzyme ultimately responsible for the synthesis of uric acid. Various arthritis conditions are controlled by combining an NSAID (naproxen or ibuprofen) with an antacid (esomeprazole or famotidine). For example, Duexis (ibuprofen + famotidine), approved in 2001, treats symptoms of osteoarthritis or rheumatoid arthritis. Steroid hormone (estrogens, progestins) combinations treat various menopausal symptoms. Bazedoxifene, a third-generation selective estrogen receptor modulator (SERM), helps prevent postmenopausal osteoporosis.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Targiniq ER combines two morphinan members (oxycodone and naloxone) in its utilization as a pain reliever. Atropine and pralidoxime have been used in combination to treat organophosphate poisoning through countering the acetylcholinesterase inhibitory effects of organophosphates.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> This combination is given as an intramuscular injection.</div><figure id="fig23" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0033.jpeg" id="GRAPHIC-d7e890-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. All musculo-skeletal approved combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Nervous System</h3><div class="NLM_p">All nervous system combination drug components are shown in <a data-tab="pane-pcw-Figures" href="#fig24A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24A" id="" class=" internalNav">24A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig24B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24B" id="" class=" internalNav">24B</a></a>. This is the largest combination drug disease category and has remained one of most frequently approved each decade from the 1940s to the present. Remarkably, 10 of the top 24 most commonly utilized combination drug components belong to this category. These notable structures are pseudoephedrine (no. 3), aspirin (no. 4), acetaminophen (no. 5), codeine (no. 12), hydrocodone (no. 13), caffeine (no. 14), ibuprofen (no. 16), lidocaine (no. 19), phenylephrine (no. 20), and andchlorpheniramine (no. 22). The most prominently occurring architectures are highlighted in boxes in <a data-tab="pane-pcw-Figures" href="#fig24A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24A" id="" class=" internalNav">24A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig24B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24B" id="" class=" internalNav">24B</a></a>. For example, 11 -morphan members, seven -caines, and seven epinephrine types have been used as components of nervous system combinations. The majority of the 78 US FDA approved nervous system combinations are used as pain relievers. Some combinations are local anesthetics, with the majority containing a vasoconstrictor of the catecholamine drug class and an anesthetic. A few of the combinations contain an antidepressant as one component and are indicated for various mood disorders. The remaining combinations are used to treat Parkinson’s and Alzheimer’s symptoms. In 1948, cafergot (ergotamine + caffeine) became the first nervous system combination to be approved. Therapeutically, ergotamine acts as a vasoconstrictor and is used to treat migraines. Interestingly, ergotamine has an affinity for serotonin, dopamine, and norepinephrine receptors.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Treximet (naproxen + sumatriptan) was approved in 2008 for the treatment of migraines and cluster headaches. In 1991, sumatriptan became the earliest member of the triptan family to be introduced. However, because of undesirable pharmacokinetic properties such as low bioavailability and lipophilicity, second-generation triptans are more commonly used.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> As a result of sumatriptan’s low lipophilicity, it acts as a peripherally restricted vasodilator.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Sumatriptan, an analogue of serotonin, acts as an 5HT<sub>1b</sub>- and 5HT<sub>1d</sub>-receptor agonist constricting cranial blood vessels.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Advil PM (diphenhydramine + ibuprofen) and Aleve p.m. (diphenhydramine + naproxen) were approved in 2005 and 2014, respectively, as sleep aids. In these combinations, the lipophilic first-generation antihistamine diphenhydramine helps initiate sleep as a result of its ability to penetrate the blood–brain barrier, inducing sedative effects. Pain reliever combinations commonly consist of an opiate (usually morphinan member) partnered with either an NSAID or another opiate. In 1950, Percodan (aspirin + oxycodone) was the earliest NSAID/opiate combination to be approved. Three decades later, Talwin NX (naloxone + pentazocine) became the first opiate/opiate combination to be approved. Opioid dependence and addiction has been a serious problem for many years. In 2013, Zubsolv (buprenorphine + naloxone) was approved to aid in the treatment of opioid dependence. Both buprenorphine and naloxone are competitive opioid receptor antagonists. Naloxone, a synthetic morphinan derived from oxymorphone, contains an allyl group on N17 of the D piperidine ring, while buprenorphine, derived from thebaine, contains a characteristic ethylene bridge at C6–C14 and unique alkyl substitutions at C7 and N17. Local anesthetics of the -caine family appear in combinations with epinephrine or with another -caine member. These combinations serve useful purposes in dentistry as well as in numbing sensitive areas during medical procedures. In 1965, Citanest Forte (epinephrine + prilocaine) became the first -caine/epinephrine combination to receive approval. Amide agents of the -caine family tend to have a longer duration of action compared with esters because amides generally take longer to hydrolyze,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and epinephrine acts as a vasoconstrictor, helping keep the anesthetic localized in the desired area. Lidocaine has also been used in combination with a corticosteroid (dexamethasone) as well as antibiotics. Triavil (amitriptyline + perphenazine) and Limbitrol DS (amitriptyline + chlordiazepoxide), originally approved in 1965 and 1977, respectively, are used to treat depression. In these combinations, amitriptyline, a tricyclic antidepressant, is used with either an antipsychotic (perphenazine) or benzodiazepine sedative (chlordiazepoxide). The remittance rate for patients treated for major depressive disorder by first-line therapies is estimated to be around 33%. As a result of this paltry remission rate, many patients continue to endure treatment-resistant depression (TRD). Various treatment strategies such as switching antidepressant and combining antidepressants among other strategies have been utilized. Symbyax (fluoxetine + olanzapine), approved in 2003, has been shown to be more effective in treating TRD when compared to monotherapy antidepressants.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is used with olanzapine, an atypical antipsychotic. Nuedexta (DM + quinidine), approved in 2010, is prescribed for the treatment of uncontrollable emotions, such as laughing and crying. These combinations target the pseudobulbar affect (PBA), which occurs secondarily in those who have either had a brain injury or neurological disorder. Patients with PBA may experience uncontrollable crying or laughing even if there is no emotional trigger. Quinidine helps increase the bioavailability of dextromethorphan through its actions as a CYP450 (CYP2D6) inhibitor. Dextromethorphan is a noncompetitive NMDA receptor antagonist.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> It is truly remarkable that two drugs, which have been used for so long, could be combined for such a unique indication. Sinemet (carbidopa + levodopa) and Stalevo 100 (carbidopa + entacapone + levodopa), approved in 1975 and 2003, respectively, are used as dopamine promoters to treat Parkinson’s disease symptoms.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Levodopa is a dopamine precursor; however, unlike dopamine, levodopa can cross the blood–brain barrier (BBB). Once levodopa has crossed the BBB, dopamine decarboxylase converts it to dopamine. Carbidopa is a dopamine decarboxylase inhibitor which functions by inhibiting the conversion of levodopa to dopamine in the peripheral nervous system; this allows more levodopa to cross the BBB. Entacapone is a reversible, selective catechol-<i>O</i>-methyltransferase (COMT) inhibitor that increases levodopa’s bioavailability in the brain by inhibiting its metabolism by methylation.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Namzaric (memantine + donepezil), approved in 2014, is used to treat Alzheimer’s symptoms, although it does not cure the disease.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Memantine, originally synthesized in the 1960s as an unsuccessful antidiabetic candidate, was found to have central nervous system (CNS) properties. It was not until 1989 that memantine was shown to be an (NMDA) antagonist but with a safer therapeutic profile than other members.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Memantine is remarkable structurally for its simplicity and symmetry; it is adamantane core is seen only in a few other approved drugs. Its combination partner donepezil, an acetylcholinesterase inhibitor, contains an indanone heterocycle. The indanone dimethoxy groups result in 20-fold increased activity compared to an unsubstituted core. The position of the piperidine as well as bridge length between the indanone and piperidine are crucial for activity. Direct connection diminishes the potency.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><figure id="fig24A" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 24A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0034.jpeg" id="GRAPHIC-d7e953-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24A. All nervous system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig24A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig24B" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 24B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0035.jpeg" id="GRAPHIC-d7e960-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24B. All nervous system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig24B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Lipophilicity is an important factor thought to facilitate blood–brain barrier penetration. The cyclopropyl moiety, as seen in buprenorphine, is being seen more frequently in pharmaceuticals. This is because cyclopropyl groups can potentially increase metabolic stability and lipophilicity while providing conformational restriction of peptide bonds, thereby slowing proteolytic cleavage.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> However, there are toxicity concerns with cyclopropylamines. For example, the cyclopropylamine moiety in trovafloxacin, an antibiotic of the fluoroquinolone family, has been shown to be metabolized in vitro by first ring opening then ultimately forming a reactive electrophilic α,β-unsaturated aldehyde.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Fluorine substituents (CF<sub>3</sub> and F) are also seen on a few pharmaceuticals (fluoxetine and dexamethasone). Fluorine has been used as a bioisostere for hydrogen in drugs. The addition of fluorine or a fluorine containing group can have a dramatic impact on properties such as bioavailability, lipophilicity, and metabolic stability of pharmaceuticals.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Additional factors thought to facilitate BBB penetration include size, structure, and charge. Most nervous system drugs contain basic amines (uncharged at physiological pH) and not acids (charged at physiological pH). The charged interactions can hinder BBB penetration. Molecular weight is also a major component of BBB penetration with a general cutoff for mass estimated to be around 400–600 Dalton, although there are exceptions.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> As compared to other disease categories such as anti-infective, nervous system pharmaceuticals tend to have smaller molecular weights overall.</div></div><div id="sec11_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Respiratory System</h3><div class="NLM_p">All 55 respiratory drug combination components are shown in <a data-tab="pane-pcw-Figures" href="#fig25A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25A" id="" class=" internalNav">25A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig25B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25B" id="" class=" internalNav">25B</a></a>. This combination drug category has great diversity of structures with major families highlighted in boxes. These include antihistamines, steroids, β-lactams, -caines, and -morphinans. Natural product structures range from complex (rifampin and reserpine) to simple (dextrose, epinephrine, and acetyl cysteine). Five respiratory system components make it on the top 24 list. These are pseudoephedrine, codeine, hydrocodone, phenylephrine, and chlorpheniramine approved for 11, five, three, three, and three total combinations, respectively. The majority of the 46 US FDA approved combinations are used as allergy and cold remedies, antibiotics to treat respiratory infections such as tuberculosis, pneumonia, and bronchitis, as well as bronchodilators to treat chronic obstructive pulmonary disease (COPD) and/or asthma are also seen. Two combinations are indicated for cystic fibrosis. In 1943, Hyocodan (homatropine + hydrocodone) became the first respiratory combination to be approved. Antitussives (codeine and DM), antihistamines (promethazine, bromodiphenhydramine, chlorpheniramine, and dexbrompheniramine), an NSAID (ibuprofen), and a decongestant (phenylephrine) are frequently used in various combinations as cough and cold remedies. For example, Tussicaps (chlorpheniramine + hydrocodone), Advil congestion relief (ibuprofen + phenylephrine), and Advil Allergy and Congestion Relief (ibuprofen + chlorpheniramine + phenylephrine) approved in 1987, 2010, and 2011, respectively, are used to treat hay fever, cold, and other allergic symptoms. In 1952, promethazine/codeine (codeine + promethazine) became the earliest cough syrup combination to be approved. This syrup is easily recognizable by its purple color. Unfortunately, the analgesic properties of codeine have frequently made it a drug of abuse. Furthermore, because both first-generation antihistamines and morphinans are CNS depressants, death can occur from respiratory depression if too much is taken. Mucinex DM (DM + guaifenesin) and Dymista (azelastine + fluticasone) are examples of recently approved combinations (2004 and 2012, respectively) used to relieve allergy symptoms such as runny nose, watery eyes, and sore throat. Muscarinic antagonists, (ipratropium bromide, umeclidinium bromide, tiotropium bromide, and glycopyrronium), which aid in relaxing smooth muscles, are frequently combined with β2 adrenergic receptor agonist bronchodilators (salbutamol, salmeterol, formoterol, vilanterol, and olodaterol) in the treatment of COPD and/or asthma management.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Glucocorticoids (fluticasone, budesonide, and mometasone) are used in combinations to control inflammation in COPD and asthma. Earlier muscarinic antagonists contained tropane pharmacophores. However, later members such as umeclidinium bromide and glycopyrronium bromide contain quinuclidine and pyrrolidine cores, respectively. Orkambi (lumacaftor + ivacaftor) and Symdeko (tezacaftor + ivacaftor), approved in 2015 and 2018, respectively, are indicated for cystic fibrosis. Cystic fibrosis, an autosomal recessive disorder, is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR, a chloride ion channel present in lung epithelium, safeguards the secretion of chloride ions and water in the airway fluid; this in turn allows mucus secretions to be cleared from the airways A deficient CFTR, which leads to decreased chloride secretion and increased sodium absorption, causes mucus secretions to become dry, thick, and build up in the airways.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The CFTR gene, located on chromosome seven, contains approximately 180000 base pairs. So far, more than a thousand mutations at the CFTR have been realized.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Both Orkambi and Symdeko target the Phe508del mutation, the most common CFTR mutation seen in cystic fibrosis patients.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Ivacaftor, the first CFTR modulator approved, improves chloride transport through binding to the ion channel; this increases the likelihood that the channel is open. Lumacaftor acts as a CFTR corrector, increasing the amount of CFTR at the cell surface. However, lumacaftor + ivacaftor can cause respiratory side effects in some patients. In addition, lumacaftor, a cytochrome P-450-3A inductor, can cause undesirable protein–protein interactions with some patients. Tezacaftor, also a CFTR corrector, was developed as an alternative for patients who encounter these unwanted side effects and drug interactions with orkambi.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Kovanaze (oxymetazoline + tetracaine), approved in 2016, is a needle-free regional anesthetic nasal spray. This distinctive indication combines a local anesthetic (tetracaine) with a decongestant (oxymetazoline). Kovanaze is indicated for regional anesthesia in dentistry on teeth A–J and 4–13 in adults. Routes of administration for respiratory combinations vary from oral (various cold remedies), inhalation (for asthma and COPD), iv (various anti-infective penicillins), and nasal sprays (i.e., Kovanaze).</div><figure id="fig25A" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 25A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0036.jpeg" id="GRAPHIC-d7e1005-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25A. All respiratory system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig25A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig25B" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 25B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0037.jpeg" id="GRAPHIC-d7e1012-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25B. All respiratory system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig25B"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Sensory Organs</h3><div class="NLM_p">All 38 sensory-organ combination structure components are presented in <a data-tab="pane-pcw-Figures" href="#fig26A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26A" id="" class=" internalNav">26A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig26B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26B" id="" class=" internalNav">26B</a></a>. A total of 30 US FDA combination drugs have been approved for the treatment of various otic and ophthalmic conditions. This disease category is rich with natural products and their derivatives, which include steroids, aminoglycosides, tetracyclines, macrolides, and complex macrocyclic peptide natural products like gramicidin, bacitracin, colistin, and polymyxin B. Six combination components from the top 24 list have been approved for sensory organ conditions. These drugs are neomycin (no. 2), polymyxin B (no. 5), hydrocortisone acetate (no. 10), hydrocortisone (no. 18), phenylephrine (no. 20), and prednisolone acetate (no. 25). In 1953, chloromycetin hydrocortisone (hydrocortisone acetate + chloramphenicol) became the first sensory organ combination to be approved for the treatment of various ear and eye infections. Ophthalmic and otic anti-infective combinations, like chloromycetin hydrocortisone, usually contain a steroid (prednisolone acetate, dexamethasone, fluorometholone acetate, hydrocortisone, loteprednol, or hydrocortisone acetate) component to control inflammation in combination with an antibiotic. Polytrim (polymyxin B + trimethoprim), approved in 1988, is an ophthalmic anti-infective used to treat conjunctivitis. Pupil dilator combinations used during eye examinations are also seen. Cyclopentolate and tropicamide, both muscarinic antagonists which dilate the pupil, share structural similarities to atropine. They are used in combination with phenylephrine and 4-hydroxyamphetamine, both phenethylamine derivatives. Timolol, which is used in formulations to treat glaucoma, contains a structurally unique beta blocker. Unlike the majority of beta blockers, which contain the aminopropanol attached to a phenyl substituted aromatic, timolol contains a morpholine–thiadiazole instead. Timolol treats glaucoma through the reduction of intraocular pressure by decreasing aqueous humor production.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Timolol is used in combination with dorzolamide, a sulfonamide diuretic of the carbonic anhydrase inhibitor class, and brimonidine, an α2 adrenergic agonist vasoconstrictor. Both brimonidine and dorzolamide reduce intraocular pressure functions: brimonidine by both decreasing aqueous humor synthesis as well as triggering the outflow of aqueous humor via the uveoscleral pathway<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> and dorzolamide by decreasing aqueous humor production. Brimonidine is also seen in a glaucoma combination with brinzolamide, another carbonic anhydrase inhibitor. Betaxolol, another beta blocker, is used in combination with pilocarpine, a saliva production stimulator to also treat glaucoma. Betaxolol’s mechanism of action is the same as timolol. Pilocarpine lowers intraocular pressure through stimulating the outward flow of aqueous humor from the eye.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Omidria (phenylephrine + ketorolac), approved in 2014, is the first intracameral FDA approved medication indicated for use during cataract surgery.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Injections into the eye cavities help prevent endophthalmitis and eye infections after cataract surgery. Phenylephrine, an α<sub>1</sub>-adrenergic receptor agonist, is used with ketorolac, an NSAID. Naphazoline, a sympathomimetic vasoconstrictor and eye decongestant, is used in combinations with antazoline and pheniramine, both antihistamines, to treat allergic conjunctivitis.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><figure id="fig26A" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 26A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0038.jpeg" id="GRAPHIC-d7e1045-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26A. All sensory organ approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig26A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig26B" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 26B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0039.jpeg" id="GRAPHIC-d7e1052-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26B. All sensory organ approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig26B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A majority of combinations in this section are given as solutions to be applied in the ear (otic route) or in the eye (ophthalmic route) as well as nasally.</div></div><div id="sec11_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Oncological Drugs</h3><div class="NLM_p">There continues to be an urgent need to develop oncological agents with limited side effects to effectively treat a variety of cancers. Because of the intense contemporary nature and importance of this disease category, we have chosen to divide our analysis of oncological combination drugs into three sections: classic chemotherapeutic combination agents, targeted oncological agents, and the current state as well as future opportunities in oncological drug development.</div><div class="NLM_p">The first chemotherapy agent arsphenamine was marketed for the treatment of syphilis over a century ago in the lab of Paul Ehrlich, the scientist who introduced the words “chemotherapy” and “magic bullet.”<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Nitrogen mustards, the first cancer chemotherapy agents, were introduced in the 1940s. These were developed after examination of World War II soldiers accidentally exposed to sulfur mustards showed a reduction in bone marrow and lymph nodes. Two decades later, Skipper and colleagues, while extensively researching cures for murine leukemia, introduced the “Cell Kill” hypothesis while hypothesizing that cancer chemotherapy combinations may be superior in curing cancer.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> The first cancer chemotherapy combination regimen dates back to 1964, when VAMP (vincristine + amethopterin, + 6-mercapto-purine + prednisone) was used for acute lymphocytic leukemia.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> These four drugs, each used previously as monotherapy to treat acute lymphocytic leukemia in children, were given to 16 patients in a study. Fourteen (88%) of the patients experienced complete remission.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Many other cancer chemotherapy combinations soon followed. However, although each one of these pharmaceuticals is FDA approved as a monotherapy, only a select few are FDA approved as combination drugs. The two latest chemotherapeutic combination agents approved are Lonsurf (trifluridine + tipiracil) and Vyxeos (cytarabine + daunorubicin). Lonsurf, approved in 2015, treats colorectal cancer.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Vyxeos, approved in 2017, was approved as a treatment for two acute myeloid leukemias (AML): therapy-related myeloid leukemia (t-AML) as well as AML with myelodysplasia-related changes (AML-MRC).<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127,128)</a> Myelodysplasia causes a disruption in the proper formation of blood cells, and some forms can ultimately lead to AML.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig27A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27A" id="" class=" internalNav">27A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig27B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27B" id="" class=" internalNav">27B</a></a>, structural as well as mechanistic diversity is seen with platinum agents, nucleoside antimetabolites, diverse natural products (rubicin family, etoposide, bleomycin, vincristine members, and taxol), and steroids. The unique mechanism of action and structures of some of these chemotherapy agents is worth mentioning. Nitrogen mustards (mechlorethamine and cyclophosphamide) are metabolized in vivo to reactive aziridinium rings, which can then be attacked by DNA to form covalent adducts.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Platinum agents act as electrophilic sources for nucleophilic DNA to attack and cross-link.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Structures containing hydrazines (dacarbazine and procarbazine) are metabolized in vivo to reactive species, such as CH<sub>3</sub><sup>+</sup>, which alkylates DNA.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The majority of non-FDA approved chemotherapy combinations are known by various acronyms and are used under the discretion of the physician (oncologist). The hallmark of these chemotherapeutic agents is to target and eradicate rapidly dividing cells, whether they be normal or cancerous. However, as result of this lack of selectivity, many undesirable side effects are seen with these chemotherapeutic agents. Gastrointestinal issues, myelosuppression, as well as alopecia are all common side effects seen by patients.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Nausea and vomiting are also common side effects with chemotherapy. In 2014, Akynzeo (netupitant + palonosetron) became approved for treatment of chemotherapy induced nausea and vomiting.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a><a data-tab="pane-pcw-Figures" href="#fig27A" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27A" id="" class=" internalNav">27A</a></a> and <a data-tab="pane-pcw-Figures" href="#fig27B" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27B" id="" class=" internalNav">27B</a></a> below show various cancer chemotherapeutic agents which appear in numerous combinations. Cyclophosphamide, doxorubicin, vincristine, etoposide, and cisplatin are seen most frequently, with 42, 36, 33, 32, and 25 appearances, respectively. A nonexhaustive compiled list of combinations of chemotherapeutic agents can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="fig27A" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 27A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0040.jpeg" id="GRAPHIC-d7e1125-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27A. Examples of primary cancer chemotherapeutic agents used in various combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig27A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig27B" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 27B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0041.jpeg" id="GRAPHIC-d7e1132-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27B. Examples of primary and secondary cancer chemotherapeutic agents used in various combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig27B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There has been considerable effort in the pursuit of developing targeted oncological agents with fewer side effects. Monoclonal antibodies and synthetic small molecules are the two drug families represented as targeted agents (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). The goal of targeted oncological therapy is to design agents which block cancer growth by interfering with specific molecular pathways and molecular targets responsible for carcinogenesis.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The year 2001 marked a groundbreaking milestone in small molecule targeted oncological agents, as Imatinib became the first approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Imatinib, a BCR-ABL kinase inhibitor, was immediately impactful, as 76% of patients had complete cytogenetic responses.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> In 2014, a combination of Dabrafenib, a BRAF inhibitor, and Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, was FDA approved to treat metastatic melanoma in patients who contain BRAF V600E or V600K mutations.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> In 2017, dabrafenib + trametinib indications were expanded for the treatment of nonsmall cell lung cancer (NSCLC) in patients with BRAF V600E mutations.<a onclick="showRef(event, 'ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref138 ref139">(138,139)</a></div><figure id="fig28" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0042.jpeg" id="GRAPHIC-d7e1155-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Examples of agents being used in immuno-oncological combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fifteen years prior to imatinib’s approval, orthoclone OKT3 became the first monoclonal antibody to be FDA approved to treat kidney transplant rejections.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> However, it was not until 2004 that a monoclonal antibody (bevacizumab) was approved in a combination regimen with 5-fluorouracil for treatment of metastatic carcinoma of the colon/rectum.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> In 2006, bevacizumab in combination with folfox (oxaliplatin + fluorouracil + folinic acid) was approved as a second line treatment of colon/rectal cancer.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p">There continues to be active interest in the potential use of immunotherapy agents in combination with targeted oncological agents and/or chemotherapy agents. The success that immunotherapy agents such as the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor Ipilimumab and the autologous dendritic cell vaccine Sipuleucel-T have had in various cancer pathologies has led researchers to investigate their potential synergistic relationship if combined with targeted oncological agents. Targeted therapies have been shown to modulate biochemical pathways critical to the immune system. This can potentially be leveraged to enhance beneficial antitumor immune responses when combined with immunotherapy agents to overcome and kill cancerous tumors. In 2009, IFN-α, a cytokine + bevacizumab, became the first combination containing an immuno-agent to be approved for treatment of renal cancer.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In 2015, two additional immunotherapy combinations were approved. Nivolumab, a programmed cell death protein 1 (PD1) inhibitor + ipilimumab, was given accelerated approval for the treatment of melanoma. Elotuzumab, which targets signaling lymphocytic activation molecule family member 7 (SLAMF7), + lenalidomide + dexamethasone, chemotherapy agents, was FDA-approved for treatment of multiple myeloma.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> The attention in this area is likely to remain after the recent failures with immuno-oncology combinations in clinical trials. The phase III clinical trial of the PD1 inhibitor Keytruda (pembrolizumab) + indoleamine-pyrrole 2,3-dioxygenase (IDO1) inhibitor epacadostat combination failed to show that the combination showed enhanced improvement as compared to pembrolizumab in monotherapy. IDO1 is an enzyme responsible for turning the amino acid tryptophan into kynurenine in the rate-limiting step of the kynurenine pathway. The kynurenine pathway has been implicated in the regulation of immune function.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Another clinical trial tested a combination of ipilimumab with vemurafenib, a BRAF inhibitor. Phase I trials showed hepatotoxicity in patients which led authors to conclude that clinical trials for combination drugs with two distinct mechanisms of actions should be “carefully conducted.”<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> A variety of immuno-agents in combination with targeted agents and/or cancer chemotherapeutic agents are in various stages of clinical trials. <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a> shows a selected survey of various immuno-agents and targeted agents being seen in combinations. The two most frequently seen immuno-agents in these combinations are atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, and nivolumab. A noncomprehensive list of immuno-oncological combinations can be found in the supplementary.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p last">Another important point raised is the question as to why various single agents which possess trifling therapeutic activity in monotherapy are being tested in oncological combination therapies for the treatment of the same diseases. These agents are indicated only for palliative care not the treatment of the cancer pathology.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Recalling the basic criteria the FDA requires for combination therapies to be approved, it is worth asking if these combinations truly offer the patient a greater therapeutic benefit as opposed to one given as a monotherapy? On the other hand, cost-effective alternative strategies such as drug repurposing has also been effective in finding potential oncology agents. For example, carbonic anhydrase inhibitors (CAIs), typically used to treat glaucoma, have been extensively investigated as anticancer agents after research showed that cancerous cells possess high carbonic anhydrase activity.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> In one study, doxorubicin’s efficacy in treating colon cancer has been shown to increase when combined with various CAIs.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Metformin, an antidiabetic already discussed in detail, has been shown to have involvement in an antioxidant pathway, ultimately leading to oxidative stress-induced apoptosis of breast cancer cells.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Repurposing histone deacetylase inhibitors (HDACi) as targets in the epigenetic modulation pathway continues to be investigated. Epigenetic pathways, primarily responsible for regulating and silencing various genes, are susceptible to stress and mutations which can lead to cancer. To this end, HDACi’s such as valproic acid (which treats epilepsy) have been evaluated in various oncological combinations.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> The potential of drug repurposing as a cost-effective strategy in future oncological combinations continues to be of contemporary pursuit.</div></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, this perspective represents the first comprehensive structural analysis of US FDA approved combination drugs. Since the earliest combination drug in our database was approved in 1943, combination drug outputs have been increasing throughout each decade. Hydrochlorothiazide continues to be the most frequently used small molecule component in combination drugs, with indications almost exclusively for the cardiovascular system. Historically, drug combinations with two INNs are most prominent. However, combinations with three and four INNs are emerging more often. The nervous system disease category currently has the most drug combinations. However, anti-infective combinations continue to be on rise, particularly in helping to combat serious viruses such as HIV-1 and hepatitis C. This speaks to the difficulty in treating some of these viruses. The schemes of all 10 disease category figures are presented in a way which allows one to both appreciate new innovative drug architectures and trends while immediately recognizing the number of similar looking drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01610" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82443" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82443" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01610" class="ext-link">10.1021/acs.jmedchem.8b01610</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Combination drugs database tables (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">List of all molecules with SMILES strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_001.pdf">jm8b01610_si_001.pdf (1.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_002.csv">jm8b01610_si_002.csv (32.3 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01610" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon T. Njardarson</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry &
Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2268-1479" title="Orcid link">http://orcid.org/0000-0003-2268-1479</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#355b5f544751544746755058545c591b54475c4f5a5b541b505140"><span class="__cf_email__" data-cfemail="dcb2b6bdaeb8bdaeaf9cb9b1bdb5b0f2bdaeb5a6b3b2bdf2b9b8a9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pradipta Das</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry &
Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Delost</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry &
Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Munaum H. Qureshi</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry &
Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David T. Smith</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry &
Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, Arizona 85721, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>P.D. and M.D.D. contributed equally to the creation of this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Pradipta Das</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=BIO-d7e1229-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Pradipta Das</b> received a B.Sc. (Hons.) in chemistry from Presidency College, University of Calcutta, India, in 2010. She also received her M.Sc. degree in chemistry from Indian Institute of Technology, Guwahati, in 2012. Pradipta entered the graduate program in chemistry at The University of Arizona in August of 2012 and in January of 2013 joined the research group of Professor Njardarson.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Michael D. Delost</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=BIO-d7e1234-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michael D. Delost</b> received a B.Sc. in chemistry from Gannon University in 2013. He then earned a M.Sc. in Organic Chemistry from Youngstown State University in 2015. Mike joined the research group of Professor Njardarson in August of 2016.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Munaum H. Qureshi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=BIO-d7e1239-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Munaum H. Qureshi</b> received a B.Sc. in chemistry from The University of Texas at Austin in 2016. Munaum entered the graduate program in chemistry at The University of Arizona in August of 2016 and in January of 2017 joined the research group of Professor Njardarson.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="43" class="article__inlineFigure"><h2 class="fig-label">David T. Smith</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=BIO-d7e1244-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>David T. Smith</b> received a B.Sc. in chemistry from The University of North Carolina at Charlotte in December of 2012. David entered the graduate program in chemistry at The University of Arizona in August of 2013 and in January of 2014 joined the research group of Professor Njardarson.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Jon T. Njardarson</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=BIO-d7e1249-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jon T. Njardarson</b> received his Ph.D. at Yale University in 2001 with Professor John L. Wood. Following postdoctoral training with Professor Samuel J. Danishefsky at The Memorial Sloan-Kettering Cancer Center, he started his independent career in 2004 at Cornell University. In 2010, Professor Njardarson moved his research group to The University of Arizona.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the National Science Foundation (CHE1565500) for financial support of the pharmaceutical poster outreach projects and the resulting analysis efforts.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACE</td><td class="NLM_def"><p class="first last">angiotensin-converting enzyme</p></td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">acquired immune deficiency syndrome</p></td></tr><tr><td class="NLM_term">ALF</td><td class="NLM_def"><p class="first last">acute liver failure</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemias</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">BHP</td><td class="NLM_def"><p class="first last">benign prostatic hyperplasia</p></td></tr><tr><td class="NLM_term">CFTR</td><td class="NLM_def"><p class="first last">cystic fibrosis transmembrane conductance regulator</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">CTL-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr><tr><td class="NLM_term">DBO</td><td class="NLM_def"><p class="first last">diazabicyclooctanes</p></td></tr><tr><td class="NLM_term">DHP</td><td class="NLM_def"><p class="first last">dihydropyridine</p></td></tr><tr><td class="NLM_term">DHT</td><td class="NLM_def"><p class="first last">dihydrotestosterone</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">dextromethorphan</p></td></tr><tr><td class="NLM_term">DPP</td><td class="NLM_def"><p class="first last">dipeptidyl-peptidase</p></td></tr><tr><td class="NLM_term">HCT</td><td class="NLM_def"><p class="first last">hydrochlorothiazide (when in a combination drug)</p></td></tr><tr><td class="NLM_term">HCTZ</td><td class="NLM_def"><p class="first last">hydrochlorothiazide</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus-1</p></td></tr><tr><td class="NLM_term">INN</td><td class="NLM_def"><p class="first last">International Nonproprietary Names</p></td></tr><tr><td class="NLM_term">MET</td><td class="NLM_def"><p class="first last">metformin</p></td></tr><tr><td class="NLM_term">MRC</td><td class="NLM_def"><p class="first last">myelodysplasia-related changes</p></td></tr><tr><td class="NLM_term">NAD</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide</p></td></tr><tr><td class="NLM_term">NADP</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NAPQI</td><td class="NLM_def"><p class="first last"><i>N</i>-acetyl-<i>p</i>-benzoquinone imine</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NS 3A/4A/5A/5B</td><td class="NLM_def"><p class="first last">nonstructural protein 3A/4A/5A/5B</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">PBA</td><td class="NLM_def"><p class="first last">pseudobulbar affect</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">seasonal allergic rhinitis</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulator</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">XR</td><td class="NLM_def"><p class="first last">extended release</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 152 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brichacek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A graphical journey of innovative organic architectures that have improved our lives</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1348</span>– <span class="NLM_lpage">1349</span>, <span class="refDoi"> DOI: 10.1021/ed1003806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed1003806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=1348-1349&author=N.+A.+McGrathauthor=M.+Brichacekauthor=J.+T.+Njardarson&title=A+graphical+journey+of+innovative+organic+architectures+that+have+improved+our+lives&doi=10.1021%2Fed1003806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives</span></div><div class="casAuthors">McGrath, Nicholas A.; Brichacek, Matthew; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1348-1349</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">A new free graphical teaching tool that highlights the beautiful org. architectures of the top selling pharmaceuticals is detailed on two posters.  In addn. to the multitude of teaching and data-mining opportunities these posters offer, they were also created to emphasize the central role org. chemists play in the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPDa7XFu1jBLVg90H21EOLACvtfcHk0lj3IgrcYqedKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP&md5=abaab52626cc29b94b88389f39727513</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1021%2Fed1003806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed1003806%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DN.%2BA.%26aulast%3DBrichacek%26aufirst%3DM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520graphical%2520journey%2520of%2520innovative%2520organic%2520architectures%2520that%2520have%2520improved%2520our%2520lives%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2010%26volume%3D87%26spage%3D1348%26epage%3D1349%26doi%3D10.1021%2Fed1003806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">An in-pharm-ative educational poster anthology highlighting the therapeutic agents that chronicle our medicinal history</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1403</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1021/ed4002317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed4002317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCgt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2013&pages=1403-1405&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=An+in-pharm-ative+educational+poster+anthology+highlighting+the+therapeutic+agents+that+chronicle+our+medicinal+history&doi=10.1021%2Fed4002317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">An In-Pharm-ative Educational Poster Anthology Highlighting the Therapeutic Agents That Chronicle Our Medicinal History</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1403-1405</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">Disease Focused Posters is a new, free, and readily accessible collection of graphical timelines that arrange the vast no. of FDA approved pharmaceuticals according to a specific theme.  Capitalizing on the elegance of structural imagery and the innovative functions of org. compds., each poster (in its simplistic appearance) has the capacity to communicate a wealth of information that appeals to the educational desires of the public, from the non-scientist to the expert.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou7hPyEhlYGLVg90H21EOLACvtfcHk0lhIwAayHrdMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCgt7nN&md5=ba2756db4be9554aef14e7ef64ac2983</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1021%2Fed4002317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed4002317%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAn%2520in-pharm-ative%2520educational%2520poster%2520anthology%2520highlighting%2520the%2520therapeutic%2520agents%2520that%2520chronicle%2520our%2520medicinal%2520history%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2013%26volume%3D90%26spage%3D1403%26epage%3D1405%26doi%3D10.1021%2Fed4002317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2842</span>, <span class="refDoi"> DOI: 10.1021/jm401375q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+design+and+discovery&doi=10.1021%2Fjm401375q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lhIwAayHrdMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842%26doi%3D10.1021%2Fjm401375q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Beyond C, H, O, and N! analysis of the elemental composition of U.S. FDA approved drug architectures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9764</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/jm501105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9764-9773&author=B.+R.+Smithauthor=C.+M.+Eastmanauthor=J.+T.+Njardarson&title=Beyond+C%2C+H%2C+O%2C+and+N%21+analysis+of+the+elemental+composition+of+U.S.+FDA+approved+drug+architectures&doi=10.1021%2Fjm501105n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond C, H, O, and N! Analysis of the Elemental Composition of U.S. FDA Approved Drug Architectures</span></div><div class="casAuthors">Smith, Brandon R.; Eastman, Candice M.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9764-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The diversity of elements among U.S.  Food and Drug Administration (FDA) approved pharmaceuticals is analyzed and reported, with a focus on atoms other than carbon, hydrogen, oxygen, and nitrogen.  Our anal. reveals that sulfur, chlorine, fluorine, and phosphorous represent about 90% of elemental substitutions, with sulfur being the fifth most used element followed closely by chlorine, then fluorine and finally phosphorous in the eighth place.  The remaining 10% of substitutions are represented by 16 other elements of which bromine, iodine, and iron occur most frequently.  The most detailed parts of our anal. are focused on chlorinated drugs as a function of approval date, disease condition, chlorine attachment, and structure.  To better aid our chlorine drug analyses, a new poster showcasing the structures of chlorinated pharmaceuticals was created specifically for this study.  Phosphorus, bromine, and iodine contg. drugs are analyzed closely as well, followed by a discussion about other elements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLwTieDN1HbVg90H21EOLACvtfcHk0lhIwAayHrdMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL&md5=95e1ab686ba41c63070059ad0987ff6c</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1021%2Fjm501105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501105n%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DEastman%26aufirst%3DC.%2BM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DBeyond%2520C%252C%2520H%252C%2520O%252C%2520and%2520N%2521%2520analysis%2520of%2520the%2520elemental%2520composition%2520of%2520U.S.%2520FDA%2520approved%2520drug%2520architectures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9764%26epage%3D9773%26doi%3D10.1021%2Fjm501105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+U.S.+FDA+approved+pharmaceuticals&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0lhoL1SqlIhlNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of US FDA drugs containing sulfur atoms</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1007/s41061-018-0184-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs41061-018-0184-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2018&pages=1-34&author=K.+A.+Scottauthor=J.+T.+Njardarson&title=Analysis+of+US+FDA+drugs+containing+sulfur+atoms&doi=10.1007%2Fs41061-018-0184-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.1007%2Fs41061-018-0184-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41061-018-0184-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520US%2520FDA%2520drugs%2520containing%2520sulfur%2520atoms%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2018%26volume%3D376%26spage%3D1%26epage%3D34%26doi%3D10.1007%2Fs41061-018-0184-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1g"><span>(<span class="NLM_label">(g) </span>) <span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span>; <span class="NLM_string-name">Smith, D. T.</span>; <span class="NLM_string-name">Anderson, B. J.</span>; <span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">From oxiranes to oligomers: architectures of US FDA approved pharmaceuticals containing oxygen heterocycles</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume">61</span> <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00876</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&author=M.+D.+Delost&author=D.+T.+Smith&author=B.+J.+Anderson&author=J.+T.+Njardarson&title=From+oxiranes+to+oligomers%3A+architectures+of+US+FDA+approved+pharmaceuticals+containing+oxygen+heterocycles&doi=10.1021%2Facs.jmedchem.8b00876"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1g&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26aulast%3DDelost%26aufirst%3DM.%2BD.%26atitle%3DFrom%2520oxiranes%2520to%2520oligomers%253A%2520architectures%2520of%2520US%2520FDA%2520approved%2520pharmaceuticals%2520containing%2520oxygen%2520heterocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26doi%3D10.1021%2Facs.jmedchem.8b00876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="note"><p class="first last">There are 25 approved combinations for which we were unable to find an approval year.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finland, M.</span></span> <span> </span><span class="NLM_article-title">Combinations of antimicrobial drugs: trimethoprim-sulfamethoxazole</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1056/NEJM197409192911209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJM197409192911209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=4851498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaE2czgtVGitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1974&pages=624-627&author=M.+Finland&title=Combinations+of+antimicrobial+drugs%3A+trimethoprim-sulfamethoxazole&doi=10.1056%2FNEJM197409192911209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: Combinations of antimicrobial drugs: trimethoprim-sulfamethoxazole</span></div><div class="casAuthors">Finland M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">624-7</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1P4-clnBof-IHSmpohpd0fW6udTcc2eapy3yD1FG1RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2czgtVGitw%253D%253D&md5=ebe3bf35b30ce9d3404ebc34b5499207</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM197409192911209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197409192911209%26sid%3Dliteratum%253Aachs%26aulast%3DFinland%26aufirst%3DM.%26atitle%3DCombinations%2520of%2520antimicrobial%2520drugs%253A%2520trimethoprim-sulfamethoxazole%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1974%26volume%3D291%26spage%3D624%26epage%3D627%26doi%3D10.1056%2FNEJM197409192911209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span> <span> </span><span class="NLM_article-title">Fluorination methods for drug discovery and development</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">999</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1223037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1080%2F17460441.2016.1223037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=27548817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyisL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=983-999&author=P.+Richardson&title=Fluorination+methods+for+drug+discovery+and+development&doi=10.1080%2F17460441.2016.1223037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorination methods for drug discovery and development</span></div><div class="casAuthors">Richardson, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">983-999</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The pivotal role that the element fluorine plays in modulating the properties of bioactive mols. is reflected by the growth of its presence in approved drugs.  In 1970, approx. 2% of drugs contained fluorine with this no. rising to 25% by 2011.  The synthetic chem. regarding incorporation of fluorine into org. mols. has also evolved over this time with a paradigm shift from harsh, toxic, hazardous reagents utilized primarily by specialist vendors to new deoxyfluorination reagents and metal-mediated techniques capable of the precise introduction of fluorine into complex org. substrates under relatively mild conditions.  This review highlights the importance of fluorinated compds. in drug discovery, and provides an overview on the synthetic strategies and methodologies developed to access them both in discovery and development.  The development of new reagents for the safe and precise regioselective fluorination of biol. relevant compds. particularly in drug discovery remains a contemporary challenge in org. chem.  However, significant strides have been made with the development of new deoxyfluorination reagents and the emergence of practical metal-mediated fluorination techniques have enabled the goal of efficient late-stage fluorination of drug-like compds. to be realized, and the extension of these methods for PET-labeling is being investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVKZBu8dlW7Vg90H21EOLACvtfcHk0lhoL1SqlIhlNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyisL7K&md5=a0f4772a1287ecef6afee01a0570b037</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1223037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1223037%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26atitle%3DFluorination%2520methods%2520for%2520drug%2520discovery%2520and%2520development%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D983%26epage%3D999%26doi%3D10.1080%2F17460441.2016.1223037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messerli, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangalore, S.</span></span> <span> </span><span class="NLM_article-title">Half a century of hydrochlorothiazide: facts, fads, fiction, and follies</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2011.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.amjmed.2011.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21962309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GgsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=896-899&author=F.+H.+Messerliauthor=S.+Bangalore&title=Half+a+century+of+hydrochlorothiazide%3A+facts%2C+fads%2C+fiction%2C+and+follies&doi=10.1016%2Fj.amjmed.2011.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies</span></div><div class="casAuthors">Messerli, Franz H.; Bangalore, Sripal</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">896-899</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US.  In 2008, 47.8 million prescriptions were written for HCTZ alone and 87.1 million prescriptions for HCTZ combinations.  However, there is no evidence that HCTZ in its usual dose of 12.5-25 mg daily reduces myocardial infarction, stroke, or death.  In a meta-anal. of 19 randomized trials with over 1400 patients, the 24-h decrease in blood pressure with HCTZ was inferior to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and calcium channel blockers (P <.001 for all).  Even in combination with an angiotensin-converting enzyme inhibitor, HCTZ was found to reduce morbidity and mortality less well than a calcium channel blocker.  As measured by the adherence rate, thiazides are less well tolerated than any other drug class.  Because outcome data at the usual daily dose of 12.5-25 mg are lacking, antihypertensive efficacy is paltry, and adherence is poor, HCTZ is an inappropriate first-line drug in hypertension.  If a "thiazide-type" diuretic is indicated, either chlorthalidone or indapamide should be selected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCbUcMK7YtbVg90H21EOLACvtfcHk0lhh8fpL50Gbgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GgsbbM&md5=eb31f622dd490824638fa7369ec2abea</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2011.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2011.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMesserli%26aufirst%3DF.%2BH.%26aulast%3DBangalore%26aufirst%3DS.%26atitle%3DHalf%2520a%2520century%2520of%2520hydrochlorothiazide%253A%2520facts%252C%2520fads%252C%2520fiction%252C%2520and%2520follies%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2011%26volume%3D124%26spage%3D896%26epage%3D899%26doi%3D10.1016%2Fj.amjmed.2011.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, J.</span></span> <span> </span><span class="NLM_article-title">From snake venom to ACE inhibitor - The discovery and rise of captopril</span>. <i>Pharm. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2009&pages=455-456&author=J.+Bryan&title=From+snake+venom+to+ACE+inhibitor+-+The+discovery+and+rise+of+captopril"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DJ.%26atitle%3DFrom%2520snake%2520venom%2520to%2520ACE%2520inhibitor%2520-%2520The%2520discovery%2520and%2520rise%2520of%2520captopril%26jtitle%3DPharm.%2520J.%26date%3D2009%26volume%3D282%26spage%3D455%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span>; <span class="NLM_string-name">Maibaum, J.</span></span> In  <i>Aspartic Acid Proteases as Therapeutic Targets</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_year">2011</span>, Chapter  <span class="NLM_volume">10</span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">296</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=265-296&author=J.+M.+Wood&author=J.+Maibaum&title=Aspartic+Acid+Proteases+as+Therapeutic+Targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DJ.%2BM.%26btitle%3DAspartic%2520Acid%2520Proteases%2520as%2520Therapeutic%2520Targets%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2011%26volume%3D10%26spage%3D265%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, M.</span></span> <span> </span><span class="NLM_article-title">Rationale for combination therapy in the management of hypertension</span>. <i>J. Clin. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1111/j.1524-6175.2003.02668.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1524-6175.2003.02668.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3sngsFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=17-25&author=M.+Moser&title=Rationale+for+combination+therapy+in+the+management+of+hypertension&doi=10.1111%2Fj.1524-6175.2003.02668.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale for combination therapy in the management of hypertension</span></div><div class="casAuthors">Moser Marvin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical hypertension (Greenwich, Conn.)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6 Suppl 4</span>),
    <span class="NLM_cas:pages">17-25</span>
        ISSN:<span class="NLM_cas:issn">1524-6175</span>.
    </div><div class="casAbstract">Combination drug therapy in the management of hypertension has been used for many years.  Recent recommendations of the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the results of several new multiple-drug trials have focused on using the approach as initial therapy in many hypertensive patients.  Results of these long-term outcome trials, as well as short-term and smaller studies, indicate the advantage of multiple-drug therapy in the management of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNZNr0MLCap_69nzq6467DfW6udTcc2ebTCEUWZnggCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3sngsFymsg%253D%253D&md5=f6bc7f647e47b043c688027907ca45fb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1524-6175.2003.02668.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1524-6175.2003.02668.x%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DM.%26atitle%3DRationale%2520for%2520combination%2520therapy%2520in%2520the%2520management%2520of%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Hypertens.%26date%3D2003%26volume%3D5%26spage%3D17%26epage%3D25%26doi%3D10.1111%2Fj.1524-6175.2003.02668.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borghi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, A. F. G.</span></span> <span> </span><span class="NLM_article-title">Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data</span>. <i>Vasc. Health Risk. Manag.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.2147/vhrm.2006.2.4.341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2Fvhrm.2006.2.4.341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17323587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1ygtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=341-349&author=C.+Borghiauthor=A.+F.+G.+Cicero&title=Fixed+combination+of+zofenopril+plus+hydrochlorothiazide+in+the+management+of+hypertension%3A+a+review+of+available+data&doi=10.2147%2Fvhrm.2006.2.4.341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data</span></div><div class="casAuthors">Borghi, Claudio; Cicero, Arrigo F. G.</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Health and Risk Management</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-349</span>CODEN:
                <span class="NLM_cas:coden">VHRMAT</span>;
        ISSN:<span class="NLM_cas:issn">1176-6344</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiotensin-converting enzyme (ACE) inhibitors effectively interfere with the renin-angiotensin system and exert various beneficial actions on vascular structure and function beyond their blood pressure-lowering effects.  Zofenopril, a potent sulphydryl ACE inhibitor, is characterized by high lipophilicity, sustained cardiac ACE inhibition, and antioxidant and tissue protective activities.  Its ancillary properties, such as antioxidant activity and cardiovascular (CV) protection, make this drug potentially suitable for the treatment and prevention of certain CV diseases.  The Survival of Myocardial Infarction Long term Evaluation trials have demonstrated that the early administration of zofenopril to patients with acute myocardial infarction is assocd. with a significant redn. in the 6-wk occurrence of major CV events in high-risk patients with anterior non-thrombolyzed myocardial infarction.  The fixed combination of zofenopril-hydrochlorothiazide (HCTZ) 30/12.5 mg/day is approved for the management of mild-to-moderate hypertension in different European countries.  In clin. trials comparing zofenopril-HCTZ with each agent administered as monotherapy, combination therapy was clearly more effective in normalizing blood pressure (BP).  In addn., combination therapy provided sustained and consistent BP control over the entire 24 h dosing interval.  The efficacy and safety profile of zofenopril-HCTZ highlights that this combination is a potentially useful addn. to currently available therapy for patients with BP inadequately controlled by monotherapy, as well as for patients who require more rapid and intensive BP control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowU7Wlkcx-j7Vg90H21EOLACvtfcHk0lhh8fpL50Gbgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1ygtLg%253D&md5=38abc639ce0054203a140b532eed5351</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2147%2Fvhrm.2006.2.4.341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fvhrm.2006.2.4.341%26sid%3Dliteratum%253Aachs%26aulast%3DBorghi%26aufirst%3DC.%26aulast%3DCicero%26aufirst%3DA.%2BF.%2BG.%26atitle%3DFixed%2520combination%2520of%2520zofenopril%2520plus%2520hydrochlorothiazide%2520in%2520the%2520management%2520of%2520hypertension%253A%2520a%2520review%2520of%2520available%2520data%26jtitle%3DVasc.%2520Health%2520Risk.%2520Manag.%26date%3D2006%26volume%3D2%26spage%3D341%26epage%3D349%26doi%3D10.2147%2Fvhrm.2006.2.4.341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, R.</span></span> <span> </span><span class="NLM_article-title">Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02833.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1365-2125.2006.02833.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17116124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsFWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=10-14&author=R.+Eccles&title=Substitution+of+phenylephrine+for+pseudoephedrine+as+a+nasal+decongeststant.+An+illogical+way+to+control+methamphetamine+abuse&doi=10.1111%2Fj.1365-2125.2006.02833.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse</span></div><div class="casAuthors">Eccles, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The aim of this review was to investigate the rationale for replacing the nasal decongestant pseudoephedrine (PDE) with phenylephrine (PE) as a means of controlling the illicit prodn. of methamphetamine.  A literature search was conducted in electronic databases and use of textbooks.  Restrictions have been placed on the sale of PDE in the USA in an attempt to control the illicit prodn. of methamphetamine.  This has caused a switch from PDE to PE in many common cold and cough medicines.  PE is a poor substitute for PDE as an orally administered decongestant as it is extensively metabolized in the gut and its efficacy as a decongestant is unproven.  Both PDE and PE have a good safety record, but the efficacy of PDE as a nasal decongestant is supported by clin. trials.  Studies in the USA indicate that restricting the sale of PDE to the public as a medicine has had little impact on the morbidity and no. of arrests assocd. with methamphetamine abuse.  Restricting the sale of PDE in order to control the illicit prodn. of methamphetamine will deprive the public of a safe and effective nasal decongestant and force the pharmaceutical industry to replace PDE with PE, which may be an ineffective decongestant.  Restrictions on sales of PDE to the public may not reduce the problems assocd. with methamphetamine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS7fSRNJzURLVg90H21EOLACvtfcHk0li3wZfWxspnuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsFWqur0%253D&md5=d95e5f8c474c040a9b9043ec785a1a38</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02833.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02833.x%26sid%3Dliteratum%253Aachs%26aulast%3DEccles%26aufirst%3DR.%26atitle%3DSubstitution%2520of%2520phenylephrine%2520for%2520pseudoephedrine%2520as%2520a%2520nasal%2520decongeststant.%2520An%2520illogical%2520way%2520to%2520control%2520methamphetamine%2520abuse%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D63%26spage%3D10%26epage%3D14%26doi%3D10.1111%2Fj.1365-2125.2006.02833.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricard, N.</span></span> <span> </span><span class="NLM_article-title">The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. <i>J</i></span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/S0091-6749(99)70120-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0091-6749%2899%2970120-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10400846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK1MXltVKhtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=100-106&author=G.+L.+Sussmanauthor=J.+Masonauthor=D.+Comptonauthor=J.+Stewartauthor=N.+Ricard&title=The+efficacy+and+safety+of+fexofenadine+HCl+and+pseudoephedrine%2C+alone+and+in+combination%2C+in+seasonal+allergic+rhinitis.+J&doi=10.1016%2FS0091-6749%2899%2970120-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis</span></div><div class="casAuthors">Sussman, Gordon L.; Mason, Jolene; Compton, Diana; Stewart, John; Ricard, Nancy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-106</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Antihistamines effectively treat seasonal allergic rhinitis (SAR), although the ability of this drug class to reduce nasal congestion is limited.  Nasal decongestants effectively treat nasal congestion but not the histamine-related components of SAR.  Therefore antihistamine/nasal decongestant combinations are commonly used to maximize the treatment of SAR.  Fexofenadine HCl is a nonsedating, long-acting H1 receptor antagonist that provides fast and effective relief from SAR.  It is well tolerated, with no sedative or cardiotoxic effects.  We sought to compare the efficacy and safety of a fexofenadine HCl/pseudoephedrine HCl combination with that of each individual component in the treatment of ragweed allergy.  In this Canadian multicenter, double-blind, parallel-group study, 651 patients allergic to ragweed were randomized to receive 60 mg of fexofenadine HCl twice daily, 120 mg of sustained-release pseudoephedrine HCl twice daily, or a combination of the 2 drugs (60 mg of fexofenadine HCl/120 mg of sustained-release pseudoephedrine HCl) twice daily for 2 wk.  Efficacy analyses were based on symptom severity.  In addn., a health economic assessment was performed.  Combination therapy was significantly more effective than pseudoephedrine alone in improving primarily histaminemediated symptoms (sneezing; rhinorrhea; itchy nose, palate, and/or throat; and itchy, watery, red eyes) and significantly more effective than fexofenadine alone in reducing nasal congestion.  Combination therapy also produced greater improvements in daily activities and work productivity compared with the individual components.  No serious adverse events were reported in any of the treatment groups.  In addn., no clin. significant changes in 12-lead ECG parameters, vital signs, or clin. lab. values were obsd.  Combination therapy is more effective than fexofenadine alone or pseudoephedrine alone in relieving the full spectrum of SAR symptoms (ie, both the primarily histamine-related symptoms and nasal congestion).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJdolt3b7UULVg90H21EOLACvtfcHk0li3wZfWxspnuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVKhtbw%253D&md5=1891918a27c7ea26ff34caded3d9c2ba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0091-6749%2899%2970120-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-6749%252899%252970120-X%26sid%3Dliteratum%253Aachs%26aulast%3DSussman%26aufirst%3DG.%2BL.%26aulast%3DMason%26aufirst%3DJ.%26aulast%3DCompton%26aufirst%3DD.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DRicard%26aufirst%3DN.%26atitle%3DThe%2520efficacy%2520and%2520safety%2520of%2520fexofenadine%2520HCl%2520and%2520pseudoephedrine%252C%2520alone%2520and%2520in%2520combination%252C%2520in%2520seasonal%2520allergic%2520rhinitis.%2520J%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1999%26volume%3D104%26spage%3D100%26epage%3D106%26doi%3D10.1016%2FS0091-6749%2899%2970120-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, D. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of antihistamines</span>. <i>Indian J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.4103/0019-5154.110832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4103%2F0019-5154.110832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23723474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=219-224&author=M.+K.+Churchauthor=D.+S.+Church&title=Pharmacology+of+antihistamines&doi=10.4103%2F0019-5154.110832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of antihistamines</span></div><div class="casAuthors">Church Martin K; Church Diana S</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">H1-antihistamines, the mainstay of treatment for urticaria, were developed from anticholinergic drugs more than 70 years ago.  They act as inverse agonists rather than antagonists of histamine H1-receptors which are members of the G-protein family.  The older first generation H1-antihistamines penetrate readily into the brain to cause sedation, drowsiness, fatigue and impaired concentration and memory causing detrimental effects on learning and examination performance in children and on impairment of the ability of adults to work and drive.  Their use should be discouraged.  The newer second-generation H1-antihistamines are safer, cause less sedation and are more efficacious.  Three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review.  Of these levocetirizine and fexofenadine are the most potent in humans in vivo.  However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection.  Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkA18dqept1EH3Rlp_k91zfW6udTcc2eaUxQYa137J8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D&md5=867adc1094106d91708347063af8a9d9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4103%2F0019-5154.110832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0019-5154.110832%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26aulast%3DChurch%26aufirst%3DD.%2BS.%26atitle%3DPharmacology%2520of%2520antihistamines%26jtitle%3DIndian%2520J.%2520Dermatol.%26date%3D2013%26volume%3D58%26spage%3D219%26epage%3D224%26doi%3D10.4103%2F0019-5154.110832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, F. E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, K. J.</span></span> <span> </span><span class="NLM_article-title">H(1) Antihistamines: current status and future directions</span>. <i>World Allergy Organ. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1186/1939-4551-1-9-145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1186%2F1939-4551-1-9-145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23282578" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=145-155&author=F.+E.+R.+Simonauthor=K.+J.+Simons&title=H%281%29+Antihistamines%3A+current+status+and+future+directions&doi=10.1186%2F1939-4551-1-9-145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2F1939-4551-1-9-145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1939-4551-1-9-145%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DF.%2BE.%2BR.%26aulast%3DSimons%26aufirst%3DK.%2BJ.%26atitle%3DH%25281%2529%2520Antihistamines%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DWorld%2520Allergy%2520Organ.%2520J.%26date%3D2008%26volume%3D1%26spage%3D145%26epage%3D155%26doi%3D10.1186%2F1939-4551-1-9-145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brune, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiegs, G.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen/paracetamol: a history of errors, failures and false decisions</span>. <i>Eur. J. Pain.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1002/ejp.621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fejp.621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25429980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2Mzht1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=953-965&author=K.+Bruneauthor=B.+Rennerauthor=G.+Tiegs&title=Acetaminophen%2Fparacetamol%3A+a+history+of+errors%2C+failures+and+false+decisions&doi=10.1002%2Fejp.621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen/paracetamol: A history of errors, failures and false decisions</span></div><div class="casAuthors">Brune K; Renner B; Tiegs G</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pain (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acetaminophen/paracetamol is the most widely used drug of the world.  At the same time, it is probably one of the most dangerous compounds in medical use, causing hundreds of deaths in all industrialized countries due to acute liver failure (ALF).  Publications of the last 130 years found in the usual databases were analyzed.  Personal contacts existed to renowned researchers having contributed to the medical use of paracetamol and its precursors as H.U.  Zollinger, S.  Moeschlin, U.  Dubach, J.  Axelrod and others.  Further information is found in earlier reviews by Eichengrun, Rodnan and Benedek, Sneader, Brune; comp. references.  The history of the discovery of paracetamol starts with an error (active against worms), continues with a false assumption (paracetamol is safer than phenacetin), describes the first side-effect 'epidemy' (phenacetin nephropathy, drug-induced interstitial nephritis) and ends with the discovery of second-generation problems due to the unavoidable production of a highly toxic metabolite of paracetamol N-acetyl-p-benzoquinone imine (NAPQI) that may cause not only ALF and kidney damage but also impaired development of the fetus and the newborn child.  It appears timely to reassess the risk/benefit ratio of this compound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLoBa7zpMO7fh3YQQtAhNufW6udTcc2eaUxQYa137J8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mzht1Wguw%253D%253D&md5=a7b6d396dcba593254c3325a52909412</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fejp.621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejp.621%26sid%3Dliteratum%253Aachs%26aulast%3DBrune%26aufirst%3DK.%26aulast%3DRenner%26aufirst%3DB.%26aulast%3DTiegs%26aufirst%3DG.%26atitle%3DAcetaminophen%252Fparacetamol%253A%2520a%2520history%2520of%2520errors%252C%2520failures%2520and%2520false%2520decisions%26jtitle%3DEur.%2520J.%2520Pain.%26date%3D2015%26volume%3D19%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fejp.621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grattan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beisel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, K.</span></span> <span> </span><span class="NLM_article-title">Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1177/0091270007299762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1177%2F0091270007299762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17442681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvF2jsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=715-726&author=B.+Rennerauthor=G.+Clarkeauthor=T.+Grattanauthor=A.+Beiselauthor=C.+Muellerauthor=U.+Wernerauthor=G.+Kobalauthor=K.+Brune&title=Caffeine+accelerates+absorption+and+enhances+the+analgesic+effect+of+acetaminophen&doi=10.1177%2F0091270007299762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen</span></div><div class="casAuthors">Renner, Bertold; Clarke, Geoff; Grattan, Tim; Beisel, Angelika; Mueller, Christian; Werner, Ulrike; Kobal, Gerd; Brune, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">715-726</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aim of this study was to det. the analgesic effect of acetaminophen compared to a combination of both caffeine and acetaminophen or caffeine alone using tonic and phasic pain stimulation.  Twenty-four subjects were treated orally with 1000 mg acetaminophen, 130 mg caffeine, and a combination of both in a 4-way crossover, double-blind, placebo-controlled study.  Pharmacokinetics and analgesic effects were assessed by means of an exptl. pain model based on pain-related cortical potentials after phasic stimulation of the nasal mucosa with CO2 and based on pain ratings after tonic stimulation with dry air.  Analgesic effects of acetaminophen and acetaminophen plus caffeine but not caffeine alone caused a significant redn. of pain-related cortical potentials beginning 30 min after medication.  The combination demonstrated an enhanced effect throughout the observation time up to 3 h.  Caffeine accelerated acetaminophen absorption, indicated by enhanced early AUCs.  Significant analgesic effects of the combination on tonic pain ratings were found throughout the observation time as compared to acetaminophen and placebo.  In this study, caffeine enhanced and prolonged the analgesic activity of acetaminophen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNq22p5Br5urVg90H21EOLACvtfcHk0lg808ysLN7gRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvF2jsbY%253D&md5=11c70aa73ece72c30d3fe765adae3b13</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F0091270007299762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007299762%26sid%3Dliteratum%253Aachs%26aulast%3DRenner%26aufirst%3DB.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DGrattan%26aufirst%3DT.%26aulast%3DBeisel%26aufirst%3DA.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DWerner%26aufirst%3DU.%26aulast%3DKobal%26aufirst%3DG.%26aulast%3DBrune%26aufirst%3DK.%26atitle%3DCaffeine%2520accelerates%2520absorption%2520and%2520enhances%2520the%2520analgesic%2520effect%2520of%2520acetaminophen%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D47%26spage%3D715%26epage%3D726%26doi%3D10.1177%2F0091270007299762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberstein, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study</span>. <i>Headache</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1111/j.1526-4610.2006.00376.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1526-4610.2006.00376.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=16618262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD283ht1ynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=444-453&author=J.+Goldsteinauthor=S.+D.+Silbersteinauthor=J.+R.+Saperauthor=R.+E.+Ryanauthor=R.+B.+Lipton&title=Acetaminophen%2C+aspirin%2C+and+caffeine+in+combination+versus+ibuprofen+for+acute+migraine%3A+results+from+a+multicenter%2C+double-blind%2C+randomized%2C+parallel-group%2C+single-dose%2C+placebo-controlled+study&doi=10.1111%2Fj.1526-4610.2006.00376.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study</span></div><div class="casAuthors">Goldstein Jerome; Silberstein Stephen D; Saper Joel R; Ryan Robert E Jr; Lipton Richard B</div><div class="citationInfo"><span class="NLM_cas:title">Headache</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-53</span>
        ISSN:<span class="NLM_cas:issn">0017-8748</span>.
    </div><div class="casAbstract">OBJECTIVE:  Compare the effectiveness of a combination analgesic containing acetaminophen, aspirin, and caffeine to that of ibuprofen in the treatment of migraine.  METHODS:  Multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study.  A total of 1555 migraineurs were included in the analysis.  No patients were excluded solely because of severity of symptoms or degree of disability.  A single 2-tablet dose for each of the 3 treatment groups: a combination product containing acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg per tablet (AAC); ibuprofen 200 mg per tablet (IB); or matching placebo.  The primary efficacy endpoint was the weighted sum of pain relief (PAR) scores at 2 hours postdose (TOTPAR2) and an important secondary endpoint was the time to onset of meaningful relief.  RESULTS:  There were 669 patients in the AAC group, 666 patients in the IB group, and 220 patients in the placebo group.  The 3 treatment groups had similar demographic profiles, migraine histories, and baseline symptom profiles.  While both active treatments were significantly better than placebo in relieving the pain and associated symptoms of migraine, AAC was superior to IB for TOTPAR2, as well as for PAR, time to onset of meaningful PAR, pain intensity reduction, headache response, and pain free.  The mean TOTPAR2 scores for AAC, IB, and placebo were 2.7, 2.4, and 2.0, respectively (AAC vs.  IB, P < .03).  The median time to meaningful PAR for AAC was 20 minutes earlier than that of IB (P < .036).  CONCLUSION:  AAC and IB are safe, cost-effective treatments for migraine; AAC provides significantly superior efficacy and speed of onset compared with IB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93b6Dffuitxgd2Wuil24tfW6udTcc2ea4XqgHTU2A6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283ht1ynsw%253D%253D&md5=160b808d879dd573b7914ff497bcafbf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1526-4610.2006.00376.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1526-4610.2006.00376.x%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DJ.%26aulast%3DSilberstein%26aufirst%3DS.%2BD.%26aulast%3DSaper%26aufirst%3DJ.%2BR.%26aulast%3DRyan%26aufirst%3DR.%2BE.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26atitle%3DAcetaminophen%252C%2520aspirin%252C%2520and%2520caffeine%2520in%2520combination%2520versus%2520ibuprofen%2520for%2520acute%2520migraine%253A%2520results%2520from%2520a%2520multicenter%252C%2520double-blind%252C%2520randomized%252C%2520parallel-group%252C%2520single-dose%252C%2520placebo-controlled%2520study%26jtitle%3DHeadache%26date%3D2006%26volume%3D46%26spage%3D444%26epage%3D453%26doi%3D10.1111%2Fj.1526-4610.2006.00376.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawaddiruk, P.</span></span> <span> </span><span class="NLM_article-title">Tramadol hydrochloride/acetaminophen combination for the relief of acute pain</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1358/dot.2011.47.10.1608924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1358%2Fdot.2011.47.10.1608924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFClt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=763-772&author=P.+Sawaddiruk&title=Tramadol+hydrochloride%2Facetaminophen+combination+for+the+relief+of+acute+pain&doi=10.1358%2Fdot.2011.47.10.1608924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tramadol hydrochloride/acetaminophen combination for the relief of acute pain</span></div><div class="casAuthors">Sawaddiruk, P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">763-772</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Tramadol hydrochloride/acetaminophen is a combination drug contg. tramadol hydrochloride 37.5 mg and acetaminophen 325 mg.  The use of 25% less tramadol in the combination product reduces the incidence of tramadol-related adverse events, while the addn. of acetaminophen reduces the onset time of analgesia and improves the degree of analgesia.  However, there was no clin. significant difference in the pharmacokinetic parameters of tramadol or acetaminophen when the fixed-dose combination was compared with the individual agents after multiple-dose administration.  The onset time of tramadol hydrochloride/acetaminophen was the fastest at only 17 min compared 51 min for tramadol and 18 min for acetaminophen.  This combination has been found to be effective in the management of postoperative pain.  It improves pain relief and provides a faster onset and longer duration of action with fewer adverse events than either component sep.  It also reduces the severity of pain, photophobia and phonophobia assocd. with migraine headache.  Tramadol hydrochloride/acetaminophen has been shown to be most effective in patients with mild to moderate pain and has a lower risk of serious adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq08NoI_du2ubVg90H21EOLACvtfcHk0lh5pWj_V6fo6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFClt70%253D&md5=83d5168a577aafd68556cce5bc2a26d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1358%2Fdot.2011.47.10.1608924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2011.47.10.1608924%26sid%3Dliteratum%253Aachs%26aulast%3DSawaddiruk%26aufirst%3DP.%26atitle%3DTramadol%2520hydrochloride%252Facetaminophen%2520combination%2520for%2520the%2520relief%2520of%2520acute%2520pain%26jtitle%3DDrugs%2520Today%26date%3D2011%26volume%3D47%26spage%3D763%26epage%3D772%26doi%3D10.1358%2Fdot.2011.47.10.1608924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rundgren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvison, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldeus, P.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1985&pages=306-311&author=E.+Albanoauthor=M.+Rundgrenauthor=P.+J.+Harvisonauthor=S.+D.+Nelsonauthor=P.+Moldeus&title=Mechanisms+of+N-acetyl-p-benzoquinone+imine+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlbano%26aufirst%3DE.%26aulast%3DRundgren%26aufirst%3DM.%26aulast%3DHarvison%26aufirst%3DP.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26aulast%3DMoldeus%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520N-acetyl-p-benzoquinone%2520imine%2520cytotoxicity%26jtitle%3DMol.%2520Pharmacol.%26date%3D1985%26volume%3D28%26spage%3D306%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rapoport, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutterman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cady, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, A. W.</span></span> <span> </span><span class="NLM_article-title">Analgesic rebound headache in clinical practice: data from a physician survey</span>. <i>Headache</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1046/j.1526-4610.1996.3601014.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1046%2Fj.1526-4610.1996.3601014.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=8666530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaK283nsVajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=14-19&author=A.+Rapoportauthor=P.+Stangauthor=D.+L.+Guttermanauthor=R.+Cadyauthor=H.+Markleyauthor=R.+Weeksauthor=J.+Saiersauthor=A.+W.+Fox&title=Analgesic+rebound+headache+in+clinical+practice%3A+data+from+a+physician+survey&doi=10.1046%2Fj.1526-4610.1996.3601014.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic rebound headache in clinical practice: data from a physician survey</span></div><div class="casAuthors">Rapoport A; Stang P; Gutterman D L; Cady R; Markley H; Weeks R; Saiers J; Fox A W</div><div class="citationInfo"><span class="NLM_cas:title">Headache</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-9</span>
        ISSN:<span class="NLM_cas:issn">0017-8748</span>.
    </div><div class="casAbstract">BACKGROUND:  Frequent, excessive use of over-the-counter or prescription analgesics may lead to analgesic rebound headache.  Little is known about the magnitude of the health problem posed by analgesic rebound headache, its epidemiology, the characteristics of analgesic rebound headache sufferers, or about physicians' approaches to treatment.  METHODS:  Four hundred seventy-three practitioners, who had previously expressed an interest in the treatment of headache, were mailed a questionnaire designed to capture information about the frequency and management of analgesic rebound headache and about the characteristics of analgesic rebound headache sufferers.  RESULTS:  Completed questionnaires were returned by 174 practitioners (37%) from 40 states, the District of Columbia, and Puerto Rico.  More than 40% of respondents indicated that analgesic rebound headache was present in at least 20% of their patients.  On average, the physicians reported that 73% of patients with analgesic rebound headache were women.  Analgesic rebound headache was most likely to occur in patients aged 31 to 40 years.  No one analgesic was consistently identified as causative, although acetaminophen, butalbital + aspirin + caffeine, and aspirin were commonly used by patients.  Eighty percent of respondents indicated that depression was commonly observed in analgesic rebound headache sufferers; 77% indicated that physical conditions (especially gastrointestinal symptoms) were commonly observed.  A variety of therapeutic strategies, including pharmacotherapy, were used in the management of analgesic rebound headache.  CONCLUSION:  Analgesic rebound headache was recognized as a distinct entity and a substantive component in more than 40% of the practices of 174 surveyed practitioners.  General practitioners, who see a wide variety of patient types with a spectrum of complaints, need to be able to diagnose analgesic rebound headache by taking a good history.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSHTXR87YQV1vAgqb2vdc5fW6udTcc2eZaKCj1BuvOrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283nsVajtA%253D%253D&md5=719f41189a2bea678de465508eea0d2d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.1526-4610.1996.3601014.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1526-4610.1996.3601014.x%26sid%3Dliteratum%253Aachs%26aulast%3DRapoport%26aufirst%3DA.%26aulast%3DStang%26aufirst%3DP.%26aulast%3DGutterman%26aufirst%3DD.%2BL.%26aulast%3DCady%26aufirst%3DR.%26aulast%3DMarkley%26aufirst%3DH.%26aulast%3DWeeks%26aufirst%3DR.%26aulast%3DSaiers%26aufirst%3DJ.%26aulast%3DFox%26aufirst%3DA.%2BW.%26atitle%3DAnalgesic%2520rebound%2520headache%2520in%2520clinical%2520practice%253A%2520data%2520from%2520a%2520physician%2520survey%26jtitle%3DHeadache%26date%3D1996%26volume%3D36%26spage%3D14%26epage%3D19%26doi%3D10.1046%2Fj.1526-4610.1996.3601014.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meek, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Laar, M. A. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonkeman, H. E.</span></span> <span> </span><span class="NLM_article-title">Non-steroidal anti-Inflammatory drugs: an overview of cardiovascular risks</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2162</span>, <span class="refDoi"> DOI: 10.3390/ph3072146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3390%2Fph3072146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=27713346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=2146-2162&author=I.+L.+Meekauthor=M.+A.+F.+J.+van+de+Laarauthor=H.+E.+Vonkeman&title=Non-steroidal+anti-Inflammatory+drugs%3A+an+overview+of+cardiovascular+risks&doi=10.3390%2Fph3072146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risks</span></div><div class="casAuthors">Meek, Inger L.; van de Laar, Mart A. F. J.; Vonkeman, Harald E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2146-2162</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  While aspirin may offer protection, other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious cardiovascular side effects and complications.  This has led to a general "black box" warning for cardiovascular adverse events for NSAIDs.  This review explores the different mechanisms underlying the protective effects of aspirin, the NSAID assocd. renovascular effects causing hypertension, edema and heart failure, the cardiovascular effects causing myocardial infarction and stroke, and the possible deleterious interaction between NSAIDs and aspirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4J7x1BpQS3LVg90H21EOLACvtfcHk0lhG0E6pNn2f0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFGlsro%253D&md5=edaefcbbb265662a468f56825d89abe1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fph3072146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph3072146%26sid%3Dliteratum%253Aachs%26aulast%3DMeek%26aufirst%3DI.%2BL.%26aulast%3Dvan%2Bde%2BLaar%26aufirst%3DM.%2BA.%2BF.%2BJ.%26aulast%3DVonkeman%26aufirst%3DH.%2BE.%26atitle%3DNon-steroidal%2520anti-Inflammatory%2520drugs%253A%2520an%2520overview%2520of%2520cardiovascular%2520risks%26jtitle%3DPharmaceuticals%26date%3D2010%26volume%3D3%26spage%3D2146%26epage%3D2162%26doi%3D10.3390%2Fph3072146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sneader, W.</span></span> <span> </span><span class="NLM_article-title">The discovery of aspirin: a reappraisal</span>. <i>BMJ. Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.1136/bmj.321.7276.1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1136%2Fbmj.321.7276.1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3M7jtFChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2000&pages=1591-1594&author=W.+Sneader&title=The+discovery+of+aspirin%3A+a+reappraisal&doi=10.1136%2Fbmj.321.7276.1591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of aspirin: a reappraisal</span></div><div class="casAuthors">Sneader W</div><div class="citationInfo"><span class="NLM_cas:title">BMJ (Clinical research ed.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1591-4</span>
        ISSN:<span class="NLM_cas:issn">0959-8138</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxJvJnuqC-nqj_yg7twvpfW6udTcc2eZaKCj1BuvOrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7jtFChtA%253D%253D&md5=a150887be4eb42e2bfce310e57360782</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1136%2Fbmj.321.7276.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.321.7276.1591%26sid%3Dliteratum%253Aachs%26aulast%3DSneader%26aufirst%3DW.%26atitle%3DThe%2520discovery%2520of%2520aspirin%253A%2520a%2520reappraisal%26jtitle%3DBMJ.%2520Br.%2520Med.%2520J.%26date%3D2000%26volume%3D321%26spage%3D1591%26epage%3D1594%26doi%3D10.1136%2Fbmj.321.7276.1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Undas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel-Ziedins, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, K. G.</span></span> <span> </span><span class="NLM_article-title">Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2285</span>– <span class="NLM_lpage">2292</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-01-010645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1182%2Fblood-2006-01-010645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17148593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslyhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=2285-2292&author=A.+Undasauthor=K.+E.+Brummel-Ziedinsauthor=K.+G.+Mann&title=Antithrombotic+properties+of+aspirin+and+resistance+to+aspirin%3A+beyond+strictly+antiplatelet+actions&doi=10.1182%2Fblood-2006-01-010645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions</span></div><div class="casAuthors">Undas, Anetta; Brummel-Ziedins, Kathleen E.; Mann, Kenneth G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2285-2292</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Aspirin is effective in the prevention of cardiovascular events in high-risk patients.  The primary established effect of aspirin on hemostasis is to impair platelet aggregation via inhibition of platelet thromboxane A2 synthesis, thus reducing thrombus formation on the surface of the damaged arterial wall.  Growing evidence also indicates that aspirin exerts addnl. antithrombotic effects, which appear to some extent unrelated to platelet thromboxane A2 prodn.  Aspirin can reduce thrombin generation with the subsequent attenuation of thrombin-mediated coagulant reactions such as factor XIII activation.  Aspirin also acetylates lysine residues in fibrinogen resulting in increased fibrin clot permeability and enhanced clot lysis as well as directly promoting fibrinolysis with high-dose aspirin.  The variable effectiveness of aspirin in terms of clin. outcomes and lab. findings, which was termed aspirin resistance, may be related to these addnl. antithrombotic effects that are altered when assocd. with common genetic polymorphisms such as the Leu33Pro β3-integrin or VaI34Leu factor XIII mutations.  However, the clin. relevance of these observations is still unclear.  Elucidation of the actual impacts of aspirin other than antiaggregation effects could be important in view of the wide-spread use of this drug in the prevention of thrombotic manifestations of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9C5QN2LA027Vg90H21EOLACvtfcHk0lhG0E6pNn2f0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslyhu7c%253D&md5=e8baa9dde57ea3925d5bc3860894703f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-01-010645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-01-010645%26sid%3Dliteratum%253Aachs%26aulast%3DUndas%26aufirst%3DA.%26aulast%3DBrummel-Ziedins%26aufirst%3DK.%2BE.%26aulast%3DMann%26aufirst%3DK.%2BG.%26atitle%3DAntithrombotic%2520properties%2520of%2520aspirin%2520and%2520resistance%2520to%2520aspirin%253A%2520beyond%2520strictly%2520antiplatelet%2520actions%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D2285%26epage%3D2292%26doi%3D10.1182%2Fblood-2006-01-010645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veltri, K. T.</span></span> <span> </span><span class="NLM_article-title">Yosprala: a fixed dose combination of aspirin and omeprazole</span>. <i>Cardiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1097/CRD.0000000000000174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2FCRD.0000000000000174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29045287" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=50-53&author=K.+T.+Veltri&title=Yosprala%3A+a+fixed+dose+combination+of+aspirin+and+omeprazole&doi=10.1097%2FCRD.0000000000000174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FCRD.0000000000000174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCRD.0000000000000174%26sid%3Dliteratum%253Aachs%26aulast%3DVeltri%26aufirst%3DK.%2BT.%26atitle%3DYosprala%253A%2520a%2520fixed%2520dose%2520combination%2520of%2520aspirin%2520and%2520omeprazole%26jtitle%3DCardiol.%2520Rev.%26date%3D2018%26volume%3D26%26spage%3D50%26epage%3D53%26doi%3D10.1097%2FCRD.0000000000000174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strack, T.</span></span> <span> </span><span class="NLM_article-title">Metformin: a review</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1358/dot.2008.44.4.1138124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1358%2Fdot.2008.44.4.1138124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotV2gsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=303-314&author=T.+Strack&title=Metformin%3A+a+review&doi=10.1358%2Fdot.2008.44.4.1138124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin: a review</span></div><div class="casAuthors">Strack, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-314</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today.  Despite low potency and a long list of contraindications, metformin has remained successful and even expanded exptl. use due to its well-established effects on glucose metab. and, as more recently demonstrated, its benefits on other cardiovascular risk factors.  Unlike insulin and secretagogues, metformin does not increase body wt. and when used as monotherapy does not likely cause hypoglycemia.  The most common adverse effects assocd. with metformin are mild, transient gastrointestinal symptoms, which are usually self-limiting.  These side effects can be minimized by initiating metformin therapy at a low dose and gradually titrating upward, and by taking metformin with meals.  Lactic acidosis caused by metformin is rare, and the risk of this complication may be diminished by the observance of prescribing precautions and contraindications that avoid accumulation of metformin or lactate in the body.  The many clin. benefits and the lack of safety risks when used with other antihyperglycemic agents have made metformin a preferred combination drug with other oral agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu4ddrOJ26k7Vg90H21EOLACvtfcHk0ljuD6aZSOOnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotV2gsbo%253D&md5=008e82b672eb68a6f0e051a0f9b547de</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1358%2Fdot.2008.44.4.1138124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2008.44.4.1138124%26sid%3Dliteratum%253Aachs%26aulast%3DStrack%26aufirst%3DT.%26atitle%3DMetformin%253A%2520a%2520review%26jtitle%3DDrugs%2520Today%26date%3D2008%26volume%3D44%26spage%3D303%26epage%3D314%26doi%3D10.1358%2Fdot.2008.44.4.1138124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. J.</span></span> <span> </span><span class="NLM_article-title">Metformin: historical overview</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1576</span>, <span class="refDoi"> DOI: 10.1007/s00125-017-4318-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs00125-017-4318-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28776081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1566-1576&author=C.+J.+Bailey&title=Metformin%3A+historical+overview&doi=10.1007%2Fs00125-017-4318-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin: historical overview</span></div><div class="casAuthors">Bailey, Clifford J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1566-1576</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes.  Its history is linked to Galega officinalis (also known as goat's rue), a traditional herbal medicine in Europe, found to be rich in guanidine, which, in 1918, was shown to lower blood glucose.  Guanidine derivs., including metformin, were synthesized and some (not metformin) were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the increased availability of insulin.  Metformin was rediscovered in the search for antimalarial agents in the 1940s and, during clin. tests, proved useful to treat influenza when it sometimes lowered blood glucose.  This property was pursued by the French physician Jean Sterne, who first reported the use of metformin to treat diabetes in 1957.  However, metformin received limited attention as it was less potent than other glucose-lowering biguanides (phenformin and buformin), which were generally discontinued in the late 1970s due to high risk of lactic acidosis.  Metformin's future was precarious, its reputation tarnished by assocn. with other biguanides despite evident differences.  The ability of metformin to counter insulin resistance and address adult-onset hyperglycemia without wt. gain or increased risk of hypoglycemia gradually gathered credence in Europe, and after intensive scrutiny metformin was introduced into the USA in 1995.  Long-term cardiovascular benefits of metformin were identified by the UK Prospective Diabetes Study (UKPDS) in 1998, providing a new rationale to adopt metformin as initial therapy to manage hyperglycemia in type 2 diabetes.  Sixty years after its introduction in diabetes treatment, metformin has become the most prescribed glucose-lowering medicine worldwide with the potential for further therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMeoptV9GjCLVg90H21EOLACvtfcHk0ljuD6aZSOOnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvO&md5=dc84ba9bdc22e7d651cb383c9b24c6c5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4318-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4318-z%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DC.%2BJ.%26atitle%3DMetformin%253A%2520historical%2520overview%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26spage%3D1566%26epage%3D1576%26doi%3D10.1007%2Fs00125-017-4318-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Home, P. D.</span></span> <span> </span><span class="NLM_article-title">Impact of the UKPDS—an overview</span>. <i>Diabetic Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1111/j.1464-5491.2008.02501.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1464-5491.2008.02501.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18717971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1cros1ygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=2-8&author=P.+D.+Home&title=Impact+of+the+UKPDS%E2%80%94an+overview&doi=10.1111%2Fj.1464-5491.2008.02501.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of the UKPDS--an overview</span></div><div class="casAuthors">Home P D</div><div class="citationInfo"><span class="NLM_cas:title">Diabetic medicine : a journal of the British Diabetic Association</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">25 Suppl 2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The UK Prospective Diabetes Study (UKPDS) is a group of clinical trials, epidemiological analyses and health-modelling studies with an influence which can be assessed across a broad range of health domains.  Original publications (n = 85) are notable for being mainly published in the key weekly or diabetes journals (78%) and being mainly in the clinical arena (68%).  Notable reference to the publications can be found in UK National Institute for Clinical Excellence (NICE) guidelines, but also in evidence-based international guidelines, where UKPDS papers form a significant fraction of the citations.  In educational materials UKPDS-derived slides remain popular (10 and 30% of some international slide sets), again as much for the epidemiological findings as for the core trial results.  Slides of the deterioration in blood glucose control with time, and evidence that this is as a result of progressive decline of pancreatic islet B-cell function, are used particularly often.  The UKPDS enhanced the promotion of glycated haemoglobin to its core role in clinical monitoring, through understanding of the quantitative relationship of vascular complications to glucose control, and thus to target setting.  Notably, metformin therapy was promoted by the UKPDS findings on macrovascular disease in the overweight study, although controversy remains regarding the significance of the effect on macrovascular disease of the core glucose-lowering study, promoting the development of further studies reporting in 2008.  The effects of decreasing blood pressure on microvascular disease have had an important impact on guidelines and health economic analyses, together with other evidence on the value of rennin-angiotensin system blockers.  The UKPDS has evidently been unusually influential in the development of treatment guidelines, clinical education and the thinking of healthcare professionals.  By inference it must be responsible for a significant part of the improvement in health outcomes in people with Type 2 diabetes over the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSI61U0h7sOLq_dlEzl_fBafW6udTcc2eb6zhiemtOfT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cros1ygug%253D%253D&md5=66438ba066af9443b8b141c3aa24508f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-5491.2008.02501.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-5491.2008.02501.x%26sid%3Dliteratum%253Aachs%26aulast%3DHome%26aufirst%3DP.%2BD.%26atitle%3DImpact%2520of%2520the%2520UKPDS%25E2%2580%2594an%2520overview%26jtitle%3DDiabetic%2520Med.%26date%3D2008%26volume%3D25%26spage%3D2%26epage%3D8%26doi%3D10.1111%2Fj.1464-5491.2008.02501.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvoor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy Dendi, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraleti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhawat, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montales, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriakose, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasapu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musham, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohani, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, W.</span></span> <span> </span><span class="NLM_article-title">Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.3389/fendo.2017.00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3389%2Ffendo.2017.00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28167928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jslyitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=6&author=A.+Chaudhuryauthor=C.+Duvoorauthor=V.+S.+Reddy+Dendiauthor=S.+Kraletiauthor=A.+Chadaauthor=R.+Ravillaauthor=A.+Marcoauthor=N.+S.+Shekhawatauthor=M.+T.+Montalesauthor=K.+Kuriakoseauthor=A.+Sasapuauthor=A.+Beebeauthor=N.+Patilauthor=C.+K.+Mushamauthor=G.+P.+Lohaniauthor=W.+Mirza&title=Clinical+review+of+antidiabetic+drugs%3A+implications+for+type+2+diabetes+mellitus+management&doi=10.3389%2Ffendo.2017.00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management</span></div><div class="casAuthors">Chaudhury Arun; Duvoor Chitharanjan; Chada Aditya; Ravilla Rahul; Reddy Dendi Vijaya Sena; Kraleti Shashank; Montales Maria Theresa; Sasapu Appalanaidu; Marco Asween; Shekhawat Nawal Singh; Kuriakose Kevin; Beebe Alexandria; Patil Naveen; Musham Chaitanya K; Lohani Govinda Prasad; Mirza Wasique</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/).  Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia.  Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas.  T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations.  In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR79GlNDVo7nOR_TJajKxJDfW6udTcc2eYzV3oiYa0lZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jslyitg%253D%253D&md5=018c81e9a18e754d2646bdbc5cfb22a9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2017.00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2017.00006%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhury%26aufirst%3DA.%26aulast%3DDuvoor%26aufirst%3DC.%26aulast%3DReddy%2BDendi%26aufirst%3DV.%2BS.%26aulast%3DKraleti%26aufirst%3DS.%26aulast%3DChada%26aufirst%3DA.%26aulast%3DRavilla%26aufirst%3DR.%26aulast%3DMarco%26aufirst%3DA.%26aulast%3DShekhawat%26aufirst%3DN.%2BS.%26aulast%3DMontales%26aufirst%3DM.%2BT.%26aulast%3DKuriakose%26aufirst%3DK.%26aulast%3DSasapu%26aufirst%3DA.%26aulast%3DBeebe%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DN.%26aulast%3DMusham%26aufirst%3DC.%2BK.%26aulast%3DLohani%26aufirst%3DG.%2BP.%26aulast%3DMirza%26aufirst%3DW.%26atitle%3DClinical%2520review%2520of%2520antidiabetic%2520drugs%253A%2520implications%2520for%2520type%25202%2520diabetes%2520mellitus%2520management%26jtitle%3DFront.%2520Endocrinol.%26date%3D2017%26volume%3D8%26spage%3D6%26doi%3D10.3389%2Ffendo.2017.00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavernia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubrook, J. H.</span></span> <span> </span><span class="NLM_article-title">Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals</span>. <i>Postgrad. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">808</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1080/00325481.2015.1085293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1080%2F00325481.2015.1085293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26439384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC283ptVKrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=808-817&author=F.+Laverniaauthor=S.+E.+Adkinsauthor=J.+H.+Shubrook&title=Use+of+oral+combination+therapy+for+type+2+diabetes+in+primary+care%3A+Meeting+individualized+patient+goals&doi=10.1080%2F00325481.2015.1085293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals</span></div><div class="casAuthors">Lavernia Frank; Adkins Sarah E; Shubrook Jay H</div><div class="citationInfo"><span class="NLM_cas:title">Postgraduate medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">808-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The management of type 2 diabetes mellitus (T2DM) by primary care physicians (PCPs) has become increasingly complex due to limitations on consultation time, an increasing array of drug treatment options, and issues of comorbidities and polypharmacy.  Diabetes is a progressive condition and treatment with a single glucose-lowering agent can only address limited pathophysiologic targets and does not provide adequate glycemic control in many cases.  Consequently, most patients with T2DM will eventually require treatment with multiple glucose-lowering medications.  Oral combination therapy in T2DM may be given as multiple-pills, or as single-pill, fixed-dose combinations (FDCs), the latter of which offer convenience, ease of administration, and a reduction in the medication burden.  Therefore, FDCs can potentially improve patients' treatment adherence and optimize achievement and maintenance of glycemic targets.  However, cost factors also need to be considered.  An understanding of the issues associated with the use of combination therapy in T2DM will help PCPs to guide patient-centered decision making and promote the effective management of T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTg_TOBG-V72EcLvDNbOD4DfW6udTcc2eYzV3oiYa0lZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ptVKrsg%253D%253D&md5=d1a4a5a9787e66e7eacd47eef2dddc7a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F00325481.2015.1085293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00325481.2015.1085293%26sid%3Dliteratum%253Aachs%26aulast%3DLavernia%26aufirst%3DF.%26aulast%3DAdkins%26aufirst%3DS.%2BE.%26aulast%3DShubrook%26aufirst%3DJ.%2BH.%26atitle%3DUse%2520of%2520oral%2520combination%2520therapy%2520for%2520type%25202%2520diabetes%2520in%2520primary%2520care%253A%2520Meeting%2520individualized%2520patient%2520goals%26jtitle%3DPostgrad.%2520Med.%26date%3D2015%26volume%3D127%26spage%3D808%26epage%3D817%26doi%3D10.1080%2F00325481.2015.1085293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, V.</span></span> <span> </span><span class="NLM_article-title">Effect of thiazolidinediones on body weight in patients with diabetes mellitus</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2003.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.amjmed.2003.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=14678865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2003&pages=42-48&author=V.+Fonseca&title=Effect+of+thiazolidinediones+on+body+weight+in+patients+with+diabetes+mellitus&doi=10.1016%2Fj.amjmed.2003.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of thiazolidinediones on body weight in patients with diabetes mellitus</span></div><div class="casAuthors">Fonseca, Vivian</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8A</span>),
    <span class="NLM_cas:pages">42S-48S</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">Treatment of diabetes mellitus with medications, including insulin, sulfonylureas, and thiazolidinediones (TZDs), often leads to wt. gain through a variety of mechanisms.  Wt. gain can have adverse consequences for patients with type 2 diabetes, many of whom are overweight or obese, because obesity is linked to insulin resistance and other medical consequences such as cardiovascular disease.  TZDs improve glycemic control and insulin sensitivity in patients with type 2 diabetes, despite their potential to cause wt. gain.  Studies have attempted to elucidate the mechanisms behind the apparent paradox of TZDs improving insulin sensitivity while causing wt. gain.  Data indicate that with TZD treatment, there is a favorable shift in fat distribution from visceral to s.c. adipose depots that is assocd. with improvements in hepatic and peripheral tissue sensitivity to insulin.  Although wt. gain, may occur with TZD therapy, it is not inevitable.  A wt.-management program combining a low-calorie, low-sodium diet with education and behavior modification has been shown to be effective in, patients with type 2 diabetes being treated with TZDs.  Further research is needed to define the optimal dietary modifications that can be used universally in TZD-treated patients,to minimize wt. gain while effectively treating insulin resistance and hyperglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSccP971Zkz7Vg90H21EOLACvtfcHk0liaHlMeUQduXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlGkug%253D%253D&md5=66a58ac348b55121f2c29dbc516bc62a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2003.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2003.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DFonseca%26aufirst%3DV.%26atitle%3DEffect%2520of%2520thiazolidinediones%2520on%2520body%2520weight%2520in%2520patients%2520with%2520diabetes%2520mellitus%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2003%26volume%3D115%26spage%3D42%26epage%3D48%26doi%3D10.1016%2Fj.amjmed.2003.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ognibene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petracca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzatini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicembrini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messeri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotella, C. M.</span></span> <span> </span><span class="NLM_article-title">Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes</span>. <i>Diabetes Nutr. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15887627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlektL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=336-342&author=E.+Mannucciauthor=F.+Tesiauthor=G.+Bardiniauthor=A.+Ognibeneauthor=M.+G.+Petraccaauthor=S.+Cianiauthor=A.+Pezzatiniauthor=M.+Brogiauthor=I.+Dicembriniauthor=F.+Cremascoauthor=G.+Messeriauthor=C.+M.+Rotella&title=Effects+of+metformin+on+glucagon-like+peptide-1+levels+in+obese+patients+with+and+without+Type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes</span></div><div class="casAuthors">Mannucci, E.; Tesi, F.; Bardini, G.; Ognibene, A.; Petracca, M. G.; Ciani, S.; Pezzatini, A.; Brogi, M.; Dicembrini, I.; Cremasco, F.; Messeri, G.; Rotella, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Nutrition & Metabolism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">336-342</span>CODEN:
                <span class="NLM_cas:coden">DNMEEW</span>;
        ISSN:<span class="NLM_cas:issn">0394-3402</span>.
    
            (<span class="NLM_cas:orgname">Editrice Kurtis s.r.l.</span>)
        </div><div class="casAbstract">Metformin has been shown to increase glucagon-like peptide-1 (GLP-1) levels after an oral glucose load in obese non-diabetic subjects.  In order to verify if this effect of the drug was also present in obese Type 2 diabetic patients who have never been treated with hypoglycemic drugs, 22 Type 2 diabetic and 12 matched non-diabetic obese patients were studied.  GLP-1 was measured before and after a 100 g glucose load at baseline, after a single oral dose of 850 mg of metformin, and after 4 wk of treatment with metformin 850 mg three times daily.  Post-load GLP-1 levels were significantly lower in diabetic patients.  A single dose of metformin did not modify GLP-1 levels.  After 4 wk of treatment, fasting GLP-1 increased in diabetic patients (3.8 vs. 4.9 pmol/l; p<0.05), while the incremental area under the curve of GLP-1 significantly increased in both diabetic [93.6 (45.6-163.2) vs. 151.2 (36.0-300.5) pmol*min/l; p<0.05] and non-diabetic [187.2 (149.4-571.8) vs. 324.0 (238.2-744.0) pmol*min/l; p<0.05] subjects.  In conclusion, GLP-1 levels after an oral glucose load in obese type 2 diabetic patients were increased by 4 wk of metformin treatment in a similar fashion as in obese subjects with normal glucose tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotY7hCzQFL0bVg90H21EOLACvtfcHk0ljvs0W_MOXidw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlektL8%253D&md5=57602645304e4da0190e36ac2b1ea675</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMannucci%26aufirst%3DE.%26aulast%3DTesi%26aufirst%3DF.%26aulast%3DBardini%26aufirst%3DG.%26aulast%3DOgnibene%26aufirst%3DA.%26aulast%3DPetracca%26aufirst%3DM.%2BG.%26aulast%3DCiani%26aufirst%3DS.%26aulast%3DPezzatini%26aufirst%3DA.%26aulast%3DBrogi%26aufirst%3DM.%26aulast%3DDicembrini%26aufirst%3DI.%26aulast%3DCremasco%26aufirst%3DF.%26aulast%3DMesseri%26aufirst%3DG.%26aulast%3DRotella%26aufirst%3DC.%2BM.%26atitle%3DEffects%2520of%2520metformin%2520on%2520glucagon-like%2520peptide-1%2520levels%2520in%2520obese%2520patients%2520with%2520and%2520without%2520Type%25202%2520diabetes%26jtitle%3DDiabetes%2520Nutr.%2520Metab.%26date%3D2004%26volume%3D17%26spage%3D336%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. H.</span></span> <span> </span><span class="NLM_article-title">Committee of clinical practice guidelines of the korean diabetes, A., combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus</span>. <i>Diabetes Metab. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.4093/dmj.2017.41.5.357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4093%2Fdmj.2017.41.5.357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29086533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtFSlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2017&pages=357-366&author=M.+K.+Moonauthor=K.+Y.+Hurauthor=S.+H.+Koauthor=S.+O.+Parkauthor=B.+W.+Leeauthor=J.+H.+Kimauthor=S.+Y.+Rheeauthor=H.+J.+Kimauthor=K.+M.+Choiauthor=N.+H.+Kim&title=Committee+of+clinical+practice+guidelines+of+the+korean+diabetes%2C+A.%2C+combination+therapy+of+oral+hypoglycemic+agents+in+patients+with+type+2+diabetes+mellitus&doi=10.4093%2Fdmj.2017.41.5.357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus</span></div><div class="casAuthors">Moon Min Kyong; Hur Kyu Yeon; Ko Seung Hyun; Park Seok O; Lee Byung Wan; Kim Jin Hwa; Rhee Sang Youl; Kim Hyun Jin; Choi Kyung Mook; Kim Nan Hee</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & metabolism journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-366</span>
        ISSN:<span class="NLM_cas:issn">2233-6079</span>.
    </div><div class="casAbstract">The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM).  In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines.  The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines.  All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different.  Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity.  In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs.  It will help to choose the appropriate drug for an individual patient with T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6t9k_XFN6cLGbPKh4T9eAfW6udTcc2eZEhbsGMH2QQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtFSlsg%253D%253D&md5=1e61ce1c15edd2859f3e8d69447ce3dd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4093%2Fdmj.2017.41.5.357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4093%252Fdmj.2017.41.5.357%26sid%3Dliteratum%253Aachs%26aulast%3DMoon%26aufirst%3DM.%2BK.%26aulast%3DHur%26aufirst%3DK.%2BY.%26aulast%3DKo%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DS.%2BO.%26aulast%3DLee%26aufirst%3DB.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DN.%2BH.%26atitle%3DCommittee%2520of%2520clinical%2520practice%2520guidelines%2520of%2520the%2520korean%2520diabetes%252C%2520A.%252C%2520combination%2520therapy%2520of%2520oral%2520hypoglycemic%2520agents%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDiabetes%2520Metab.%2520J.%26date%3D2017%26volume%3D41%26spage%3D357%26epage%3D366%26doi%3D10.4093%2Fdmj.2017.41.5.357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pletzer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerschbaum, H. H.</span></span> <span> </span><span class="NLM_article-title">50 years of hormonal contraception—time to find out, what it does to our brain</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">256</span>, <span class="refDoi"> DOI: 10.3389/fnins.2014.00256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3389%2Ffnins.2014.00256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25191220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FosFWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=256&author=B.+A.+Pletzerauthor=H.+H.+Kerschbaum&title=50+years+of+hormonal+contraception%E2%80%94time+to+find+out%2C+what+it+does+to+our+brain&doi=10.3389%2Ffnins.2014.00256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">50 years of hormonal contraception-time to find out, what it does to our brain</span></div><div class="casAuthors">Pletzer Belinda A; Kerschbaum Hubert H</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Hormonal contraceptives are on the market for more than 50 years and used by 100 million women worldwide.  However, while endogenous steroids have been convincingly associated with change in brain structure, function and cognitive performance, the effects of synthetic steroids contained in hormonal contraceptives on brain and cognition have barely been investigated.  In this article we summarize the sparse findings, describing brain structural, functional and behavioral findings from the literature and suggest that synthetic steroids may contribute to masculinizing as well as feminizing effects on brain and behavior.  We try to identify methodological challenges, explain, how results on endogenous steroids may transfer into research on hormonal contraceptives and point out factors that need to be controlled in the study of hormonal contraceptive dependent effects.  We conclude that there is a strong need for more systematic studies, especially on brain structural, functional and cognitive changes due to hormonal contraceptive use.  The hormonal contraceptive pill is the major tool for population control.  Hence, such behavioral changes could cause a shift in society dynamics and should not stay unattended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQArY3Rx4ms8MSzjBFCN0BJfW6udTcc2eZEhbsGMH2QQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FosFWisw%253D%253D&md5=d06bb2a1a0373f13ba494e992b110e75</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2014.00256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2014.00256%26sid%3Dliteratum%253Aachs%26aulast%3DPletzer%26aufirst%3DB.%2BA.%26aulast%3DKerschbaum%26aufirst%3DH.%2BH.%26atitle%3D50%2520years%2520of%2520hormonal%2520contraception%25E2%2580%2594time%2520to%2520find%2520out%252C%2520what%2520it%2520does%2520to%2520our%2520brain%26jtitle%3DFront.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D256%26doi%3D10.3389%2Ffnins.2014.00256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, A. J.</span></span> <span> </span><span class="NLM_article-title">Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive</span>. <i>Treat. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.2165/00024677-200302010-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00024677-200302010-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15871554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1eqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=49-70&author=S.+J.+Keamauthor=A.+J.+Wagstaff&title=Ethinylestradiol%2Fdrospirenone%3A+a+review+of+its+use+as+an+oral+contraceptive&doi=10.2165%2F00024677-200302010-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive</span></div><div class="casAuthors">Keam, Susan J.; Wagstaff, Antona J.</div><div class="citationInfo"><span class="NLM_cas:title">Treatments in Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-70</span>CODEN:
                <span class="NLM_cas:coden">TERNAN</span>;
        ISSN:<span class="NLM_cas:issn">1175-6349</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review which discusses the effectiveness of ethinylestradiol 30 μg/drospirenone 3 mg, a combined contraceptive pill for the prevention of pregnancy in women of reproductive age, as an oral contraceptive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPnFhRQDP8l7Vg90H21EOLACvtfcHk0lhHL9FMgdMKxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1eqs78%253D&md5=d9d8741664a9bf68d762cacf3a17019f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2165%2F00024677-200302010-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00024677-200302010-00005%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26aulast%3DWagstaff%26aufirst%3DA.%2BJ.%26atitle%3DEthinylestradiol%252Fdrospirenone%253A%2520a%2520review%2520of%2520its%2520use%2520as%2520an%2520oral%2520contraceptive%26jtitle%3DTreat.%2520Endocrinol.%26date%3D2003%26volume%3D2%26spage%3D49%26epage%3D70%26doi%3D10.2165%2F00024677-200302010-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> In  <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7th</span> ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">1393</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1393&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D1393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulds, D.</span></span> <span> </span><span class="NLM_article-title">Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.2165/00003495-199753040-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00003495-199753040-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=9098665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK2sXisFGgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=657-680&author=C.+M.+Perryauthor=D.+Faulds&title=Lamivudine.+A+review+of+its+antiviral+activity%2C+pharmacokinetic+properties+and+therapeutic+efficacy+in+the+management+of+HIV+infection&doi=10.2165%2F00003495-199753040-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Lamivudine A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection</span></div><div class="casAuthors">Perry, Caroline M.; Faulds, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-680</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 114 refs.  Lamivudine is a dideoxynucleoside analog which undergoes intracellular phosphorylation to the putative active metabolite, lamivudine triphosphate.  Lamivudine triphosphate prevents HIV replication by competitively inhibiting viral reverse transcriptase.  Lamivudine has a unique resistance profile and has the ability to delay resistance to zidovudine and restore zidovudine sensitivity in zidovudine-experienced patients.  Combination antiretroviral drug therapy is now generally considered preferable to monotherapy as first-line treatment for patients with HIV infection.  In double-blind trials in antiretroviral drug-experienced or-naive adults, improvements in surrogate markers of disease progression were significantly greater in patients receiving lamivudine plus zidovudine combination therapy than in patients who received either drug as monotherapy.  Preliminary results of CAESAR, a large multicenter trial in patients with moderately advanced HIV infection receiving zidovudine-based treatment regimens, show a 54% redn. in the rate of disease progression or death with the addn. of lamivudine, compared with the addn. of placebo.  Initial virol. data from studies of combination regimens including lamivudine and protease inhibitors are also promising, although the longer term efficacy of these regimens remains to be established.  Improvements in surrogate disease markers were also seen in children and adolescents with symptomatic HIV infection who received lamivudine monotherapy.  Studies of lamivudine-contg. combination therapy in children and adolescents are in progress, but few data have yet been published.  Lamivudine is generally well tolerated as monotherapy or in combination with other antiretroviral agents in HIV-infected adults with CD4+ counts ≥100 cells/μl.  Gastrointestinal disturbances were reported as the most common adverse events during lamivudine monotherapy or combination therapy.  Lamivudine appears to be less well tolerated in patients with advanced disease (CD4+ cell counts <100 cells/μl), but more data are required to clarify its tolerability in such patients.  Pancreatitis has been reported in children with advanced disease during treatment with the drug, but was not directly attributable to lamivudine therapy.  Thus, lamivudine, administered in combination with zidovudine, is now established as an effective agent for the treatment of antiretroviral drug-experienced or -naive individuals with asymptomatic or symptomatic HIV disease.  Moreover, encouraging preliminary data suggest that lamivudine is poised to become and important component of other regimens, in combination with drugs such as the protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNVyw67EImbVg90H21EOLACvtfcHk0lhHL9FMgdMKxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisFGgurg%253D&md5=0ca5dc09c2eecf4ac548bd9a1c87e8c2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2165%2F00003495-199753040-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199753040-00008%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DC.%2BM.%26aulast%3DFaulds%26aufirst%3DD.%26atitle%3DLamivudine.%2520A%2520review%2520of%2520its%2520antiviral%2520activity%252C%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%2520in%2520the%2520management%2520of%2520HIV%2520infection%26jtitle%3DDrugs%26date%3D1997%26volume%3D53%26spage%3D657%26epage%3D680%26doi%3D10.2165%2F00003495-199753040-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larson, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otofokun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, E. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic enhancers in HIV therapeutics</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1007/s40262-014-0167-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40262-014-0167-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25164142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=865-872&author=K.+B.+Larsonauthor=K.+Wangauthor=C.+Delilleauthor=I.+Otofokunauthor=E.+P.+Acosta&title=Pharmacokinetic+enhancers+in+HIV+therapeutics&doi=10.1007%2Fs40262-014-0167-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Enhancers in HIV Therapeutics</span></div><div class="casAuthors">Larson, Kajal B.; Wang, Kun; Delille, Cecile; Otofokun, Igho; Acosta, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">865-872</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Maximal and durable viral load suppression is one of the most important goals of HIV therapy and is directly related to adequate drug exposure.  Protease inhibitors (PIs), an important component of the antiretroviral armada, were historically assocd. with poor oral bioavailability and high pill burden.  However, because the PIs are metabolized by cytochrome P 450 (CYP) 3A enzymes, intentional inhibition of these enzymes leads to higher drug exposure, lower pill burden, and therefore simplified dosing schedules with this class of drug.  This is the basis of pharmacokinetic enhancement.  In HIV therapy, two pharmacokinetic enhancers or boosting agents are used: ritonavir and cobicistat.  Both agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than ritonavir.  Unlike ritonavir, cobicistat does not have antiretroviral activity.  Cobicistat has been evaluated in clin. trials and was recently approved in the USA as a fixed-dose combination with the integrase inhibitor, elvitegravir and two nucleos(t)ide analogs.  Addnl. studies are examg. cobicistat in fixed-dose combinations with various PIs.  In this review, we summarize current knowledge of these agents and clin. relevant drug regimens and ongoing trials.  Studies with elvitegravir and the novel PI TMC319011 are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgjPsIIAS3K7Vg90H21EOLACvtfcHk0lhHL9FMgdMKxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK&md5=b4fe83cebea17842fa9cda633e76ff2e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs40262-014-0167-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-014-0167-9%26sid%3Dliteratum%253Aachs%26aulast%3DLarson%26aufirst%3DK.%2BB.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DDelille%26aufirst%3DC.%26aulast%3DOtofokun%26aufirst%3DI.%26aulast%3DAcosta%26aufirst%3DE.%2BP.%26atitle%3DPharmacokinetic%2520enhancers%2520in%2520HIV%2520therapeutics%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2014%26volume%3D53%26spage%3D865%26epage%3D872%26doi%3D10.1007%2Fs40262-014-0167-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemsek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacArthur, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuritzkes, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M.</span></span> <span> </span><span class="NLM_article-title">Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">1662</span>– <span class="NLM_lpage">1669</span>, <span class="refDoi"> DOI: 10.1056/NEJM199512213332502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJM199512213332502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=7477218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK28XkvFyqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1995&pages=1662-1669&author=J.+J.+Eronauthor=S.+L.+Benoitauthor=J.+Jemsekauthor=R.+D.+MacArthurauthor=J.+Santanaauthor=J.+B.+Quinnauthor=D.+R.+Kuritzkesauthor=M.+A.+Fallonauthor=M.+Rubin&title=Treatment+with+lamivudine%2C+zidovudine%2C+or+both+in+HIV-positive+patients+with+200+to+500+CD4%2B+cells+per+cubic+millimeter&doi=10.1056%2FNEJM199512213332502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter</span></div><div class="casAuthors">Eron, Joseph J.; Benoit, Sharon L.; Jemsek, Joseph; MacArthur, Rodger D.; Santana, Jorge; Quinn, Joseph B.; Kuritzkes, Daniel R.; Fallon, Mary Ann; Rubin, Marc</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1662-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The reverse-transcriptase inhibitor lamivudine has in vitro synergy with zidovudine against the human immunodeficiency virus (HIV).  We studied the activity and safety of lamivudine plus zidovudine as compared with either drug alone as treatment for patients with HIV infection, most of whom had not previously received zidovudine.  Three hundred sixty-six patients with 200 to 500 CD4+ cells per cubic millimeter who had received zidovudine for four wk or less were randomly assigned to treatment with one of four regimens: 300 mg of lamivudine every 12 h; 200 mg of zidovudine every 8 h; 150 mg of lamivudine every 12 h plus zidovudine; or 300 mg of lamivudine every 12 h plus zidovudine.  The study was double-blind and lasted 24 wk, with an extension phase for another 28 wk.  Over the 24-wk period, the low-dose and high-dose regimens combining lamivudine and zidovudine were assocd. with greater increases in the CD4+ cell count (P=0.002 and P=0.015, resp.) and the percentage of CD4+ cells (P<0.001 for both) and with greater decreases in plasma levels of HIV type 1 (HIV-1) RNA (P<0.001 for both) than was treatment with zidovudine alone.  Combination therapy was also more effective than lamivudine alone in lowering plasma HIV-1 RNA levels and increasing the percentage of CD4+ cells (P<0.001 for all comparisons), and these advantages persisted through 52 wk.  Adverse events were not more frequent with combination therapy than with zidovudine along.  In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-yr period and produces more improvement in immunol. and virol. measures than does treatment with either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh794526E5MrVg90H21EOLACvtfcHk0lhSnmsrUFGUeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvFyqtA%253D%253D&md5=726048170b5d8114da881ba69654cab7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1056%2FNEJM199512213332502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199512213332502%26sid%3Dliteratum%253Aachs%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DBenoit%26aufirst%3DS.%2BL.%26aulast%3DJemsek%26aufirst%3DJ.%26aulast%3DMacArthur%26aufirst%3DR.%2BD.%26aulast%3DSantana%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DJ.%2BB.%26aulast%3DKuritzkes%26aufirst%3DD.%2BR.%26aulast%3DFallon%26aufirst%3DM.%2BA.%26aulast%3DRubin%26aufirst%3DM.%26atitle%3DTreatment%2520with%2520lamivudine%252C%2520zidovudine%252C%2520or%2520both%2520in%2520HIV-positive%2520patients%2520with%2520200%2520to%2520500%2520CD4%252B%2520cells%2520per%2520cubic%2520millimeter%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D333%26spage%3D1662%26epage%3D1669%26doi%3D10.1056%2FNEJM199512213332502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccarelli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiros Roldan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Ettorre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antinori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orofino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeddu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Pin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Avino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focà, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colafigli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giambenedetto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group">ATLAS-M Study Group</span> <span> </span><span class="NLM_article-title">Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96-week outcomes of a randomized trial</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1955</span>– <span class="NLM_lpage">1964</span>, <span class="refDoi"> DOI: 10.1093/jac/dky123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1093%2Fjac%2Fdky123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29668978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVahtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1955-1964&author=M.+Fabbianiauthor=R.+Gagliardiniauthor=N.+Ciccarelliauthor=E.+Quiros+Roldanauthor=A.+Latiniauthor=G.+d%E2%80%99Ettorreauthor=A.+Antinoriauthor=A.+Castagnaauthor=G.+Orofinoauthor=D.+Francisciauthor=P.+Chinelloauthor=G.+Madedduauthor=P.+Grimaauthor=S.+Rusconiauthor=B.+Del+Pinauthor=F.+Lombardiauthor=A.+D%E2%80%99Avinoauthor=E.+Foc%C3%A0author=M.+Colafigliauthor=R.+Caudaauthor=S.+Di+Giambenedettoauthor=A.+De+Lucaauthor=ATLAS-M+Study+Group&title=Atazanavir%2Fritonavir+with+lamivudine+as+maintenance+therapy+in+virologically+suppressed+HIV-infected+patients%3A+96-week+outcomes+of+a+randomized+trial&doi=10.1093%2Fjac%2Fdky123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial</span></div><div class="casAuthors">Fabbiani, Massimiliano; Gagliardini, Roberta; Ciccarelli, Nicoletta; Roldan, Eugenia Quiros; Latini, Alessandra; D'ettorre, Gabriella; Antinori, Andrea; Castagna, Antonella; Orofino, Giancarlo; Francisci, Daniela; Chinello, Pierangelo; Madeddu, Giordano; Grima, Pierfrancesco; Rusconi, Stefano; Del Pin, Barbara; Lombardi, Francesca; D'avino, Alessandro; Foca, Emanuele; Colafigli, Manuela; Cauda, Roberto; Di Giambenedetto, Simona; De Luca, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1955-1964</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ ritonavir + lamivudine vs. continuing a std. regimen with atazanavir/ritonavir + 2NRTI in virol. suppressed patients.  Methods: ATLAS-M is a 96 wk open-label, randomized, non-inferiority (margin #12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA,50 copies/mL and CD4 counts.200 cells/mm3.  At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir + lamivudine or to continue the previous regimen.  Here, we report the 96 wk efficacy and safety data.  The study was registered with ClinicalTrials.gov, no. NCT01599364.  Results: Overall, 266 subjects were enrolled (133 in each arm).  At 96 wk, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir + lamivudine and 87 (65.4%) with triple therapy (difference +12.0%, 95% CI +1.2/+22.8, P"0.030), demonstrating the superiority of dual therapy.  Two (1.5%) and 9 (6.8%) virol. failures occurred in the dual-therapy arm and the triple-therapy arm, resp., without development of resistance to any study drug.  Clin. adverse events occurred at similar rates in both arms.  A higher frequency of grade 3-4 hyperbilirubinemia (66.9% vs. 50.4%, P"0.006) and hypertriglyceridemia (6.8% vs. 1.5%, P"0.031) occurred with dual therapy, although this never led to treatment discontinuation.  A significant improvement in renal function and lumbar spine bone mineral d. occurred in the dual-therapy arm.  The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms.  Conclusions: In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virol. suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoD8TUq-An7Vg90H21EOLACvtfcHk0lhSnmsrUFGUeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVahtr4%253D&md5=6e4badb6563dd8e54a6d6c398a42568c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky123%26sid%3Dliteratum%253Aachs%26aulast%3DFabbiani%26aufirst%3DM.%26aulast%3DGagliardini%26aufirst%3DR.%26aulast%3DCiccarelli%26aufirst%3DN.%26aulast%3DQuiros%2BRoldan%26aufirst%3DE.%26aulast%3DLatini%26aufirst%3DA.%26aulast%3Dd%25E2%2580%2599Ettorre%26aufirst%3DG.%26aulast%3DAntinori%26aufirst%3DA.%26aulast%3DCastagna%26aufirst%3DA.%26aulast%3DOrofino%26aufirst%3DG.%26aulast%3DFrancisci%26aufirst%3DD.%26aulast%3DChinello%26aufirst%3DP.%26aulast%3DMadeddu%26aufirst%3DG.%26aulast%3DGrima%26aufirst%3DP.%26aulast%3DRusconi%26aufirst%3DS.%26aulast%3DDel%2BPin%26aufirst%3DB.%26aulast%3DLombardi%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Avino%26aufirst%3DA.%26aulast%3DFoc%25C3%25A0%26aufirst%3DE.%26aulast%3DColafigli%26aufirst%3DM.%26aulast%3DCauda%26aufirst%3DR.%26aulast%3DDi%2BGiambenedetto%26aufirst%3DS.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3D%26atitle%3DAtazanavir%252Fritonavir%2520with%2520lamivudine%2520as%2520maintenance%2520therapy%2520in%2520virologically%2520suppressed%2520HIV-infected%2520patients%253A%252096-week%2520outcomes%2520of%2520a%2520randomized%2520trial%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1955%26epage%3D1964%26doi%3D10.1093%2Fjac%2Fdky123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Emtricitabine: a review of its use in the management of HIV infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1448</span>, <span class="refDoi"> DOI: 10.2165/00003495-200565100-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00003495-200565100-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15977972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFWks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1427-1448&author=J.+E.+Framptonauthor=C.+M.+Perry&title=Emtricitabine%3A+a+review+of+its+use+in+the+management+of+HIV+infection&doi=10.2165%2F00003495-200565100-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Emtricitabine: a review of its use in the management of HIV infection</span></div><div class="casAuthors">Frampton, James E.; Perry, Caroline M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1427-1448</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Emtricitabine (Emtriva) is an orally administered nucleoside reverse transcriptase inhibitor (NRTI) that is indicated in combination with other antiretroviral agents in the treatment of HIV infection in adults.  As a component of antiretroviral therapy (ART), emtricitabine effectively reduces and/or maintains suppression of viral load in ART-naive adults or ART-experienced adults switching from stable combination regimens, and is generally well tolerated.  Emtricitabine is a component of preferred initial HIV combination therapy regimens; it can be used in place of lamivudine as part of the dual NRTI backbone in non-nucleoside reverse transcriptase inhibitor (NNRTI)- and protease inhibitor (PI)-based regimens.  Moreover, preliminary data from a randomized, open-label study suggest that emtricitabine plus tenofovir DF, a preferred dual-NRTI combination, is better tolerated than co-formulated lamivudine/zidovudine, another preferred dual-NRTI combination, resulting in a higher persistent virol. response rate, as analyzed using the US FDA time to loss of virol. response (TLOVR) algorithm.  With the convenience of once-daily (single pill) administration, no dietary restrictions and a favorable drug interaction and tolerability profile, emtricitabine should facilitate patient adherence to treatment, which, in turn, is central to the success of antiretroviral therapy.  Similarly, emtricitabine is attractive as an option for ART-experienced stable adults requiring regimen simplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqixOB__jI7W7Vg90H21EOLACvtfcHk0lhc-ap49dn2dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFWks7k%253D&md5=b70f30dc8cc5fa7f9ce7a10a9db0252d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2165%2F00003495-200565100-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200565100-00008%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DEmtricitabine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520HIV%2520infection%26jtitle%3DDrugs%26date%3D2005%26volume%3D65%26spage%3D1427%26epage%3D1448%26doi%3D10.2165%2F00003495-200565100-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masho, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, D. E.</span></span> <span> </span><span class="NLM_article-title">Review of tenofovir-emtricitabine</span>. <i>Ther. Clin. Risk Manag.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18516268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=1097-1104&author=S.+W.+Mashoauthor=C.-L.+Wangauthor=D.+E.+Nixon&title=Review+of+tenofovir-emtricitabine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Review of tenofovir-emtricitabine</span></div><div class="casAuthors">Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1097-1104</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality.  Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized.  Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations.  In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clin. trials, one-pill-a-day dosing convenience, and relatively low toxicity.  In addn., the drug is active against hepatitis B virus.  Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs.  This manuscript reviews the use of TDF-FTC in the treatment of HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb-BC_sxiqxrVg90H21EOLACvtfcHk0lhc-ap49dn2dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOks74%253D&md5=bcfad153d98a241a89b9d643d3ddbf37</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasho%26aufirst%3DS.%2BW.%26aulast%3DWang%26aufirst%3DC.-L.%26aulast%3DNixon%26aufirst%3DD.%2BE.%26atitle%3DReview%2520of%2520tenofovir-emtricitabine%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manag.%26date%3D2007%26volume%3D3%26spage%3D1097%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trustman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalong, A.</span></span> <span> </span><span class="NLM_article-title">HIV pharmacotherapy: A review of integrase inhibitors</span>. <i>JAAPA</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1097/01.JAA.0000475465.07971.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2F01.JAA.0000475465.07971.19" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=36-40&author=E.+Wongauthor=N.+Trustmanauthor=A.+Yalong&title=HIV+pharmacotherapy%3A+A+review+of+integrase+inhibitors&doi=10.1097%2F01.JAA.0000475465.07971.19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1097%2F01.JAA.0000475465.07971.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.JAA.0000475465.07971.19%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DE.%26aulast%3DTrustman%26aufirst%3DN.%26aulast%3DYalong%26aufirst%3DA.%26atitle%3DHIV%2520pharmacotherapy%253A%2520A%2520review%2520of%2520integrase%2520inhibitors%26jtitle%3DJAAPA%26date%3D2016%26volume%3D29%26spage%3D36%26epage%3D40%26doi%3D10.1097%2F01.JAA.0000475465.07971.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedziela-Majka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukolj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7086</span>– <span class="NLM_lpage">7097</span>, <span class="refDoi"> DOI: 10.1128/AAC.01474-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1128%2FAAC.01474-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=27645238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=7086-7097&author=M.+Tsiangauthor=G.+S.+Jonesauthor=J.+Goldsmithauthor=A.+Mulatoauthor=D.+Hansenauthor=E.+Kanauthor=L.+Tsaiauthor=R.+A.+Bamauthor=G.+Stepanauthor=K.+M.+Strayauthor=A.+Niedziela-Majkaauthor=S.+R.+Yantauthor=H.+Yuauthor=G.+Kukoljauthor=T.+Cihlarauthor=S.+E.+Lazerwithauthor=K.+L.+Whiteauthor=H.+Jin&title=Antiviral+activity+of+bictegravir+%28GS-9883%29%2C+a+novel+potent+HIV-1+integrase+strand+transfer+inhibitor+with+an+improved+resistance+profile&doi=10.1128%2FAAC.01474-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile</span></div><div class="casAuthors">Tsiang, Manuel; Jones, Gregg S.; Goldsmith, Joshua; Mulato, Andrew; Hansen, Derek; Kan, Elaine; Tsai, Luong; Bam, Rujuta A.; Stepan, George; Stray, Kirsten M.; Niedziela-Majka, Anita; Yant, Stephen R.; Yu, Helen; Kukolj, George; Cihlar, Tomas; Lazerwith, Scott E.; White, Kirsten L.; Jin, Haolun</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7086-7097</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concn. [IC50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells.  BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concns. ranging from 1.5 to 2.4 nM and selectivity indexes up to 8,700 relative to cytotoxicity.  BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals.  BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants.  BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with highlevel INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG.  In dose-escalation expts. conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, resp.  A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus.  All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals.  A high barrier to in vitro resistance emergence for both BIC and DTG was also obsd. in viral breakthrough studies in the presence of const. clin. relevant drug concns.  The overall virol. profile of BIC supports its ongoing clin. investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC24EKhD8sNbVg90H21EOLACvtfcHk0lhc-ap49dn2dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D&md5=87a180a313ffaa8b03201b06a8c875ff</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FAAC.01474-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01474-16%26sid%3Dliteratum%253Aachs%26aulast%3DTsiang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DG.%2BS.%26aulast%3DGoldsmith%26aufirst%3DJ.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DHansen%26aufirst%3DD.%26aulast%3DKan%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DJin%26aufirst%3DH.%26atitle%3DAntiviral%2520activity%2520of%2520bictegravir%2520%2528GS-9883%2529%252C%2520a%2520novel%2520potent%2520HIV-1%2520integrase%2520strand%2520transfer%2520inhibitor%2520with%2520an%2520improved%2520resistance%2520profile%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D7086%26epage%3D7097%26doi%3D10.1128%2FAAC.01474-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0160-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40265-013-0160-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24343782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=195-206&author=E.+D.+Deeks&title=Cobicistat%3A+a+review+of+its+use+as+a+pharmacokinetic+enhancer+of+atazanavir+and+darunavir+in+patients+with+HIV-1+infection&doi=10.1007%2Fs40265-013-0160-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Cobicistat (Tybost®) is a mechanism-based inhibitor of cytochrome P 450 (CYP) 3A enzymes that is indicated in the EU as a pharmacokinetic enhancer (i.e. booster) of the HIV-1 protease inhibitors (PIs) atazanavir and darunavir in adults.  Cobicistat has a lower potential for off-target drug interactions than the std. boosting agent ritonavir, due to its more selective inhibition of CYP3A and lower likelihood for enzymic induction, and is devoid of anti-HIV activity.  When used to boost darunavir or atazanavir in healthy volunteers, oral cobicistat 150 mg once daily provided bioequivalent PI exposure to that seen with oral ritonavir 100 mg once daily (i.e. low-dose ritonavir).  Moreover, in treatment-naive adults infected with HIV-1 participating in a large, double-blind, phase III trial, an atazanavir-based antiretroviral regimen boosted with cobicistat 150 mg once daily provided a high rate of virol. suppression after 48 wk of therapy that was noninferior to that seen with low-dose ritonavir boosting.  Cobicistat was generally well tolerated in this study, with a tolerability profile similar to that of ritonavir.  Cobicistat may increase serum creatinine levels (possibly via inhibition of proximal renal tubular cell transporters) and thus reduce estd. glomerular filtration rate (GFR), although it does not appear to affect actual GFR.  The drug is more sol. than ritonavir, making coformulation easier, and fixed-dose formulations combining cobicistat with darunavir and atazanavir are in development.  Thus, cobicistat is an emerging alternative to ritonavir for the pharmacokinetic enhancement of PIs in adults with HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk_LsSZwyKR7Vg90H21EOLACvtfcHk0ljctsTRyF1B6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7k%253D&md5=f121c1314a97499f723b7bc22642854d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0160-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0160-x%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DCobicistat%253A%2520a%2520review%2520of%2520its%2520use%2520as%2520a%2520pharmacokinetic%2520enhancer%2520of%2520atazanavir%2520and%2520darunavir%2520in%2520patients%2520with%2520HIV-1%2520infection%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D195%26epage%3D206%26doi%3D10.1007%2Fs40265-013-0160-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fares, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNicolantonio, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Keefe, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavie, C. J.</span></span> <span> </span><span class="NLM_article-title">Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes</span>. <i>Open Heart.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e000473</span> 1–7. <span class="refDoi"> DOI: 10.1136/openhrt-2016-000473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1136%2Fopenhrt-2016-000473" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&author=H.+Faresauthor=J.+J.+DiNicolantonioauthor=J.+H.+O%E2%80%99Keefeauthor=C.+J.+Lavie&title=Amlodipine+in+hypertension%3A+a+first-line+agent+with+efficacy+for+improving+blood+pressure+and+patient+outcomes&doi=10.1136%2Fopenhrt-2016-000473"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fopenhrt-2016-000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fopenhrt-2016-000473%26sid%3Dliteratum%253Aachs%26aulast%3DFares%26aufirst%3DH.%26aulast%3DDiNicolantonio%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DJ.%2BH.%26aulast%3DLavie%26aufirst%3DC.%2BJ.%26atitle%3DAmlodipine%2520in%2520hypertension%253A%2520a%2520first-line%2520agent%2520with%2520efficacy%2520for%2520improving%2520blood%2520pressure%2520and%2520patient%2520outcomes%26jtitle%3DOpen%2520Heart.%26date%3D2016%26volume%3D3%26doi%3D10.1136%2Fopenhrt-2016-000473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noji-Sakikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshigae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">11892</span>– <span class="NLM_lpage">11902</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.072629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1074%2Fjbc.M109.072629" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=11892-11902&author=T.+Ishizukaauthor=I.+Fujimoriauthor=M.+Katoauthor=C.+Noji-Sakikawaauthor=M.+Saitoauthor=Y.+Yoshigaeauthor=K.+Kubotaauthor=A.+Kuriharaauthor=T.+Izumiauthor=T.+Ikedaauthor=O.+Okazaki&title=Human+carboxymethylenebutenolidase+as+a+bioactivating+hydrolase+of+olmesartan+medoxomil+in+liver+and+intestine&doi=10.1074%2Fjbc.M109.072629"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.072629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.072629%26sid%3Dliteratum%253Aachs%26aulast%3DIshizuka%26aufirst%3DT.%26aulast%3DFujimori%26aufirst%3DI.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DNoji-Sakikawa%26aufirst%3DC.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DYoshigae%26aufirst%3DY.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DIzumi%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DHuman%2520carboxymethylenebutenolidase%2520as%2520a%2520bioactivating%2520hydrolase%2520of%2520olmesartan%2520medoxomil%2520in%2520liver%2520and%2520intestine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D11892%26epage%3D11902%26doi%3D10.1074%2Fjbc.M109.072629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zisaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskovic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzimanikatis, V.</span></span> <span> </span><span class="NLM_article-title">Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.2174/1381612820666141024151119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2174%2F1381612820666141024151119" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=806-822&author=A.+Zisakiauthor=L.+Miskovicauthor=V.+Hatzimanikatis&title=Antihypertensive+drugs+metabolism%3A+an+update+to+pharmacokinetic+profiles+and+computational+approaches&doi=10.2174%2F1381612820666141024151119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F1381612820666141024151119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612820666141024151119%26sid%3Dliteratum%253Aachs%26aulast%3DZisaki%26aufirst%3DA.%26aulast%3DMiskovic%26aufirst%3DL.%26aulast%3DHatzimanikatis%26aufirst%3DV.%26atitle%3DAntihypertensive%2520drugs%2520metabolism%253A%2520an%2520update%2520to%2520pharmacokinetic%2520profiles%2520and%2520computational%2520approaches%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D806%26epage%3D822%26doi%3D10.2174%2F1381612820666141024151119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waksman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechevalier, H. A.</span></span> <span> </span><span class="NLM_article-title">Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1126/science.109.2830.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1126%2Fscience.109.2830.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17782716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3czot1Siuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1949&pages=305-307&author=S.+A.+Waksmanauthor=H.+A.+Lechevalier&title=Neomycin%2C+a+new+antibiotic+active+against+streptomycin-resistant+bacteria%2C+including+tuberculosis+organisms&doi=10.1126%2Fscience.109.2830.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis Organisms</span></div><div class="casAuthors">Waksman S A; Lechevalier H A</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2830</span>),
    <span class="NLM_cas:pages">305-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyhgjk39aGkz69zv1FsJFMfW6udTcc2ebO6o9CQRyZa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czot1Siuw%253D%253D&md5=79ba78fd176e4ff2ce148b9198b2070d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1126%2Fscience.109.2830.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.109.2830.305%26sid%3Dliteratum%253Aachs%26aulast%3DWaksman%26aufirst%3DS.%2BA.%26aulast%3DLechevalier%26aufirst%3DH.%2BA.%26atitle%3DNeomycin%252C%2520a%2520new%2520antibiotic%2520active%2520against%2520streptomycin-resistant%2520bacteria%252C%2520including%2520tuberculosis%2520organisms%26jtitle%3DScience%26date%3D1949%26volume%3D109%26spage%3D305%26epage%3D307%26doi%3D10.1126%2Fscience.109.2830.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M.</span></span> <span> </span><span class="NLM_article-title">Neomycin: a review with particular reference to dermatological usage</span>. <i>Clin. Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2230.1983.tb01777.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1365-2230.1983.tb01777.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=6224608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaL3s3os1Siug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1983&pages=249-258&author=R.+H.+Macdonaldauthor=M.+Beck&title=Neomycin%3A+a+review+with+particular+reference+to+dermatological+usage&doi=10.1111%2Fj.1365-2230.1983.tb01777.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Neomycin: a review with particular reference to dermatological usage</span></div><div class="casAuthors">Macdonald R H; Beck M</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental dermatology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-58</span>
        ISSN:<span class="NLM_cas:issn">0307-6938</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFYJm8BeTjdXl8icjszYl0fW6udTcc2eZKCmTRQxAz0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s3os1Siug%253D%253D&md5=4f622e254683ed8dddc97352092f1b88</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2230.1983.tb01777.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2230.1983.tb01777.x%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DR.%2BH.%26aulast%3DBeck%26aufirst%3DM.%26atitle%3DNeomycin%253A%2520a%2520review%2520with%2520particular%2520reference%2520to%2520dermatological%2520usage%26jtitle%3DClin.%2520Exp.%2520Dermatol.%26date%3D1983%26volume%3D8%26spage%3D249%26epage%3D258%26doi%3D10.1111%2Fj.1365-2230.1983.tb01777.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, A.</span></span> <span> </span><span class="NLM_article-title">Colistin and polymyxin B: a re-emergence</span>. <i>Indian J. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.4103/0972-5229.56048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4103%2F0972-5229.56048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19881183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjtFCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=49-53&author=S.+Guptaauthor=D.+Govilauthor=P.+N.+Kakarauthor=O.+Prakashauthor=D.+Aroraauthor=S.+Dasauthor=P.+Govilauthor=A.+Malhotra&title=Colistin+and+polymyxin+B%3A+a+re-emergence&doi=10.4103%2F0972-5229.56048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Colistin and polymyxin B: a re-emergence</span></div><div class="casAuthors">Gupta Sachin; Govil Deepak; Kakar Prem N; Prakash Om; Arora Deep; Das Shibani; Govil Pradeep; Malhotra Ashima</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">49-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the greatest achievements of modern medicine is the development of antibiotics against life-threatening infections, but the emergence of multidrug-resistant (MDR) gram negative bacteria has drastically narrowed down the therapeutic options against them.  This limitation has led clinicians to reappraise the clinical application of polymyxins, an old class of cationic, cyclic polypeptide antibiotics.  Polymyxins are active against selected gram-negative bacteria, including the Acinetobacter species, Pseudomonas aeruginosa, Klebsiella species, and Enterobacter species.  In this article, we summarise the chemistry, pharmacokinetics, and pharmacodynamics of polymyxins and the latest understanding of their action against MDR pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfDfCQOJlejQaK-_ZudimnfW6udTcc2eZKCmTRQxAz0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjtFCmtQ%253D%253D&md5=0ba8fd42636548f144f967d13b6f1c66</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4103%2F0972-5229.56048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0972-5229.56048%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGovil%26aufirst%3DD.%26aulast%3DKakar%26aufirst%3DP.%2BN.%26aulast%3DPrakash%26aufirst%3DO.%26aulast%3DArora%26aufirst%3DD.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DGovil%26aufirst%3DP.%26aulast%3DMalhotra%26aufirst%3DA.%26atitle%3DColistin%2520and%2520polymyxin%2520B%253A%2520a%2520re-emergence%26jtitle%3DIndian%2520J.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D13%26spage%3D49%26epage%3D53%26doi%3D10.4103%2F0972-5229.56048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleney, F. L.</span></span> <span> </span><span class="NLM_article-title">Bacitracin: a new antibiotic produced by a member of the B. Subtilis group</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1945</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1126/science.102.2650.376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1126%2Fscience.102.2650.376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17770204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3czotFCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1945&pages=376-377&author=B.+A.+Johnsonauthor=H.+Ankerauthor=F.+L.+Meleney&title=Bacitracin%3A+a+new+antibiotic+produced+by+a+member+of+the+B.+Subtilis+group&doi=10.1126%2Fscience.102.2650.376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">BACITRACIN: A NEW ANTIBIOTIC PRODUCED BY A MEMBER OF THE B. SUBTILIS GROUP</span></div><div class="casAuthors">Johnson B A; Anker H; Meleney F L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1945</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2650</span>),
    <span class="NLM_cas:pages">376-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A new antibiotic "bacitracin" has been recovered from a strain of the B. subtilis group of organisms.  It is neutral, water-soluble, non-toxic and relatively heat stable.  In vitro it is active chiefly against Grampositive organisms, but the gonococcus and meningococcus are susceptible to its action.  It is also active in vivo against experimentally produced hemolytic streptococcal infections in mice and gas gangrene infections in guinea pigs.  Clinical use in hemolytic streptococcal and staphylococcal infections in man have given encouraging results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv92foddKM1uR_TJajKxJDfW6udTcc2eZKCmTRQxAz0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czotFCgsg%253D%253D&md5=eca1cdcf3accb83fc025be2cf446e3e0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.102.2650.376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.102.2650.376%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BA.%26aulast%3DAnker%26aufirst%3DH.%26aulast%3DMeleney%26aufirst%3DF.%2BL.%26atitle%3DBacitracin%253A%2520a%2520new%2520antibiotic%2520produced%2520by%2520a%2520member%2520of%2520the%2520B.%2520Subtilis%2520group%26jtitle%3DScience%26date%3D1945%26volume%3D102%26spage%3D376%26epage%3D377%26doi%3D10.1126%2Fscience.102.2650.376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenhouse, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryle, W. C.</span></span> <span> </span><span class="NLM_article-title">Combined bacitracin-neomycin ointment in treatment of pyogenic infections of the skin</span>. <i>Arch. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1954</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1001/archderm.1954.01540150112012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1001%2Farchderm.1954.01540150112012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaG2c%252FlslCqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1954&pages=366-367&author=J.+M.+Greenhouseauthor=W.+C.+Ryle&title=Combined+bacitracin-neomycin+ointment+in+treatment+of+pyogenic+infections+of+the+skin&doi=10.1001%2Farchderm.1954.01540150112012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Combined bacitracin-neomycin ointment in treatment of pyogenic infections of the skin</span></div><div class="casAuthors">GREENHOUSE J M; RYLE W C</div><div class="citationInfo"><span class="NLM_cas:title">A.M.A. archives of dermatology and syphilology</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-7</span>
        ISSN:<span class="NLM_cas:issn">0096-5979</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyVeE8YxaahVQKX3ooHxWjfW6udTcc2eZKCmTRQxAz0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG2c%252FlslCqtQ%253D%253D&md5=fc87c2b0bf724c481c16c398e7329baa</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1001%2Farchderm.1954.01540150112012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchderm.1954.01540150112012%26sid%3Dliteratum%253Aachs%26aulast%3DGreenhouse%26aufirst%3DJ.%2BM.%26aulast%3DRyle%26aufirst%3DW.%2BC.%26atitle%3DCombined%2520bacitracin-neomycin%2520ointment%2520in%2520treatment%2520of%2520pyogenic%2520infections%2520of%2520the%2520skin%26jtitle%3DArch.%2520Dermatol.%26date%3D1954%26volume%3D69%26spage%3D366%26epage%3D367%26doi%3D10.1001%2Farchderm.1954.01540150112012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubos, R. J.</span></span> <span> </span><span class="NLM_article-title">Studies on a bactericidal agent extracted from a soil bacillus: I. preparation of the agent. its activity in vitro</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1939</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1084/jem.70.1.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1084%2Fjem.70.1.1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1939&pages=1-10&author=R.+J.+Dubos&title=Studies+on+a+bactericidal+agent+extracted+from+a+soil+bacillus%3A+I.+preparation+of+the+agent.+its+activity+in+vitro&doi=10.1084%2Fjem.70.1.1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1084%2Fjem.70.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.70.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DDubos%26aufirst%3DR.%2BJ.%26atitle%3DStudies%2520on%2520a%2520bactericidal%2520agent%2520extracted%2520from%2520a%2520soil%2520bacillus%253A%2520I.%2520preparation%2520of%2520the%2520agent.%2520its%2520activity%2520in%2520vitro%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1939%26volume%3D70%26spage%3D1%26epage%3D10%26doi%3D10.1084%2Fjem.70.1.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubos, R. J.</span></span> <span> </span><span class="NLM_article-title">Studies on a bactericidal agent extracted from a soil bacillus: ii. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1939</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1084/jem.70.1.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1084%2Fjem.70.1.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19870886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaA1MXkvValsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1939&pages=11-17&author=R.+J.+Dubos&title=Studies+on+a+bactericidal+agent+extracted+from+a+soil+bacillus%3A+ii.+Protective+effect+of+the+bactericidal+agent+against+experimental+pneumococcus+infections+in+mice&doi=10.1084%2Fjem.70.1.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal agent extracted from a soil bacillus. II. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice</span></div><div class="casAuthors">Dubos, Rene J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1939</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-17</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">The above agent protects white mice against infection with large nos. of virulent pneumococci.  It is entirely ineffective against infection with virulent Friedl.ovrddot.ander bacilli (type B).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2oofuj2RNHLVg90H21EOLACvtfcHk0linFdDlDbpESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA1MXkvValsg%253D%253D&md5=cc1b9441299395a514268e2451957aaf</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1084%2Fjem.70.1.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.70.1.11%26sid%3Dliteratum%253Aachs%26aulast%3DDubos%26aufirst%3DR.%2BJ.%26atitle%3DStudies%2520on%2520a%2520bactericidal%2520agent%2520extracted%2520from%2520a%2520soil%2520bacillus%253A%2520ii.%2520Protective%2520effect%2520of%2520the%2520bactericidal%2520agent%2520against%2520experimental%2520pneumococcus%2520infections%2520in%2520mice%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1939%26volume%3D70%26spage%3D11%26epage%3D17%26doi%3D10.1084%2Fjem.70.1.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macander, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulitta, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, B. T.</span></span> <span> </span><span class="NLM_article-title">Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing</span>. <i>Pharmacotherapy.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1592/phco.30.12.1279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1592%2Fphco.30.12.1279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21114395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1emsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=1279-1291&author=L.+M.+Limauthor=N.+Lyauthor=D.+Andersonauthor=J.+C.+Yangauthor=L.+Macanderauthor=A.+Jarkowskiauthor=A.+Forrestauthor=J.+B.+Bulittaauthor=B.+T.+Tsuji&title=Resurgence+of+colistin%3A+a+review+of+resistance%2C+toxicity%2C+pharmacodynamics%2C+and+dosing&doi=10.1592%2Fphco.30.12.1279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing</span></div><div class="casAuthors">Lim, Lauren M.; Ly, Neang; Anderson, Dana; Yang, Jenny C.; Macander, Laurie; Jarkowski, Anthony, III; Forrest, Alan; Bulitta, Jurgen B.; Tsuji, Brian T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1279-1291</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review.  Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of gram-neg. infections.  After several years of clin. use, its popularity diminished because of reports of significant nephrotoxicity and neurotoxicity.  Recently, the antibiotic has resurfaced as a last-line treatment option for multidrug-resistant organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.  The need for antibiotics with coverage of these gram-neg. pathogens is crit. because of their high morbidity and mortality, making colistin a very important treatment option.  Unfortunately, however, resistance to colistin has been documented among all three of these organisms in case reports.  Although the exact mechanism causing colistin resistance has not been defined, it is hypothesized that the PmrA-PmrB and PhoP-PhoQ genetic regulatory systems may play a role.  Colistin dosages must be optimized, as colistin is a last-line treatment option; in addn., suboptimal doses have been linked to the development of resistance.  The lack of pharmacokinetic and pharmacodynamic studies and no universal harmonization of dose units, however, have made it difficult to derive optimal dosing regimens and specific dosing guidelines for colistin.  In critically ill patients who may have multiorgan failure, renal insufficiency may alter colistin pharmacokinetics.  Therefore, dosage alterations in this patient population are imperative to achieve maximal efficacy and minimal toxicity With regard to colistin toxicity, most studies show that nephrotoxicity is reversible and less frequent than once thought, and neurotoxicity is rare.  Further research is needed to fully understand the impact that the two regulatory systems have on resistance, as well as the dosages of colistin needed to inhibit and overcome these developing patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopU7sumZvnMbVg90H21EOLACvtfcHk0linFdDlDbpESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1emsbrO&md5=8659470ab8d9c8d95c82faf5fb9e624d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1592%2Fphco.30.12.1279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1592%252Fphco.30.12.1279%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DL.%2BM.%26aulast%3DLy%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DMacander%26aufirst%3DL.%26aulast%3DJarkowski%26aufirst%3DA.%26aulast%3DForrest%26aufirst%3DA.%26aulast%3DBulitta%26aufirst%3DJ.%2BB.%26aulast%3DTsuji%26aufirst%3DB.%2BT.%26atitle%3DResurgence%2520of%2520colistin%253A%2520a%2520review%2520of%2520resistance%252C%2520toxicity%252C%2520pharmacodynamics%252C%2520and%2520dosing%26jtitle%3DPharmacotherapy.%26date%3D2010%26volume%3D30%26spage%3D1279%26epage%3D1291%26doi%3D10.1592%2Fphco.30.12.1279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podolsky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. A.</span></span> <span> </span><span class="NLM_article-title">Combination drugs — hype, harm, and hope</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1106161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMp1106161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21830965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVars7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=488-491&author=S.+H.+Podolskyauthor=J.+A.+Greene&title=Combination+drugs+%E2%80%94+hype%2C+harm%2C+and+hope&doi=10.1056%2FNEJMp1106161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: combination drugs - hype, Harm and hope</span></div><div class="casAuthors">Podolsky, Scott H.; Greene, Jeremy A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-491</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKfDYCjD5hPbVg90H21EOLACvtfcHk0linFdDlDbpESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVars7jL&md5=c6dd3d4479c1af1400675e9a9769d14b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1106161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1106161%26sid%3Dliteratum%253Aachs%26aulast%3DPodolsky%26aufirst%3DS.%2BH.%26aulast%3DGreene%26aufirst%3DJ.%2BA.%26atitle%3DCombination%2520drugs%2520%25E2%2580%2594%2520hype%252C%2520harm%252C%2520and%2520hope%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D488%26epage%3D491%26doi%3D10.1056%2FNEJMp1106161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clissold, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campoli-Richards, D. M.</span></span> <span> </span><span class="NLM_article-title">Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.2165/00003495-198733030-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00003495-198733030-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=3552595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaL2sXitVOjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1987&pages=183-241&author=S.+P.+Clissoldauthor=P.+A.+Toddauthor=D.+M.+Campoli-Richards&title=Imipenem%2Fcilastatin.+A+review+of+its+antibacterial+activity%2C+pharmacokinetic+properties+and+therapeutic+efficacy&doi=10.2165%2F00003495-198733030-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Imipenem/cilastatin.  A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy</span></div><div class="casAuthors">Clissold, Stephen P.; Todd, Peter A.; Campoli-Richards, Deborah M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-241</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with ∼360 refs. of the in vitro antibacterial activity and pharmacokinetics and therapeutic efficacy in humans and lab. animals of the imipenem-cilastatin mixt.  [85960-17-4].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9NRLX4pcDiLVg90H21EOLACvtfcHk0liP35J4UIzFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXitVOjsbs%253D&md5=0774ce138bf7c6791b3e88bd187c4113</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2165%2F00003495-198733030-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198733030-00001%26sid%3Dliteratum%253Aachs%26aulast%3DClissold%26aufirst%3DS.%2BP.%26aulast%3DTodd%26aufirst%3DP.%2BA.%26aulast%3DCampoli-Richards%26aufirst%3DD.%2BM.%26atitle%3DImipenem%252Fcilastatin.%2520A%2520review%2520of%2520its%2520antibacterial%2520activity%252C%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%26jtitle%3DDrugs%26date%3D1987%26volume%3D33%26spage%3D183%26epage%3D241%26doi%3D10.2165%2F00003495-198733030-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deretic, V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of action of isoniazid</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1220</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2958.2006.05467.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1365-2958.2006.05467.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17074073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlenu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=1220-1227&author=G.+S.+Timminsauthor=V.+Deretic&title=Mechanisms+of+action+of+isoniazid&doi=10.1111%2Fj.1365-2958.2006.05467.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of action of isoniazid</span></div><div class="casAuthors">Timmins, Graham S.; Deretic, Vojo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1220-1227</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  For decades after its introduction, the mechanisms of action of the front-line antituberculosis therapeutic agent isoniazid (INH) remained unclear.  Recent developments have shown that peroxidative activation of isoniazid by the mycobacterial enzyme KatG generates reactive species that form adducts with NAD+ and NADP+ that are potent inhibitors of lipid and nucleic acid biosynthetic enzymes.  A direct role for some isoniazid-derived reactive species, such as nitric oxide, in inhibiting mycobacterial metabolic enzymes has also been shown.  The concerted effects of these activities - inhibition of cell wall lipid synthesis, depletion of nucleic acid pools and metabolic depression - drive the exquisite potency and selectivity of this agent.  To understand INH action and resistance fully, a synthesis of knowledge is required from multiple sep. lines of research - including mol. genetic approaches, in vitro biochem. studies and free radical chem. - which is the intent of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq9OybVddk-rVg90H21EOLACvtfcHk0liP35J4UIzFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlenu7jE&md5=fbc095f0f79cd443b55d54c19b36f932</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2958.2006.05467.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2958.2006.05467.x%26sid%3Dliteratum%253Aachs%26aulast%3DTimmins%26aufirst%3DG.%2BS.%26aulast%3DDeretic%26aufirst%3DV.%26atitle%3DMechanisms%2520of%2520action%2520of%2520isoniazid%26jtitle%3DMol.%2520Microbiol.%26date%3D2006%26volume%3D62%26spage%3D1220%26epage%3D1227%26doi%3D10.1111%2Fj.1365-2958.2006.05467.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio-Aparicio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>, <span class="NLM_elocation-id">e01443-17</span> <span class="refDoi"> DOI: 10.1128/AAC.01443-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1128%2FAAC.01443-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28848018" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&author=O.+Lomovskayaauthor=D.+Sunauthor=D.+Rubio-Aparicioauthor=K.+Nelsonauthor=R.+Tsivkovskiauthor=D.+C.+Griffithauthor=M.+N.+Dudley&title=Vaborbactam%3A+spectrum+of+beta-lactamase+inhibition+and+impact+of+resistance+mechanisms+on+activity+in+enterobacteriaceae&doi=10.1128%2FAAC.01443-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.01443-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01443-17%26sid%3Dliteratum%253Aachs%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DRubio-Aparicio%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DK.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DVaborbactam%253A%2520spectrum%2520of%2520beta-lactamase%2520inhibition%2520and%2520impact%2520of%2520resistance%2520mechanisms%2520on%2520activity%2520in%2520enterobacteriaceae%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26doi%3D10.1128%2FAAC.01443-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denisuik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0013-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40265-013-0013-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23371303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWms7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=159-77&author=G.+G.+Zhanelauthor=C.+D.+Lawsonauthor=H.+Adamauthor=F.+Schweizerauthor=S.+Zelenitskyauthor=P.+R.+Lagace-Wiensauthor=A.+Denisuikauthor=E.+Rubinsteinauthor=A.+S.+Ginauthor=D.+J.+Hobanauthor=J.+P.+Lynchauthor=J.+A.+Karlowsky&title=Ceftazidime-avibactam%3A+a+novel+cephalosporin%2Fbeta-lactamase+inhibitor+combination&doi=10.1007%2Fs40265-013-0013-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination</span></div><div class="casAuthors">Zhanel, George G.; Lawson, Christopher D.; Adam, Heather; Schweizer, Frank; Zelenitsky, Sheryl; Lagace-Wiens, Philippe R. S.; Denisuik, Andrew; Rubinstein, Ethan; Gin, Alfred S.; Hoban, Daryl J.; Lynch, Joseph P., 3rd; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-177</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.  This review summarizes the existing data published for ceftazidime-avibactam, including relevant chem., mechanisms of action and resistance, microbiol., pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials.  Although not a β-lactam, the chem. structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to β-lactamases.  Very little is known about the potential for avibactam to select for resistance.  The addn. of avibactam greatly (4-1024-fold min. inhibitory concn. [MIC] redn.) improves the activity of ceftazidime vs. most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzyme(s).  Against Pseudomonas aeruginosa, the addn. of avibactam also improves the activity of ceftazidime (∼fourfold MIC redn.).  Limited data suggest that the addn. of avibactam does not improve the activity of ceftazidime vs. Acinetobacter species or most anaerobic bacteria (exceptions: Bacteroides fragilis, Clostridium perfringens, Prevotella spp. and Porphyromonas spp.).  The pharmacokinetics of avibactam follow a two-compartment model and do not appear to be altered by the co-administration of ceftazidime.  The max. plasma drug concn. (Cmax) and area under the plasma concn.-time curve (AUC) of avibactam increase linearly with doses ranging from 50 mg to 2,000 mg.  The mean vol. of distribution and half-life of 22 L (∼0.3 L/kg) and ∼2 h, resp., are similar to ceftazidime.  Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance.  Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal vs. β-lactamase-producing Gram-neg. bacilli that are not inhibited by ceftazidime alone.  Clin. trials to date have reported that ceftazidime-avibactam is as effective as std. carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-neg. isolates.  The safety and tolerability of ceftazidime-avibactam has been reported in three phase I pharmacokinetic studies and two phase II clin. studies.  Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.  In conclusion, avibactam serves to broaden the spectrum of ceftazidime vs. ss-lactamase-producing Gram-neg. bacilli.  The exact roles for ceftazidime-avibactam will be defined by efficacy and safety data from further clin. trials.  Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-neg.-bacilli producing extended-spectrum ss-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ss-lactamases.  In addn., ceftazidime-avibactam may be used in combination (with metronidazole) for suspected polymicrobial infections.  Finally, the increased activity of ceftazidime-avibactam vs. P. aeruginosa may be of clin. benefit in patients with suspected or documented P. aeruginosa infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6FoMOMncBbVg90H21EOLACvtfcHk0liP35J4UIzFnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWms7zO&md5=29776a4dd902a5e75f1971270fa545a5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0013-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0013-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DLawson%26aufirst%3DC.%2BD.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%26aulast%3DDenisuik%26aufirst%3DA.%26aulast%3DRubinstein%26aufirst%3DE.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DCeftazidime-avibactam%253A%2520a%2520novel%2520cephalosporin%252Fbeta-lactamase%2520inhibitor%2520combination%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D159%26epage%3D77%26doi%3D10.1007%2Fs40265-013-0013-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span> <span> </span><span class="NLM_article-title">Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors</span>. <i>Curr. Opin. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1016/j.mib.2011.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.mib.2011.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21840248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlCntrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=550-555&author=K.+Coleman&title=Diazabicyclooctanes+%28DBOs%29%3A+a+potent+new+class+of+non-%CE%B2-lactam+%CE%B2-lactamase+inhibitors&doi=10.1016%2Fj.mib.2011.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors</span></div><div class="casAuthors">Coleman, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-555</span>CODEN:
                <span class="NLM_cas:coden">COMIF7</span>;
        ISSN:<span class="NLM_cas:issn">1369-5274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The β-lactams have been among the most successful classes of antibacterial agents for the past half century.  However, a disturbing increase in resistance to β-lactams has been noted among Gram-neg. bacteria, which is attributable to β-lactamase enzymes not within the spectrum of currently marketed β-lactams or β-lactam/β-lactamase inhibitor combinations.  Diazabicyclooctanes (DBOs) were first investigated as β-lactam mimics in the mid-1990s by chemists at Hoechst Marion Roussel (now part of Sanofi-Aventis) and proved to be a rich source of β-lactamase inhibitors (BLI).  Two members of this novel series of highly potent, broad spectrum BLIs are now in clin. development and their properties are reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpneNkuutLgqrVg90H21EOLACvtfcHk0lhXuWz64iYqJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlCntrjN&md5=0aafa5daac59fc737d464d7a7b637b2c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.mib.2011.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mib.2011.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DK.%26atitle%3DDiazabicyclooctanes%2520%2528DBOs%2529%253A%2520a%2520potent%2520new%2520class%2520of%2520non-%25CE%25B2-lactam%2520%25CE%25B2-lactamase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Microbiol.%26date%3D2011%26volume%3D14%26spage%3D550%26epage%3D555%26doi%3D10.1016%2Fj.mib.2011.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span> <span> </span><span class="NLM_article-title">Avibactam and class c β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5704</span>– <span class="NLM_lpage">5713</span>, <span class="refDoi"> DOI: 10.1128/AAC.03057-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1128%2FAAC.03057-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5704-5713&author=S.+D.+Lahiriauthor=M.+R.+Johnstoneauthor=P.+L.+Rossauthor=R.+E.+McLaughlinauthor=N.+B.+Olivierauthor=R.+A.+Alm&title=Avibactam+and+class+c+%CE%B2-lactamases%3A+mechanism+of+inhibition%2C+conservation+of+the+binding+pocket%2C+and+implications+for+resistance&doi=10.1128%2FAAC.03057-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FAAC.03057-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03057-14%26sid%3Dliteratum%253Aachs%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DJohnstone%26aufirst%3DM.%2BR.%26aulast%3DRoss%26aufirst%3DP.%2BL.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DOlivier%26aufirst%3DN.%2BB.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26atitle%3DAvibactam%2520and%2520class%2520c%2520%25CE%25B2-lactamases%253A%2520mechanism%2520of%2520inhibition%252C%2520conservation%2520of%2520the%2520binding%2520pocket%252C%2520and%2520implications%2520for%2520resistance%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5704%26epage%3D5713%26doi%3D10.1128%2FAAC.03057-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, P.</span></span> <span> </span><span class="NLM_article-title">Not boring at all. Boron is the new carbon in the quest for novel drug candidates</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1038/embor.2009.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fembor.2009.2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=125-128&author=P.+Hunter&title=Not+boring+at+all.+Boron+is+the+new+carbon+in+the+quest+for+novel+drug+candidates&doi=10.1038%2Fembor.2009.2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fembor.2009.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2009.2%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DP.%26atitle%3DNot%2520boring%2520at%2520all.%2520Boron%2520is%2520the%2520new%2520carbon%2520in%2520the%2520quest%2520for%2520novel%2520drug%2520candidates%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D125%26epage%3D128%26doi%3D10.1038%2Fembor.2009.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loutit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabetauthor=Z.+Taraziauthor=M.+C.+Cliftonauthor=K.+Atkinsauthor=A.+Raymondauthor=K.+T.+Pottsauthor=J.+Abendrothauthor=S.+H.+Boyerauthor=J.+S.+Loutitauthor=E.+E.+Morganauthor=S.+Dursoauthor=M.+N.+Dudley&title=Discovery+of+a+cyclic+boronic+acid+%CE%B2-lactamase+inhibitor+%28RPX7009%29+with+utility+vs+class+A+serine+carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0lhXuWz64iYqJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26aulast%3DTarazi%26aufirst%3DZ.%26aulast%3DClifton%26aufirst%3DM.%2BC.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DRaymond%26aufirst%3DA.%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BH.%26aulast%3DLoutit%26aufirst%3DJ.%2BS.%26aulast%3DMorgan%26aufirst%3DE.%2BE.%26aulast%3DDurso%26aufirst%3DS.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DDiscovery%2520of%2520a%2520cyclic%2520boronic%2520acid%2520%25CE%25B2-lactamase%2520inhibitor%2520%2528RPX7009%2529%2520with%2520utility%2520vs%2520class%2520A%2520serine%2520carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allington, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivey, M. P.</span></span> <span> </span><span class="NLM_article-title">Quinupristin/dalfopristin: A therapeutic review</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/S0149-2918(01)80028-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0149-2918%2801%2980028-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=11219478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVamsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=24-44&author=D.+R.+Allingtonauthor=M.+P.+Rivey&title=Quinupristin%2Fdalfopristin%3A+A+therapeutic+review&doi=10.1016%2FS0149-2918%2801%2980028-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Quinupristin/dalfopristin: a therapeutic review</span></div><div class="casAuthors">Allington, Douglas R.; Rivey, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-44</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review with 47 refs.  Background: The proliferation of multidrug-resistant gram-pos. bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium (VREF), has created a pressing need for effective alternative antibiotics.  Quinupristin/dalfopristin is a new combination streptogramin product with a selective spectrum of antibacterial activity, mainly against gram-pos. aerobic bacteria.  It has been assessed primarily in emergency-use protocols, in hospitalized patients with skin and skin-structure infections, and in patients with VREF bacteremia.  Objectives: The objectives of this review were to summarize important results of in vitro microbiol. studies; to provide information on relevant pharmacokinetic parameters, drug interactions, and Y-site compatibility; and to assess efficacy and safety data from clin. studies of quinupristin/dalfopristin.  Methods: Articles included in this review were identified by a MEDLINE search of the literature published between 1966 and Sept. 2000 using the terms Synercid, quinupristin, and dalfopristin.  Addnl. articles were retrieved from the ref. lists of articles identified in the MEDLINE search.  Results: In vitro anal. of the spectrum of activity of quinupristin/dalfopristin has confirmed its relatively selective coverage of gram-pos. aerobic bacteria.  Both quinupristin and dalfopristin undergo hepatic metab. and are extensively excreted in the feces.  Combination quinupristin/dalfopristin inhibits the cytochrome P 450 3A4 pathway, and caution is warranted with concomitant use of other medications eliminated via this pathway.  In trials in patients with VREF infections, treatment success with quinupristin/dalfopristin varied depending on the site of infection, ranging from 51.9% in bacteremia of unknown origin to 88.9% in urinary tract infections.  The results of comparative clin. trials suggest that quinupristin/dalfopristin has similar efficacy to that of commonly used antibiotics, including cefazolin, oxacillin, and vancomycin, in patients with skin and skin-structure infections or nosocomial pneumonia.  The most frequently reported adverse effects with administration of quinupristin/dalfopristin were infusion-site inflammation, pain, and edema; other infusion-site reactions; and thrombophlebitis.  Arthralgia, myalgia, nausea, diarrhea, vomiting, and rash occurred in 2.5% to 4.6% of patients and were the most frequently reported systemic adverse events.  Conclusions: Outcomes data from clin. trials indicate that quinupristin/dalfopristin has the potential to play an important role in the treatment of bacteremia, complicated skin and skin-structure infections, and nosocomial pneumonia caused by VREF.  Issues of bacterial resistance to quinupristin/dalfopristin and other appropriate uses of this combination agent remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnk7wTFdXDLVg90H21EOLACvtfcHk0lhvoBvp4Li1rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVamsL8%253D&md5=15be911d7b3578e999ebd3178a5e3b9a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0149-2918%2801%2980028-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-2918%252801%252980028-X%26sid%3Dliteratum%253Aachs%26aulast%3DAllington%26aufirst%3DD.%2BR.%26aulast%3DRivey%26aufirst%3DM.%2BP.%26atitle%3DQuinupristin%252Fdalfopristin%253A%2520A%2520therapeutic%2520review%26jtitle%3DClin.%2520Ther.%26date%3D2001%26volume%3D23%26spage%3D24%26epage%3D44%26doi%3D10.1016%2FS0149-2918%2801%2980028-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prachayasittikul, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prachayasittikul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prachayasittikul, V.</span></span> <span> </span><span class="NLM_article-title">Prachayasittikul. V. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S49763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FDDDT.S49763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=1157-1178&author=V.+Prachayasittikulauthor=S.+Prachayasittikulauthor=S.+Ruchirawatauthor=V.+Prachayasittikul&title=Prachayasittikul.+V.+8-Hydroxyquinolines%3A+a+review+of+their+metal+chelating+properties+and+medicinal+applications&doi=10.2147%2FDDDT.S49763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S49763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S49763%26sid%3Dliteratum%253Aachs%26aulast%3DPrachayasittikul%26aufirst%3DV.%26aulast%3DPrachayasittikul%26aufirst%3DS.%26aulast%3DRuchirawat%26aufirst%3DS.%26aulast%3DPrachayasittikul%26aufirst%3DV.%26atitle%3DPrachayasittikul.%2520V.%25208-Hydroxyquinolines%253A%2520a%2520review%2520of%2520their%2520metal%2520chelating%2520properties%2520and%2520medicinal%2520applications%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D2013%26spage%3D1157%26epage%3D1178%26doi%3D10.2147%2FDDDT.S49763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, D.</span></span> <span> </span><span class="NLM_article-title">Lomotil (Diphenoxylate) dependence in India</span>. <i>Indian J. Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.4103/0253-7176.119474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4103%2F0253-7176.119474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24249925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2c7osVCntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=248-250&author=A.+Mehraauthor=S.+Sarkarauthor=D.+Basu&title=Lomotil+%28Diphenoxylate%29+dependence+in+India&doi=10.4103%2F0253-7176.119474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Lomotil (diphenoxylate) dependence in India</span></div><div class="casAuthors">Mehra Aseem; Sarkar Siddharth; Basu Debasish</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of psychological medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-50</span>
        ISSN:<span class="NLM_cas:issn">0253-7176</span>.
    </div><div class="casAbstract">BACKGROUND:  Lomotil (diphenoxylate atropine combination) has been in use as an antidiarrhoeal agent.  Due to presence of opioid (diphenoxylate), there are chances of abuse.  The reports of abuse of lomotil have been few in published literature.  This chart review aimed to evaluate the characteristics of patients with dependence on lomotil coming to our centre.  MATERIALS AND METHODS:  This retrospective chart review was conducted at the Drug De-addiction and Treatment Centre of PGIMER, Chandigarh, India.  The records of patients who had presented to the centre with dependence on Lomotil in the last five years were identified, and clinical details were extracted from the records.  RESULTS:  We identified 41 patients who had presented to our centre with dependence upon lomotil as the primary substance of abuse.  The cases were typically married and employed males, educated up to 10(th) grade, belonging to a rural Sikh extended or joint family.  Most of the patients had taken other opioids too.  The number of tablets taken in a day varied from 3- to 250 (median 25).  The reasons of initiation were to relieve withdrawals, as a cheap substitute opioid, curiosity, and on suggestion of friends.  CONCLUSION:  Lomotil is a medication with a potential of abuse and regulatory controls are required to prevent escalation of misuse of this easily available prescription drug.  Lomotil (diphenoxylate and atropine combination) has been used since a long time as an anti-diarrheal agent.  Reports of abuse of diphenoxylate had surfaced.  We present a series of 41 cases of opioid dependence presenting with the use of the diphenoxylate as the primary substance.  The cases were typically married and employed males, educated up to 10(th) grade, belonging to a rural Sikh extended or joint family.  Most of the patients had taken other opioids too.  The number of tablets taken in a day varied from 3 to 250 (median 25).  The reasons of initiation of diphenoxylate were to relieve withdrawals, as a cheap substitute opioid, curiosity, and suggestion of friends.  Regulatory controls are needed to prevent escalation of use of this easily available prescription opioid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdwkSFKli2az0SWnHPWbmmfW6udTcc2eaHKWtRAeuqm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7osVCntw%253D%253D&md5=603b2ae4c429d149c8ac23ea9ab80300</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.4103%2F0253-7176.119474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0253-7176.119474%26sid%3Dliteratum%253Aachs%26aulast%3DMehra%26aufirst%3DA.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DBasu%26aufirst%3DD.%26atitle%3DLomotil%2520%2528Diphenoxylate%2529%2520dependence%2520in%2520India%26jtitle%3DIndian%2520J.%2520Psychol.%2520Med.%26date%3D2013%26volume%3D35%26spage%3D248%26epage%3D250%26doi%3D10.4103%2F0253-7176.119474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enns, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhead, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brusilow, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamosh, A.</span></span> <span> </span><span class="NLM_article-title">Survival after treatment with phenylacetate and benzoate for urea-cycle disorders</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">2282</span>– <span class="NLM_lpage">2292</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa066596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa066596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17538087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2282-2292&author=G.+M.+Ennsauthor=S.+A.+Berryauthor=G.+T.+Berryauthor=W.+J.+Rheadauthor=S.+W.+Brusilowauthor=A.+Hamosh&title=Survival+after+treatment+with+phenylacetate+and+benzoate+for+urea-cycle+disorders&doi=10.1056%2FNEJMoa066596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Survival after treatment with phenylacetate and benzoate for urea-cycle disorders</span></div><div class="casAuthors">Enns, Gregory M.; Berry, Susan A.; Berry, Gerard T.; Rhead, William J.; Brusilow, Saul W.; Hamosh, Ada</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2282-2292</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The combination of i.v. sodium phenylacetate and sodium benzoate has been shown to lower plasma ammonium levels and improve survival in small cohorts of patients with historically lethal urea-cycle enzyme defects.  We report the results of a 25-yr, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia.  Overall survival was 84% (250 of 299 patients).  Ninety-six percent of the patients survived episodes of hyperammonemia (1132 of 1181 episodes).  Patients over 30 days of age were more likely than neonates to survive an episode (98% vs. 73%, P < 0.001).  Patients 12 or more years of age (93 patients), who had 437 episodes, were more likely than all younger patients to survive (99%, P < 0.001).  Eighty-one percent of patients who were comatose at admission survived.  Patients less than 30 days of age with a peak ammonium level above 1000 μmol per L (1804 μg per dL) were least likely to survive a hyperammonemic episode (38%, P < 0.001).  Dialysis was also used in 56 neonates during 60% of episodes and in 80 patients 30 days of age or older during 7% of episodes.  Prompt recognition of a urea-cycle disorder and treatment with both sodium phenylacetate and sodium benzoate, in conjunction with other therapies, such as i.v. arginine hydrochloride and the provision of adequate calories to prevent catabolism, effectively lower plasma ammonium levels and result in survival in the majority of patients.  Hemodialysis may also be needed to control hyperammonemia, esp. in neonates and older patients who do not have a response to i.v. sodium phenylacetate and sodium benzoate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAtLnbNCW1PrVg90H21EOLACvtfcHk0lhvoBvp4Li1rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7o%253D&md5=e358df4111d1872f7c40e73b54f77f27</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa066596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa066596%26sid%3Dliteratum%253Aachs%26aulast%3DEnns%26aufirst%3DG.%2BM.%26aulast%3DBerry%26aufirst%3DS.%2BA.%26aulast%3DBerry%26aufirst%3DG.%2BT.%26aulast%3DRhead%26aufirst%3DW.%2BJ.%26aulast%3DBrusilow%26aufirst%3DS.%2BW.%26aulast%3DHamosh%26aufirst%3DA.%26atitle%3DSurvival%2520after%2520treatment%2520with%2520phenylacetate%2520and%2520benzoate%2520for%2520urea-cycle%2520disorders%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2282%26epage%3D2292%26doi%3D10.1056%2FNEJMoa066596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ornellas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, B.</span></span> <span> </span><span class="NLM_article-title">Naltrexone SR/Bupropion SR (Contrave): A new approach to weight loss in obese adults</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=255-262&author=T.+Ornellasauthor=B.+Chavez&title=Naltrexone+SR%2FBupropion+SR+%28Contrave%29%3A+A+new+approach+to+weight+loss+in+obese+adults"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrnellas%26aufirst%3DT.%26aulast%3DChavez%26aufirst%3DB.%26atitle%3DNaltrexone%2520SR%252FBupropion%2520SR%2520%2528Contrave%2529%253A%2520A%2520new%2520approach%2520to%2520weight%2520loss%2520in%2520obese%2520adults%26jtitle%3DPharm.%2520Ther.%26date%3D2011%26volume%3D36%26spage%3D255%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inzucchi, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seufert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekki, Q.</span></span> <span> </span><span class="NLM_article-title">Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2408</span>, <span class="refDoi"> DOI: 10.2337/dc10-0159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2337%2Fdc10-0159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=20724648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=2406-2408&author=J.+Rosenstockauthor=S.+E.+Inzucchiauthor=J.+Seufertauthor=P.+R.+Fleckauthor=C.+A.+Wilsonauthor=Q.+Mekki&title=Initial+combination+therapy+with+alogliptin+and+pioglitazone+in+drug-na%C3%AFve+patients+with+type+2+diabetes&doi=10.2337%2Fdc10-0159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes</span></div><div class="casAuthors">Rosenstock, Julio; Inzucchi, Silvio E.; Seufert, Jochen; Fleck, Penny R.; Wilson, Craig A.; Mekki, Qais</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2406-2408</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">OBJECTIVE: To assess the efficacy and tolerability of alogliptin plus pioglitazone for initial combination therapy in drug-naive type 2 diabetic patients.  RESEARCH DESIGN AND METHODS: This 26-wk, double-blind, parallel-group study randomized 655 patients with inadequately controlled type 2 diabetes to four arms: 25 mg alogliptin (A25) q.d. monotherapy, 30 mg pioglitazone (P30) q.d. monotherapy, or 12.5 (A12.5) or 25 mg alogliptin q.d. plus pioglitazone (P30) q.d. combination therapy.  Primary efficacy was A1C change from baseline with the high-dose combination (A25 + P30) vs. each monotherapy.  RESULTS: Combination therapy with A25 + P30 resulted in greater redns. in A1C (-1.7 ± 0.1% from an 8.8% mean baseline) vs. A25 (-1.0 ± 0.1%, P < 0.001) or P30 (-1.2 ± 0.1%, P < 0.001) and in fasting plasma glucose (-2.8 ± 0.2 mmol/l) vs. A25 (-1.4 ± 0.2 mmol/l, P < 0.001) or P30 (-2.1 ± 0.2 mmol/l, P = 0.006).  The A25 + P30 safety profile was consistent with those of its component monotherapies.  CONCLUSIONS: Alogliptin plus pioglitazone combination treatment appears to be an efficacious initial therapeutic option for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZj0Xht0o8v7Vg90H21EOLACvtfcHk0lg_XfqfTAgJOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisrzP&md5=4d9506bfae4582dc9daa94b55351dac2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2337%2Fdc10-0159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc10-0159%26sid%3Dliteratum%253Aachs%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DInzucchi%26aufirst%3DS.%2BE.%26aulast%3DSeufert%26aufirst%3DJ.%26aulast%3DFleck%26aufirst%3DP.%2BR.%26aulast%3DWilson%26aufirst%3DC.%2BA.%26aulast%3DMekki%26aufirst%3DQ.%26atitle%3DInitial%2520combination%2520therapy%2520with%2520alogliptin%2520and%2520pioglitazone%2520in%2520drug-na%25C3%25AFve%2520patients%2520with%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2010%26volume%3D33%26spage%3D2406%26epage%3D2408%26doi%3D10.2337%2Fdc10-0159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neff, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawarskas, J. J.</span></span> <span> </span><span class="NLM_article-title">Hydrochlorothiazide versus chlorthalidone in the management of hypertension</span>. <i>Cardiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1097/CRD.0b013e3181c61b52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2FCRD.0b013e3181c61b52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=20010338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MfisFOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=51-56&author=K.+M.+Neffauthor=J.+J.+Nawarskas&title=Hydrochlorothiazide+versus+chlorthalidone+in+the+management+of+hypertension&doi=10.1097%2FCRD.0b013e3181c61b52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrochlorothiazide versus chlorthalidone in the management of hypertension</span></div><div class="casAuthors">Neff Kimberly M; Nawarskas James J</div><div class="citationInfo"><span class="NLM_cas:title">Cardiology in review</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thiazide diuretics are a mainstay for the treatment of hypertension.  Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure.  This is despite several clinical trials that have used and documented the benefits of chlorthalidone for hypertension management.  In terms of blood pressure lowering, both HCTZ and chlorthalidone appear to be very effective.  Head-to-head studies have shown trends favoring chlorthalidone as a more effective blood pressure lowering agent compared with HCTZ, but statistical significance in this regard has not been consistently demonstrated.  Also unclear is the relative benefits of these 2 drugs with regards to reducing clinical complications of hypertension, namely cardiovascular morbidity and mortality.  Whereas there is more aggregate clinical trial data documenting the benefits of chlorthalidone compared with HCTZ in terms of hard clinical outcomes, these trials are not direct comparisons and can only be used to fuel the debate as to which of the 2 thiazides are better.  From a safety perspective, hypokalemia is a risk with any of the thiazide diuretics and has been shown to be dose-related.  However, at equipotent dosages, the incidence of hypokalemia between chlorthalidone and HCTZ appears comparable.  The available evidence therefore supports both HCTZ and chlorthalidone as safe and effective drugs for treating hypertension.  Although there are favorable trends both in terms of antihypertensive efficacy as well as clinical outcomes data with chlorthalidone compared with HCTZ, the results are not conclusive, and as such may not be enough to shift the treatment paradigm in favor of chlorthalidone, given the comfort level that most prescribers have with HCTZ.  A head-to-head study looking at hard clinical outcomes, which may or may not ever be performed, may be the only way to resolve the ongoing debate as to which is the preferred thiazide for treating hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToajfqAoubLOWhZTslLrfffW6udTcc2eYMJl1XW_sYGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfisFOmsA%253D%253D&md5=1a2809be893c66c373e1b0485f36caa2</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1097%2FCRD.0b013e3181c61b52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCRD.0b013e3181c61b52%26sid%3Dliteratum%253Aachs%26aulast%3DNeff%26aufirst%3DK.%2BM.%26aulast%3DNawarskas%26aufirst%3DJ.%2BJ.%26atitle%3DHydrochlorothiazide%2520versus%2520chlorthalidone%2520in%2520the%2520management%2520of%2520hypertension%26jtitle%3DCardiol.%2520Rev.%26date%3D2010%26volume%3D18%26spage%3D51%26epage%3D56%26doi%3D10.1097%2FCRD.0b013e3181c61b52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. D.</span></span> <span> </span><span class="NLM_article-title">Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000103632.19915.0E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1161%2F01.HYP.0000103632.19915.0E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=14638621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3snht1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4-9&author=B.+L.+Carterauthor=M.+E.+Ernstauthor=J.+D.+Cohen&title=Hydrochlorothiazide+versus+chlorthalidone%3A+evidence+supporting+their+interchangeability&doi=10.1161%2F01.HYP.0000103632.19915.0E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability</span></div><div class="casAuthors">Carter Barry L; Ernst Michael E; Cohen Jerome D</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension (Dallas, Tex. : 1979)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thiazide diuretics are one of the preferred pharmacologic treatments for hypertension.  Hydrochlorothiazide and chlorthalidone have been the 2 most commonly used diuretics in major clinical trials.  Treatment guidelines and compendia often consider these 2 drugs interchangeable agents within the class of thiazide or thiazide-like diuretics.  Many sources list them as equipotent.  Despite these beliefs, there is some suggestion that cardiovascular outcomes are not necessarily the same with these 2 drugs.  We conducted a literature search from 1960 to 2003 to identify studies that evaluated the pharmacokinetic and blood pressure-lowering effects of these 2 agents.  There are significant pharmacokinetic and pharmacodynamic differences between these diuretics.  Chlorthalidone is approximately 1.5 to 2.0 times as potent as hydrochlorothiazide, and the former has a much longer duration of action.  Whether these pharmacokinetic and pharmacodynamic features cause differences in outcomes is not known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8_FIu9-6Enn6HPRus0rAafW6udTcc2eauekrH_QzJkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3snht1GjsQ%253D%253D&md5=bf91553c63d8f93351c8f41fa93a98e7</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000103632.19915.0E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000103632.19915.0E%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DB.%2BL.%26aulast%3DErnst%26aufirst%3DM.%2BE.%26aulast%3DCohen%26aufirst%3DJ.%2BD.%26atitle%3DHydrochlorothiazide%2520versus%2520chlorthalidone%253A%2520evidence%2520supporting%2520their%2520interchangeability%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26spage%3D4%26epage%3D9%26doi%3D10.1161%2F01.HYP.0000103632.19915.0E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vongpatanasin, W.</span></span> <span> </span><span class="NLM_article-title">Hydrochlorothiazide (HCTZ) is not the most useful nor versatile thiazide diuretic</span>. <i>Curr. Opin. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1097/HCO.0000000000000178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2FHCO.0000000000000178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26049382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2MbhtlKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=361-365&author=W.+Vongpatanasin&title=Hydrochlorothiazide+%28HCTZ%29+is+not+the+most+useful+nor+versatile+thiazide+diuretic&doi=10.1097%2FHCO.0000000000000178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic</span></div><div class="casAuthors">Vongpatanasin Wanpen</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension.  RECENT FINDINGS:  HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide.  A recent meta-analysis also suggested HCTZ (12.5-25 mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists.  The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar.  Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD.  SUMMARY:  Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide.  Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics.  CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwwrmjUqMDQFVwdslNBF-tfW6udTcc2eauekrH_QzJkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbhtlKhtA%253D%253D&md5=bddaa2fdcedaeaa04fb5c0db1f4b14e5</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1097%2FHCO.0000000000000178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHCO.0000000000000178%26sid%3Dliteratum%253Aachs%26aulast%3DVongpatanasin%26aufirst%3DW.%26atitle%3DHydrochlorothiazide%2520%2528HCTZ%2529%2520is%2520not%2520the%2520most%2520useful%2520nor%2520versatile%2520thiazide%2520diuretic%26jtitle%3DCurr.%2520Opin.%2520Cardiol.%26date%3D2015%26volume%3D30%26spage%3D361%26epage%3D365%26doi%3D10.1097%2FHCO.0000000000000178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitka, M.</span></span> <span> </span><span class="NLM_article-title">Experts argue not all diuretics the same</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">31</span>, <span class="refDoi"> DOI: 10.1001/jama.298.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1001%2Fjama.298.1.31" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2007&pages=31&author=M.+Mitka&title=Experts+argue+not+all+diuretics+the+same&doi=10.1001%2Fjama.298.1.31"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1001%2Fjama.298.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.298.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DMitka%26aufirst%3DM.%26atitle%3DExperts%2520argue%2520not%2520all%2520diuretics%2520the%2520same%26jtitle%3DJAMA%26date%3D2007%26volume%3D298%26spage%3D31%26doi%3D10.1001%2Fjama.298.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidt, D. G.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187s</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1981.tb02539.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fj.1875-9114.1981.tb02539.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=6927605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaL38Xmt1CjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1981&pages=179-187s&author=D.+G.+Vidt&title=Mechanism+of+action%2C+pharmacokinetics%2C+adverse+effects%2C+and+therapeutic+uses+of+amiloride+hydrochloride%2C+a+new+potassium-sparing+diuretic&doi=10.1002%2Fj.1875-9114.1981.tb02539.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic</span></div><div class="casAuthors">Vidt, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">179-87</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    </div><div class="casAbstract">A review with 57 refs. of amiloride (I)  [2609-46-3].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqchyX0LJ9yx7Vg90H21EOLACvtfcHk0ljsAPspSQmoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xmt1CjtA%253D%253D&md5=ba23cd636c8f17fcf072fed0c141745b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1981.tb02539.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1981.tb02539.x%26sid%3Dliteratum%253Aachs%26aulast%3DVidt%26aufirst%3DD.%2BG.%26atitle%3DMechanism%2520of%2520action%252C%2520pharmacokinetics%252C%2520adverse%2520effects%252C%2520and%2520therapeutic%2520uses%2520of%2520amiloride%2520hydrochloride%252C%2520a%2520new%2520potassium-sparing%2520diuretic%26jtitle%3DPharmacotherapy%26date%3D1981%26volume%3D1%26spage%3D179%26epage%3D187s%26doi%3D10.1002%2Fj.1875-9114.1981.tb02539.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Thabaiti, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiekh, R. A.</span></span> <span> </span><span class="NLM_article-title">Tetrazoles as carboxylic acid isosteres: chemistry and biology</span>. <i>J. Inclusion Phenom. Macrocyclic Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1007/s10847-013-0334-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs10847-013-0334-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1ekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2014&pages=15-37&author=M.+A.+Malikauthor=M.+Y.+Waniauthor=S.+A.+Al-Thabaitiauthor=R.+A.+Shiekh&title=Tetrazoles+as+carboxylic+acid+isosteres%3A+chemistry+and+biology&doi=10.1007%2Fs10847-013-0334-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrazoles as carboxylic acid isosteres: chemistry and biology</span></div><div class="casAuthors">Malik, Maqsood Ahmad; Wani, Mohmmad Younus; Al-Thabaiti, Shaeel Ahmed; Shiekh, Rayees Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inclusion Phenomena and Macrocyclic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">15-37</span>CODEN:
                <span class="NLM_cas:coden">JIPCF5</span>;
        ISSN:<span class="NLM_cas:issn">1388-3127</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tetrazoles are used as isosteric substituents of various functional groups in the development of biol. active substances.  The tetrazole motif has been used in various drug pharmacophores as a suitable replacement of carboxylic acid moiety and different methods have been used for the synthesis of tetrazoles using different reaction conditions.  The different synthetic methods, using catalysts or different reagents for the synthesis of tetrazoles were discussed.  The biol. importance of tetrazoles has also been highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-i6TX70KSH7Vg90H21EOLACvtfcHk0lgcPEcVPuKH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1ekug%253D%253D&md5=b08182a12adbb5d68e2c5aadbe2e3621</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs10847-013-0334-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10847-013-0334-x%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DM.%2BA.%26aulast%3DWani%26aufirst%3DM.%2BY.%26aulast%3DAl-Thabaiti%26aufirst%3DS.%2BA.%26aulast%3DShiekh%26aufirst%3DR.%2BA.%26atitle%3DTetrazoles%2520as%2520carboxylic%2520acid%2520isosteres%253A%2520chemistry%2520and%2520biology%26jtitle%3DJ.%2520Inclusion%2520Phenom.%2520Macrocyclic%2520Chem.%26date%3D2014%26volume%3D78%26spage%3D15%26epage%3D37%26doi%3D10.1007%2Fs10847-013-0334-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleckenstein, A.</span></span> <span> </span><span class="NLM_article-title">History of calcium antagonists</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">I3</span>– <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1983&pages=I3-16&author=A.+Fleckenstein&title=History+of+calcium+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleckenstein%26aufirst%3DA.%26atitle%3DHistory%2520of%2520calcium%2520antagonists%26jtitle%3DCirc.%2520Res.%26date%3D1983%26volume%3D52%26spage%3DI3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frishman, W. H.</span></span> <span> </span><span class="NLM_article-title">Verapamil therapy for stable and unstable angina pectoris: Calcium channel antagonists in perspective</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1016/0002-9149(82)91249-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0002-9149%2882%2991249-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1982&pages=881-885&author=M.+Packerauthor=W.+H.+Frishman&title=Verapamil+therapy+for+stable+and+unstable+angina+pectoris%3A+Calcium+channel+antagonists+in+perspective&doi=10.1016%2F0002-9149%2882%2991249-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2882%2991249-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252882%252991249-8%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DFrishman%26aufirst%3DW.%2BH.%26atitle%3DVerapamil%2520therapy%2520for%2520stable%2520and%2520unstable%2520angina%2520pectoris%253A%2520Calcium%2520channel%2520antagonists%2520in%2520perspective%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1982%26volume%3D50%26spage%3D881%26epage%3D885%26doi%3D10.1016%2F0002-9149%2882%2991249-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roule, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milliez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, J.</span></span> <span> </span><span class="NLM_article-title">Verapamil and vasospastic angina: underuse in the elderly population</span>. <i>J. Geriatr. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.11909/j.issn.1671-5411.2017.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.11909%2Fj.issn.1671-5411.2017.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28868071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=430-435&author=X.+Humbertauthor=V.+Rouleauthor=P.+Milliezauthor=J.+Alexandre&title=Verapamil+and+vasospastic+angina%3A+underuse+in+the+elderly+population&doi=10.11909%2Fj.issn.1671-5411.2017.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Verapamil and vasospastic angina: underuse in the elderly population</span></div><div class="casAuthors">Humbert, Xavier; Roule, Vincent; Milliez, Paul; Alexandre, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Geriatric Cardiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">430-435</span>CODEN:
                <span class="NLM_cas:coden">JGCOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1671-5411</span>.
    
            (<span class="NLM_cas:orgname">Science Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLSfRJ3tW9k7Vg90H21EOLACvtfcHk0lgcPEcVPuKH4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVOisr8%253D&md5=9b75a418bea6be9cdece3d46f3204fb1</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.11909%2Fj.issn.1671-5411.2017.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.11909%252Fj.issn.1671-5411.2017.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DX.%26aulast%3DRoule%26aufirst%3DV.%26aulast%3DMilliez%26aufirst%3DP.%26aulast%3DAlexandre%26aufirst%3DJ.%26atitle%3DVerapamil%2520and%2520vasospastic%2520angina%253A%2520underuse%2520in%2520the%2520elderly%2520population%26jtitle%3DJ.%2520Geriatr.%2520Cardiol.%26date%3D2017%26volume%3D14%26spage%3D430%26epage%3D435%26doi%3D10.11909%2Fj.issn.1671-5411.2017.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H.</span>; <span class="NLM_string-name">Schnermann, J.</span></span> <span> </span><span class="NLM_article-title">Methylxanthines and the kidney</span>. In  <i>Methylxanthines</i>; <span class="NLM_publisher-name">Springer Berlin Heidelberg</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">412</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2F978-3-642-13443-2_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=391-412&author=H.+Osswald&author=J.+Schnermann&title=Methylxanthines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-13443-2_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-13443-2_15%26sid%3Dliteratum%253Aachs%26aulast%3DOsswald%26aufirst%3DH.%26atitle%3DMethylxanthines%2520and%2520the%2520kidney%26btitle%3DMethylxanthines%26pub%3DSpringer%2520Berlin%2520Heidelberg%26date%3D2011%26spage%3D391%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eichenfield, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paller, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzenberger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamlin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordoro, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanifin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmets, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begolka, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidbury, R.</span></span> <span> </span><span class="NLM_article-title">Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2014.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.jaad.2014.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24813302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhtlKrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=116-132&author=L.+F.+Eichenfieldauthor=W.+L.+Tomauthor=T.+G.+Bergerauthor=A.+Krolauthor=A.+S.+Pallerauthor=K.+Schwarzenbergerauthor=J.+Bergmanauthor=S.+L.+Chamlinauthor=D.+E.+Cohenauthor=K.+D.+Cooperauthor=K.+M.+Cordoroauthor=D.+M.+Davisauthor=S.+R.+Feldmanauthor=J.+M.+Hanifinauthor=D.+J.+Margolisauthor=R.+A.+Silvermanauthor=E.+L.+Simpsonauthor=H.+C.+Williamsauthor=C.+A.+Elmetsauthor=J.+Blockauthor=C.+G.+Harrodauthor=W.+S.+Begolkaauthor=R.+Sidbury&title=Guidelines+of+care+for+the+management+of+atopic+dermatitis%3A+Section+2.+Management+and+treatment+of+atopic+dermatitis+with+topical+therapies&doi=10.1016%2Fj.jaad.2014.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies</span></div><div class="casAuthors">Eichenfield Lawrence F; Tom Wynnis L; Berger Timothy G; Cordoro Kelly M; Krol Alfons; Hanifin Jon M; Simpson Eric L; Paller Amy S; Schwarzenberger Kathryn; Bergman James N; Chamlin Sarah L; Cohen David E; Cooper Kevin D; Davis Dawn M; Feldman Steven R; Margolis David J; Silverman Robert A; Williams Hywel C; Elmets Craig A; Block Julie; Harrod Christopher G; Smith Begolka Wendy; Sidbury Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups.  This evidence-based guideline addresses important clinical questions that arise in its management.  In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed.  Where possible, suggestions on dosing and monitoring are given based on available evidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9pnzyTNi1Y75oR8RchjrrfW6udTcc2eYseZyvfgtJaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhtlKrsg%253D%253D&md5=71b0771572d704aa1d13485239bc6821</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2014.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2014.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DEichenfield%26aufirst%3DL.%2BF.%26aulast%3DTom%26aufirst%3DW.%2BL.%26aulast%3DBerger%26aufirst%3DT.%2BG.%26aulast%3DKrol%26aufirst%3DA.%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DSchwarzenberger%26aufirst%3DK.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DChamlin%26aufirst%3DS.%2BL.%26aulast%3DCohen%26aufirst%3DD.%2BE.%26aulast%3DCooper%26aufirst%3DK.%2BD.%26aulast%3DCordoro%26aufirst%3DK.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BM.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DHanifin%26aufirst%3DJ.%2BM.%26aulast%3DMargolis%26aufirst%3DD.%2BJ.%26aulast%3DSilverman%26aufirst%3DR.%2BA.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26aulast%3DWilliams%26aufirst%3DH.%2BC.%26aulast%3DElmets%26aufirst%3DC.%2BA.%26aulast%3DBlock%26aufirst%3DJ.%26aulast%3DHarrod%26aufirst%3DC.%2BG.%26aulast%3DBegolka%26aufirst%3DW.%2BS.%26aulast%3DSidbury%26aufirst%3DR.%26atitle%3DGuidelines%2520of%2520care%2520for%2520the%2520management%2520of%2520atopic%2520dermatitis%253A%2520Section%25202.%2520Management%2520and%2520treatment%2520of%2520atopic%2520dermatitis%2520with%2520topical%2520therapies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2014%26volume%3D71%26spage%3D116%26epage%3D132%26doi%3D10.1016%2Fj.jaad.2014.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treffel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derancourt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agache, P.</span></span> <span> </span><span class="NLM_article-title">The tetracyclines in dermatology</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1016/0190-9622(91)70255-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0190-9622%2891%2970255-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1791227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaK387ms1SgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1991&pages=691-697&author=P.+Humbertauthor=P.+Treffelauthor=J.-F.+Chapuisauthor=S.+Buchetauthor=C.+Derancourtauthor=P.+Agache&title=The+tetracyclines+in+dermatology&doi=10.1016%2F0190-9622%2891%2970255-Z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The tetracyclines in dermatology</span></div><div class="casAuthors">Humbert P; Treffel P; Chapuis J F; Buchet S; Derancourt C; Agache P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">691-7</span>
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    </div><div class="casAbstract">Tetracycline is one of the most widely used antibiotics.  It may share some properties with conventional immunosuppressive drugs and act as an anti-inflammatory agent in the treatment of inflammatory disease.  This article reviews cutaneous diseases that have been treated with tetracyclines and their antiinflammatory and immunosuppressive properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7v7oJvqnQzBFwe7cAcrfPfW6udTcc2eYseZyvfgtJaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387ms1SgtQ%253D%253D&md5=40f4522ba9579f22017fb3dabc74c46e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2F0190-9622%2891%2970255-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0190-9622%252891%252970255-Z%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DP.%26aulast%3DTreffel%26aufirst%3DP.%26aulast%3DChapuis%26aufirst%3DJ.-F.%26aulast%3DBuchet%26aufirst%3DS.%26aulast%3DDerancourt%26aufirst%3DC.%26aulast%3DAgache%26aufirst%3DP.%26atitle%3DThe%2520tetracyclines%2520in%2520dermatology%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1991%26volume%3D25%26spage%3D691%26epage%3D697%26doi%3D10.1016%2F0190-9622%2891%2970255-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, H. C.</span></span> <span> </span><span class="NLM_article-title">Clotrimazole as a pharmaceutical: past, present and future</span>. <i>J. Appl. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1111/jam.12554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fjam.12554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24863842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSrtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2014&pages=611-617&author=P.+D.+Crowleyauthor=H.+C.+Gallagher&title=Clotrimazole+as+a+pharmaceutical%3A+past%2C+present+and+future&doi=10.1111%2Fjam.12554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Clotrimazole as a pharmaceutical: past, present and future.</span></div><div class="casAuthors">Crowley, P. D.; Gallagher, H. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">611-617</span>CODEN:
                <span class="NLM_cas:coden">JAMIFK</span>;
        ISSN:<span class="NLM_cas:issn">1364-5072</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : Clotrimazole is a broad-spectrum antimycotic drug mainly used for the treatment of Candida albicans and other fungal infections.  A synthetic, azole antimycotic, clotrimazole is widely used as a topical treatment for tinea pedis (athlete's foot), as well as vulvovaginal and oropharyngeal candidiasis.  It displays fungistatic antimycotic activity by targeting the biosynthesis of ergosterol, thereby inhibiting fungal growth.  As well as its antimycotic activity, clotrimazole has become a drug of interest against several other diseases such as sickle cell disease, malaria and some cancers.  It has also been combined with other mols., such as the metals, to produce clotrimazole complexes that show improved pharmacol. efficacy.  Moreover, several new, modified-release pharmaceutical formulations are also undergoing development.  Clotrimazole is a very well-tolerated product with few side effects, although there is some drug resistance appearing among immunocompromised patients.  Here, we review the pharmaceutical chem., application and pharmacol. of clotrimazole and discuss future prospects for its further development as a chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8PAH-8cBX07Vg90H21EOLACvtfcHk0lglCRLhQV8b4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSrtbrN&md5=3323c4d5b684e3737422fc93e125f3e3</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1111%2Fjam.12554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjam.12554%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DP.%2BD.%26aulast%3DGallagher%26aufirst%3DH.%2BC.%26atitle%3DClotrimazole%2520as%2520a%2520pharmaceutical%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DJ.%2520Appl.%2520Microbiol.%26date%3D2014%26volume%3D117%26spage%3D611%26epage%3D617%26doi%3D10.1111%2Fjam.12554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Rosso, J. Q.</span></span> <span> </span><span class="NLM_article-title">What is the role of benzoyl peroxide cleansers in acne management?: Do they decrease propionibacterium acnes counts? Do they reduce acne lesions?</span>. <i>J. Clin. Aesthet. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21218192" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=48-51&author=J.+Q.+Del%0ARosso&title=What+is+the+role+of+benzoyl+peroxide+cleansers+in+acne+management%3F%3A+Do+they+decrease+propionibacterium+acnes+counts%3F+Do+they+reduce+acne+lesions%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BRosso%26aufirst%3DJ.%2BQ.%26atitle%3DWhat%2520is%2520the%2520role%2520of%2520benzoyl%2520peroxide%2520cleansers%2520in%2520acne%2520management%253F%253A%2520Do%2520they%2520decrease%2520propionibacterium%2520acnes%2520counts%253F%2520Do%2520they%2520reduce%2520acne%2520lesions%253F%26jtitle%3DJ.%2520Clin.%2520Aesthet.%2520Dermatol.%26date%3D2008%26volume%3D1%26spage%3D48%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torok, H. M.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream</span>. <i>Am. J. Clin. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.2165/00128071-200607040-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00128071-200607040-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=16901182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD28vnslarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=223-230&author=H.+M.+Torok&title=A+comprehensive+review+of+the+long-term+and+short-term+treatment+of+melasma+with+a+triple+combination+cream&doi=10.2165%2F00128071-200607040-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream</span></div><div class="casAuthors">Torok Helen M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of clinical dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">223-30</span>
        ISSN:<span class="NLM_cas:issn">1175-0561</span>.
    </div><div class="casAbstract">Melasma is a common disorder of hyperpigmentation and generally involves areas of the face and neck.  Hyperpigmentation is especially prevalent in darker complected patients and is often difficult to treat.  Hydroquinone, tretinoin, and topical corticosteroids are well established monotherapeutic agents for treating melasma and hyperpigmentation; however, a stable, once-daily formulation triple combination cream containing 0.05% tretinoin, 4.0% hydroquinone, and 0.01% fluocinolone acetonide (Tri-Luma) represents the only commercially available combination of all three agents.  This product is approved by the US FDA for the treatment of facial melasma.  A number of publications have described the safety and efficacy of triple combination cream in over 2000 patients with melasma, some of whom were treated for >12 months.  In the initial 8-week study, 29% of patients experienced complete clearing of melasma by week 8, and 77% were clear or almost clear by week 8.  Similarly, good results were seen in the two long-term studies, with the clear/mild rate ranging from 78% to 84% of patients at month 6 and from 81% to 94% of patients at month 12.  Adverse events were almost always mild in severity and typically occurred only at the application site.  The primary concern for most physicians using corticosteroid-containing products on the face is skin atrophy.  However, only two cases of skin atrophy were reported across the three published studies.  Overall, the results of these extensive studies indicate that triple combination cream is efficacious in treating melasma and exhibits a safe profile with low potential for adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW0r9d7c8iJwWRJ3OJdH_qfW6udTcc2eZ-nEOJRscsN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vnslarsw%253D%253D&md5=f7989c6b85908d7723976b3478ead402</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2165%2F00128071-200607040-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00128071-200607040-00003%26sid%3Dliteratum%253Aachs%26aulast%3DTorok%26aufirst%3DH.%2BM.%26atitle%3DA%2520comprehensive%2520review%2520of%2520the%2520long-term%2520and%2520short-term%2520treatment%2520of%2520melasma%2520with%2520a%2520triple%2520combination%2520cream%26jtitle%3DAm.%2520J.%2520Clin.%2520Dermatol.%26date%3D2006%26volume%3D7%26spage%3D223%26epage%3D230%26doi%3D10.2165%2F00128071-200607040-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmets, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfand, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhees, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, R.</span></span> <span> </span><span class="NLM_article-title">Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2008.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.jaad.2008.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19217694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=643-659&author=A.+Menterauthor=N.+J.+Kormanauthor=C.+A.+Elmetsauthor=S.+R.+Feldmanauthor=J.+M.+Gelfandauthor=K.+B.+Gordonauthor=A.+Gottliebauthor=J.+Y.+M.+Kooauthor=M.+Lebwohlauthor=H.+W.+Limauthor=A.+S.+Van+Voorheesauthor=K.+R.+Beutnerauthor=R.+Bhushan&title=Guidelines+of+care+for+the+management+of+psoriasis+and+psoriatic+arthritis%3A+section+3.+Guidelines+of+care+for+the+management+and+treatment+of+psoriasis+with+topical+therapies&doi=10.1016%2Fj.jaad.2008.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span></div><div class="casAuthors">Menter Alan; Korman Neil J; Elmets Craig A; Feldman Steven R; Gelfand Joel M; Gordon Kenneth B; Gottlieb Alice; Koo John Y M; Lebwohl Mark; Lim Henry W; Van Voorhees Abby S; Beutner Karl R; Bhushan Reva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the population.  In this third of 6 sections of the guidelines of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis.  The majority of patients with psoriasis have limited disease (<5% body surface area involvement) and can be treated with topical agents, which generally provide a high efficacy-to-safety ratio.  Topical agents may also be used adjunctively for patients with more extensive psoriasis undergoing therapy with either ultraviolet light, systemic or biologic medications.  However, the use of topical agents as monotherapy in the setting of extensive disease or in the setting of limited, but recalcitrant, disease is not routinely recommended.  Treatment should be tailored to meet individual patients' needs.  We will discuss the efficacy and safety of as well as offer recommendations for the use of topical corticosteroids, vitamin D analogues, tazarotene, tacrolimus, pimecrolimus, emollients, salicylic acid, anthralin, coal tar, as well as combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNrA_ozK6QJHy-c-E1v-fmfW6udTcc2eZ-nEOJRscsN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D&md5=c4975aee4050bd186fb5ff428a8f23bd</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2008.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2008.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DKorman%26aufirst%3DN.%2BJ.%26aulast%3DElmets%26aufirst%3DC.%2BA.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGelfand%26aufirst%3DJ.%2BM.%26aulast%3DGordon%26aufirst%3DK.%2BB.%26aulast%3DGottlieb%26aufirst%3DA.%26aulast%3DKoo%26aufirst%3DJ.%2BY.%2BM.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DVan%2BVoorhees%26aufirst%3DA.%2BS.%26aulast%3DBeutner%26aufirst%3DK.%2BR.%26aulast%3DBhushan%26aufirst%3DR.%26atitle%3DGuidelines%2520of%2520care%2520for%2520the%2520management%2520of%2520psoriasis%2520and%2520psoriatic%2520arthritis%253A%2520section%25203.%2520Guidelines%2520of%2520care%2520for%2520the%2520management%2520and%2520treatment%2520of%2520psoriasis%2520with%2520topical%2520therapies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2009%26volume%3D60%26spage%3D643%26epage%3D659%26doi%3D10.1016%2Fj.jaad.2008.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span> <span> </span><span class="NLM_article-title">Dutasteride for the treatment of benign prostatic hyperplasia</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1399</span>– <span class="NLM_lpage">1408</span>, <span class="refDoi"> DOI: 10.1517/14656566.2013.797965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1517%2F14656566.2013.797965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23750593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1CjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1399-1408&author=C.+Wuauthor=A.+Kapoor&title=Dutasteride+for+the+treatment+of+benign+prostatic+hyperplasia&doi=10.1517%2F14656566.2013.797965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dutasteride for the treatment of benign prostatic hyperplasia</span></div><div class="casAuthors">Wu, Christopher; Kapoor, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1399-1408</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Benign prostatic hyperplasia (BPH) is an age-related phenomenon assocd. with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms that greatly affect quality of life. is a selective inhibitor of type 1 and type 2 isoforms of 5-α-reductase, an enzyme responsible for the conversion of testosterone to 5-α-dihydrotestosterone, approved as a treatment for symptomatic BPH.  Areas covered: This article will cover the efficacy and safety of dutasteride in the treatment of BPH, with focus on landmark trials conducted on this drug.  Medical literature on the use of dutasteride in men with BPH were identified by searching databases since 1996 (including MEDLINE and EMBASE) as well as bibliogs. from published literature, clin. trial registries and manufacturer and federal drug regulatory websites.  Expert opinion: Dutasteride is an effective, safe and well-tolerated treatment either as monotherapy or in combination with an α-blocker, for the management of symptomatic BPH to improve symptoms, reduce the risk of acute urinary retention and risk for BPH-related surgery.  A new prostate-specific antigen baseline should be established after 6 mo of therapy for clin. decision making.  The relationship between dutasteride and high-grade prostate cancer is not clear, and dutasteride is not approved for prostate cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3DL5sS37_bVg90H21EOLACvtfcHk0lhVn3VIb4wZ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1CjsLg%253D&md5=eeb3716f00bd8f22cb0014c66058e07c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.797965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.797965%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DKapoor%26aufirst%3DA.%26atitle%3DDutasteride%2520for%2520the%2520treatment%2520of%2520benign%2520prostatic%2520hyperplasia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D1399%26epage%3D1408%26doi%3D10.1517%2F14656566.2013.797965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, F. C.</span></span> <span> </span><span class="NLM_article-title">Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia</span>. <i>Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">S13</span>– <span class="NLM_lpage">S21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=16986050" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=S13-S21&author=F.+C.+Lowe&title=Summary+of+clinical+experiences+with+tamsulosin+for+the+treatment+of+benign+prostatic+hyperplasia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DF.%2BC.%26atitle%3DSummary%2520of%2520clinical%2520experiences%2520with%2520tamsulosin%2520for%2520the%2520treatment%2520of%2520benign%2520prostatic%2520hyperplasia%26jtitle%3DRev.%2520Urol.%26date%3D2005%26volume%3D7%26spage%3DS13%26epage%3DS21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams-Frame, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, J. S.</span></span> <span> </span><span class="NLM_article-title">Costs of hormonal and nonhormonal prescription medications for hot flashes</span>. <i>Women's Health</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.2217/WHE.09.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2217%2FWHE.09.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MrnsF2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=497-502&author=A.+Williams-Frameauthor=J.+S.+Carpenter&title=Costs+of+hormonal+and+nonhormonal+prescription+medications+for+hot+flashes&doi=10.2217%2FWHE.09.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Costs of hormonal and nonhormonal prescription medications for hot flashes</span></div><div class="casAuthors">Williams-Frame Amie; Carpenter Janet S</div><div class="citationInfo"><span class="NLM_cas:title">Women's health (London, England)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-502</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hot flashes are the cardinal symptom of menopause and can be treated with hormonal and nonhormonal prescription medications.  However, considering that 6000 women enter menopause daily in the USA, and many of these women are symptomatic, the costs of these treatments can be a significant public health issue.  We evaluated annual individual and population costs of hormonal and nonhormonal prescription treatments for hot flashes.  Cost information may be helpful to clinicians and consumers in making treatment decisions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3AzUZDQsrd8ULxIEhxUjPfW6udTcc2eZyZYI-Z14SHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrnsF2ltg%253D%253D&md5=f9bb444a26eff66b55263d5a57cddce8</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2217%2FWHE.09.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252FWHE.09.49%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams-Frame%26aufirst%3DA.%26aulast%3DCarpenter%26aufirst%3DJ.%2BS.%26atitle%3DCosts%2520of%2520hormonal%2520and%2520nonhormonal%2520prescription%2520medications%2520for%2520hot%2520flashes%26jtitle%3DWomen%2527s%2520Health%26date%3D2009%26volume%3D5%26spage%3D497%26epage%3D502%26doi%3D10.2217%2FWHE.09.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niebyl, J.</span></span> <span> </span><span class="NLM_article-title">Bendectin: how a safe and effective drug was removed from the market by our legal system</span>. <i>ACOG Clin. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=25-27&author=R.+W.+Haleauthor=J.+Niebyl&title=Bendectin%3A+how+a+safe+and+effective+drug+was+removed+from+the+market+by+our+legal+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DR.%2BW.%26aulast%3DNiebyl%26aufirst%3DJ.%26atitle%3DBendectin%253A%2520how%2520a%2520safe%2520and%2520effective%2520drug%2520was%2520removed%2520from%2520the%2520market%2520by%2520our%2520legal%2520system%26jtitle%3DACOG%2520Clin.%2520Rev.%26date%3D2012%26volume%3D17%26spage%3D25%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ornstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, G.</span></span> <span> </span><span class="NLM_article-title">Bendectin/Diclectin for morning sickness: A canadian follow-up of an American tragedy</span>. <i>Reprod. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/0890-6238(94)00050-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0890-6238%2894%2900050-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=8520127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK2MXktVOitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=1-6&author=M.+Ornsteinauthor=A.+Einarsonauthor=G.+Koren&title=Bendectin%2FDiclectin+for+morning+sickness%3A+A+canadian+follow-up+of+an+American+tragedy&doi=10.1016%2F0890-6238%2894%2900050-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Bendectin/dicletin for morning sickness: a Canadian follow-up of American tragedy</span></div><div class="casAuthors">Ornstein, Melanie; Einarson, Adrianne; Koren, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Reproductive Toxicology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">REPTED</span>;
        ISSN:<span class="NLM_cas:issn">0890-6238</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHy3VD3Bqc6LVg90H21EOLACvtfcHk0lh7QlcWaY4RIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktVOitbc%253D&md5=01a12649c78994038ebc20b39b70bee4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2F0890-6238%2894%2900050-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0890-6238%252894%252900050-7%26sid%3Dliteratum%253Aachs%26aulast%3DOrnstein%26aufirst%3DM.%26aulast%3DEinarson%26aufirst%3DA.%26aulast%3DKoren%26aufirst%3DG.%26atitle%3DBendectin%252FDiclectin%2520for%2520morning%2520sickness%253A%2520A%2520canadian%2520follow-up%2520of%2520an%2520American%2520tragedy%26jtitle%3DReprod.%2520Toxicol.%26date%3D1995%26volume%3D9%26spage%3D1%26epage%3D6%26doi%3D10.1016%2F0890-6238%2894%2900050-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuangchamnong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niebyl, J.</span></span> <span> </span><span class="NLM_article-title">Doxylamine succinate–pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview</span>. <i>Int. J. Women's Health</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.2147/IJWH.S46653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FIJWH.S46653" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=401-409&author=N.+Nuangchamnongauthor=J.+Niebyl&title=Doxylamine+succinate%E2%80%93pyridoxine+hydrochloride+%28Diclegis%29+for+the+management+of+nausea+and+vomiting+in+pregnancy%3A+an+overview&doi=10.2147%2FIJWH.S46653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2147%2FIJWH.S46653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJWH.S46653%26sid%3Dliteratum%253Aachs%26aulast%3DNuangchamnong%26aufirst%3DN.%26aulast%3DNiebyl%26aufirst%3DJ.%26atitle%3DDoxylamine%2520succinate%25E2%2580%2593pyridoxine%2520hydrochloride%2520%2528Diclegis%2529%2520for%2520the%2520management%2520of%2520nausea%2520and%2520vomiting%2520in%2520pregnancy%253A%2520an%2520overview%26jtitle%3DInt.%2520J.%2520Women%2527s%2520Health%26date%3D2014%26volume%3D2014%26spage%3D401%26epage%3D409%26doi%3D10.2147%2FIJWH.S46653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span> </span><span class="NLM_article-title">Lesinurad/allopurinol (Duzallo) for gout-associated
hyperuricemia</span>.  <i>Med. Lett. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>.  <span class="NLM_volume">59</span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">183</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29125593" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lesinurad%2Fallopurinol+%28Duzallo%29+for+gout-associated%0Ahyperuricemia.+Med.+Lett.+Drugs+Ther.+2017.+59%2C+182%E2%80%93183."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DLesinurad%252Fallopurinol%2520%2528Duzallo%2529%2520for%2520gout-associated%250Ahyperuricemia%26jtitle%3DMed.%2520Lett.%2520Drugs%2520Ther.%26date%3D2017%26volume%3D59%26spage%3D182%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komm, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chines, A. A.</span></span> <span> </span><span class="NLM_article-title">Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis</span>. <i>Ther. Adv. Musculoskeletal Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1177/1759720X11422602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1177%2F1759720X11422602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=22870492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsVSkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=21-34&author=B.+S.+Kommauthor=A.+A.+Chines&title=Bazedoxifene%3A+the+evolving+role+of+third-generation+selective+estrogen-receptor+modulators+in+the+management+of+postmenopausal+osteoporosis&doi=10.1177%2F1759720X11422602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis</span></div><div class="casAuthors">Komm, Barry S.; Chines, Arkadi A.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Musculoskeletal Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-34</span>CODEN:
                <span class="NLM_cas:coden">TAMDDB</span>;
        ISSN:<span class="NLM_cas:issn">1759-720X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Osteoporosis is a significant public health concern, particularly for postmenopausal women.  Current treatment options may not be appropriate for all women.  Selective estrogen-receptor modulators (SERMs) are a class of mols. with tissue-selective activity.  Bazedoxifene is currently in clin. development for the prevention and treatment of postmenopausal osteoporosis.  In a 2-yr, phase III, osteoporosis prevention study (N=1583), bazedoxifene 10, 20, and 40 mg was shown to preserve bone mineral d. and decrease biochem. markers of bone turnover compared with placebo in postmenopausal women at risk for osteoporosis.  In a pivotal 3-yr, phase III, osteoporosis treatment study (N=7492), bazedoxifene 20 and 40 mg significantly reduced the incidence of new vertebral fractures compared with placebo (p < 0.05 for both) in postmenopausal women with osteoporosis.  In a post hoc subgroup anal. of women at higher risk for fracture (n = 1772), bazedoxifene 20 mg significantly reduced the risk of nonvertebral fractures vs. placebo (p = 0.02) and raloxifene 60 mg (p = 0.05).  Bazedoxifene 20 mg has demonstrated sustained efficacy in reducing the risk of vertebral fractures over 5 and 7 years.  Overall, bazedoxifene was generally safe and well tolerated, with favorable endometrial and breast safety profiles.  As with other SERMs, the rate of deep vein thrombosis was higher in the bazedoxifene groups compared with placebo at 3 and 5 years.  Considering its demonstrated efficacy and safety, bazedoxifene may be an appropriate osteoporosis therapy for women who cannot take or are unwilling to take bisphosphonates because of safety or tolerability issues.  Bazedoxifene may also be appropriate for younger women at increased fracture risk who are concerned about the effects of long-term bisphosphonate therapy.  This article reviews the results of key clin. trials of bazedoxifene for the prevention and treatment of postmenopausal osteoporosis and describes its role in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU7eE7Fh2LN7Vg90H21EOLACvtfcHk0lh7QlcWaY4RIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsVSkuro%253D&md5=34fec43fb64cb96e4d432cf0bee5b4b3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1177%2F1759720X11422602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1759720X11422602%26sid%3Dliteratum%253Aachs%26aulast%3DKomm%26aufirst%3DB.%2BS.%26aulast%3DChines%26aufirst%3DA.%2BA.%26atitle%3DBazedoxifene%253A%2520the%2520evolving%2520role%2520of%2520third-generation%2520selective%2520estrogen-receptor%2520modulators%2520in%2520the%2520management%2520of%2520postmenopausal%2520osteoporosis%26jtitle%3DTher.%2520Adv.%2520Musculoskeletal%2520Dis.%26date%3D2012%26volume%3D4%26spage%3D21%26epage%3D34%26doi%3D10.1177%2F1759720X11422602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddleston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szinicz, L.</span></span> <span> </span><span class="NLM_article-title">Oximes for acute organophosphate pesticide poisoning</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD005085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2F14651858.CD005085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=1&author=N.+Buckleyauthor=M.+Eddlestonauthor=L.+Szinicz&title=Oximes+for+acute+organophosphate+pesticide+poisoning&doi=10.1002%2F14651858.CD005085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD005085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD005085%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DN.%26aulast%3DEddleston%26aufirst%3DM.%26aulast%3DSzinicz%26aufirst%3DL.%26atitle%3DOximes%2520for%2520acute%2520organophosphate%2520pesticide%2520poisoning%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2005%26spage%3D1%26doi%3D10.1002%2F14651858.CD005085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tfelt-Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Láinez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Ergotamine in the acute treatment of migraine: a review and European consensus</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1093/brain/123.1.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1093%2Fbrain%2F123.1.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10611116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FnvV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2000&pages=9-18&author=P.+Tfelt-Hansenauthor=P.+R.+Saxenaauthor=C.+Dahl%C3%B6fauthor=J.+Pascualauthor=M.+L%C3%A1inezauthor=P.+Henryauthor=H.+C.+Dienerauthor=J.+Schoenenauthor=M.+D.+Ferrariauthor=P.+J.+Goadsby&title=Ergotamine+in+the+acute+treatment+of+migraine%3A+a+review+and+European+consensus&doi=10.1093%2Fbrain%2F123.1.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Ergotamine in the acute treatment of migraine: a review and European consensus</span></div><div class="casAuthors">Tfelt-Hansen P; Saxena P R; Dahlof C; Pascual J; Lainez M; Henry P; Diener H; Schoenen J; Ferrari M D; Goadsby P J</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">123 ( Pt 1)</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-18</span>
        ISSN:<span class="NLM_cas:issn">0006-8950</span>.
    </div><div class="casAbstract">Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice.  An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine.  From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed.  In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions.  For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQow0IwdymLFX6CEoQgWY10fW6udTcc2ebexEA6z-Dzsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FnvV2ktg%253D%253D&md5=54558d2207c9d2932bbb8bcbfc9f8ac1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2F123.1.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252F123.1.9%26sid%3Dliteratum%253Aachs%26aulast%3DTfelt-Hansen%26aufirst%3DP.%26aulast%3DSaxena%26aufirst%3DP.%2BR.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DC.%26aulast%3DPascual%26aufirst%3DJ.%26aulast%3DL%25C3%25A1inez%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DP.%26aulast%3DDiener%26aufirst%3DH.%2BC.%26aulast%3DSchoenen%26aufirst%3DJ.%26aulast%3DFerrari%26aufirst%3DM.%2BD.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DErgotamine%2520in%2520the%2520acute%2520treatment%2520of%2520migraine%253A%2520a%2520review%2520and%2520European%2520consensus%26jtitle%3DBrain%26date%3D2000%26volume%3D123%26spage%3D9%26epage%3D18%26doi%3D10.1093%2Fbrain%2F123.1.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonaci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiotto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A.</span></span> <span> </span><span class="NLM_article-title">Recent advances in migraine therapy</span>. <i>SpringerPlus</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>, <span class="refDoi"> DOI: 10.1186/s40064-016-2211-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1186%2Fs40064-016-2211-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=637&author=F.+Antonaciauthor=N.+Ghiottoauthor=S.+Wuauthor=E.+Pucciauthor=A.+Costa&title=Recent+advances+in+migraine+therapy&doi=10.1186%2Fs40064-016-2211-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1186%2Fs40064-016-2211-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40064-016-2211-8%26sid%3Dliteratum%253Aachs%26aulast%3DAntonaci%26aufirst%3DF.%26aulast%3DGhiotto%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DPucci%26aufirst%3DE.%26aulast%3DCosta%26aufirst%3DA.%26atitle%3DRecent%2520advances%2520in%2520migraine%2520therapy%26jtitle%3DSpringerPlus%26date%3D2016%26volume%3D5%26spage%3D637%26doi%3D10.1186%2Fs40064-016-2211-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, P. R.</span></span> <span> </span><span class="NLM_article-title">Clinical effects and mechanism of action of sumatriptan in migraine</span>. <i>Clin. Neurol. Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/0303-8467(92)90028-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0303-8467%2892%2990028-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1321704" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1992&pages=73-77&author=M.+D.+Ferrariauthor=P.+R.+Saxena&title=Clinical+effects+and+mechanism+of+action+of+sumatriptan+in+migraine&doi=10.1016%2F0303-8467%2892%2990028-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0303-8467%2892%2990028-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-8467%252892%252990028-2%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DM.%2BD.%26aulast%3DSaxena%26aufirst%3DP.%2BR.%26atitle%3DClinical%2520effects%2520and%2520mechanism%2520of%2520action%2520of%2520sumatriptan%2520in%2520migraine%26jtitle%3DClin.%2520Neurol.%2520Neurosurg.%26date%3D1992%26volume%3D94%26spage%3D73%26epage%3D77%26doi%3D10.1016%2F0303-8467%2892%2990028-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaffenrath, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, T. J.</span></span> <span> </span><span class="NLM_article-title">Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1046/j.1468-2982.1995.1505337.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1046%2Fj.1468-2982.1995.1505337.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=8536293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaK287hsVWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=337-357&author=M.+Wilkinsonauthor=V.+Pfaffenrathauthor=J.+Schoenenauthor=H.+C.+Dienerauthor=T.+J.+Steiner&title=Migraine+and+cluster+headache%2D%2Dtheir+management+with+sumatriptan%3A+a+critical+review+of+the+current+clinical+experience&doi=10.1046%2Fj.1468-2982.1995.1505337.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience</span></div><div class="casAuthors">Wilkinson M; Pfaffenrath V; Schoenen J; Diener H C; Steiner T J</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-57</span>
        ISSN:<span class="NLM_cas:issn">0333-1024</span>.
    </div><div class="casAbstract">Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater following activation of the trigeminovascular system.  The mode of action of this drug in migraine and cluster headache is discussed.  On the basis of a detailed review of all published trials and available data from post-marketing studies, the efficacy, safety, tolerability and the place of oral and subcutaneous sumatriptan in the treatment of both conditions are assessed.  A number of double-blind clinical trials have demonstrated that sumatriptan 100 mg administered orally is clearly superior to placebo in the acute treatment of migraine headache and achieves significantly greater response rates than ergotamine or aspirin.  In other studies, 70 to 80% of patients receiving sumatriptan 6 mg sc experienced relief of migraine headaches by 1 or 2 h after administration, and patients consistently required less rescue medication for unresolved symptoms.  Sumatriptan was also effective in relieving associated migraine symptoms like nausea and vomiting.  Sumatriptan was equally effective regardless of migraine type or duration of migraine symptoms.  Overall, approximately 40% of patients who initially responded to oral or subcutaneous sumatriptan experienced recurrence of their headache usually within 24 h, effectively treated by a further dose of this drug.  In 75% of patients with cluster headache treated with sumatriptan 6 mg sc, relief was achieved within 15 min.  Based on pooled study data, sumatriptan is generally well tolerated and most adverse events are transient.  Adverse events following oral administration include nausea, vomiting, malaise, fatigue and dizziness.  With the subcutaneous injection, injection site reactions occur in approximately 30%.  Chest syumptoms are reported in 3 to 5% but have been associated with myocardial ischaemia only in rare isolated cases.  The recommended dosage of sumatriptan at the onset of migraine symptoms is 100 mg orally or 6 mg subcutaneously.  The recommended dosage for cluster headache is 6 mg sumatriptan sc.  Sumatriptan must not be given together with vasoconstrictive substances, e.g., ergotamines, or with migraine prophylactics with similar properties, e.g., methysergide.  Sumatriptan should not be given during the migraine aura.  It is contraindicated in patients with ischaemic heart disease, previous myocardial infarction, Prinzmetal (variant) angina and uncontrolled hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLJjCtJ_Y3iMjl5L8hwNX0fW6udTcc2ebexEA6z-Dzsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287hsVWhtg%253D%253D&md5=ca57418538a02c109fdaa5319eabdfbd</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1046%2Fj.1468-2982.1995.1505337.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1468-2982.1995.1505337.x%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DM.%26aulast%3DPfaffenrath%26aufirst%3DV.%26aulast%3DSchoenen%26aufirst%3DJ.%26aulast%3DDiener%26aufirst%3DH.%2BC.%26aulast%3DSteiner%26aufirst%3DT.%2BJ.%26atitle%3DMigraine%2520and%2520cluster%2520headache--their%2520management%2520with%2520sumatriptan%253A%2520a%2520critical%2520review%2520of%2520the%2520current%2520clinical%2520experience%26jtitle%3DCephalalgia%26date%3D1995%26volume%3D15%26spage%3D337%26epage%3D357%26doi%3D10.1046%2Fj.1468-2982.1995.1505337.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLure, H. A.</span></span> <span> </span><span class="NLM_article-title">Review of local anaesthetic agents</span>. <i>Curr. Anaesth. Crit. Care.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/j.cacc.2004.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.cacc.2004.08.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=247-254&author=G.+Laganauthor=H.+A.+McLure&title=Review+of+local+anaesthetic+agents&doi=10.1016%2Fj.cacc.2004.08.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.cacc.2004.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cacc.2004.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DLagan%26aufirst%3DG.%26aulast%3DMcLure%26aufirst%3DH.%2BA.%26atitle%3DReview%2520of%2520local%2520anaesthetic%2520agents%26jtitle%3DCurr.%2520Anaesth.%2520Crit.%2520Care.%26date%3D2004%26volume%3D15%26spage%3D247%26epage%3D254%26doi%3D10.1016%2Fj.cacc.2004.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuntokun, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2549</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1038/npp.2014.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fnpp.2014.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24801768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1ehsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=2549-2559&author=E.+Brunnerauthor=M.+Tohenauthor=O.+Osuntokunauthor=J.+Landryauthor=M.+E.+Thase&title=Efficacy+and+safety+of+olanzapine%2Ffluoxetine+combination+vs+fluoxetine+monotherapy+following+successful+combination+therapy+of+treatment-resistant+major+depressive+disorder&doi=10.1038%2Fnpp.2014.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder</span></div><div class="casAuthors">Brunner, Elizabeth; Tohen, Mauricio; Osuntokun, Olawale; Landry, John; Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2549-2559</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study assessed prevention of relapse in patients with treatment-resistant depression (TRD) taking olanzapine/fluoxetine combination (OFC).  Patients with major depressive disorder (MDD) who failed to satisfactorily respond to ≥2 different antidepressants for ≥6 wk within the current MDD episode were acutely treated for 6-8 wk, followed by stabilization (12 wk) on OFC.  Those who remained stable were randomized to OFC or fluoxetine for up to 27 wk.  Time-to-relapse was the primary efficacy outcome defined as 50% increase in Montgomery-Åsberg Depression Rating Scale score with Clin. Global Impressions-Severity of Depression score of ≥4; hospitalization for depression or suicidality; or discontinuation for lack of efficacy or worsening of depression or suicidality.  A total of 444 patients were randomized 1:1 to OFC (N=221) or fluoxetine (N=223).  Time-to-relapse was significantly longer in OFC-treated patients compared with fluoxetine-treated patients (p<0.001).  Treatment-emergent wt. gain and some mean and categorical fasting metabolic changes were significantly greater in OFC-treated patients.  Clin. significant wt. gain (≥7%) was obsd. in 55.7% of patients who remained on OFC throughout the study, including the relapse-prevention phase (up to 47 wk).  There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events.  We believe this is the first controlled relapse-prevention study in subjects with TRD that supports continued use of a second-generation antipsychotic beyond stabilization.  A thorough assessment of benefits and risks (in particular metabolic changes) assocd. with continuing treatment with OFC or fluoxetine must be done based on individual patient needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxeZo4ppELNrVg90H21EOLACvtfcHk0li1ZIsXfXo6bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1ehsb8%253D&md5=38dac2fd5deab2ebb35832aef9b8ad0b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2014.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2014.101%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DE.%26aulast%3DTohen%26aufirst%3DM.%26aulast%3DOsuntokun%26aufirst%3DO.%26aulast%3DLandry%26aufirst%3DJ.%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520olanzapine%252Ffluoxetine%2520combination%2520vs%2520fluoxetine%2520monotherapy%2520following%2520successful%2520combination%2520therapy%2520of%2520treatment-resistant%2520major%2520depressive%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D2549%26epage%3D2559%26doi%3D10.1038%2Fnpp.2014.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M. P.</span></span> <span> </span><span class="NLM_article-title">Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=325-328&author=M.+P.+Cruz&title=Nuedexta+for+the+treatment+of+pseudobulbar+affect%3A+a+condition+of+involuntary+crying+or+laughing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DM.%2BP.%26atitle%3DNuedexta%2520for%2520the%2520treatment%2520of%2520pseudobulbar%2520affect%253A%2520a%2520condition%2520of%2520involuntary%2520crying%2520or%2520laughing%26jtitle%3DPharm.%2520Ther.%26date%3D2013%26volume%3D38%26spage%3D325%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D.
J.</span></span> <span> </span><span class="NLM_article-title">Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective</span>. <i>Neuropsych. Dis. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.2147/NDT.S1660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FNDT.S1660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18728816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=39-47&author=D.%0AJ.+Brooks&title=Optimizing+levodopa+therapy+for+Parkinson%E2%80%99s+disease+with+levodopa%2Fcarbidopa%2Fentacapone%3A+implications+from+a+clinical+and+patient+perspective&doi=10.2147%2FNDT.S1660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacepone: implications from a clinical and patient perspective</span></div><div class="casAuthors">Brooks, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychiatric Disease and Treatment</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1A</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">NDTEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1176-6328</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  After 40 years of clin. experience, levodopa remains the gold std. treatment for Parkinson's disease (PD) despite the recent emergence of a host of new therapies.  Some physicians are cautious when prescribing levodopa because of its assocn. with motor complications.  Evidence now suggests that levodopa-assocd. complications are a result of deep troughs in delivery of levodopa to the brain caused by the short plasma half-life of conventional levodopa formulations (levodopa and a dopa decarboxylase inhibitor [DDCI]).  Dosing strategies, such as dose increases and dose fractionation, may be effective in the short term.  For the longer-term, levodopa/carbidopa/entacapone provides pharmacokinetically optimized levodopa therapy that significantly increases the plasma half-life and bioavailability of levodopa, providing more consistent plasma levodopa levels without deep troughs.  Evidence from clin. trials in PD patients experiencing re-emergence of symptoms due to wearing-off has consistently shown that levodopa/DDCI and entacapone significantly increases ON-time and affords greater functionality, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) with conventional levodopa.  These trials have also shown that levodopa/DDCI and entacapone is generally well tolerated, with notable adverse events including worsening dyskinesia, nausea and diarrhea.  Patients experiencing re-emergence of symptoms due to wearing-off may benefit from optimized levodopa therapy with levodopa/carbidopa/entacapone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmoeEowCYzFbVg90H21EOLACvtfcHk0li1ZIsXfXo6bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVeisL4%253D&md5=a59711859027f788c28576c2ceb4d1b8</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.2147%2FNDT.S1660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FNDT.S1660%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DOptimizing%2520levodopa%2520therapy%2520for%2520Parkinson%25E2%2580%2599s%2520disease%2520with%2520levodopa%252Fcarbidopa%252Fentacapone%253A%2520implications%2520from%2520a%2520clinical%2520and%2520patient%2520perspective%26jtitle%3DNeuropsych.%2520Dis.%2520Treat.%26date%3D2008%26volume%3D4%26spage%3D39%26epage%3D47%26doi%3D10.2147%2FNDT.S1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeberger, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R. A.</span></span> <span> </span><span class="NLM_article-title">Levodopa/carbidopa/entacapone in Parkinson’s disease</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1586/ern.09.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1586%2Fern.09.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19589043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1egtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=929-940&author=L.+C.+Seebergerauthor=R.+A.+Hauser&title=Levodopa%2Fcarbidopa%2Fentacapone+in+Parkinson%E2%80%99s+disease&doi=10.1586%2Fern.09.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa/carbidopa/entacapone in Parkinson's disease</span></div><div class="casAuthors">Seeberger, Lauren C.; Hauser, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">929-940</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is assocd. with the development of motor complications.  Mounting evidence indicates the short half-life of levodopa and resultant pulsatile stimulation of striatal dopamine receptors leads to wearing off, motor fluctuations and dyskinesias.  Longer acting dopaminergic agents, such as dopamine agonists, are less likely to cause motor fluctuations and dyskinesias but are not as efficacious for control of motor symptoms.  Therefore, there is interest in exploring ways to deliver levodopa in a more continuous fashion, in an effort to maintain benefit through the day and reduce the development of motor fluctuations and dyskinesias.  A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central bioavailability.  When levodopa is administered with a DDCI, its main route of peripheral metab. is via catechol-O-Me transferase (COMT).  A COMT inhibitor can be added to the combination of levodopa and a DDCI to further extend the levodopa peripheral half-life and increase central bioavailability.  Stalevo is a combination tablet comprised of levodopa, carbidopa, and the COMT inhibitor entacapone.  It is available in fixed-dose combinations of levodopa/carbidopa/entacapone, 50/12.5/200, 75/18.75/200, 100/25/200, 125/31.25/200, 150/37.5/200 and 200/50/200 mg.  Stalevo is currently approved for use in Parkinson's disease patients with end-of-dose wearing off.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGVC48bEG7YrVg90H21EOLACvtfcHk0li1ZIsXfXo6bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1egtLs%253D&md5=e4fd4790ddf82f86134bde9dc17231ca</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1586%2Fern.09.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fern.09.64%26sid%3Dliteratum%253Aachs%26aulast%3DSeeberger%26aufirst%3DL.%2BC.%26aulast%3DHauser%26aufirst%3DR.%2BA.%26atitle%3DLevodopa%252Fcarbidopa%252Fentacapone%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2009%26volume%3D9%26spage%3D929%26epage%3D940%26doi%3D10.1586%2Fern.09.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Memantine ER/Donepezil: a review in alzheimer’s disease</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1007/s40263-015-0287-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40263-015-0287-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26519339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=963-970&author=S.+L.+Greig&title=Memantine+ER%2FDonepezil%3A+a+review+in+alzheimer%E2%80%99s+disease&doi=10.1007%2Fs40263-015-0287-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Memantine ER/Donepezil: A Review in Alzheimer's Disease</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">963-970</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric) is available in the USA for patients with moderate to severe Alzheimer's disease (AD) on stable memantine and donepezil therapy.  The fixed-dose formulation is bioequivalent to coadministration of the individual drugs.  In a 24-wk, phase III trial in patients with moderate to severe AD, addn. of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clin. status, dementia behavior and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ.  In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behavior and semantic processing, although there were no significant between-group differences on measures of global clin. status and daily function.  Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients.  Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD.  The fixed-dose combination is potentially more convenient than coadministration of the individual agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJHr-ptRHLU7Vg90H21EOLACvtfcHk0lg8moEvDS26nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyks7vL&md5=875120e768f3f0343f23925e21909e2d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs40263-015-0287-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-015-0287-2%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DMemantine%2520ER%252FDonepezil%253A%2520a%2520review%2520in%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCNS%2520Drugs%26date%3D2015%26volume%3D29%26spage%3D963%26epage%3D970%26doi%3D10.1007%2Fs40263-015-0287-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Memantine hydrochloride</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1038/nrd1311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fnrd1311" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=109-110&author=A.+Wittauthor=N.+Macdonaldauthor=P.+Kirkpatrick&title=Memantine+hydrochloride&doi=10.1038%2Fnrd1311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fnrd1311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1311%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DA.%26aulast%3DMacdonald%26aufirst%3DN.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DMemantine%2520hydrochloride%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D109%26epage%3D110%26doi%3D10.1038%2Fnrd1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsu, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4821</span>– <span class="NLM_lpage">4829</span>, <span class="refDoi"> DOI: 10.1021/jm00024a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00024a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK2MXptVGqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=4821-4829&author=H.+Sugimotoauthor=Y.+Iimuraauthor=Y.+Yamanishiauthor=K.+Yamatsu&title=Synthesis+and+structure-activity+relationships+of+acetylcholinesterase+inhibitors%3A+1-benzyl-4-%5B%285%2C6-dimethoxy-1-oxoindan-2-yl%29methyl%5Dpiperidine+hydrochloride+and+related+compounds&doi=10.1021%2Fjm00024a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds</span></div><div class="casAuthors">Sugimoto, Hachiro; Iimura, Youichi; Yamanishi, Yoshiharu; Yamatsu, Kiyomi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4821-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following the discovery of a new series of anti-acetylcholinesterase (anti-AChE) inhibitors such as 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine we reported that its rigid analog, 1-benzyl-4-(2-isoindolin-2-ylethyl)piperidine, had more potent activity.  The structure-activity relationship (SAR) study for the rigid analog was extended and it was found that the 2-isoindoline moiety in 1-benzyl-4-(2-isoindolin-2-ylethyl)piperidine can be replaced with a indanone moiety without a major loss in potency.  Among the indanone derivs., 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine [i.e., 2-[[1-(cyclohexylmethyl)-4-piperidinyl]methylene]-2,3-dihydro-5,6-dimetoxy-1H-inden-1-one] (E2020) (IC50 = 5.7 nM) was found to be one of the most potent anti-AChE inhibitors.  This compd. showed a selective affinity 1250 times greater for AChE than for butyrylcholinesterase.  In vivo studies demonstrated that 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine has a longer duration of action than physostigmine at a dose of 5 mg/kg (po) and produced a marked and significant increase in acetylcholine content in rat cerebral cortex.  The synthesis, SAR, and a proposed hypothetical binding site of 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine (E2020) were described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeF7RhU-sVW7Vg90H21EOLACvtfcHk0lg8moEvDS26nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptVGqtro%253D&md5=b2e5643010562e11d3015b86c6b6ecd1</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm00024a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00024a009%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DIimura%26aufirst%3DY.%26aulast%3DYamanishi%26aufirst%3DY.%26aulast%3DYamatsu%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520acetylcholinesterase%2520inhibitors%253A%25201-benzyl-4-%255B%25285%252C6-dimethoxy-1-oxoindan-2-yl%2529methyl%255Dpiperidine%2520hydrochloride%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D4821%26epage%3D4829%26doi%3D10.1021%2Fjm00024a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8712</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8712-8756&author=T.+T.+Talele&title=The+%E2%80%9Ccyclopropyl+fragment%E2%80%9D+is+a+versatile+player+that+frequently+appears+in+preclinical%2Fclinical+drug+molecules&doi=10.1021%2Facs.jmedchem.6b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8712-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclin. to clin. stage.  Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes.  The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs contg. it.  Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIJAG1XVRG7Vg90H21EOLACvtfcHk0lg8moEvDS26nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D&md5=b5586458ec4ab5e2d7586f5739663d1f</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DThe%2520%25E2%2580%259Ccyclopropyl%2520fragment%25E2%2580%259D%2520is%2520a%2520versatile%2520player%2520that%2520frequently%2520appears%2520in%2520preclinical%252Fclinical%2520drug%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8712%26epage%3D8756%26doi%3D10.1021%2Facs.jmedchem.6b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">In vitro Metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1021/tx7003085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7003085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=711-719&author=Q.+Sunauthor=R.+Zhuauthor=F.+W.+Fossauthor=T.+L.+Macdonald&title=In+vitro+Metabolism+of+a+model+cyclopropylamine+to+reactive+intermediate%3A+insights+into+trovafloxacin-induced+hepatotoxicity&doi=10.1021%2Ftx7003085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Metabolism of a Model Cyclopropylamine to Reactive Intermediate: Insights into Trovafloxacin-Induced Hepatotoxicity</span></div><div class="casAuthors">Sun, Qin; Zhu, Ran; Foss, Frank W.; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">711-719</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trovafloxacin (Trovan) is a fluoroquinolone antibiotic drug with a long half-life and broad-spectrum activity.  Since its entry into the market in 1998, trovafloxacin has been assocd. with numerous cases of hepatotoxicity, which has limited its clin. usefulness.  Trovafloxacin possesses two substructural elements that have the potential to generate reactive intermediates: a cyclopropylamine moiety and a difluoroanilino system.  The results presented here describe the in vitro metabolic activation of a synthetic drug model (DM) of trovafloxacin that contains the cyclopropylamine moiety.  Cyclopropylamine can be oxidized to reactive ring-opened products-a carbon-centered radical and a subsequently oxidized α,β-unsatd. aldehyde.  Expts. with monoamine oxygenases, horseradish peroxidase, flavin monooxygenase 3, and cDNA-expressed P 450 isoenzymes revealed that P 450 1A2 oxidizes DM to a reactive α,β-unsatd. aldehyde, M1.  Furthermore, myeloperoxidase (MPO) was also demonstrated to oxidize DM in the presence of chloride ion to produce M1.  DM proved to be a suicide inhibitor of MPO while showing no inhibition of P 450 1A2.  The structure of the reactive metabolite was confirmed by LC-MS/MS anal. by comparison with a synthetic std. M1 was further shown to react with glutathione and the related thiol nucleophile, 4-bromobenzyl mercaptan, suggesting the potential of this intermediate to react with protein nucleophiles.  In summary, these data provide evidence that trovafloxacin-induced hepatotoxicity may be mediated through the oxidn. of the cyclopropylamine substructure to reactive intermediates that may form covalent adducts to hepatic proteins, resulting in damage to liver tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr211JADO6oxbVg90H21EOLACvtfcHk0ljrdTdcjtztog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D&md5=cb587b2776c7af787f6527a01765ebdb</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Ftx7003085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7003085%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DIn%2520vitro%2520Metabolism%2520of%2520a%2520model%2520cyclopropylamine%2520to%2520reactive%2520intermediate%253A%2520insights%2520into%2520trovafloxacin-induced%2520hepatotoxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D711%26epage%3D719%26doi%3D10.1021%2Ftx7003085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, T.</span></span> <span> </span><span class="NLM_article-title">Introduction of fluorine and fluorine-containing functional groups</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8214</span>– <span class="NLM_lpage">8264</span>, <span class="refDoi"> DOI: 10.1002/anie.201206566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fanie.201206566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8214-8264&author=T.+Liangauthor=C.+N.+Neumannauthor=T.+Ritter&title=Introduction+of+fluorine+and+fluorine-containing+functional+groups&doi=10.1002%2Fanie.201206566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction of Fluorine and Fluorine-Containing Functional Groups</span></div><div class="casAuthors">Liang, Theresa; Neumann, Constanze N.; Ritter, Tobias</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8214-8264</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This Review gives a brief summary of conventional fluorination reactions, including those reactions that introduce fluorinated functional groups, and focuses on modern developments in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdUas7duMW7Vg90H21EOLACvtfcHk0ljrdTdcjtztog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7bI&md5=1dafdf60409a792e78d946731f6cc2b9</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fanie.201206566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201206566%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DNeumann%26aufirst%3DC.%2BN.%26aulast%3DRitter%26aufirst%3DT.%26atitle%3DIntroduction%2520of%2520fluorine%2520and%2520fluorine-containing%2520functional%2520groups%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8214%26epage%3D8264%26doi%3D10.1002%2Fanie.201206566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banks, W. A.</span></span> <span> </span><span class="NLM_article-title">Characteristics of compounds that cross the blood-brain barrier</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">S3</span>, <span class="refDoi"> DOI: 10.1186/1471-2377-9-S1-S3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1186%2F1471-2377-9-S1-S3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19534732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MvktFyhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=S3&author=W.+A.+Banks&title=Characteristics+of+compounds+that+cross+the+blood-brain+barrier&doi=10.1186%2F1471-2377-9-S1-S3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Characteristics of compounds that cross the blood-brain barrier</span></div><div class="casAuthors">Banks William A</div><div class="citationInfo"><span class="NLM_cas:title">BMC neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Substances cross the blood-brain barrier (BBB) by a variety of mechanisms.  These include transmembrane diffusion, saturable transporters, adsorptive endocytosis, and the extracellular pathways.  Here, we focus on the chief characteristics of two mechanisms especially important in drug delivery: transmembrane diffusion and transporters.  Transmembrane diffusion is non-saturable and depends, on first analysis, on the physicochemical characteristics of the substance.  However, brain-to-blood efflux systems, enzymatic activity, plasma protein binding, and cerebral blood flow can greatly alter the amount of the substance crossing the BBB.  Transport systems increase uptake of ligands by roughly 10-fold and are modified by physiological events and disease states.  Most drugs in clinical use to date are small, lipid soluble molecules that cross the BBB by transmembrane diffusion.  However, many drug delivery strategies in development target peptides, regulatory proteins, oligonucleotides, glycoproteins, and enzymes for which transporters have been described in recent years.  We discuss two examples of drug delivery for newly discovered transporters: that for phosphorothioate oligonucleotides and for enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIZxs0Ddmv8a69lAbTj9rGfW6udTcc2eYLKiW_6Slvrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvktFyhtw%253D%253D&md5=8063f8a2a4184aac2d36a9a5c6f67d30</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1186%2F1471-2377-9-S1-S3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2377-9-S1-S3%26sid%3Dliteratum%253Aachs%26aulast%3DBanks%26aufirst%3DW.%2BA.%26atitle%3DCharacteristics%2520of%2520compounds%2520that%2520cross%2520the%2520blood-brain%2520barrier%26jtitle%3DBMC%2520Neurol.%26date%3D2009%26volume%3D9%26spage%3DS3%26doi%3D10.1186%2F1471-2377-9-S1-S3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alagha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofalvi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouitaa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanez, P.</span></span> <span> </span><span class="NLM_article-title">Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases</span>. <i>Ther. Adv. Chronic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1177/2040622313518227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1177%2F2040622313518227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24587893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=85-98&author=K.+Alaghaauthor=A.+Palotauthor=T.+Sofalviauthor=L.+Pahusauthor=M.+Gouitaaauthor=C.+Tumminoauthor=S.+Martinezauthor=D.+Charpinauthor=A.+Bourdinauthor=P.+Chanez&title=Long-acting+muscarinic+receptor+antagonists+for+the+treatment+of+chronic+airway+diseases&doi=10.1177%2F2040622313518227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases</span></div><div class="casAuthors">Alagha, Khuder; Palot, Alain; Sofalvi, Tunde; Pahus, Laurie; Gouitaa, Marion; Tummino, Celine; Martinez, Stephanie; Charpin, Denis; Bourdin, Arnaud; Chanez, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Chronic Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-98, 14</span>CODEN:
                <span class="NLM_cas:coden">TACDCS</span>;
        ISSN:<span class="NLM_cas:issn">2040-6223</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion.  It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells.  Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors.  Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide.  All have higher selectivity for M3 receptors than for M2 receptors, and dissoc. more slowly from the M3 receptors than they do from the M2 receptors.  Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-pos. goblet cell no., decrease in MUC5AC overexpression).  In the clinic, LAMAs showed a significant improvement of forced expiratory vol. in 1 s (FEV1), quality of life, dyspnea and reduced the no. of exacerbations in COPD and more recently in asthma.  This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVv9hvW4HRY7Vg90H21EOLACvtfcHk0ljrdTdcjtztog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF&md5=4f1bf29c29adced609e3c61c36cec938</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1177%2F2040622313518227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040622313518227%26sid%3Dliteratum%253Aachs%26aulast%3DAlagha%26aufirst%3DK.%26aulast%3DPalot%26aufirst%3DA.%26aulast%3DSofalvi%26aufirst%3DT.%26aulast%3DPahus%26aufirst%3DL.%26aulast%3DGouitaa%26aufirst%3DM.%26aulast%3DTummino%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DCharpin%26aufirst%3DD.%26aulast%3DBourdin%26aufirst%3DA.%26aulast%3DChanez%26aufirst%3DP.%26atitle%3DLong-acting%2520muscarinic%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520chronic%2520airway%2520diseases%26jtitle%3DTher.%2520Adv.%2520Chronic%2520Dis.%26date%3D2014%26volume%3D5%26spage%3D85%26epage%3D98%26doi%3D10.1177%2F2040622313518227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vankeerberghen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuppens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiman, J. J.</span></span> <span> </span><span class="NLM_article-title">The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions</span>. <i>J. Cystic Fibrosis</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/S1569-1993(01)00003-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS1569-1993%2801%2900003-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15463806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=13-29&author=A.+Vankeerberghenauthor=H.+Cuppensauthor=J.+J.+Cassiman&title=The+cystic+fibrosis+transmembrane+conductance+regulator%3A+an+intriguing+protein+with+pleiotropic+functions&doi=10.1016%2FS1569-1993%2801%2900003-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions</span></div><div class="casAuthors">Vankeerberghen, Anne; Cuppens, Harry; Cassiman, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-29</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Cystic fibrosis is a frequent autosomal recessive disorder that is caused by the malfunctioning of a small chloride channel, the cystic fibrosis transmembrane conductance regulator.  The protein is found in the apical membrane of epithelial cells lining exocrine glands.  Absence of this channel results in imbalance of ion concns. across the cell membrane.  As a result, fluids secreted through these glands become more viscous and, in the end, ducts become plugged and atrophic.  Little is known about the pathways that link the malfunctioning of the CFTR protein with the obsd. clin. phenotype.  Moreover, there is no strict correlation between specific CFTR mutations and the CF phenotype.  This might be explained by the fact that environmental and addnl. genetic factors may influence the phenotype.  The CFTR protein itself is regulated at the maturational level by chaperones and SNARE proteins and at the functional level by several protein kinases.  Moreover, CFTR functions also as a regulator of other ion channels and of intracellular membrane transport processes.  To be able to function as a protein with pleiotropic actions, CFTR seems to be linked with other proteins and with the cytoskeleton through interaction with PDZ-domain-contg. proteins at the apical pole of the cell.  Progress in cystic fibrosis research is substantial, but still leaves many questions unanswered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeb5SM-sSMUbVg90H21EOLACvtfcHk0lj1FkeiRRD9fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslKmtbw%253D&md5=a7c0b3bcbf4c641fc90b8c1199c9deef</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS1569-1993%2801%2900003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1569-1993%252801%252900003-0%26sid%3Dliteratum%253Aachs%26aulast%3DVankeerberghen%26aufirst%3DA.%26aulast%3DCuppens%26aufirst%3DH.%26aulast%3DCassiman%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%253A%2520an%2520intriguing%2520protein%2520with%2520pleiotropic%2520functions%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2002%26volume%3D1%26spage%3D13%26epage%3D29%26doi%3D10.1016%2FS1569-1993%2801%2900003-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1992</span>– <span class="NLM_lpage">2001</span>, <span class="refDoi"> DOI: 10.1056/NEJMra043184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMra043184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15888700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFyrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1992-2001&author=S.+M.+Roweauthor=S.+Millerauthor=E.+J.+Sorscher&title=Cystic+Fibrosis&doi=10.1056%2FNEJMra043184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis</span></div><div class="casAuthors">Rowe, Steven M.; Miller, Stacey; Sorscher, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1992-2001</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Important advances have improved our understanding of the role of the CFTR protein in the progression of suppurative pulmonary failure in cystic fibrosis.  These discoveries are ushering in a new era of translational research that incorporates specific therapeutic targets and new cellular pathways.  Progress in research on cystic fibrosis will continue to rely on an improved understanding of CFTR function and its relationship to mucociliary clearance, airway secretion, and other ion channels.  Clin. advances directed at the correction of CFTR function predict an optimistic future for patients with cystic fibrosis and their families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKiiafli4tp7Vg90H21EOLACvtfcHk0lj1FkeiRRD9fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFyrtLY%253D&md5=e6bc05b49d7b177d43dd7592ad63f0fb</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1056%2FNEJMra043184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra043184%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26atitle%3DCystic%2520Fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1992%26epage%3D2001%26doi%3D10.1056%2FNEJMra043184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marigowda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flume, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstan, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McColley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratjen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, M. P.</span></span> <span> </span><span class="NLM_article-title">Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1409547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa1409547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25981758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=220-231&author=C.+E.+Wainwrightauthor=J.+S.+Elbornauthor=B.+W.+Ramseyauthor=G.+Marigowdaauthor=X.+Huangauthor=M.+Cipolliauthor=C.+Colomboauthor=J.+C.+Daviesauthor=K.+De+Boeckauthor=P.+A.+Flumeauthor=M.+W.+Konstanauthor=S.+A.+McColleyauthor=K.+McCoyauthor=E.+F.+McKoneauthor=A.+Munckauthor=F.+Ratjenauthor=S.+M.+Roweauthor=D.+Waltzauthor=M.+P.+Boyle&title=Lumacaftor%E2%80%93ivacaftor+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del+CFTR&doi=10.1056%2FNEJMoa1409547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span></div><div class="casAuthors">Wainwright, C. E.; Elborn, J. S.; Ramsey, B. W.; Marigowda, G.; Huang, X.; Cipolli, M.; Colombo, C.; Davies, J. C.; De Boeck, K.; Flume, P. A.; Konstan, M. W.; McColley, S. A.; McCoy, K.; McKone, E. F.; Munck, A.; Ratjen, F.; Rowe, S. M.; Waltz, D.; Boyle, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-231</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity.  Phe508del is the most common CFTR mutation.  We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who had cystic fibrosis and were homozygous for the Phe508del CFTR mutation.  In both studies, patients were randomly assigned to receive either lumacaftor (600 mg once daily or 400 mg every 12 h) in combination with ivacaftor (250 mg every 12 h) or matched placebo for 24 wk.  The primary end point was the abs. change from baseline in the percentage of predicted forced expiratory vol. in 1 s (FEV1) at week 24.  A total of 1108 patients underwent randomization and received study drug.  The mean baseline FEV1 was 61% of the predicted value.  In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean abs. improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 percentage points (P<0.001), which corresponded to a mean relative treatment difference of 4.3 to 6.7% (P<0.001).  Pooled analyses showed that the rate of pulmonary exacerbations was 30 to 39% lower in the lumacaftor-ivacaftor groups than in the placebo group; the rate of events leading to hospitalization or the use of i.v. antibiotics was lower in the lumacaftor-ivacaftor groups as well.  The incidence of adverse events was generally similar in the lumacaftor-ivacaftor and placebo groups.  The rate of discontinuation due to an adverse event was 4.2% among patients who received lumacaftor-ivacaftor vs. 1.6% among those who received placebo.  These data show that lumacaftor in combination with ivacaftor provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZ6NBA6wsbbVg90H21EOLACvtfcHk0lj1FkeiRRD9fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ&md5=223bb13c5c677a4db798be91ccedc665</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1409547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1409547%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCipolli%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BBoeck%26aufirst%3DK.%26aulast%3DFlume%26aufirst%3DP.%2BA.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DMcColley%26aufirst%3DS.%2BA.%26aulast%3DMcCoy%26aufirst%3DK.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DRatjen%26aufirst%3DF.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DBoyle%26aufirst%3DM.%2BP.%26atitle%3DLumacaftor%25E2%2580%2593ivacaftor%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%2520CFTR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D220%26epage%3D231%26doi%3D10.1056%2FNEJMoa1409547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor-Cousar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Ent, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingenito, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa1709846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29099344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFyr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2013-2023&author=J.+L.+Taylor-Cousarauthor=A.+Munckauthor=E.+F.+McKoneauthor=C.+K.+van+der%0AEntauthor=A.+Moellerauthor=C.+Simardauthor=L.+T.+Wangauthor=E.+P.+Ingenitoauthor=C.+McKeeauthor=Y.+Luauthor=J.+Lekstrom-Himesauthor=J.+S.+Elborn&title=Tezacaftor%E2%80%93ivacaftor+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del&doi=10.1056%2FNEJMoa1709846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del</span></div><div class="casAuthors">Taylor-Cousar, Jennifer L.; Munck, Anne; McKone, Edward F.; van der Ent, Cornelis K.; Moeller, Alexander; Simard, Christopher; Wang, Linda T.; Ingenito, Edward P.; McKee, Charlotte; Lu, Yimeng; Lekstrom-Himes, Julie; Elborn, J. Stuart</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2013-2023</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis.  In this phase 3, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial, we evaluated combination therapy with tezacaftor and ivacaftor in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.  Patients were randomly assigned in a 1:1 ratio to receive either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily or matched placebo for 24 wk.  The primary end point was the abs. change in the percentage of the predicted forced expiratory vol. in 1 s (FEV1) through week 24 (calcd. in percentage points); relative change in the percentage of the predicted FEV1 through week 24 (calcd. as a percentage) was a key secondary end point.  Of the 510 patients who underwent randomization, 509 received tezacaftor-ivacaftor or placebo, and 475 completed 24 wk of the trial regimen.  The mean FEV1 at baseline was 60.0% of the predicted value.  The effects on the abs. and relative changes in the percentage of the predicted FEV1 in favor of tezacaftor-ivacaftor over placebo were 4.0 percentage points and 6.8%, resp. (P<0.001 for both comparisons).  The rate of pulmonary exacerbation was 35% lower in the tezacaftor-ivacaftor group than in the placebo group (P = 0.005).  The incidence of adverse events was similar in the two groups.  Most adverse events were of mild severity (in 41.8% of patients overall) or moderate severity (in 40.9% overall), and serious adverse events were less frequent with tezacaftor-ivacaftor (12.4%) than with placebo (18.2%).  A total of 2.9% of patients discontinued the assigned regimen owing to adverse events.  Fewer patients in the tezacaftor-ivacaftor group than in the placebo group had respiratory adverse events, none of which led to discontinuation. conclusions The combination of tezacaftor and ivacaftor was efficacious and safe in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry28bA5s2HMrVg90H21EOLACvtfcHk0lgpXsTZrymuTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFyr&md5=a8aec50415d3dec5202ce53b5176960d</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709846%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor-Cousar%26aufirst%3DJ.%2BL.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3Dvan%2Bder%2BEnt%26aufirst%3DC.%2BK.%26aulast%3DMoeller%26aufirst%3DA.%26aulast%3DSimard%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DIngenito%26aufirst%3DE.%2BP.%26aulast%3DMcKee%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26atitle%3DTezacaftor%25E2%2580%2593ivacaftor%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2013%26epage%3D2023%26doi%3D10.1056%2FNEJMoa1709846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichhpujani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, L. J.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension</span>. <i>Drug, Healthcare Patient Saf.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.2147/DHPS.S9757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FDHPS.S9757" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=73-83&author=P.+Ichhpujaniauthor=L.+J.+Katz&title=Efficacy%2C+safety+and+tolerability+of+combination+therapy+with+timolol+and+dorzolamide+in+glaucoma+and+ocular+hypertension&doi=10.2147%2FDHPS.S9757"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2147%2FDHPS.S9757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDHPS.S9757%26sid%3Dliteratum%253Aachs%26aulast%3DIchhpujani%26aufirst%3DP.%26aulast%3DKatz%26aufirst%3DL.%2BJ.%26atitle%3DEfficacy%252C%2520safety%2520and%2520tolerability%2520of%2520combination%2520therapy%2520with%2520timolol%2520and%2520dorzolamide%2520in%2520glaucoma%2520and%2520ocular%2520hypertension%26jtitle%3DDrug%252C%2520Healthcare%2520Patient%2520Saf.%26date%3D2010%26volume%3D2010%26spage%3D73%26epage%3D83%26doi%3D10.2147%2FDHPS.S9757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantor, L. B.</span></span> <span> </span><span class="NLM_article-title">Brimonidine in the treatment of glaucoma and ocular hypertension</span>. <i>Ther. Clin. Risk Manag.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.2147/tcrm.2006.2.4.337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2Ftcrm.2006.2.4.337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18360646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=337-346&author=L.+B.+Cantor&title=Brimonidine+in+the+treatment+of+glaucoma+and+ocular+hypertension&doi=10.2147%2Ftcrm.2006.2.4.337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Brimonidine in the treatment of glaucoma and ocular hypertension</span></div><div class="casAuthors">Cantor, Louis B.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-346</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss.  The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension.  A fixed combination of brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop.  Brimonidine is safe and well tolerated.  Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus.  The newest formulation of brimonidine, brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of brimonidine.  This formulation contains the lowest effective concn. of brimonidine and is preserved with Purite'" to enhance ocular tolerability.  Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% soln. preserved with benzalkonium chloride.  Recent results from preclin. and clin. studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP.  The potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkwBNY0ZB1U7Vg90H21EOLACvtfcHk0lgpXsTZrymuTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislOqtA%253D%253D&md5=507dd6199884e7e3d6b5015ae2b325de</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.2147%2Ftcrm.2006.2.4.337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Ftcrm.2006.2.4.337%26sid%3Dliteratum%253Aachs%26aulast%3DCantor%26aufirst%3DL.%2BB.%26atitle%3DBrimonidine%2520in%2520the%2520treatment%2520of%2520glaucoma%2520and%2520ocular%2520hypertension%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manag.%26date%3D2006%26volume%3D2%26spage%3D337%26epage%3D346%26doi%3D10.2147%2Ftcrm.2006.2.4.337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tǎtaru, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcǎrea, V. L.</span></span> <span> </span><span class="NLM_article-title">Antiglaucoma pharmacotherapy</span>. <i>J. Med. Life</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23049625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FjslSqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=247-251&author=C.+P.+T%C7%8Etaruauthor=V.+L.+Purc%C7%8Erea&title=Antiglaucoma+pharmacotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antiglaucoma pharmacotherapy</span></div><div class="casAuthors">Tataru C P; Purcarea V L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicine and life</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review presents the pharmacotherapeutic approaches available in the treatment of glaucomatous optic neuropathy.  Although its etiology is multi-factorial, currently, the main therapy is to decrease intraocular pressure.  New therapies are being developed; the current trend is a retinal ganglion cell neuroprotection.  Neuroprotection is achieved by combining antihypertensive agents with drugs that directly protect the optic nerve by promoting cell survival and inhibition of neuronal signals that initiate apoptosis.  The treatment should also preserve the ocular hemodynamics, ensure proper patient compliance and be free of side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMwJt9ij_06gqdek-gHSrIfW6udTcc2eaRKu7NH6snx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FjslSqtA%253D%253D&md5=c8d0d80408273737f97f14cc36b9748c</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DT%25C7%258Etaru%26aufirst%3DC.%2BP.%26aulast%3DPurc%25C7%258Erea%26aufirst%3DV.%2BL.%26atitle%3DAntiglaucoma%2520pharmacotherapy%26jtitle%3DJ.%2520Med.%2520Life%26date%3D2012%26volume%3D5%26spage%3D247%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawuyi, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbaxani, A.</span></span> <span> </span><span class="NLM_article-title">The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery</span>. <i>Clin. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.2147/OPTH.S72321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FOPTH.S72321" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1249-1254&author=L.+E.+Lawuyiauthor=A.+Gurbaxani&title=The+clinical+utility+of+new+combination+phenylephrine%2Fketorolac+injection+in+cataract+surgery&doi=10.2147%2FOPTH.S72321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.2147%2FOPTH.S72321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOPTH.S72321%26sid%3Dliteratum%253Aachs%26aulast%3DLawuyi%26aufirst%3DL.%2BE.%26aulast%3DGurbaxani%26aufirst%3DA.%26atitle%3DThe%2520clinical%2520utility%2520of%2520new%2520combination%2520phenylephrine%252Fketorolac%2520injection%2520in%2520cataract%2520surgery%26jtitle%3DClin.%2520Ophthalmol.%26date%3D2015%26volume%3D2015%26spage%3D1249%26epage%3D1254%26doi%3D10.2147%2FOPTH.S72321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udell, I. J.</span></span> <span> </span><span class="NLM_article-title">A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.clinthera.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15978305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=568-577&author=J.+V.+Greinerauthor=I.+J.+Udell&title=A+comparison+of+the+clinical+efficacy+of+pheniramine+maleate%2Fnaphazoline+hydrochloride+ophthalmic+solution+and+olopatadine+hydrochloride+ophthalmic+solution+in+the+conjunctival+allergen+challenge+model&doi=10.1016%2Fj.clinthera.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model</span></div><div class="casAuthors">Greiner, Jack V.; Udell, Ira J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-577</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">The signs and symptoms of allergic conjunctivitis include ocular redness and itching.  Two treatment options currently indicated for acute ocular allergic reaction are pheniramine maleate 0.3%/naphazoline hydrochloride 0.025% ophthalmic soln., an over-the-counter antihistamine/vasoconstrictor combination; and olopatadine hydrochloride 0.1% ophthalmic soln., a prescription antihistamine/mast cell stabilizer.  This study was designed to compare, at onset of action, the relative effectiveness of pheniramine/naphazoline and olopatadine, when administered before conjunctival allergen challenge (CAC), using the ocular allergy index (OAI) as the primary end point.  This was a prospective, randomized, double-masked, contralateral, active- and placebo-controlled, single-center study of the CAC model.  The first 2 study visits established and confirmed the subjects' ocular allergic reaction (no medication administered).  At visit 3, the subjects were randomly assigned to 1 of 3 contralateral (right eye vs left eye) treatment combinations: pheniramine/naphazoline + olopatadine, pheniramine/naphazoline + placebo, or olopatadine + placebo.  Medication was given 10 min before CAC.  The subjects' erythema in the ciliary, conjunctival, and episcleral vessel beds; eyelid swelling; chemosis; and itching were evaluated at 7, 12, and 20 min after CAC.  The OAI was calcd. as a composite score of 6 signs and symptoms of allergic conjunctivitis to assess global severity.  Between-treatment differences in OAI scores were used to evaluate efficacy.  Subjects were asked their eye drop preference at the conclusion of visit 3.  Subjects (n = 83) ranged in age from 20 to 70 years (mean, 42.5 years), 61.4% (n = 51) were female, and 94.0% (n = 78) were white.  Both pheniramine/naphazoline and olopatadine were assocd. with significantly lower OAI scores than placebo at all 3 time points (all, P < 0.001). OAI scores were significantly lower with pheniramine/naphazoline than with olopatadine at 12 and 20 min (P = 0.005 and P = 0.001, resp.).  In this patient sample, studied in a CAC model of onset of action, prophylactic pheniramine/naphazoline was more effective than olopatadine and placebo in alleviating the signs and symptoms of the acute ocular allergic reaction, as measured by the OAI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR97YSN3KHzrVg90H21EOLACvtfcHk0lgdZ1ZwlbNKsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLzO&md5=e4c8b46cade177bd14d9a6f6df7ea86b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DGreiner%26aufirst%3DJ.%2BV.%26aulast%3DUdell%26aufirst%3DI.%2BJ.%26atitle%3DA%2520comparison%2520of%2520the%2520clinical%2520efficacy%2520of%2520pheniramine%2520maleate%252Fnaphazoline%2520hydrochloride%2520ophthalmic%2520solution%2520and%2520olopatadine%2520hydrochloride%2520ophthalmic%2520solution%2520in%2520the%2520conjunctival%2520allergen%2520challenge%2520model%26jtitle%3DClin.%2520Ther.%26date%3D2005%26volume%3D27%26spage%3D568%26epage%3D577%26doi%3D10.1016%2Fj.clinthera.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. J.</span></span> <span> </span><span class="NLM_article-title">The introduction of ‘chemotherapy’ using arsphenamine – the first magic bullet</span>. <i>J. R. Soc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1258/jrsm.2009.09k036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1258%2Fjrsm.2009.09k036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19679737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1Mrltl2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2009&pages=343-348&author=K.+J.+Williams&title=The+introduction+of+%E2%80%98chemotherapy%E2%80%99+using+arsphenamine+%E2%80%93+the+first+magic+bullet&doi=10.1258%2Fjrsm.2009.09k036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The introduction of 'chemotherapy' using arsphenamine - the first magic bullet</span></div><div class="casAuthors">Williams K J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">343-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShc9t9tsOM4w20zIbnCCI3fW6udTcc2ebtLLjj3LePCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mrltl2nsA%253D%253D&md5=dbb34b41116e73fb7e3395913c53ec13</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1258%2Fjrsm.2009.09k036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1258%252Fjrsm.2009.09k036%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520introduction%2520of%2520%25E2%2580%2598chemotherapy%25E2%2580%2599%2520using%2520arsphenamine%2520%25E2%2580%2593%2520the%2520first%2520magic%2520bullet%26jtitle%3DJ.%2520R.%2520Soc.%2520Med.%26date%3D2009%26volume%3D102%26spage%3D343%26epage%3D348%26doi%3D10.1258%2Fjrsm.2009.09k036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skipper, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schabel, F. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, W. S.</span></span> <span> </span><span class="NLM_article-title">Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with “curability” of experimental leukemia</span>. <i>Cancer Chemother. Rep.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=14117037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaF2c%252FnsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1964&pages=1-111&author=H.+E.+Skipperauthor=F.+R.+Schabelauthor=W.+S.+Wilcox&title=Experimental+evaluation+of+potential+anticancer+agents.+XII.+On+the+criteria+and+kinetics+associated+with+%E2%80%9Ccurability%E2%80%9D+of+experimental+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH   "CURABILITY" OF EXPERIMENTAL LEUKEMIA</span></div><div class="casAuthors">SKIPPER H E; SCHABEL F M Jr; WILCOX W S</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy reports</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-111</span>
        ISSN:<span class="NLM_cas:issn">0069-0112</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpEmGT4if7p_x2phytoz6_fW6udTcc2ebtLLjj3LePCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF2c%252FnsVOmtw%253D%253D&md5=6caccfebe1883b6606c8dcc7f8612bb9</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkipper%26aufirst%3DH.%2BE.%26aulast%3DSchabel%26aufirst%3DF.%2BR.%26aulast%3DWilcox%26aufirst%3DW.%2BS.%26atitle%3DExperimental%2520evaluation%2520of%2520potential%2520anticancer%2520agents.%2520XII.%2520On%2520the%2520criteria%2520and%2520kinetics%2520associated%2520with%2520%25E2%2580%259Ccurability%25E2%2580%259D%2520of%2520experimental%2520leukemia%26jtitle%3DCancer%2520Chemother.%2520Rep.%26date%3D1964%26volume%3D35%26spage%3D1%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, M. A.</span>; <span class="NLM_string-name">Spivak, J. L.</span>; <span class="NLM_string-name">Boxer, L. A.</span>; <span class="NLM_string-name">Shattil, S. J.</span>; <span class="NLM_string-name">Henderson, E. S.</span></span> <span> </span><span class="NLM_article-title">Commentary on and reprint of Freireich EJ, Karon M, Frei E III, Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood, in Proceedings of the American Association for Cancer Research (1964) 5:20</span>. In  <i>Hematology: Landmark Papers of the Twentieth Century</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2000</span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">657</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FB978-012448510-5%2F50152-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=655-657&author=M.+A.+Lichtman&author=J.+L.+Spivak&author=L.+A.+Boxer&author=S.+J.+Shattil&author=E.+S.+Henderson&title=Hematology%3A+Landmark+Papers+of+the+Twentieth+Century"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FB978-012448510-5%2F50152-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-012448510-5%252F50152-7%26sid%3Dliteratum%253Aachs%26aulast%3DLichtman%26aufirst%3DM.%2BA.%26atitle%3DCommentary%2520on%2520and%2520reprint%2520of%2520Freireich%2520EJ%252C%2520Karon%2520M%252C%2520Frei%2520E%2520III%252C%2520Quadruple%2520combination%2520therapy%2520%2528VAMP%2529%2520for%2520acute%2520lymphocytic%2520leukemia%2520of%2520childhood%252C%2520in%2520Proceedings%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%25281964%2529%25205%253A20%26btitle%3DHematology%253A%2520Landmark%2520Papers%2520of%2520the%2520Twentieth%2520Century%26pub%3DAcademic%2520Press%26date%3D2000%26spage%3D655%26epage%3D657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span> <span> </span><span class="NLM_article-title">A history of cancer chemotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">8643</span>– <span class="NLM_lpage">8653</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1158%2F0008-5472.CAN-07-6611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18974103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSktbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=8643-8653&author=V.+T.+DeVitaauthor=E.+Chu&title=A+history+of+cancer+chemotherapy&doi=10.1158%2F0008-5472.CAN-07-6611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A History of Cancer Chemotherapy</span></div><div class="casAuthors">DeVita, Vincent T., Jr.; Chu, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8643-8653</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of chemotherapy to treat cancer began at the start of the 20th century with attempts to narrow the universe of chems. that might affect the disease by developing methods to screen chems. using transplantable tumors in rodents.  It was, however, four World War II-related programs, and the effects of drugs that evolved from them, that provided the impetus to establish in 1955 the national drug development effort known as the Cancer Chemotherapy National Service Center.  The ability of combination chemotherapy to cure acute childhood leukemia and advanced Hodgkin's disease in the 1960s and early 1970s overcame the prevailing pessimism about the ability of drugs to cure advanced cancers, facilitated the study of adjuvant chemotherapy, and helped foster the national cancer program.  Today, chemotherapy has changed as important mol. abnormalities are being used to screen for potential new drugs as well as for targeted treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe683yjb5O2bVg90H21EOLACvtfcHk0lipzteucq56vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSktbbJ&md5=0b7460caa70c04f8421903b5b417e935</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6611%26sid%3Dliteratum%253Aachs%26aulast%3DDeVita%26aufirst%3DV.%2BT.%26aulast%3DChu%26aufirst%3DE.%26atitle%3DA%2520history%2520of%2520cancer%2520chemotherapy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D8643%26epage%3D8653%26doi%3D10.1158%2F0008-5472.CAN-07-6611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freireich, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frei, E.,  III.</span></span> <span> </span><span class="NLM_article-title">Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood</span>. <i>Proc. Am. Assoc. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">20</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1964&pages=20&author=E.+J.+Freireichauthor=M.+Karonauthor=E.+Frei&title=Quadruple+combination+therapy+%28VAMP%29+for+acute+lymphocytic+leukemia+of+childhood"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFreireich%26aufirst%3DE.%2BJ.%26aulast%3DKaron%26aufirst%3DM.%26aulast%3DFrei%26aufirst%3DE.%26atitle%3DQuadruple%2520combination%2520therapy%2520%2528VAMP%2529%2520for%2520acute%2520lymphocytic%2520leukemia%2520of%2520childhood%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D1964%26volume%3D5%26spage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppal, P.</span></span> <span> </span><span class="NLM_article-title">Trifluridine/Tipiracil (Lonsurf) for the treatment of metastatic colorectal cancer</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">325</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=314-325&author=T.+Kishauthor=P.+Uppal&title=Trifluridine%2FTipiracil+%28Lonsurf%29+for+the+treatment+of+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKish%26aufirst%3DT.%26aulast%3DUppal%26aufirst%3DP.%26atitle%3DTrifluridine%252FTipiracil%2520%2528Lonsurf%2529%2520for%2520the%2520treatment%2520of%2520metastatic%2520colorectal%2520cancer%26jtitle%3DPharm.%2520Ther.%26date%3D2016%26volume%3D41%26spage%3D314%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentikis, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A. C.</span></span> <span> </span><span class="NLM_article-title">CPX-351 ((Cytarabine:Daunorubicin) liposome injection, (Vyxeos)) does not prolong Qtcf intervals, requires no dose adjustment for impaired renal function and induces high rates of complete remission in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">2510</span>– <span class="NLM_lpage">2510</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=2510-2510&author=T.+L.+Linauthor=L.+F.+Newellauthor=R.+K.+Stuartauthor=L.+C.+Michaelisauthor=S.+E.+Rubensteinauthor=H.+S.+Pentikisauthor=T.+Callahanauthor=D.+Alvarezauthor=L.+D.+Mayerauthor=A.+C.+Louie&title=CPX-351+%28%28Cytarabine%3ADaunorubicin%29+liposome+injection%2C+%28Vyxeos%29%29+does+not+prolong+Qtcf+intervals%2C+requires+no+dose+adjustment+for+impaired+renal+function+and+induces+high+rates+of+complete+remission+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BL.%26aulast%3DNewell%26aufirst%3DL.%2BF.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DMichaelis%26aufirst%3DL.%2BC.%26aulast%3DRubenstein%26aufirst%3DS.%2BE.%26aulast%3DPentikis%26aufirst%3DH.%2BS.%26aulast%3DCallahan%26aufirst%3DT.%26aulast%3DAlvarez%26aufirst%3DD.%26aulast%3DMayer%26aufirst%3DL.%2BD.%26aulast%3DLouie%26aufirst%3DA.%2BC.%26atitle%3DCPX-351%2520%2528%2528Cytarabine%253ADaunorubicin%2529%2520liposome%2520injection%252C%2520%2528Vyxeos%2529%2529%2520does%2520not%2520prolong%2520Qtcf%2520intervals%252C%2520requires%2520no%2520dose%2520adjustment%2520for%2520impaired%2520renal%2520function%2520and%2520induces%2520high%2520rates%2520of%2520complete%2520remission%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D2510%26epage%3D2510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoering, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B.</span></span> <span> </span><span class="NLM_article-title">Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary) AML</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">7000</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.34.15_suppl.7000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1200%2FJCO.2016.34.15_suppl.7000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=7000&author=J.+Lancetauthor=G.+Uyauthor=J.+Cortesauthor=+Newellauthor=T.+Linauthor=E.+Ritchieauthor=R.+Stuartauthor=A.+Stricklandauthor=D.+Hoggeauthor=S.+Solomonauthor=R.+Stoneauthor=D.+Bixbyauthor=J.+Kolitzauthor=G.+Schillerauthor=J.+Wieduwiltauthor=D.+Ryanauthor=A.+Hoeringauthor=M.+Chiarellaauthor=A.+Louieauthor=B.+Medeiros&title=Final+results+of+a+phase+III+randomized+trial+of+CPX-351+versus+7+%2B+3+in+older+patients+with+newly+diagnosed+high+risk+%28secondary%29+AML&doi=10.1200%2FJCO.2016.34.15_suppl.7000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.7000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.7000%26sid%3Dliteratum%253Aachs%26aulast%3DLancet%26aufirst%3DJ.%26aulast%3DUy%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DNewell%26aulast%3DLin%26aufirst%3DT.%26aulast%3DRitchie%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DR.%26aulast%3DStrickland%26aufirst%3DA.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DSolomon%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DKolitz%26aufirst%3DJ.%26aulast%3DSchiller%26aufirst%3DG.%26aulast%3DWieduwilt%26aufirst%3DJ.%26aulast%3DRyan%26aufirst%3DD.%26aulast%3DHoering%26aufirst%3DA.%26aulast%3DChiarella%26aufirst%3DM.%26aulast%3DLouie%26aufirst%3DA.%26aulast%3DMedeiros%26aufirst%3DB.%26atitle%3DFinal%2520results%2520of%2520a%2520phase%2520III%2520randomized%2520trial%2520of%2520CPX-351%2520versus%25207%2520%252B%25203%2520in%2520older%2520patients%2520with%2520newly%2520diagnosed%2520high%2520risk%2520%2528secondary%2529%2520AML%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D7000%26doi%3D10.1200%2FJCO.2016.34.15_suppl.7000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzykson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenaux, P.</span></span> <span> </span><span class="NLM_article-title">Myelodysplastic syndromes</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">2239</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)61901-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0140-6736%2813%2961901-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24656536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2crmt1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=2239-2252&author=L.+Ad%C3%A8sauthor=R.+Itzyksonauthor=P.+Fenaux&title=Myelodysplastic+syndromes&doi=10.1016%2FS0140-6736%2813%2961901-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Myelodysplastic syndromes</span></div><div class="casAuthors">Ades Lionel; Itzykson Raphael; Fenaux Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9936</span>),
    <span class="NLM_cas:pages">2239-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people.  The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages.  Clinical manifestations result from cytopenias (anaemia, infection, and bleeding).  Diagnosis is based on examination of blood and bone marrow showing blood cytopenias and hypercellular marrow with dysplasia, with or without excess of blasts.  Prognosis depends largely on the marrow blast percentage, number and extent of cytopenias, and cytogenetic abnormalities.  Treatment of patients with lower-risk myelodysplastic syndromes, especially for anaemia, includes growth factors, lenalidomide, and transfusions.  Treatment of higher-risk patients is with hypomethylating agents and, whenever possible, allogeneic stem-cell transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5Er73mKiVSohLSh9fo81bfW6udTcc2eYpRUpoaU15H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmt1Shsw%253D%253D&md5=4d1f1ed2087f436803eac644355969ba</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2961901-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252961901-7%26sid%3Dliteratum%253Aachs%26aulast%3DAd%25C3%25A8s%26aufirst%3DL.%26aulast%3DItzykson%26aufirst%3DR.%26aulast%3DFenaux%26aufirst%3DP.%26atitle%3DMyelodysplastic%2520syndromes%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D2239%26epage%3D2252%26doi%3D10.1016%2FS0140-6736%2813%2961901-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. R.</span></span> <span> </span><span class="NLM_article-title">Nitrogen mustard inhibits transcription and translation in a cell free system</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3508</span>– <span class="NLM_lpage">3515</span>, <span class="refDoi"> DOI: 10.1093/nar/23.17.3508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1093%2Fnar%2F23.17.3508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=3508-3515&author=A.+Mastaauthor=P.+J.+Grayauthor=D.+R.+Phillips&title=Nitrogen+mustard+inhibits+transcription+and+translation+in+a+cell+free+system&doi=10.1093%2Fnar%2F23.17.3508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F23.17.3508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F23.17.3508%26sid%3Dliteratum%253Aachs%26aulast%3DMasta%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DP.%2BJ.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26atitle%3DNitrogen%2520mustard%2520inhibits%2520transcription%2520and%2520translation%2520in%2520a%2520cell%2520free%2520system%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1995%26volume%3D23%26spage%3D3508%26epage%3D3515%26doi%3D10.1093%2Fnar%2F23.17.3508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dasari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchounwou, P. B.</span></span> <span> </span><span class="NLM_article-title">Cisplatin in cancer therapy: molecular mechanisms of action</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>740</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.ejphar.2014.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25058905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GksbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=740&publication_year=2014&pages=364-378&author=S.+Dasariauthor=P.+B.+Tchounwou&title=Cisplatin+in+cancer+therapy%3A+molecular+mechanisms+of+action&doi=10.1016%2Fj.ejphar.2014.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin in cancer therapy: Molecular mechanisms of action</span></div><div class="casAuthors">Dasari, Shaloam; Bernard Tchounwou, Paul</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">740</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">364-378</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known chemotherapeutic drug.  It has been used for treatment of numerous human cancers including bladder, head and neck, lung, ovarian, and testicular cancers.  It is effective against various types of cancers, including carcinomas, germ cell tumors, lymphomas, and sarcomas.  Its mode of action has been linked to its ability to crosslink with the purine bases on the DNA; interfering with DNA repair mechanisms, causing DNA damage, and subsequently inducing apoptosis in cancer cells.  However, because of drug resistance and numerous undesirable side effects such as severe kidney problems, allergic reactions, decrease immunity to infections, gastrointestinal disorders, hemorrhage, and hearing loss esp. in younger patients, other platinum-contg. anti-cancer drugs such as carboplatin, oxaliplatin and others, have also been used.  Furthermore, combination therapies of cisplatin with other drugs have been highly considered to overcome drug-resistance and reduce toxicity.  This comprehensive review highlights the physicochem. properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various human cancers.  A special attention is paid to its mol. mechanisms of action, and its undesirable side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Hf3tjZX2tbVg90H21EOLACvtfcHk0lh0Hf2bOXA4DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GksbvL&md5=02206e68034a31198d1bf70d09920013</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DDasari%26aufirst%3DS.%26aulast%3DTchounwou%26aufirst%3DP.%2BB.%26atitle%3DCisplatin%2520in%2520cancer%2520therapy%253A%2520molecular%2520mechanisms%2520of%2520action%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D740%26spage%3D364%26epage%3D378%26doi%3D10.1016%2Fj.ejphar.2014.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrousseau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrey, L.</span></span> <span> </span><span class="NLM_article-title">Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors</span>. <i>Ther. Clin. Risk. Manag.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.2147/tcrm.2007.3.2.213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2Ftcrm.2007.3.2.213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18360630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1SrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=213-224&author=J.+P.+Armandauthor=V.+Ribragauthor=J.+L.+Harrousseauauthor=L.+Abrey&title=Reappraisal+of+the+use+of+procarbazine+in+the+treatment+of+lymphomas+and+brain+tumors&doi=10.2147%2Ftcrm.2007.3.2.213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors</span></div><div class="casAuthors">Armand, Jean-Pierre; Ribrag, Vincent; Harrousseau, Jean-Luc; Abrey, Lauren</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-224</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Procarbazine HCl is a 'nonclassical' oral alkylating anticancer agent that was first synthesized in the late 1950s.  It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin's lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin's lymphoma and primary central nervous system lymphoma.  Procarbazine is a prodrug that undergoes metabolic transformation into active intermediates that are thought to inhibit DNA, RNA, and protein synthesis.  Early use of procarbazine in combination with mechlorethamine, vincristine, and prednisone (MOPP) was effective in the treatment of advanced Hodgkin's lymphoma, but late toxic effects such as secondary cancer and infertility led to its replacement by other regimens.  However, its recent reintroduction in the dose-intensified BEACOPP (belomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has yielded very promising findings.  Procarbazine alone, or more commonly combined in the PCV (procarbazine, lomustine [CCNU], and vincristine) regimen, is also effective in treating gliomas comprising astrocytomas, glioblastomas, and oligodendrogliomas.  The most common side effects of procarbazine are gastrointestinal disturbances, myelosuppression, and central nervous system effects.  In conclusion, the use of procarbazine in combination with other drugs means that it remains a major anticancer drug in the management of Hodgkin's lymphoma and gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJcsgYzQnZaLVg90H21EOLACvtfcHk0lh0Hf2bOXA4DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1SrtL8%253D&md5=29c8330dd166870de19e32055d7f3243</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2147%2Ftcrm.2007.3.2.213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Ftcrm.2007.3.2.213%26sid%3Dliteratum%253Aachs%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DRibrag%26aufirst%3DV.%26aulast%3DHarrousseau%26aufirst%3DJ.%2BL.%26aulast%3DAbrey%26aufirst%3DL.%26atitle%3DReappraisal%2520of%2520the%2520use%2520of%2520procarbazine%2520in%2520the%2520treatment%2520of%2520lymphomas%2520and%2520brain%2520tumors%26jtitle%3DTher.%2520Clin.%2520Risk.%2520Manag.%26date%3D2007%26volume%3D3%26spage%3D213%26epage%3D224%26doi%3D10.2147%2Ftcrm.2007.3.2.213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span> <span> </span><span class="NLM_article-title">Targeted therapies: a new generation of cancer treatments</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18297955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1c7jvFyjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=311-319&author=D.+E.+Gerber&title=Targeted+therapies%3A+a+new+generation+of+cancer+treatments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapies: a new generation of cancer treatments</span></div><div class="casAuthors">Gerber David E</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-9</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, have significantly changed the treatment of cancer over the past 10 years.  These drugs are now a component of therapy for many common malignancies, including breast, colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma.  The mechanisms of action and toxicities of targeted therapies differ from those of traditional cytotoxic chemotherapy.  Targeted therapies are generally better tolerated than traditional chemotherapy, but they are associated with several adverse effects, such as acneiform rash, cardiac dysfunction, thrombosis, hypertension, and proteinuria.  Small molecule inhibitors are metabolized by cytochrome P450 enzymes and are subject to multiple drug interactions.  Targeted therapy has raised new questions about the tailoring of cancer treatment to an individual patient's tumor, the assessment of drug effectiveness and toxicity, and the economics of cancer care.  As more persons are diagnosed with cancer and as these patients live longer, primary care physicians will increasingly provide care for patients who have received targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfa1lMyMst9HWEEzDrymxmfW6udTcc2eaWB4FJwnVUbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7jvFyjtw%253D%253D&md5=4d67592cced2e7ab64bf2218e1bcd821</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26atitle%3DTargeted%2520therapies%253A%2520a%2520new%2520generation%2520of%2520cancer%2520treatments%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2008%26volume%3D77%26spage%3D311%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raedler, L. A.</span></span> <span> </span><span class="NLM_article-title">Akynzeo (Netupitant and Palonosetron), a dual-acting oral agent, approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting</span>. <i>Am. Health Drug Benefits</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">48</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26629265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC28rgvVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=44-48&author=L.+A.+Raedler&title=Akynzeo+%28Netupitant+and+Palonosetron%29%2C+a+dual-acting+oral+agent%2C+approved+by+the+FDA+for+the+prevention+of+chemotherapy-induced+nausea+and+vomiting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting</span></div><div class="casAuthors">Raedler Lisa A</div><div class="citationInfo"><span class="NLM_cas:title">American health & drug benefits</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">Spec Feature</span>),
    <span class="NLM_cas:pages">44-8</span>
        ISSN:<span class="NLM_cas:issn">1942-2962</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGt-9WtWJAKpI8NvIb08rbfW6udTcc2eaWB4FJwnVUbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgvVyhtg%253D%253D&md5=79fc1f18510503dce012faea2d52a08e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaedler%26aufirst%3DL.%2BA.%26atitle%3DAkynzeo%2520%2528Netupitant%2520and%2520Palonosetron%2529%252C%2520a%2520dual-acting%2520oral%2520agent%252C%2520approved%2520by%2520the%2520FDA%2520for%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DAm.%2520Health%2520Drug%2520Benefits%26date%3D2015%26volume%3D8%26spage%3D44%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joo, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visintin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, G.</span></span> <span> </span><span class="NLM_article-title">Targeted cancer therapy – Are the days of systemic chemotherapy numbered?</span>. <i>Maturitas</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.maturitas.2013.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.maturitas.2013.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24128673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Witr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=308-314&author=W.+D.+Jooauthor=I.+Visintinauthor=G.+Mor&title=Targeted+cancer+therapy+%E2%80%93+Are+the+days+of+systemic+chemotherapy+numbered%3F&doi=10.1016%2Fj.maturitas.2013.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy - Are the days of systemic chemotherapy numbered?</span></div><div class="casAuthors">Joo, Won Duk; Visintin, Irene; Mor, Gil</div><div class="citationInfo"><span class="NLM_cas:title">Maturitas</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-314</span>CODEN:
                <span class="NLM_cas:coden">MATUDK</span>;
        ISSN:<span class="NLM_cas:issn">0378-5122</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapy or mol. targeted therapy has been defined as a type of treatment that blocks the growth of cancer cells by interfering with specific cell mols. required for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells as with traditional chemotherapy.  There is a growing no. of FDA approved monoclonal antibodies and small mols. targeting specific types of cancer suggestive of the growing relevance of this therapeutic approach.  Targeted cancer therapies, also referred to as "Personalized Medicine", are being studied for use alone, in combination with other targeted therapies, and in combination with chemotherapy.  The objective of personalized medicine is the identification of patients that would benefit from a specific treatment based on the expression of mol. markers.  Examples of this approach include bevacizumab and olaparib, which have been designated as promising targeted therapies for ovarian cancer.  Combinations of trastuzumab with pertuzumab, or T-DM1 and mTOR inhibitors added to an aromatase inhibitor are new therapeutic strategies for breast cancer.  Although this approach has been seen as a major step in the expansion of personalized medicine, it has substantial limitations including its high cost and the presence of serious adverse effects.  The Cancer Genome Atlas is a useful resource to identify novel and more effective targets, which may help to overcome the present limitations.  In this review we will discuss the clin. outcome of some of these new therapies with a focus on ovarian and breast cancer.  We will also discuss novel concepts in targeted therapy, the target of cancer stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGwe46iKHWZ7Vg90H21EOLACvtfcHk0lgVlju5LRN9TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Witr7O&md5=70a2650bea41a64585582255bcc43751</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.maturitas.2013.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.maturitas.2013.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DJoo%26aufirst%3DW.%2BD.%26aulast%3DVisintin%26aufirst%3DI.%26aulast%3DMor%26aufirst%3DG.%26atitle%3DTargeted%2520cancer%2520therapy%2520%25E2%2580%2593%2520Are%2520the%2520days%2520of%2520systemic%2520chemotherapy%2520numbered%253F%26jtitle%3DMaturitas%26date%3D2013%26volume%3D76%26spage%3D308%26epage%3D314%26doi%3D10.1016%2Fj.maturitas.2013.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilhot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gathmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousselot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiffers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saglio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratwohl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoef, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa022457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa022457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=12637609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvF2qsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=994-1004&author=S.+G.+O%E2%80%99Brienauthor=F.+Guilhotauthor=R.+A.+Larsonauthor=I.+Gathmannauthor=M.+Baccaraniauthor=F.+Cervantesauthor=J.+J.+Cornelissenauthor=T.+Fischerauthor=A.+Hochhausauthor=T.+Hughesauthor=K.+Lechnerauthor=J.+L.+Nielsenauthor=P.+Rousselotauthor=J.+Reiffersauthor=G.+Saglioauthor=J.+Shepherdauthor=B.+Simonssonauthor=A.+Gratwohlauthor=J.+M.+Goldmanauthor=H.+Kantarjianauthor=K.+Taylorauthor=G.+Verhoefauthor=A.+E.+Boltonauthor=R.+Capdevilleauthor=B.+J.+Druker&title=Imatinib+compared+with+interferon+and+low-dose+cytarabine+for+newly+diagnosed+chronic-phase+chronic+myeloid+leukemia&doi=10.1056%2FNEJMoa022457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</span></div><div class="casAuthors">O'Brien, Stephen G.; Guilhot, Francois; Larson, Richard A.; Gathmann, Insa; Baccarani, Michele; Cervantes, Francisco; Cornelissen, Jan J.; Fischer, Thomas; Hochhaus, Andreas; Hughes, Timothy; Lechner, Klaus; Nielsen, Johan L.; Rousselot, Philippe; Reiffers, Josy; Saglio, Giuseppe; Shepherd, John; Simonsson, Bengt; Gratwohl, Alois; Goldman, John M.; Kantarjian, D. M. Hagop; Taylor, Kerry; Verhoef, Gregor; Bolton, Ann E.; Capdeville, Renaud; Druker, Brian J.; Durrant, S.; Schwarer, A.; Joske, D.; Seymour, J.; Grigg, A.; Ma, D.; Arthur, C.; Bradstock, K.; Joshua, D.; Louwagie, A.; Martiat, P.; Straetmans, N.; Bosly, A.; Shustik, C.; Lipton, J.; Forrest, D.; Walker, I.; Roy, D.-C.; Rubinger, M.; Bence-Bruckler, I.; Stewart, D.; Kovacs, M.; Turner, A. R.; Birgens, H.; Bjerrum, O.; Facon, T.; Harousseau, J.-L.; Tulliez, M.; Guerci, A.; Blaise, D.; Maloisel, F.; Michallet, M.; Hossfeld, D.; Mertelsmann, R.; Andreesen, R.; Nerl, C.; Freund, M.; Gattermann, N.; Hoeffken, K.; Ehninger, G.; Deininger, M.; Ottmann, O.; Peschel, C.; Fruehauf, S.; Neubauer, A.; Le Coutre, P.; Aulitzky, W.; Fanin, R.; Rosti, G.; Mandelli, F.; Morra, E.; Carella, A.; Lazzarino, M.; Petrini, M.; Rossi Ferrini, P.; Nobile, F.; Liso, V.; Ferrara, F.; Rizzoli, V.; Fioritoni, G.; Martinelli, G.; Ossenkoppele, G.; Browett, P.; Gedde-Dahl, T.; Tangen, J.-M.; Dahl, I.; Odriozola, J.; Hernandez Boluda, J. C.; Steegmann, J. L.; Canizo, C.; Sureda, A.; Diaz, J.; Granena, A.; Fernandez, M. N.; Stenke, L.; Paul, C.; Bjoreman, M.; Malm, C.; Wadenvik, H.; Nilsson, P.-G.; Turesson, I.; Hess, U.; Solenthaler, M.; Russel, N.; Mufti, G.; Cavenagh, J.; Clark, R. E.; Green, A. R.; Holyoake, T. L.; Lucas, G. S.; Smith, G.; Milligan, D. W.; Rule, S. J.; Burnett, A. K.; Moroose, R.; Wetzler, M.; Bearden, J.; Brown, R.; Lobell, M.; Cataland, S.; Rabinowitz, I.; Meisenberg, B.; Gabrilove, J.; Thompson, K.; Graziano, S.; Emanuel, P.; Gross, H.; Cobb, P.; Bhatia, R.; Dakhil, S.; Irwin, D.; Issell, B.; Pavletic, S.; Kuebler, P.; Layhe, E.; Butera, P.; Glass, J.; Moore, J.; Grant, B.; Niell, H.; Herzig, R.; Burris, H.; Peterson, B.; Powell, B.; Kalaycio, M.; Stirewalt, D.; Samlowski, W.; Berman, E.; Limentani, S.; Seay, T.; Shea, T.; Akard, L.; Smith, G.; Becker, P.; DeVine, S.; Hart, R.; Veith, R.; Wade, J.; Brunvand, M.; Silver, R.; Kalman, L.; Strickland, D.; Shurafa, M.; Bashey, A.; Shadduck, R.; Cooper, S.; Safah, H.; Rubenstein, M.; Collins, R.; Keller, A.; Stone, R.; Tallman, M.; Stevens, D.; Pecora, A.; Agha, M.; Holmes, H.; Druker, B. J.; Guilhot, E.; Larson, R. A.; O'Brien, S. G.; Rowe, J.; Schiffer, C. A.; Buyse, M.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Kantarjian, H.; Lechner, K.; Nielsen, J. L.; Reiffers, J.; Rousselot, P.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J. M.; Taylor, K.; Verhoef, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">994-1004</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The efficacy of imatinib was compared with that of interferon-α combined with low-dose cytarabine in newly diagnosed chronic-phase chronic myeloid leukemia (CML).  After a median follow-up of 19 mo, the estd. rate of a major cytogenetic response (0-35% of cells in metaphase pos. for the Philadelphia chromosome) at 18 mo was 87.1% in the imatinib group and 34.7% in the group given interferon-α plus cytarabine. The estd. rates of complete cytogenetic response were 76.2% and 14.5%, resp. At 18 mo, the estd. rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7% in the imatinib group and 91.5% in the combination-therapy group. Imatinib was better tolerated than combination therapy.  Thus, in terms of hematol. and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon-α plus low-dose cytarabine as 1st-line therapy in newly diagnosed chronic-phase CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Klg6CHKdKrVg90H21EOLACvtfcHk0liyHQssLgr1Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvF2qsL8%253D&md5=cab11b39f0131f03d12e97893526764d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa022457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa022457%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DGathmann%26aufirst%3DI.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DCornelissen%26aufirst%3DJ.%2BJ.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DLechner%26aufirst%3DK.%26aulast%3DNielsen%26aufirst%3DJ.%2BL.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DReiffers%26aufirst%3DJ.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3DSimonsson%26aufirst%3DB.%26aulast%3DGratwohl%26aufirst%3DA.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DBolton%26aufirst%3DA.%2BE.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DImatinib%2520compared%2520with%2520interferon%2520and%2520low-dose%2520cytarabine%2520for%2520newly%2520diagnosed%2520chronic-phase%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D994%26epage%3D1004%26doi%3D10.1056%2FNEJMoa022457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib and trametinib, alone and in combination for <i>BRAF</i>-mutant metastatic melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2035</span>– <span class="NLM_lpage">2043</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1158%2F1078-0432.CCR-13-2054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24583796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2msro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2035-2043&author=A.+M.+Menziesauthor=G.+V.+Long&title=Dabrafenib+and+trametinib%2C+alone+and+in+combination+for+BRAF-mutant+metastatic+melanoma&doi=10.1158%2F1078-0432.CCR-13-2054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma</span></div><div class="casAuthors">Menzies, Alexander M.; Long, Georgina V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2035-2043</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant metastatic melanoma by the U.S. Food and Drug Administration (FDA) in 2013, and most recently, their use in combination has received accelerated FDA approval.  Both drugs target the mitogen-activated protein kinase (MAPK) pathway: dabrafenib selectively inhibits mutant BRAF that constitutively activates the pathway, and trametinib selectively inhibits MEK1 and MEK2 proteins activated by RAF kinases.  The phase III study of dabrafenib in BRAFV600E metastatic melanoma reported rapid tumor regression in most patients and a 59% objective RECIST response rate.  The median progression-free survival (PFS) and overall survival (OS) were improved compared with dacarbazine.  Toxicities were well tolerated and different from those reported for vemurafenib, the first FDA-approved BRAF inhibitor.  Efficacy has been demonstrated in other BRAF-mutant genotypes.  The phase III study of trametinib in BRAF inhibitor-naive patients with BRAFV600E or BRAFV600K also showed benefit with a prolonged median PFS and OS compared with chemotherapy.  Trametinib is ineffective in patients who have progressed on BRAF inhibitors.  A phase II trial of combined dabrafenib and trametinib demonstrated higher response rates and longer median PFS than dabrafenib monotherapy, with less cutaneous toxicity.  Here, we review the clin. development of both drugs as monotherapies and in combination, and discuss their role in the management of BRAF-mutant melanoma.  Clin Cancer Res; 20(8); 2035-43. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNH1htKPDY_rVg90H21EOLACvtfcHk0liyHQssLgr1Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2msro%253D&md5=af0a14b04bef23de579b4745603bf27c</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2054%26sid%3Dliteratum%253Aachs%26aulast%3DMenzies%26aufirst%3DA.%2BM.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DDabrafenib%2520and%2520trametinib%252C%2520alone%2520and%2520in%2520combination%2520for%2520BRAF-mutant%2520metastatic%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2035%26epage%3D2043%26doi%3D10.1158%2F1078-0432.CCR-13-2054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraresi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probachai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarini, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irani, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)60898-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0140-6736%2815%2960898-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26037941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVyrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=444-451&author=G.+V.+Longauthor=D.+Stroyakovskiyauthor=H.+Gogasauthor=E.+Levchenkoauthor=F.+de+Braudauthor=J.+Larkinauthor=C.+Garbeauthor=T.+Jouaryauthor=A.+Hauschildauthor=J.+J.+Grobauthor=V.+Chiarion-Sileniauthor=C.+Lebbeauthor=M.+Mandalaauthor=M.+Millwardauthor=A.+Aranceauthor=I.+Bondarenkoauthor=J.+B.+Haanenauthor=J.+Hanssonauthor=J.+Utikalauthor=V.+Ferraresiauthor=N.+Kovalenkoauthor=P.+Mohrauthor=V.+Probachaiauthor=D.+Schadendorfauthor=P.+Nathanauthor=C.+Robertauthor=A.+Ribasauthor=D.+J.+DeMariniauthor=J.+G.+Iraniauthor=S.+Swannauthor=J.+J.+Legosauthor=F.+Jinauthor=B.+Mookerjeeauthor=K.+Flaherty&title=Dabrafenib+and+trametinib+versus+dabrafenib+and+placebo+for+Val600+BRAF-mutant+melanoma%3A+a+multicentre%2C+double-blind%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2815%2960898-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial</span></div><div class="casAuthors">Long, Georgina V.; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandala, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B. A. G.; Hansson, Johan; Utikal, Jochen; Ferraresi, Virginia; Kovalenko, Nadezhda; Mohr, Peter; Probachai, Volodymr; Schadendorf, Dirk; Nathan, Paul; Robert, Caroline; Ribas, Antoni; De Marini, Douglas J.; Irani, Jhangir G.; Swann, Suzanne; Legos, Jeffrey J.; Jin, Fan; Mookerjee, Bijoyesh; Flaherty, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9992</span>),
    <span class="NLM_cas:pages">444-451</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with dabrafenib and placebo in patients with BRAF Val600Lys/Glu mutation-pos. metastatic melanoma.  The study was continued to assess the secondary endpoint of overall survival, which we report in this Article.  We did this double-blind phase 3 study at 113 sites in 14 countries.  We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-pos. unresectable stage IIIC or stage IV melanoma.  Participants were computer-randomised (1:1) to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily), or dabrafenib and placebo.  The primary endpoint was progression-free survival and overall survival was a secondary endpoint.  This study is registered with ClinicalTrials.gov, no. NCT01584648.  Between May 4, 2012, and Nov 30, 2012, we screened 947 patients for eligibility, of whom 423 were randomly assigned to receive dabrafenib and trametinib (n=211) or dabrafenib only (n=212).  The final data cutoff was Jan 12, 2015, at which time 222 patients had died.  Median overall survival was 25·1 mo (95% CI 19·2-not reached) in the dabrafenib and trametinib group vs. 18·7 mo (15·2-23·7) in the dabrafenib only group (hazard ratio [HR] 0·71, 95% CI 0·55-0·92; p=0·0107).  Overall survival was 74% at 1 yr and 51% at 2 years in the dabrafenib and trametinib group vs. 68% and 42%, resp., in the dabrafenib only group.  Based on 301 events, median progression-free survival was 11·0 mo (95% CI 8·0-13·9) in the dabrafenib and trametinib group and 8·8 mo (5·9-9·3) in the dabrafenib only group (HR 0·67, 95% CI 0·53-0·84; p=0·0004; unadjusted for multiple testing).  Treatment-related adverse events occurred in 181 (87%) of 209 patients in the dabrafenib and trametinib group and 189 (90%) of 211 patients in the dabrafenib only group; the most common was pyrexia (108 patients, 52%) in the dabrafenib and trametinib group, and hyperkeratosis (70 patients, 33%) in the dabrafenib only group.  Grade 3 or 4 adverse events occurred in 67 (32%) patients in the dabrafenib and trametinib group and 66 (31%) patients in the dabrafenib only group.  The improvement in overall survival establishes the combination of dabrafenib and trametinib as the std. targeted treatment for BRAF Val600 mutation-pos. melanoma.  Studies assessing dabrafenib and trametinib in combination with immunotherapies are ongoing.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeIg9L7TouB7Vg90H21EOLACvtfcHk0lgLp0jaKBuXog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVyrt7k%253D&md5=3de7b0a659267f73299e8111ff2a09bb</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960898-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960898-4%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DFerraresi%26aufirst%3DV.%26aulast%3DKovalenko%26aufirst%3DN.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DProbachai%26aufirst%3DV.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDeMarini%26aufirst%3DD.%2BJ.%26aulast%3DIrani%26aufirst%3DJ.%2BG.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DLegos%26aufirst%3DJ.%2BJ.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DMookerjee%26aufirst%3DB.%26aulast%3DFlaherty%26aufirst%3DK.%26atitle%3DDabrafenib%2520and%2520trametinib%2520versus%2520dabrafenib%2520and%2520placebo%2520for%2520Val600%2520BRAF-mutant%2520melanoma%253A%2520a%2520multicentre%252C%2520double-blind%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D444%26epage%3D451%26doi%3D10.1016%2FS0140-6736%2815%2960898-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroiakovski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grange, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crist, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">Improved overall survival in melanoma with combined dabrafenib and trametinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1412690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa1412690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25399551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=30-39&author=C.+Robertauthor=B.+Karaszewskaauthor=J.+Schachterauthor=P.+Rutkowskiauthor=A.+Mackiewiczauthor=D.+Stroiakovskiauthor=M.+Lichinitserauthor=R.+Dummerauthor=F.+Grangeauthor=L.+Mortierauthor=V.+Chiarion-Sileniauthor=K.+Drucisauthor=I.+Krajsovaauthor=A.+Hauschildauthor=P.+Loriganauthor=P.+Wolterauthor=G.+V.+Longauthor=K.+Flahertyauthor=P.+Nathanauthor=A.+Ribasauthor=A.+M.+Martinauthor=P.+Sunauthor=W.+Cristauthor=J.+Legosauthor=S.+D.+Rubinauthor=S.+M.+Littleauthor=D.+Schadendorf&title=Improved+overall+survival+in+melanoma+with+combined+dabrafenib+and+trametinib&doi=10.1056%2FNEJMoa1412690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Improved overall survival in melanoma with combined dabrafenib and trametinib</span></div><div class="casAuthors">Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V.; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D.; Little, Shonda M.; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39/1-30-39/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.  Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.  Methods: In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy.  The primary end point was overall survival.  Results: At the preplanned interim overall survival anal., which was performed after 77% of the total no. of expected events occurred, the overall survival rate at 12 mo was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005).  The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014.  Median progression-free survival was 11.4 mo in the combination therapy group and 7.3 mo in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).  The objective response rate was 64% in the combination therapy group and 51% in the vemurafenib group (P<0.001).  Rates of severe adverse events and study-drug discontinuations were similar in the two groups.  Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group.  Conclusions: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov no., NCT01597908.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5of4j14YrP7Vg90H21EOLACvtfcHk0lgLp0jaKBuXog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D&md5=9d6a8f49bbd196f9463ec15958eb15d1</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1412690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1412690%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DStroiakovski%26aufirst%3DD.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGrange%26aufirst%3DF.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDrucis%26aufirst%3DK.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DCrist%26aufirst%3DW.%26aulast%3DLegos%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DS.%2BD.%26aulast%3DLittle%26aufirst%3DS.%2BM.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520overall%2520survival%2520in%2520melanoma%2520with%2520combined%2520dabrafenib%2520and%2520trametinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D30%26epage%3D39%26doi%3D10.1056%2FNEJMoa1412690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. K. H.</span></span> <span> </span><span class="NLM_article-title">The history of monoclonal antibody development – progress, remaining challenges and future innovations</span>. <i>Ann. Med. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.amsu.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.amsu.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25568796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2Mvks1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=113-116&author=J.+K.+H.+Liu&title=The+history+of+monoclonal+antibody+development+%E2%80%93+progress%2C+remaining+challenges+and+future+innovations&doi=10.1016%2Fj.amsu.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The history of monoclonal antibody development - Progress, remaining challenges and future innovations</span></div><div class="casAuthors">Liu Justin K H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of medicine and surgery (2012)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">113-6</span>
        ISSN:<span class="NLM_cas:issn">2049-0801</span>.
    </div><div class="casAbstract">As medicine progresses into a new era of personalised therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront.  Since the licencing of the first monoclonal antibody for clinical use 30 years ago, the monoclonal antibody industry has expanded exponentially and is now valued at billions of dollars.  With major advances in genetic sequencing and biomedical research, much research into monoclonal antibodies now focuses on identifying new targets for development and maximising their efficacy for use in clinical practice.  However, a balance has to be struck with regards to reducing numbers of side-effects and overall economic cost, which arguably somewhat blighted their early clinical and commercial successes.  Nowadays, there are approximately 30 monoclonal antibodies that have been approved for use in clinical practice with many more currently being tested in clinical trials.  Some of the current major limitations include: the use of inefficient models for generation, a lack of efficacy and issues of cost-effectiveness.  Some of the current research focuses on ways to improve the efficacy of existing monoclonal antibodies through optimising their effects and the addition of beneficial modifications.  This review will focus on the history of monoclonal antibody development - how it has increasingly moved away from using laborious animal models to a more effective phage display system, some of the major drawbacks from a clinical and economical point of view and future innovations that are currently being researched to maximise their effectiveness for future clinical use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2Zr12D3tJgOxsqfvU0ziafW6udTcc2eb2cUR_2eBZ37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mvks1GjsQ%253D%253D&md5=c00607a5afc71b2c1bc8bf1dd7491dae</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.amsu.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amsu.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BK.%2BH.%26atitle%3DThe%2520history%2520of%2520monoclonal%2520antibody%2520development%2520%25E2%2580%2593%2520progress%252C%2520remaining%2520challenges%2520and%2520future%2520innovations%26jtitle%3DAnn.%2520Med.%2520Surg.%26date%3D2014%26volume%3D3%26spage%3D113%26epage%3D116%26doi%3D10.1016%2Fj.amsu.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starlinger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlberger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weibrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitmayr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberger, T.</span></span> <span> </span><span class="NLM_article-title">5-FU based chemotherapy with bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">e23208</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.34.15_suppl.e23208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1200%2FJCO.2016.34.15_suppl.e23208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=e23208&author=B.+Gruenbergerauthor=P.+Starlingerauthor=E.+Messingerauthor=L.+Oehlbergerauthor=S.+Weibrechtauthor=J.+P.+Jonasauthor=B.+Weitmayrauthor=T.+Gruenberger&title=5-FU+based+chemotherapy+with+bevacizumab+in+synchronous+metastatic+colorectal+cancer+patients+with+bleeding+primary+tumor&doi=10.1200%2FJCO.2016.34.15_suppl.e23208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.e23208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.e23208%26sid%3Dliteratum%253Aachs%26aulast%3DGruenberger%26aufirst%3DB.%26aulast%3DStarlinger%26aufirst%3DP.%26aulast%3DMessinger%26aufirst%3DE.%26aulast%3DOehlberger%26aufirst%3DL.%26aulast%3DWeibrecht%26aufirst%3DS.%26aulast%3DJonas%26aufirst%3DJ.%2BP.%26aulast%3DWeitmayr%26aufirst%3DB.%26aulast%3DGruenberger%26aufirst%3DT.%26atitle%3D5-FU%2520based%2520chemotherapy%2520with%2520bevacizumab%2520in%2520synchronous%2520metastatic%2520colorectal%2520cancer%2520patients%2520with%2520bleeding%2520primary%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3De23208%26doi%3D10.1200%2FJCO.2016.34.15_suppl.e23208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gootenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-3-356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1634%2Ftheoncologist.12-3-356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17405901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVSqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=356-361&author=M.+H.+Cohenauthor=J.+Gootenbergauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+bevacizumab+plus+FOLFOX4+as+second-line+treatment+of+colorectal+cancer&doi=10.1634%2Ftheoncologist.12-3-356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer</span></div><div class="casAuthors">Cohen, Martin H.; Gootenberg, Joe; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">356-361</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On June 20, 2006, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA), administered in combination with FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) for the second-line treatment of metastatic carcinoma of the colon or rectum.  Efficacy and safety were demonstrated in one Eastern Cooperative Oncol. Group (ECOG) open-label, multicenter, randomized, three-arm, active-controlled trial enrolling 829 adult patients.  Patients had received a fluoropyrimidine- and irinotecan-based regimen as initial therapy for metastatic disease; or they had received prior adjuvant irinotecan-based chemotherapy and had recurred within 6 mo of completing therapy.  Treatments included bevacizumab, 10 mg/kg, as a 90-min i.v. infusion on day 1, every 2 wk, either alone or in combination with FOLFOX4, or FOLFOX4 alone.  The bevacizumab monotherapy arm was closed to accrual after an interim efficacy anal. suggested a possibly shorter survival in that arm.  Overall survival (OS), the primary study endpoint, was significantly longer for patients receiving bevacizumab in combination with FOLFOX4 than for those receiving FOLFOX4 alone.  The objective response rate was significantly higher in the FOLFOX4 plus bevacizumab arm than in the FOLFOX4 alone arm.  The duration of response was approx. 6 mo for both treatment arms.  Patients treated with the bevacizumab combination were also reported, based on investigator assessment, to have significantly longer progression-free survival.  There were no new bevacizumab safety signals.  The most serious, and sometimes fatal, bevacizumab toxicities are gastrointestinal perforation, wound-healing complications, hemorrhage, arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, and congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUvJ7p7P5LrVg90H21EOLACvtfcHk0ljmqlFTLQPkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVSqur8%253D&md5=9d2d63712aec278adaa57e968dc4643c</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-3-356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-3-356%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DGootenberg%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520bevacizumab%2520plus%2520FOLFOX4%2520as%2520second-line%2520treatment%2520of%2520colorectal%2520cancer%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D356%26epage%3D361%26doi%3D10.1634%2Ftheoncologist.12-3-356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Summers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2009-0250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1634%2Ftheoncologist.2009-0250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=20061402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVaktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=104-111&author=J.+Summersauthor=M.+H.+Cohenauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+bevacizumab+plus+interferon+for+advanced+renal+cell+carcinoma&doi=10.1634%2Ftheoncologist.2009-0250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">FDA drug approval summary: bevacizumab plus interferon advanced renal cell carcinoma</span></div><div class="casAuthors">Summers, Jeff; Cohen, Martin H.; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-111</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-α2a for the treatment of patients with metastatic renal cell carcinoma.  The approval was primarily based on results from a randomized, double-blind, placebo-controlled clin. trial.  The primary efficacy endpoint, progression-free survival (PFS), was assessed by investigators and by an independent review committee (IRC) blinded to treatment assignment.  In total, 649 patients (bevacizumab plus IFN, 327; placebo plus IFN, 322) were enrolled.  The median PFS times, by investigator detn., were 10.2 mo for the bevacizumab plus IFN arm and 5.4 mo for the placebo plus IFN arm (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.49-0.72; p < .0001).  The IRC anal. of 569 patients with available radiographs yielded similar results (median PFS time, 10.4 mo vs. 5.5 mo; HR, 0.57; 95% CI, 0.45-0.72; p < .0001).  There was no survival advantage (HR, 0.86; 95% CI, 0.72-1.04; p = .13).  Support for the above results was provided by summarized results of a North American cooperative group study of bevacizumab plus IFN-α2b vs. IFN-α2b alone.  The median PFS times were 8.4 mo vs. 4.9 mo in favor of the bevacizumab combination.  There was no survival advantage.  In the reviewed trial, serious adverse events and National Cancer Institute Common Terminol. Criteria for Adverse Events grade ≥3 adverse events were reported more frequently in bevacizumab-treated patients (31% vs. 19% and 63% vs. 47%, resp.).  The most common bevacizumab-related toxicities were bleeding/hemorrhage, hypertension, proteinuria, and venous or arterial thromboembolic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVZWPBjxfhlbVg90H21EOLACvtfcHk0ljmqlFTLQPkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVaktbw%253D&md5=de8d0470fc9a9b11636ce23b6f846d39</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2009-0250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2009-0250%26sid%3Dliteratum%253Aachs%26aulast%3DSummers%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520bevacizumab%2520plus%2520interferon%2520for%2520advanced%2520renal%2520cell%2520carcinoma%26jtitle%3DOncologist%26date%3D2010%26volume%3D15%26spage%3D104%26epage%3D111%26doi%3D10.1634%2Ftheoncologist.2009-0250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormanik, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval: elotuzumab in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6759</span>– <span class="NLM_lpage">6763</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1158%2F1078-0432.CCR-16-2870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28249893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSnu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6759-6763&author=N.+J.+Gormleyauthor=C.+W.+Koauthor=A.+Deisserothauthor=L.+Nieauthor=E.+Kaminskasauthor=N.+Kormanikauthor=K.+B.+Goldbergauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+drug+approval%3A+elotuzumab+in+combination+with+lenalidomide+and+dexamethasone+for+the+treatment+of+relapsed+or+refractory+multiple+myeloma&doi=10.1158%2F1078-0432.CCR-16-2870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma</span></div><div class="casAuthors">Gormley, Nicole J.; Ko, Chia-Wen; Deisseroth, Albert; Nie, Lei; Kaminskas, Edvardas; Kormanik, Natasha; Goldberg, Kirsten B.; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6759-6763</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Nov. 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received one to three prior therapies.  FDA approval was based primarily on the results of a phase III, randomized, open-label, multicenter trial, CA204004, which evaluated elotuzumab in combination with lenalidomide and dexamethasone (E-Ld) compared with lenalidomide and dexamethasone (Ld) alone in patients with relapsed or refractory multiple myeloma.  Coprimary endpoints were progression-free survival (PFS) and overall response rate (ORR).  The key secondary endpoint was overall survival, but these data were not mature at the time of clin. database cutoff.  The trial demonstrated a statistically significant improvement in PFS, with an estd. HR of 0.70 for E-Ld over Ld [95% confidence interval (CI), 0.57-0.85; P = 0.0004. Estd. median PFS was 19.4 mo in the E-Ld arm and 14.9 mo in the Ld arm.  ORR was 75.8% in the E-Ld arm compared with 65.5% in the Ld arm.  Serious adverse reactions were reported in 65% of patients in the E-Ld arm compared with 57% in the Ld arm.  The FDA approved elotuzumab with the following warnings and precautions: infusion reactions, infections, second primary malignancies, hepatotoxicity, and interference with the detn. of complete response.  Clin Cancer Res; 23(22); 6759-63. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOVYhlp1UfTLVg90H21EOLACvtfcHk0ljw5gsg8hdE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSnu77M&md5=b910506811469b7c06816bad555a996d</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2870%26sid%3Dliteratum%253Aachs%26aulast%3DGormley%26aufirst%3DN.%2BJ.%26aulast%3DKo%26aufirst%3DC.%2BW.%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DKormanik%26aufirst%3DN.%26aulast%3DGoldberg%26aufirst%3DK.%2BB.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%253A%2520elotuzumab%2520in%2520combination%2520with%2520lenalidomide%2520and%2520dexamethasone%2520for%2520the%2520treatment%2520of%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D6759%26epage%3D6763%26doi%3D10.1158%2F1078-0432.CCR-16-2870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span> <span> </span><span class="NLM_article-title">What is the tryptophan kynurenine pathway and why is it important to neurotherapy?</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1586/14737175.2015.1049999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1586%2F14737175.2015.1049999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26004930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=719-721&author=I.+Davisauthor=A.+Liu&title=What+is+the+tryptophan+kynurenine+pathway+and+why+is+it+important+to+neurotherapy%3F&doi=10.1586%2F14737175.2015.1049999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?</span></div><div class="casAuthors">Davis, Ian; Liu, Aimin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">719-721</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The kynurenine pathway has received increasing attention as its connection to inflammation, the immune system and neurol. conditions has become more apparent.  It is the primary route for tryptophan catabolism in the liver and the starting point for the synthesis of NAD in mammals.  Dysregulation or overactivation of this pathway can lead to immune system activation and accumulation of potentially neurotoxic compds.  These aspects make the kynurenine pathway a promising target for therapeutic development to treat inflammation and disease with neurol. aspects, esp. in cancer patients undergoing chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_7WSU8_CGLVg90H21EOLACvtfcHk0ljw5gsg8hdE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfK&md5=9f4539d9101fbf39f6ebe4f20f027556</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.1049999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.1049999%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DA.%26atitle%3DWhat%2520is%2520the%2520tryptophan%2520kynurenine%2520pathway%2520and%2520why%2520is%2520it%2520important%2520to%2520neurotherapy%253F%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D719%26epage%3D721%26doi%3D10.1586%2F14737175.2015.1049999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity with combination of vemurafenib and ipilimumab</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1366</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1302338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMc1302338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23550685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1365-1366&author=A.+Ribasauthor=F.+S.+Hodiauthor=M.+Callahanauthor=C.+Kontoauthor=J.+Wolchok&title=Hepatotoxicity+with+combination+of+vemurafenib+and+ipilimumab&doi=10.1056%2FNEJMc1302338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity with combination of vemurafenib and ipilimumab</span></div><div class="casAuthors">Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1365-1366</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4C-d0ldXxG7Vg90H21EOLACvtfcHk0ljw5gsg8hdE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D&md5=e903ecac16e34bc5ee83d9d24338d950</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1302338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1302338%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DCallahan%26aufirst%3DM.%26aulast%3DKonto%26aufirst%3DC.%26aulast%3DWolchok%26aufirst%3DJ.%26atitle%3DHepatotoxicity%2520with%2520combination%2520of%2520vemurafenib%2520and%2520ipilimumab%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1365%26epage%3D1366%26doi%3D10.1056%2FNEJMc1302338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuraszeck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasichayanula, S.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1111/cts.12391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fcts.12391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26924066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC28jlt1Gmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=89-104&author=K.+M.+Morrisseyauthor=T.+M.+Yuraszeckauthor=C.+C.+Liauthor=Y.+Zhangauthor=S.+Kasichayanula&title=Immunotherapy+and+novel+combinations+in+oncology%3A+current+landscape%2C+challenges%2C+and+opportunities&doi=10.1111%2Fcts.12391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities</span></div><div class="casAuthors">Morrissey K M; Li C-C; Yuraszeck T M; Zhang Y; Kasichayanula S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ70p9dYFGYP9pSBfyDvp7fW6udTcc2eZhCebHwFYv7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jlt1Gmug%253D%253D&md5=670ae50afa7e62835e3b4e50d32b177b</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1111%2Fcts.12391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12391%26sid%3Dliteratum%253Aachs%26aulast%3DMorrissey%26aufirst%3DK.%2BM.%26aulast%3DYuraszeck%26aufirst%3DT.%2BM.%26aulast%3DLi%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKasichayanula%26aufirst%3DS.%26atitle%3DImmunotherapy%2520and%2520novel%2520combinations%2520in%2520oncology%253A%2520current%2520landscape%252C%2520challenges%252C%2520and%2520opportunities%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2016%26volume%3D9%26spage%3D89%26epage%3D104%26doi%3D10.1111%2Fcts.12391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gyawali, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, V.</span></span> <span> </span><span class="NLM_article-title">Drugs that lack single-agent activity: are they worth pursuing in combination?</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">193</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fnrclinonc.2017.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28266519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC1czjsFSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=193&author=B.+Gyawaliauthor=V.+Prasad&title=Drugs+that+lack+single-agent+activity%3A+are+they+worth+pursuing+in+combination%3F&doi=10.1038%2Fnrclinonc.2017.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that lack single-agent activity: are they worth pursuing in combination?</span></div><div class="casAuthors">Gyawali Bishal; Prasad Vinay; Prasad Vinay; Prasad Vinay</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-194</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_zBuwd5i4JVUIs6wFK5xJfW6udTcc2eZhCebHwFYv7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czjsFSrsA%253D%253D&md5=0f2ef679b3e22301d5c41464b81b8051</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.27%26sid%3Dliteratum%253Aachs%26aulast%3DGyawali%26aufirst%3DB.%26aulast%3DPrasad%26aufirst%3DV.%26atitle%3DDrugs%2520that%2520lack%2520single-agent%2520activity%253A%2520are%2520they%2520worth%2520pursuing%2520in%2520combination%253F%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D193%26doi%3D10.1038%2Fnrclinonc.2017.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtari, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayouni, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgatskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeger, H.</span></span> <span> </span><span class="NLM_article-title">Combination therapy in combating cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">38022</span>– <span class="NLM_lpage">38043</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.16723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.18632%2Foncotarget.16723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28410237" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=38022-38043&author=R.+B.+Mokhtariauthor=T.+S.+Homayouniauthor=N.+Baluchauthor=E.+Morgatskayaauthor=S.+Kumarauthor=B.+Dasauthor=H.+Yeger&title=Combination+therapy+in+combating+cancer&doi=10.18632%2Foncotarget.16723"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16723%26sid%3Dliteratum%253Aachs%26aulast%3DMokhtari%26aufirst%3DR.%2BB.%26aulast%3DHomayouni%26aufirst%3DT.%2BS.%26aulast%3DBaluch%26aufirst%3DN.%26aulast%3DMorgatskaya%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DYeger%26aufirst%3DH.%26atitle%3DCombination%2520therapy%2520in%2520combating%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D38022%26epage%3D38043%26doi%3D10.18632%2Foncotarget.16723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gieling, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.3109/14756366.2012.736979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3109%2F14756366.2012.736979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23163664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3s7ksFGjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=360-369&author=R.+G.+Gielingauthor=C.+A.+Parkerauthor=L.+A.+De+Costaauthor=N.+Robertsonauthor=A.+L.+Harrisauthor=I.+J.+Stratfordauthor=K.+J.+Williams&title=Inhibition+of+carbonic+anhydrase+activity+modifies+the+toxicity+of+doxorubicin+and+melphalan+in+tumour+cells+in+vitro&doi=10.3109%2F14756366.2012.736979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro</span></div><div class="casAuthors">Gieling Roben G; Parker Catriona A; De Costa Lisa A; Robertson Naomi; Harris Adrian L; Stratford Ian J; Williams Kaye J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of enzyme inhibition and medicinal chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">360-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Carbonic anhydrase IX (CA IX) is a hypoxia-regulated enzyme, overexpressed in many types of human cancer.  CA IX is involved in pH homeostasis, contributing to extracellular acidification and tumourigenesis.  Acidification of the extracellular milieu can impact upon cellular uptake of chemotherapeutic drugs by favouring weak acids (e.g. melphalan), but limiting access of weak bases (e.g. doxorubicin).  We investigated whether alterations of CA IX activity affected anti-cancer drug uptake and toxicity.  CA inhibitor acetazolamide (AZM) enhanced doxorubicin toxicity but reduced melphalan toxicity in cell lines that highly expressed CA IX under anoxic conditions (HT29 and MDA435 CA9/18).  The toxicity changes reflected modification of passive drug uptake.  AZM did not alter toxicity or uptake in cells with low CA IX activity (HCT116 and MDA435 EV1).  AZM lowered intracellular pH in HT29 and MDA435 CA9/18 cells under anoxic conditions.  CA IX activity has chemomodulatory properties and is an attractive target for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAE0BYK_Myi2K_SFaaT9INfW6udTcc2eZhCebHwFYv7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7ksFGjsQ%253D%253D&md5=5ca30aaff1e3a838b09055a8557d4854</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.3109%2F14756366.2012.736979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756366.2012.736979%26sid%3Dliteratum%253Aachs%26aulast%3DGieling%26aufirst%3DR.%2BG.%26aulast%3DParker%26aufirst%3DC.%2BA.%26aulast%3DDe%2BCosta%26aufirst%3DL.%2BA.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DStratford%26aufirst%3DI.%2BJ.%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26atitle%3DInhibition%2520of%2520carbonic%2520anhydrase%2520activity%2520modifies%2520the%2520toxicity%2520of%2520doxorubicin%2520and%2520melphalan%2520in%2520tumour%2520cells%2520in%2520vitro%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2013%26volume%3D28%26spage%3D360%26epage%3D369%26doi%3D10.3109%2F14756366.2012.736979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H. G.</span></span> <span> </span><span class="NLM_article-title">Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.freeradbiomed.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24970682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2cfntV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=21-34&author=M.+T.+Doauthor=H.+G.+Kimauthor=J.+H.+Choiauthor=H.+G.+Jeong&title=Metformin+induces+microRNA-34a+to+downregulate+the+Sirt1%2FPgc-1alpha%2FNrf2+pathway%2C+leading+to+increased+susceptibility+of+wild-type+p53+cancer+cells+to+oxidative+stress+and+therapeutic+agents&doi=10.1016%2Fj.freeradbiomed.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents</span></div><div class="casAuthors">Do Minh Truong; Kim Hyung Gyun; Choi Jae Ho; Jeong Hye Gwang</div><div class="citationInfo"><span class="NLM_cas:title">Free radical biology & medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sirtuin 1 (Sirt1) plays an important role in cellular redox balance and resistance to oxidative stress.  Sirt1 exhibits oncogenic properties in wild-type p53 cancer cells, whereas it acts as a tumor suppressor in p53-mutated cancer cells.  Here, we investigated the effects of metformin on Sirt1 expression in several cancer cell lines.  Using human cancer cell lines that exhibit differential expression of p53, we found that metformin reduced Sirt1 protein levels in cancer cells bearing wild-type p53, but did not affect Sirt1 protein levels in cancer cell lines harboring mutant forms of p53.  Metformin-induced p53 protein levels in wild-type p53 cancer cells resulted in upregulation of microRNA (miR)-34a.  The use of a miR-34a inhibitor confirmed that metformin-induced miR-34a was required for Sirt1 downregulation.  Metformin suppressed peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (Pgc-1α) expression and its downstream target Nrf2 in MCF-7 cells.  Genetic tools demonstrated that the reduction of Sirt1 and Pgc-1α by metformin caused Nrf2 downregulation via suppression of PPARγ transcriptional activity.  Metformin reduced heme oxygenase-1 and superoxide dismutase 2 but upregulated catalase expression in MCF-7 cells.  Metformin-treated MCF-7 cells had no increase in basal levels of reactive oxygen species but were more susceptible to oxidative stress.  Furthermore, upregulation of death receptor 5 by metformin-mediated Sirt1 downregulation enhanced the sensitivity of wild-type p53 cancer cells to TRAIL-induced apoptosis.  Our results demonstrated that metformin induces miR-34a to suppress the Sirt1/Pgc-1α/Nrf2 pathway and increases susceptibility of wild-type p53 cancer cells to oxidative stress and TRAIL-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvPBEjXDiwaoNpW7w2tapOfW6udTcc2eZSjGy2aLwnxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfntV2ntg%253D%253D&md5=796479ce8d150e3fd36c3c26a7f0b6de</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DM.%2BT.%26aulast%3DKim%26aufirst%3DH.%2BG.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DJeong%26aufirst%3DH.%2BG.%26atitle%3DMetformin%2520induces%2520microRNA-34a%2520to%2520downregulate%2520the%2520Sirt1%252FPgc-1alpha%252FNrf2%2520pathway%252C%2520leading%2520to%2520increased%2520susceptibility%2520of%2520wild-type%2520p53%2520cancer%2520cells%2520to%2520oxidative%2520stress%2520and%2520therapeutic%2520agents%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2014%26volume%3D74%26spage%3D21%26epage%3D34%26doi%3D10.1016%2Fj.freeradbiomed.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span> <span> </span><span class="NLM_article-title">Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1002/cncr.29085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fcncr.29085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25336333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12lu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=556-561&author=J.+P.+Issaauthor=G.+Garcia-Maneroauthor=X.+Huangauthor=J.+Cortesauthor=F.+Ravandiauthor=E.+Jabbourauthor=G.+Borthakurauthor=M.+Brandtauthor=S.+Pierceauthor=H.+M.+Kantarjian&title=Results+of+phase+2+randomized+study+of+low-dose+decitabine+with+or+without+valproic+acid+in+patients+with+myelodysplastic+syndrome+and+acute+myelogenous+leukemia&doi=10.1002%2Fcncr.29085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia</span></div><div class="casAuthors">Issa, Jean-Pierre; Garcia-Manero, Guillermo; Huang, Xuelin; Cortes, Jorge; Ravandi, Farhad; Jabbour, Elias; Borthakur, Gautam; Brandt, Mark; Pierce, Sherry; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">556-561</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).  Preclin. and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results.  METHODS : The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML.  RESULTS : Patients with higher risk MDS or with AML aged ≥60 years were eligible.  Patients were randomized in a Bayesian response-adaptive design to receive i.v. decitabine 20 mg/m2 daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days.  Courses were repeated every 4 to 6 wk.  A max. of 150 patients were to be treated.  In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML.  The median patient age was 69 years (range, 20-89 years; 42% of patients were aged ≥70 years).  Overall, 34% of patients achieved complete remission, and 55% had an objective response.  The median survival was 11.9 mo, and the estd. 2-yr survival rate was 27%.  Outcome was not different with the addn. of valproic acid to decitabine vs. decitabine alone in relation to the rates of complete remission, overall response, or survival.  Subset analyses did not demonstrate a benefit within the MDS or AML categories.  Toxicities-particularly neurotoxicities-were higher with the combination arm.  CONCLUSIONS : Adding valproic acid to decitabine was not assocd. with improved outcome in the treatment of patients with MDS or elderly patients with AML.  Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.  Cancer 2015;121:556-561. © 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvZR8IxSwLrVg90H21EOLACvtfcHk0lgIWSwBus2flQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12lu7g%253D&md5=94bda8d8fdfd9d327bc563204dba1846</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29085%26sid%3Dliteratum%253Aachs%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DResults%2520of%2520phase%25202%2520randomized%2520study%2520of%2520low-dose%2520decitabine%2520with%2520or%2520without%2520valproic%2520acid%2520in%2520patients%2520with%2520myelodysplastic%2520syndrome%2520and%2520acute%2520myelogenous%2520leukemia%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D556%26epage%3D561%26doi%3D10.1002%2Fcncr.29085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d','cit1e','cit1f','cit1g'],'ref2':[],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 61 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pradipta Das, Michael D. Delost, Munaum H. Qureshi, Jianhua Bao, Jason S. Fell, Kendall N. Houk, <span class="NLM_string-name hlFld-ContribAuthor">Jon T. Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">Dramatic Effect of γ-Heteroatom Dienolate Substituents on Counterion Assisted Asymmetric Anionic Amino-Cope Reaction Cascades. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (15)
                                     , 5793-5804. <a href="https://doi.org/10.1021/jacs.1c00745" title="DOI URL">https://doi.org/10.1021/jacs.1c00745</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c00745%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDramatic%252BEffect%252Bof%252B%2525CE%2525B3-Heteroatom%252BDienolate%252BSubstituents%252Bon%252BCounterion%252BAssisted%252BAsymmetric%252BAnionic%252BAmino-Cope%252BReaction%252BCascades%26aulast%3DDas%26aufirst%3DPradipta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D20012021%26date%3D12042021%26volume%3D143%26issue%3D15%26spage%3D5793%26epage%3D5804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K. Rajanna, Hemant Bhutani, Atish T. Paul, <span class="NLM_string-name hlFld-ContribAuthor">Raj Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">U.S. FDA Approved Drugs from 2015–June 2020: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2339-2381. <a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DU.S.%252BFDA%252BApproved%252BDrugs%252Bfrom%252B2015%2525E2%252580%252593June%252B2020%25253A%252BA%252BPerspective%26aulast%3DBhutani%26aufirst%3DPriyadeep%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin Zhou, Zhiyuan Peng, Peng George Wang, Qingchao Liu, <span class="NLM_string-name hlFld-ContribAuthor">Tiezheng Jia</span>. </span><span class="cited-content_cbyCitation_article-title">Atom Transfer Radical Addition to Styrenes with Thiosulfonates Enabled by Synergetic Copper/Photoredox Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     , 1054-1059. <a href="https://doi.org/10.1021/acs.orglett.0c04254" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c04254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c04254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c04254%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAtom%252BTransfer%252BRadical%252BAddition%252Bto%252BStyrenes%252Bwith%252BThiosulfonates%252BEnabled%252Bby%252BSynergetic%252BCopper%25252FPhotoredox%252BCatalysis%26aulast%3DZhou%26aufirst%3DXin%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D24122020%26date%3D11012021%26volume%3D23%26issue%3D3%26spage%3D1054%26epage%3D1059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xunbo Lu, Yulong Bai, Jingyang Qin, Nan Wang, Yuzhou Wu, <span class="NLM_string-name hlFld-ContribAuthor">Fangrui Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Alleviating Catalyst Decay Enables Efficient Intermolecular C(sp3)–H Amination under Mechanochemical Conditions. </span><span class="cited-content_cbyCitation_journal-name">ACS Sustainable Chemistry & Engineering</span><span> <strong>2021,</strong> <em>9 </em>
                                    (4)
                                     , 1684-1691. <a href="https://doi.org/10.1021/acssuschemeng.0c07512" title="DOI URL">https://doi.org/10.1021/acssuschemeng.0c07512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssuschemeng.0c07512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssuschemeng.0c07512%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Sustainable%2520Chemistry%2520%2526%2520Engineering%26atitle%3DAlleviating%252BCatalyst%252BDecay%252BEnables%252BEfficient%252BIntermolecular%252BC%252528sp3%252529%2525E2%252580%252593H%252BAmination%252Bunder%252BMechanochemical%252BConditions%26aulast%3DLu%26aufirst%3DXunbo%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D13102020%26date%3D26112020%26date%3D15012021%26volume%3D9%26issue%3D4%26spage%3D1684%26epage%3D1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pradip Ramdas Thorve, <span class="NLM_string-name hlFld-ContribAuthor">Biplab Maji</span>. </span><span class="cited-content_cbyCitation_article-title">Deaminative Olefination of Methyl N-Heteroarenes by an Amine Oxidase Inspired Catalyst. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (2)
                                     , 542-547. <a href="https://doi.org/10.1021/acs.orglett.0c04060" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c04060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c04060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c04060%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDeaminative%252BOlefination%252Bof%252BMethyl%252BN-Heteroarenes%252Bby%252Ban%252BAmine%252BOxidase%252BInspired%252BCatalyst%26aulast%3DThorve%26aufirst%3DPradip%2BRamdas%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D08122020%26date%3D07012021%26volume%3D23%26issue%3D2%26spage%3D542%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kevin A. Scott, M. Haziq Qureshi, Philip B. Cox, Christopher M. Marshall, Bailey C. Bellaire, Michael Wilcox, Bradey A. R. Stuart, <span class="NLM_string-name hlFld-ContribAuthor">Jon T. Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15449-15482. <a href="https://doi.org/10.1021/acs.jmedchem.0c01502" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01502%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BStructural%252BAnalysis%252Bof%252Bthe%252BFDA%252BGreen%252BBook-Approved%252BVeterinary%252BDrugs%252Band%252BRoles%252Bin%252BHuman%252BMedicine%26aulast%3DScott%26aufirst%3DKevin%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27082020%26date%3D30102020%26volume%3D63%26issue%3D24%26spage%3D15449%26epage%3D15482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dmitry M. Bystrov, Ivan V. Ananyev, Leonid L. Fershtat, <span class="NLM_string-name hlFld-ContribAuthor">Nina N. Makhova</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Synthesis of N-(1,2,5-Oxadiazolyl)hydrazones through a Diazotization/Reduction/Condensation Cascade. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (23)
                                     , 15466-15475. <a href="https://doi.org/10.1021/acs.joc.0c02243" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02243%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDirect%252BSynthesis%252Bof%252BN-%2525281%25252C2%25252C5-Oxadiazolyl%252529hydrazones%252Bthrough%252Ba%252BDiazotization%25252FReduction%25252FCondensation%252BCascade%26aulast%3DBystrov%26aufirst%3DDmitry%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17092020%26date%3D13112020%26volume%3D85%26issue%3D23%26spage%3D15466%26epage%3D15475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aleksandra Nilova, Louis-Charles Campeau, Edward C. Sherer, <span class="NLM_string-name hlFld-ContribAuthor">David R. Stuart</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Benzenoid Substitution Patterns in Small Molecule Active Pharmaceutical Ingredients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13389-13396. <a href="https://doi.org/10.1021/acs.jmedchem.0c00915" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00915%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAnalysis%252Bof%252BBenzenoid%252BSubstitution%252BPatterns%252Bin%252BSmall%252BMolecule%252BActive%252BPharmaceutical%252BIngredients%26aulast%3DNilova%26aufirst%3DAleksandra%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D31082020%26date%3D13082020%26volume%3D63%26issue%3D22%26spage%3D13389%26epage%3D13396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maheshwerreddy Chilamari, Jacob R. Immel, <span class="NLM_string-name hlFld-ContribAuthor">Steven Bloom</span>. </span><span class="cited-content_cbyCitation_article-title">General Access to C-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (21)
                                     , 12727-12737. <a href="https://doi.org/10.1021/acscatal.0c03422" title="DOI URL">https://doi.org/10.1021/acscatal.0c03422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c03422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c03422%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DGeneral%252BAccess%252Bto%252BC-Centered%252BRadicals%25253A%252BCombining%252Ba%252BBioinspired%252BPhotocatalyst%252Bwith%252BBoronic%252BAcids%252Bin%252BAqueous%252BMedia%26aulast%3DChilamari%26aufirst%3DMaheshwerreddy%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05082020%26date%3D06102020%26date%3D19102020%26volume%3D10%26issue%3D21%26spage%3D12727%26epage%3D12737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">Essential Medicinal Chemistry of Essential Medicines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10170-10187. <a href="https://doi.org/10.1021/acs.jmedchem.0c00415" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00415%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEssential%252BMedicinal%252BChemistry%252Bof%252BEssential%252BMedicines%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11032020%26date%3D12052020%26date%3D30042020%26volume%3D63%26issue%3D18%26spage%3D10170%26epage%3D10187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yiming Zhou, Yu Chen, <span class="NLM_string-name hlFld-ContribAuthor">You Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent Domino Reactions of Prop-2-ynylsulfonium Salts: Access to Sulfur-Containing Benzo-Fused Dioxabicyclo[3.3.1]nonanes and Dihydrofuro[2,3-c]chromenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (15)
                                     , 5941-5946. <a href="https://doi.org/10.1021/acs.orglett.0c02025" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02025%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDivergent%252BDomino%252BReactions%252Bof%252BProp-2-ynylsulfonium%252BSalts%25253A%252BAccess%252Bto%252BSulfur-Containing%252BBenzo-Fused%252BDioxabicyclo%25255B3.3.1%25255Dnonanes%252Band%252BDihydrofuro%25255B2%25252C3-c%25255Dchromenes%26aulast%3DZhou%26aufirst%3DYiming%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18062020%26date%3D29072020%26volume%3D22%26issue%3D15%26spage%3D5941%26epage%3D5946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Munenori Inoue, Yuji Sumii, <span class="NLM_string-name hlFld-ContribAuthor">Norio Shibata</span>. </span><span class="cited-content_cbyCitation_article-title">Contribution of Organofluorine Compounds to Pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (19)
                                     , 10633-10640. <a href="https://doi.org/10.1021/acsomega.0c00830" title="DOI URL">https://doi.org/10.1021/acsomega.0c00830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c00830%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DContribution%252Bof%252BOrganofluorine%252BCompounds%252Bto%252BPharmaceuticals%26aulast%3DInoue%26aufirst%3DMunenori%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D25022020%26date%3D10042020%26date%3D22042020%26volume%3D5%26issue%3D19%26spage%3D10633%26epage%3D10640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Cheng, Yuntong Li, Taimin Wang, Xinping Zhang, Hui Li, Yixuan He, Yun Li, <span class="NLM_string-name hlFld-ContribAuthor">Hongbin Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Pyridinium 1,4-Zwitterionic Thiolates: Synthesis of Benzopyridothiazepines and Benzothiophenes. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (10)
                                     , 6794-6802. <a href="https://doi.org/10.1021/acs.joc.0c00374" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00374%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DApplication%252Bof%252BPyridinium%252B1%25252C4-Zwitterionic%252BThiolates%25253A%252BSynthesis%252Bof%252BBenzopyridothiazepines%252Band%252BBenzothiophenes%26aulast%3DCheng%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14022020%26date%3D07052020%26date%3D24042020%26volume%3D85%26issue%3D10%26spage%3D6794%26epage%3D6802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiao-Ye Yu, Jun Chen, Hong-Wei Chen, Wen-Jing Xiao, <span class="NLM_string-name hlFld-ContribAuthor">Jia-Rong Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Driven Copper-Catalyzed C(sp3)–O Cross-Coupling of Benzylic Radicals with Phenols. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (6)
                                     , 2333-2338. <a href="https://doi.org/10.1021/acs.orglett.0c00532" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00532</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00532%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DVisible-Light-Driven%252BCopper-Catalyzed%252BC%252528sp3%252529%2525E2%252580%252593O%252BCross-Coupling%252Bof%252BBenzylic%252BRadicals%252Bwith%252BPhenols%26aulast%3DYu%26aufirst%3DXiao-Ye%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10022020%26date%3D11032020%26volume%3D22%26issue%3D6%26spage%3D2333%26epage%3D2338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pengpeng Zhang, David Huang, <span class="NLM_string-name hlFld-ContribAuthor">Timothy R. Newhouse</span>. </span><span class="cited-content_cbyCitation_article-title">Aryl-Nickel-Catalyzed Benzylic Dehydrogenation of Electron-Deficient Heteroarenes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (4)
                                     , 1757-1762. <a href="https://doi.org/10.1021/jacs.9b12706" title="DOI URL">https://doi.org/10.1021/jacs.9b12706</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b12706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b12706%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAryl-Nickel-Catalyzed%252BBenzylic%252BDehydrogenation%252Bof%252BElectron-Deficient%252BHeteroarenes%26aulast%3DZhang%26aufirst%3DPengpeng%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D25112019%26date%3D14012020%26date%3D17122019%26volume%3D142%26issue%3D4%26spage%3D1757%26epage%3D1762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hiroto Uno, Takanori Imai, Kyosuke Harada, <span class="NLM_string-name hlFld-ContribAuthor">Norio Shibata</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Highly Functionalized 12-Membered Trifluoromethyl Heterocycles via a Nondecarboxylative Pd-Catalyzed [6 + 6] Annulation. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (2)
                                     , 1454-1459. <a href="https://doi.org/10.1021/acscatal.9b05377" title="DOI URL">https://doi.org/10.1021/acscatal.9b05377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b05377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b05377%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DSynthesis%252Bof%252BHighly%252BFunctionalized%252B12-Membered%252BTrifluoromethyl%252BHeterocycles%252Bvia%252Ba%252BNondecarboxylative%252BPd-Catalyzed%252B%25255B6%252B%25252B%252B6%25255D%252BAnnulation%26aulast%3DUno%26aufirst%3DHiroto%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D13122019%26date%3D29122019%26date%3D07012020%26volume%3D10%26issue%3D2%26spage%3D1454%26epage%3D1459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sandip B. Jadhav, <span class="NLM_string-name hlFld-ContribAuthor">Rambabu Chegondi</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective Desymmetrization of p-Quinamines through Regioselective Ring Opening of Epoxides and Aziridines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (24)
                                     , 10115-10119. <a href="https://doi.org/10.1021/acs.orglett.9b04110" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b04110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b04110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b04110%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDiastereoselective%252BDesymmetrization%252Bof%252Bp-Quinamines%252Bthrough%252BRegioselective%252BRing%252BOpening%252Bof%252BEpoxides%252Band%252BAziridines%26aulast%3DJadhav%26aufirst%3DSandip%2BB.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18112019%26date%3D05122019%26volume%3D21%26issue%3D24%26spage%3D10115%26epage%3D10119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joseph Becica, Damian P. Hruszkewycz, Janelle E. Steves, Jennifer M. Elward, David C. Leitch, <span class="NLM_string-name hlFld-ContribAuthor">Graham E. Dobereiner</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Discovery and Evaluation of a General Catalytic Method for N-Arylation of Weakly Nucleophilic Sulfonamides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (22)
                                     , 8981-8986. <a href="https://doi.org/10.1021/acs.orglett.9b03380" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03380%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DHigh-Throughput%252BDiscovery%252Band%252BEvaluation%252Bof%252Ba%252BGeneral%252BCatalytic%252BMethod%252Bfor%252BN-Arylation%252Bof%252BWeakly%252BNucleophilic%252BSulfonamides%26aulast%3DBecica%26aufirst%3DJoseph%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24092019%26date%3D25102019%26volume%3D21%26issue%3D22%26spage%3D8981%26epage%3D8986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David Huang, Diego Olivieri, Yang Sun, Pengpeng Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Timothy R. Newhouse</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel-Catalyzed Difunctionalization of Unactivated Alkenes Initiated by Unstabilized Enolates. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (41)
                                     , 16249-16254. <a href="https://doi.org/10.1021/jacs.9b09245" title="DOI URL">https://doi.org/10.1021/jacs.9b09245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b09245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b09245%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DNickel-Catalyzed%252BDifunctionalization%252Bof%252BUnactivated%252BAlkenes%252BInitiated%252Bby%252BUnstabilized%252BEnolates%26aulast%3DHuang%26aufirst%3DDavid%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26082019%26date%3D02102019%26date%3D26092019%26volume%3D141%26issue%3D41%26spage%3D16249%26epage%3D16254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shengbiao Tang, Ziyong Li, Ying Shao, <span class="NLM_string-name hlFld-ContribAuthor">Jiangtao Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Ir-Catalyzed Regiocontrolled Allylic Amination of Di-/Trienyl Allylic Alcohols with Secondary Amines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (18)
                                     , 7228-7232. <a href="https://doi.org/10.1021/acs.orglett.9b02435" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02435%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIr-Catalyzed%252BRegiocontrolled%252BAllylic%252BAmination%252Bof%252BDi-%25252FTrienyl%252BAllylic%252BAlcohols%252Bwith%252BSecondary%252BAmines%26aulast%3DTang%26aufirst%3DShengbiao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14072019%26date%3D11092019%26volume%3D21%26issue%3D18%26spage%3D7228%26epage%3D7232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lara Amini-Rentsch, Ennio Vanoli, Sylvia Richard-Bildstein, Roger Marti, <span class="NLM_string-name hlFld-ContribAuthor">Gianvito Vilé</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel and Efficient Continuous-Flow Route To Prepare Trifluoromethylated N-Fused Heterocycles for Drug Discovery and Pharmaceutical Manufacturing. </span><span class="cited-content_cbyCitation_journal-name">Industrial & Engineering Chemistry Research</span><span> <strong>2019,</strong> <em>58 </em>
                                    (24)
                                     , 10164-10171. <a href="https://doi.org/10.1021/acs.iecr.9b01906" title="DOI URL">https://doi.org/10.1021/acs.iecr.9b01906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.iecr.9b01906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.iecr.9b01906%26sid%3Dliteratum%253Aachs%26jtitle%3DIndustrial%2520%2526%2520Engineering%2520Chemistry%2520Research%26atitle%3DA%252BNovel%252Band%252BEfficient%252BContinuous-Flow%252BRoute%252BTo%252BPrepare%252BTrifluoromethylated%252BN-Fused%252BHeterocycles%252Bfor%252BDrug%252BDiscovery%252Band%252BPharmaceutical%252BManufacturing%26aulast%3DAmini-Rentsch%26aufirst%3DLara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D09042019%26date%3D27052019%26date%3D27052019%26date%3D11062019%26date%3D27052019%26volume%3D58%26issue%3D24%26spage%3D10164%26epage%3D10171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arif  Mermer</span>, <span class="hlFld-ContribAuthor ">Turgut  Keles</span>, <span class="hlFld-ContribAuthor ">Yakup  Sirin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105076. <a href="https://doi.org/10.1016/j.bioorg.2021.105076" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105076%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DRecent%252Bstudies%252Bof%252Bnitrogen%252Bcontaining%252Bheterocyclic%252Bcompounds%252Bas%252Bnovel%252Bantiviral%252Bagents%25253A%252BA%252Breview%26aulast%3DMermer%26aufirst%3DArif%26date%3D2021%26volume%3D114%26spage%3D105076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>186 </em>, 1003-1166. <a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D186%26spage%3D1003%26epage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Betül  Güvenç Paltun</span>, <span class="hlFld-ContribAuthor ">Samuel  Kaski</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Mamitsuka</span>. </span><span class="cited-content_cbyCitation_article-title">Machine learning approaches for drug combination therapies. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2021,</strong> <em>42 </em><a href="https://doi.org/10.1093/bib/bbab293" title="DOI URL">https://doi.org/10.1093/bib/bbab293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bbab293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbbab293%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DMachine%252Blearning%252Bapproaches%252Bfor%252Bdrug%252Bcombination%252Btherapies%26aulast%3DG%25C3%25BCven%25C3%25A7%25C2%25A0Paltun%26aufirst%3DBet%25C3%25BCl%26date%3D2021%26date%3D2021%26volume%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianduanyi  Wang</span>, <span class="hlFld-ContribAuthor ">Sandor  Szedmak</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Tero  Aittokallio</span>, <span class="hlFld-ContribAuthor ">Tapio  Pahikkala</span>, <span class="hlFld-ContribAuthor ">Anna  Cichonska</span>, <span class="hlFld-ContribAuthor ">Juho  Rousu</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling drug combination effects via latent tensor reconstruction. </span><span class="cited-content_cbyCitation_journal-name">Bioinformatics</span><span> <strong>2021,</strong> <em>37 </em>
                                    (Supplement_1)
                                     , i93-i101. <a href="https://doi.org/10.1093/bioinformatics/btab308" title="DOI URL">https://doi.org/10.1093/bioinformatics/btab308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bioinformatics/btab308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbioinformatics%2Fbtab308%26sid%3Dliteratum%253Aachs%26jtitle%3DBioinformatics%26atitle%3DModeling%252Bdrug%252Bcombination%252Beffects%252Bvia%252Blatent%252Btensor%252Breconstruction%26aulast%3DWang%26aufirst%3DTianduanyi%26date%3D2021%26date%3D2021%26volume%3D37%26issue%3DSupplement_1%26spage%3Di93%26epage%3Di101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changchao  Huan</span>, <span class="hlFld-ContribAuthor ">Yao  Xu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Tingting  Guo</span>, <span class="hlFld-ContribAuthor ">Haochun  Pan</span>, <span class="hlFld-ContribAuthor ">Song  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress on the Antiviral Activity of Glycyrrhizin and its Derivatives in Liquorice. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.680674" title="DOI URL">https://doi.org/10.3389/fphar.2021.680674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.680674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.680674%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DResearch%252BProgress%252Bon%252Bthe%252BAntiviral%252BActivity%252Bof%252BGlycyrrhizin%252Band%252Bits%252BDerivatives%252Bin%252BLiquorice%26aulast%3DHuan%26aufirst%3DChangchao%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jérémy  Merad</span>, <span class="hlFld-ContribAuthor ">Ján  Matyašovský</span>, <span class="hlFld-ContribAuthor ">Tobias  Stopka</span>, <span class="hlFld-ContribAuthor ">Bogdan R.  Brutiu</span>, <span class="hlFld-ContribAuthor ">Alexandre  Pinto</span>, <span class="hlFld-ContribAuthor ">Martina  Drescher</span>, <span class="hlFld-ContribAuthor ">Nuno  Maulide</span>. </span><span class="cited-content_cbyCitation_article-title">Stable and easily available sulfide surrogates allow a stereoselective activation of alcohols. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (22)
                                     , 7770-7774. <a href="https://doi.org/10.1039/D1SC01602D" title="DOI URL">https://doi.org/10.1039/D1SC01602D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC01602D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC01602D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DStable%252Band%252Beasily%252Bavailable%252Bsulfide%252Bsurrogates%252Ballow%252Ba%252Bstereoselective%252Bactivation%252Bof%252Balcohols%26aulast%3DMerad%26aufirst%3DJ%25C3%25A9r%25C3%25A9my%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D22%26spage%3D7770%26epage%3D7774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhixiong  Ruan</span>, <span class="hlFld-ContribAuthor ">Zhixing  Huang</span>, <span class="hlFld-ContribAuthor ">Zhongnan  Xu</span>, <span class="hlFld-ContribAuthor ">Shaogao  Zeng</span>, <span class="hlFld-ContribAuthor ">Pengju  Feng</span>, <span class="hlFld-ContribAuthor ">Ping-Hua  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Late-stage azolation of benzylic C‒H bonds enabled by electrooxidation. </span><span class="cited-content_cbyCitation_journal-name">Science China Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 800-807. <a href="https://doi.org/10.1007/s11426-020-9938-9" title="DOI URL">https://doi.org/10.1007/s11426-020-9938-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11426-020-9938-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11426-020-9938-9%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520China%2520Chemistry%26atitle%3DLate-stage%252Bazolation%252Bof%252Bbenzylic%252BC%2525E2%252580%252592H%252Bbonds%252Benabled%252Bby%252Belectrooxidation%26aulast%3DRuan%26aufirst%3DZhixiong%26date%3D2021%26date%3D2021%26volume%3D64%26issue%3D5%26spage%3D800%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sebastian A.  Testero</span>, <span class="hlFld-ContribAuthor ">Leticia I.  Llarrull</span>, <span class="hlFld-ContribAuthor ">Jed F.  Fisher</span>, <span class="hlFld-ContribAuthor ">Shahriar  Mobashery</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry of β‐Lactam Antibiotics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-188. <a href="https://doi.org/10.1002/0471266949.bmc226.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc226.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc226.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc226.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DMedicinal%252BChemistry%252Bof%252B%2525CE%2525B2%2525E2%252580%252590Lactam%252BAntibiotics%26aulast%3DTestero%26aufirst%3DSebastian%2BA.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D188%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mussa  Yussuf Khamis</span>, <span class="hlFld-ContribAuthor ">Hui-Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qin  Ma</span>, <span class="hlFld-ContribAuthor ">Yi-Han  Li</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Xin-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104754. <a href="https://doi.org/10.1016/j.bioorg.2021.104754" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104754%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DOvercome%252Bthe%252Btumor%252Bimmunotherapy%252Bresistance%252Bby%252Bcombination%252Bof%252Bthe%252BHDAC6%252Binhibitors%252Bwith%252Bantitumor%252Bimmunomodulatory%252Bagents%26aulast%3DYussuf%2BKhamis%26aufirst%3DMussa%26date%3D2021%26volume%3D109%26spage%3D104754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji  Lv</span>, <span class="hlFld-ContribAuthor ">Senyi  Deng</span>, <span class="hlFld-ContribAuthor ">Le  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A review of artificial intelligence applications for antimicrobial resistance. </span><span class="cited-content_cbyCitation_journal-name">Biosafety and Health</span><span> <strong>2021,</strong> <em>3 </em>
                                    (1)
                                     , 22-31. <a href="https://doi.org/10.1016/j.bsheal.2020.08.003" title="DOI URL">https://doi.org/10.1016/j.bsheal.2020.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bsheal.2020.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bsheal.2020.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBiosafety%2520and%2520Health%26atitle%3DA%252Breview%252Bof%252Bartificial%252Bintelligence%252Bapplications%252Bfor%252Bantimicrobial%252Bresistance%26aulast%3DLv%26aufirst%3DJi%26date%3D2021%26volume%3D3%26issue%3D1%26spage%3D22%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sofiane  Hocine</span>, <span class="hlFld-ContribAuthor ">Claire  Montagnon</span>, <span class="hlFld-ContribAuthor ">Jithender  Reddy Vakiti</span>, <span class="hlFld-ContribAuthor ">Jean‐Marie  Fourquez</span>, <span class="hlFld-ContribAuthor ">Stephen  Hanessian</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of Oxabicyclic Pyrrolidines of Medicinal Relevance: Merging Chemoenzymatic and Catalytic Methods. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (2)
                                     , 274-283. <a href="https://doi.org/10.1002/ejoc.202001276" title="DOI URL">https://doi.org/10.1002/ejoc.202001276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001276%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereoselective%252BSynthesis%252Bof%252BOxabicyclic%252BPyrrolidines%252Bof%252BMedicinal%252BRelevance%25253A%252BMerging%252BChemoenzymatic%252Band%252BCatalytic%252BMethods%26aulast%3DHocine%26aufirst%3DSofiane%26date%3D2021%26date%3D2020%26volume%3D2021%26issue%3D2%26spage%3D274%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunya  Sakurai</span>, <span class="hlFld-ContribAuthor ">Taichi  Kano</span>, <span class="hlFld-ContribAuthor ">Keiji  Maruoka</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-Catalyzed
              O
              -alkylation of phenol derivatives with alkylsilyl peroxides. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (1)
                                     , 81-84. <a href="https://doi.org/10.1039/D0CC07305A" title="DOI URL">https://doi.org/10.1039/D0CC07305A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC07305A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC07305A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCu-Catalyzed%252BO%252B-alkylation%252Bof%252Bphenol%252Bderivatives%252Bwith%252Balkylsilyl%252Bperoxides%26aulast%3DSakurai%26aufirst%3DShunya%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D1%26spage%3D81%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlos A.  Echeverry-Gonzalez</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Kouznetsov</span>. </span><span class="cited-content_cbyCitation_article-title">Pursuit for simple and efficient ligands promoting copper-catalyzed Ullmann type reactions for N-aryl heterocycles and aromatic amines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 399-430. <a href="https://doi.org/10.1016/B978-0-12-821263-9.00011-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-821263-9.00011-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821263-9.00011-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821263-9.00011-4%26sid%3Dliteratum%253Aachs%26atitle%3DPursuit%252Bfor%252Bsimple%252Band%252Befficient%252Bligands%252Bpromoting%252Bcopper-catalyzed%252BUllmann%252Btype%252Breactions%252Bfor%252BN-aryl%252Bheterocycles%252Band%252Baromatic%252Bamines%26aulast%3DEcheverry-Gonzalez%26aufirst%3DCarlos%2BA.%26date%3D2021%26spage%3D399%26epage%3D430%26pub%3DElsevier%26atitle%3DCopper%252Bin%252BN-Heterocyclic%252BChemistry%26date%3D2021%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natesh  Singh</span>, <span class="hlFld-ContribAuthor ">Bruno O.  Villoutreix</span>. </span><span class="cited-content_cbyCitation_article-title">Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2021,</strong> <em>19 </em>, 2537-2548. <a href="https://doi.org/10.1016/j.csbj.2021.04.059" title="DOI URL">https://doi.org/10.1016/j.csbj.2021.04.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2021.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2021.04.059%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DResources%252Band%252Bcomputational%252Bstrategies%252Bto%252Badvance%252Bsmall%252Bmolecule%252BSARS-CoV-2%252Bdiscovery%25253A%252BLessons%252Bfrom%252Bthe%252Bpandemic%252Band%252Bpreparing%252Bfor%252Bfuture%252Bhealth%252Bcrises%26aulast%3DSingh%26aufirst%3DNatesh%26date%3D2021%26volume%3D19%26spage%3D2537%26epage%3D2548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuwen  Jia</span>, <span class="hlFld-ContribAuthor ">Chunxi  Huang</span>, <span class="hlFld-ContribAuthor ">Xuemei  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhong  Lian</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free sulfonylative annulations of alkyl diiodides with sulfur dioxide: synthesis of cyclic aliphatic sulfones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>62 </em><a href="https://doi.org/10.1039/D1QO00804H" title="DOI URL">https://doi.org/10.1039/D1QO00804H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00804H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00804H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DMetal-free%252Bsulfonylative%252Bannulations%252Bof%252Balkyl%252Bdiiodides%252Bwith%252Bsulfur%252Bdioxide%25253A%252Bsynthesis%252Bof%252Bcyclic%252Baliphatic%252Bsulfones%26aulast%3DJia%26aufirst%3DXiuwen%26date%3D2021%26date%3D2021%26volume%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Yu</span>, <span class="hlFld-ContribAuthor ">Xueping  Chang</span>, <span class="hlFld-ContribAuthor ">Ruitian  Ma</span>, <span class="hlFld-ContribAuthor ">Qiuju  Zhou</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Wei</span>, <span class="hlFld-ContribAuthor ">Xinhua  Cao</span>, <span class="hlFld-ContribAuthor ">Xiantao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Water‐Promoted Dehydrative Tsuji–Trost Reaction of Non‐Derivatized Allylic Alcohols with Sulfinic Acids. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (46)
                                     , 7238-7242. <a href="https://doi.org/10.1002/ejoc.202001306" title="DOI URL">https://doi.org/10.1002/ejoc.202001306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001306%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DWater%2525E2%252580%252590Promoted%252BDehydrative%252BTsuji%2525E2%252580%252593Trost%252BReaction%252Bof%252BNon%2525E2%252580%252590Derivatized%252BAllylic%252BAlcohols%252Bwith%252BSulfinic%252BAcids%26aulast%3DYu%26aufirst%3DJing%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D46%26spage%3D7238%26epage%3D7242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothé  Maujean</span>, <span class="hlFld-ContribAuthor ">Nicolas  Girard</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>, <span class="hlFld-ContribAuthor ">Mihaela  Gulea</span>, <span class="hlFld-ContribAuthor ">Dominique  Bonnet</span>. </span><span class="cited-content_cbyCitation_article-title">Three cheers for nitrogen: aza-DKPs, the aza analogues of 2,5-diketopiperazines. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (71)
                                     , 43358-43370. <a href="https://doi.org/10.1039/D0RA09457A" title="DOI URL">https://doi.org/10.1039/D0RA09457A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA09457A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA09457A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DThree%252Bcheers%252Bfor%252Bnitrogen%25253A%252Baza-DKPs%25252C%252Bthe%252Baza%252Banalogues%252Bof%252B2%25252C5-diketopiperazines%26aulast%3DMaujean%26aufirst%3DTimoth%25C3%25A9%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D71%26spage%3D43358%26epage%3D43370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guochen  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Lanthanide complexes for drug delivery and therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Luminescence</span><span> <strong>2020,</strong> <em>228 </em>, 117622. <a href="https://doi.org/10.1016/j.jlumin.2020.117622" title="DOI URL">https://doi.org/10.1016/j.jlumin.2020.117622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jlumin.2020.117622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jlumin.2020.117622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Luminescence%26atitle%3DLanthanide%252Bcomplexes%252Bfor%252Bdrug%252Bdelivery%252Band%252Btherapeutics%26aulast%3DBao%26aufirst%3DGuochen%26date%3D2020%26volume%3D228%26spage%3D117622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yucheng  Cao</span>, <span class="hlFld-ContribAuthor ">Kaiyi  Wang</span>, <span class="hlFld-ContribAuthor ">Si  Xu</span>, <span class="hlFld-ContribAuthor ">Lingtan  Kong</span>, <span class="hlFld-ContribAuthor ">Yi  Bi</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Semisynthesis, Modifications and Biological Activities of Ocotillol-Type Triterpenoids. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (23)
                                     , 5562. <a href="https://doi.org/10.3390/molecules25235562" title="DOI URL">https://doi.org/10.3390/molecules25235562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25235562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25235562%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BSemisynthesis%25252C%252BModifications%252Band%252BBiological%252BActivities%252Bof%252BOcotillol-Type%252BTriterpenoids%26aulast%3DCao%26aufirst%3DYucheng%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D23%26spage%3D5562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Dayou  Zhong</span>, <span class="hlFld-ContribAuthor ">Muhammad  Usman</span>, <span class="hlFld-ContribAuthor ">Peng  Xue</span>, <span class="hlFld-ContribAuthor ">Wen‐Bo  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Iron‐Catalyzed
              Primary C—H Amination of Sulfamate Esters and Its Application in Synthesis of Azetidines
              †. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2020,</strong> <em>38 </em>
                                    (12)
                                     , 1651-1655. <a href="https://doi.org/10.1002/cjoc.202000299" title="DOI URL">https://doi.org/10.1002/cjoc.202000299</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.202000299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.202000299%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DIron%2525E2%252580%252590Catalyzed%252BPrimary%252BC%2525E2%252580%252594H%252BAmination%252Bof%252BSulfamate%252BEsters%252Band%252BIts%252BApplication%252Bin%252BSynthesis%252Bof%252BAzetidines%252B%2525E2%252580%2525A0%26aulast%3DZhang%26aufirst%3DYan%26date%3D2020%26date%3D2020%26volume%3D38%26issue%3D12%26spage%3D1651%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Sun</span>, <span class="hlFld-ContribAuthor ">Han  Yang</span>, <span class="hlFld-ContribAuthor ">Kai  Zheng</span>, <span class="hlFld-ContribAuthor ">Liqun  Jin</span>, <span class="hlFld-ContribAuthor ">Baoxiang  Hu</span>, <span class="hlFld-ContribAuthor ">Zhenlu  Shen</span>, <span class="hlFld-ContribAuthor ">Xinquan  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">TBAF‐Catalyzed Tandem Synthesis of Triazolo[4,5‐
              c
              ]quinolines at Ambient Temperature. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (43)
                                     , 6805-6812. <a href="https://doi.org/10.1002/ejoc.202001280" title="DOI URL">https://doi.org/10.1002/ejoc.202001280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001280%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTBAF%2525E2%252580%252590Catalyzed%252BTandem%252BSynthesis%252Bof%252BTriazolo%25255B4%25252C5%2525E2%252580%252590%252Bc%252B%25255Dquinolines%252Bat%252BAmbient%252BTemperature%26aulast%3DSun%26aufirst%3DNan%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D43%26spage%3D6805%26epage%3D6812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang-Long  Chen</span>, <span class="hlFld-ContribAuthor ">Bo-Cheng  Tang</span>, <span class="hlFld-ContribAuthor ">Cai  He</span>, <span class="hlFld-ContribAuthor ">Jin-Tian  Ma</span>, <span class="hlFld-ContribAuthor ">Shi-Yi  Zhuang</span>, <span class="hlFld-ContribAuthor ">Yan-Dong  Wu</span>, <span class="hlFld-ContribAuthor ">An-Xin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Rongalite as a sulfone source: a novel copper-catalyzed sulfur dioxide anion incorporation process. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (88)
                                     , 13653-13656. <a href="https://doi.org/10.1039/D0CC05800A" title="DOI URL">https://doi.org/10.1039/D0CC05800A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC05800A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC05800A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DRongalite%252Bas%252Ba%252Bsulfone%252Bsource%25253A%252Ba%252Bnovel%252Bcopper-catalyzed%252Bsulfur%252Bdioxide%252Banion%252Bincorporation%252Bprocess%26aulast%3DChen%26aufirst%3DXiang-Long%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D88%26spage%3D13653%26epage%3D13656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dennis W.  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Excitotoxicity: Still Hammering the Ischemic Brain in 2020. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neuroscience</span><span> <strong>2020,</strong> <em>14 </em><a href="https://doi.org/10.3389/fnins.2020.579953" title="DOI URL">https://doi.org/10.3389/fnins.2020.579953</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnins.2020.579953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnins.2020.579953%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neuroscience%26atitle%3DExcitotoxicity%25253A%252BStill%252BHammering%252Bthe%252BIschemic%252BBrain%252Bin%252B2020%26aulast%3DChoi%26aufirst%3DDennis%2BW.%26date%3D2020%26date%3D2020%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Xia</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingbo  Zhang</span>, <span class="hlFld-ContribAuthor ">Songwen  Lin</span>, <span class="hlFld-ContribAuthor ">Kehui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hua  Tian</span>, <span class="hlFld-ContribAuthor ">Yi  Dong</span>, <span class="hlFld-ContribAuthor ">Heng  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Thiazolo[5,4-b]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4630. <a href="https://doi.org/10.3390/molecules25204630" title="DOI URL">https://doi.org/10.3390/molecules25204630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204630%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIdentification%252Bof%252BNovel%252BThiazolo%25255B5%25252C4-b%25255DPyridine%252BDerivatives%252Bas%252BPotent%252BPhosphoinositide%252B3-Kinase%252BInhibitors%26aulast%3DXia%26aufirst%3DLiang%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sayuri  Chong-Canto</span>, <span class="hlFld-ContribAuthor ">Efrén V.  García-Báez</span>, <span class="hlFld-ContribAuthor ">Francisco J.  Martínez-Martínez</span>, <span class="hlFld-ContribAuthor ">Angel A.  Ramos-Organillo</span>, <span class="hlFld-ContribAuthor ">Itzia I.  Padilla-Martínez</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanochemical Synthesis and Structure of the Tetrahydrate and Mesoporous Anhydrous Metforminium(2+)-N,N′-1,4-Phenylenedioxalamic Acid (1:2) Salt: The Role of Hydrogen Bonding and n→π * Charge Assisted Interactions. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 998. <a href="https://doi.org/10.3390/pharmaceutics12100998" title="DOI URL">https://doi.org/10.3390/pharmaceutics12100998</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics12100998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics12100998%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DMechanochemical%252BSynthesis%252Band%252BStructure%252Bof%252Bthe%252BTetrahydrate%252Band%252BMesoporous%252BAnhydrous%252BMetforminium%2525282%25252B%252529-N%25252CN%2525E2%252580%2525B2-1%25252C4-Phenylenedioxalamic%252BAcid%252B%2525281%25253A2%252529%252BSalt%25253A%252BThe%252BRole%252Bof%252BHydrogen%252BBonding%252Band%252Bn%2525E2%252586%252592%2525CF%252580%252B%252A%252BCharge%252BAssisted%252BInteractions%26aulast%3DChong-Canto%26aufirst%3DSayuri%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Hiren A.  Donga</span>, <span class="hlFld-ContribAuthor ">Punit V.  Vaghela</span>, <span class="hlFld-ContribAuthor ">Bhoomi G.  Panchal</span>, <span class="hlFld-ContribAuthor ">Dipen K.  Sureja</span>, <span class="hlFld-ContribAuthor ">Kunjan B.  Bodiwala</span>, <span class="hlFld-ContribAuthor ">Mahesh T.  Chhabria</span>. </span><span class="cited-content_cbyCitation_article-title">A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (54)
                                     , 32740-32820. <a href="https://doi.org/10.1039/D0RA02272A" title="DOI URL">https://doi.org/10.1039/D0RA02272A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02272A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02272A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bdecennary%252Bupdate%252Bon%252Bapplications%252Bof%252Bmetal%252Bnanoparticles%252B%252528MNPs%252529%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnitrogen-%252Band%252Boxygen-containing%252Bheterocyclic%252Bscaffolds%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D54%26spage%3D32740%26epage%3D32820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liliana  Damas</span>, <span class="hlFld-ContribAuthor ">Fábio M.S.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Andreia C.S.  Gonzalez</span>, <span class="hlFld-ContribAuthor ">Rui M.B.  Carrilho</span>, <span class="hlFld-ContribAuthor ">Marta  Pineiro</span>, <span class="hlFld-ContribAuthor ">Mariette M.  Pereira</span>. </span><span class="cited-content_cbyCitation_article-title">Sequential catalytic carbonylation reactions for sustainable synthesis of biologically relevant entities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organometallic Chemistry</span><span> <strong>2020,</strong> <em>923 </em>, 121417. <a href="https://doi.org/10.1016/j.jorganchem.2020.121417" title="DOI URL">https://doi.org/10.1016/j.jorganchem.2020.121417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jorganchem.2020.121417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jorganchem.2020.121417%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organometallic%2520Chemistry%26atitle%3DSequential%252Bcatalytic%252Bcarbonylation%252Breactions%252Bfor%252Bsustainable%252Bsynthesis%252Bof%252Bbiologically%252Brelevant%252Bentities%26aulast%3DDamas%26aufirst%3DLiliana%26date%3D2020%26volume%3D923%26spage%3D121417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mostafa  Karimi</span>, <span class="hlFld-ContribAuthor ">Arman  Hasanzadeh</span>, <span class="hlFld-ContribAuthor ">Yang  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Network-principled deep generative models for designing drug combinations as graph sets. </span><span class="cited-content_cbyCitation_journal-name">Bioinformatics</span><span> <strong>2020,</strong> <em>36 </em>
                                    (Supplement_1)
                                     , i445-i454. <a href="https://doi.org/10.1093/bioinformatics/btaa317" title="DOI URL">https://doi.org/10.1093/bioinformatics/btaa317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bioinformatics/btaa317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbioinformatics%2Fbtaa317%26sid%3Dliteratum%253Aachs%26jtitle%3DBioinformatics%26atitle%3DNetwork-principled%252Bdeep%252Bgenerative%252Bmodels%252Bfor%252Bdesigning%252Bdrug%252Bcombinations%252Bas%252Bgraph%252Bsets%26aulast%3DKarimi%26aufirst%3DMostafa%26date%3D2020%26date%3D2020%26volume%3D36%26issue%3DSupplement_1%26spage%3Di445%26epage%3Di454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pranab K.  Pramanick</span>, <span class="hlFld-ContribAuthor ">Zhibing  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhenlin  Hou</span>, <span class="hlFld-ContribAuthor ">Yufei  Ao</span>, <span class="hlFld-ContribAuthor ">Bo  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Native amine-directed site-selective C(sp3)-H arylation of primary aliphatic amines with aryl iodides. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (5)
                                     , 1327-1331. <a href="https://doi.org/10.1016/j.cclet.2019.10.034" title="DOI URL">https://doi.org/10.1016/j.cclet.2019.10.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2019.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2019.10.034%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DNative%252Bamine-directed%252Bsite-selective%252BC%252528sp3%252529-H%252Barylation%252Bof%252Bprimary%252Baliphatic%252Bamines%252Bwith%252Baryl%252Biodides%26aulast%3DPramanick%26aufirst%3DPranab%2BK.%26date%3D2020%26volume%3D31%26issue%3D5%26spage%3D1327%26epage%3D1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serguei  Nabirotchkin</span>, <span class="hlFld-ContribAuthor ">Alex E  Peluffo</span>, <span class="hlFld-ContribAuthor ">Philippe  Rinaudo</span>, <span class="hlFld-ContribAuthor ">Jinchao  Yu</span>, <span class="hlFld-ContribAuthor ">Rodolphe  Hajj</span>, <span class="hlFld-ContribAuthor ">Daniel  Cohen</span>. </span><span class="cited-content_cbyCitation_article-title">Next-generation drug repurposing using human genetics and network biology. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>51 </em>, 78-92. <a href="https://doi.org/10.1016/j.coph.2019.12.004" title="DOI URL">https://doi.org/10.1016/j.coph.2019.12.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2019.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2019.12.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DNext-generation%252Bdrug%252Brepurposing%252Busing%252Bhuman%252Bgenetics%252Band%252Bnetwork%252Bbiology%26aulast%3DNabirotchkin%26aufirst%3DSerguei%26date%3D2020%26volume%3D51%26spage%3D78%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel G.  Sergeev</span>, <span class="hlFld-ContribAuthor ">Valentin G.  Nenajdenko</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the chemistry of pyridazine — an important representative of six-membered nitrogen heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Reviews</span><span> <strong>2020,</strong> <em>89 </em>
                                    (4)
                                     , 393-429. <a href="https://doi.org/10.1070/RCR4922" title="DOI URL">https://doi.org/10.1070/RCR4922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1070/RCR4922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1070%2FRCR4922%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bchemistry%252Bof%252Bpyridazine%252B%2525E2%252580%252594%252Ban%252Bimportant%252Brepresentative%252Bof%252Bsix-membered%252Bnitrogen%252Bheterocycles%26aulast%3DSergeev%26aufirst%3DPavel%2BG.%26date%3D2020%26date%3D2020%26volume%3D89%26issue%3D4%26spage%3D393%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Narasimharao  Mukku</span>, <span class="hlFld-ContribAuthor ">Barnali  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">On water catalyst-free synthesis of benzo[
              d
              ]imidazo[2,1-
              b
              ] thiazoles and novel
              N
              -alkylated 2-aminobenzo[
              d
              ]oxazoles under microwave irradiation. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (2)
                                     , 770-778. <a href="https://doi.org/10.1039/C9RA08929B" title="DOI URL">https://doi.org/10.1039/C9RA08929B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA08929B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA08929B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DOn%252Bwater%252Bcatalyst-free%252Bsynthesis%252Bof%252Bbenzo%25255B%252Bd%252B%25255Dimidazo%25255B2%25252C1-%252Bb%252B%25255D%252Bthiazoles%252Band%252Bnovel%252BN%252B-alkylated%252B2-aminobenzo%25255B%252Bd%252B%25255Doxazoles%252Bunder%252Bmicrowave%252Birradiation%26aulast%3DMukku%26aufirst%3DNarasimharao%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D2%26spage%3D770%26epage%3D778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irshad Maajid  Taily</span>, <span class="hlFld-ContribAuthor ">Debarshi  Saha</span>, <span class="hlFld-ContribAuthor ">Prabal  Banerjee</span>. </span><span class="cited-content_cbyCitation_article-title">[3+3] Annulation via Ring Opening/Cyclization of Donor-Acceptor Cyclopropanes with (Un)symmetrical Ureas: A Quick Access to Highly Functionalized Tetrahydropyrimidinones. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (48)
                                     , 7804-7813. <a href="https://doi.org/10.1002/ejoc.201901400" title="DOI URL">https://doi.org/10.1002/ejoc.201901400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901400%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3D%25255B3%25252B3%25255D%252BAnnulation%252Bvia%252BRing%252BOpening%25252FCyclization%252Bof%252BDonor-Acceptor%252BCyclopropanes%252Bwith%252B%252528Un%252529symmetrical%252BUreas%25253A%252BA%252BQuick%252BAccess%252Bto%252BHighly%252BFunctionalized%252BTetrahydropyrimidinones%26aulast%3DTaily%26aufirst%3DIrshad%2BMaajid%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D48%26spage%3D7804%26epage%3D7813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Cheng</span>, <span class="hlFld-ContribAuthor ">Yuntong  Li</span>, <span class="hlFld-ContribAuthor ">Taimin  Wang</span>, <span class="hlFld-ContribAuthor ">Xinping  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Yun  Li</span>, <span class="hlFld-ContribAuthor ">Hongbin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridinium 1,4-zwitterionic thiolates as a useful class of sulfur-containing synthons: application to the synthesis of 2,5-dihydro-1,4,5-thiadiazepines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (97)
                                     , 14606-14608. <a href="https://doi.org/10.1039/C9CC08326J" title="DOI URL">https://doi.org/10.1039/C9CC08326J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC08326J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC08326J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DPyridinium%252B1%25252C4-zwitterionic%252Bthiolates%252Bas%252Ba%252Buseful%252Bclass%252Bof%252Bsulfur-containing%252Bsynthons%25253A%252Bapplication%252Bto%252Bthe%252Bsynthesis%252Bof%252B2%25252C5-dihydro-1%25252C4%25252C5-thiadiazepines%26aulast%3DCheng%26aufirst%3DBin%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D97%26spage%3D14606%26epage%3D14608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gabriela  Pastuch-Gawołek</span>, <span class="hlFld-ContribAuthor ">Danuta  Gillner</span>, <span class="hlFld-ContribAuthor ">Ewelina  Król</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Walczak</span>, <span class="hlFld-ContribAuthor ">Ilona  Wandzik</span>. </span><span class="cited-content_cbyCitation_article-title">Selected nucleos(t)ide-based prescribed drugs and their multi-target activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2019,</strong> <em>865 </em>, 172747. <a href="https://doi.org/10.1016/j.ejphar.2019.172747" title="DOI URL">https://doi.org/10.1016/j.ejphar.2019.172747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2019.172747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2019.172747%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DSelected%252Bnucleos%252528t%252529ide-based%252Bprescribed%252Bdrugs%252Band%252Btheir%252Bmulti-target%252Bactivity%26aulast%3DPastuch-Gawo%25C5%2582ek%26aufirst%3DGabriela%26date%3D2019%26volume%3D865%26spage%3D172747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Egor S.  Zhilin</span>, <span class="hlFld-ContribAuthor ">Dmitry M.  Bystrov</span>, <span class="hlFld-ContribAuthor ">Ivan V.  Ananyev</span>, <span class="hlFld-ContribAuthor ">Leonid L.  Fershtat</span>, <span class="hlFld-ContribAuthor ">Nina N.  Makhova</span>. </span><span class="cited-content_cbyCitation_article-title">Straightforward Access to the Nitric Oxide Donor Azasydnone Scaffold by Cascade Reactions of Amines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (63)
                                     , 14284-14289. <a href="https://doi.org/10.1002/chem.201903526" title="DOI URL">https://doi.org/10.1002/chem.201903526</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201903526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201903526%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DStraightforward%252BAccess%252Bto%252Bthe%252BNitric%252BOxide%252BDonor%252BAzasydnone%252BScaffold%252Bby%252BCascade%252BReactions%252Bof%252BAmines%26aulast%3DZhilin%26aufirst%3DEgor%2BS.%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D63%26spage%3D14284%26epage%3D14289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Run  Wang</span>, <span class="hlFld-ContribAuthor ">Xiong  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(III)-Catalyzed C–H Bond Activation for the Construction of Heterocycles with sp3-Carbon Centers. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 823. <a href="https://doi.org/10.3390/catal9100823" title="DOI URL">https://doi.org/10.3390/catal9100823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal9100823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal9100823%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DRh%252528III%252529-Catalyzed%252BC%2525E2%252580%252593H%252BBond%252BActivation%252Bfor%252Bthe%252BConstruction%252Bof%252BHeterocycles%252Bwith%252Bsp3-Carbon%252BCenters%26aulast%3DWang%26aufirst%3DRun%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D10%26spage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Shang</span>, <span class="hlFld-ContribAuthor ">Karla S.  Feu</span>, <span class="hlFld-ContribAuthor ">Julien C.  Vantourout</span>, <span class="hlFld-ContribAuthor ">Lisa M.  Barton</span>, <span class="hlFld-ContribAuthor ">Heather L.  Osswald</span>, <span class="hlFld-ContribAuthor ">Nobutaka  Kato</span>, <span class="hlFld-ContribAuthor ">Kerstin  Gagaring</span>, <span class="hlFld-ContribAuthor ">Case W.  McNamara</span>, <span class="hlFld-ContribAuthor ">Gang  Chen</span>, <span class="hlFld-ContribAuthor ">Liang  Hu</span>, <span class="hlFld-ContribAuthor ">Shengyang  Ni</span>, <span class="hlFld-ContribAuthor ">Paula  Fernández-Canelas</span>, <span class="hlFld-ContribAuthor ">Miao  Chen</span>, <span class="hlFld-ContribAuthor ">Rohan R.  Merchant</span>, <span class="hlFld-ContribAuthor ">Tian  Qin</span>, <span class="hlFld-ContribAuthor ">Stuart L.  Schreiber</span>, <span class="hlFld-ContribAuthor ">Bruno  Melillo</span>, <span class="hlFld-ContribAuthor ">Jin-Quan  Yu</span>, <span class="hlFld-ContribAuthor ">Phil S.  Baran</span>. </span><span class="cited-content_cbyCitation_article-title">Modular, stereocontrolled C
              β
              –H/C
              α
              –C activation of alkyl carboxylic acids. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2019,</strong> <em>116 </em>
                                    (18)
                                     , 8721-8727. <a href="https://doi.org/10.1073/pnas.1903048116" title="DOI URL">https://doi.org/10.1073/pnas.1903048116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1903048116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1903048116%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DModular%25252C%252Bstereocontrolled%252BC%252B%2525CE%2525B2%252B%2525E2%252580%252593H%25252FC%252B%2525CE%2525B1%252B%2525E2%252580%252593C%252Bactivation%252Bof%252Balkyl%252Bcarboxylic%252Bacids%26aulast%3DShang%26aufirst%3DMing%26date%3D2019%26date%3D2019%26volume%3D116%26issue%3D18%26spage%3D8721%26epage%3D8727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael Dominic  Delost</span>, <span class="hlFld-ContribAuthor ">Jon Tryggvi  Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">Oxiranes and Oxirenes: Monocyclic. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14758-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14758-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14758-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14758-4%26sid%3Dliteratum%253Aachs%26atitle%3DOxiranes%252Band%252BOxirenes%25253A%252BMonocyclic%26aulast%3DDelost%26aufirst%3DMichael%2BDominic%26date%3D2019%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Graphical breakdown of US FDA approved small molecule combination drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Number of combination drugs approved by decade.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Frequency and disease distribution of combination drugs with 2, 3, and 4 small molecule components</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Distribution of US FDA approved combination drugs according to disease category.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Top 24 most frequently utilized small molecule combination drug components.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6A" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0007.jpeg" id="rightTab-GRAPHIC-d7e265-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6A. Combination structure relationship diagram for hydrochlorothiazide containing two INNs</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig6A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6B" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0008.jpeg" id="rightTab-GRAPHIC-d7e272-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6B. Combination structure relationship diagram for hydrochlorothiazide containing three INNs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig6B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Combination structure relationship diagram for pseudoephedrine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Combination structure relationship diagram for acetaminophen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Combination structure relationship diagram for aspirin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Combination structure relationship diagram for metformin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Combination structure relationship diagram for ethinyl estradiol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Combination structure relationship diagram for Lamivudine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Combination structure relationship diagram for Emtricitabine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Combination structure relationship diagram for Amlodipine</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0019.jpeg" id="rightTab-GRAPHIC-d7e534-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Combination structure relationship diagram for neomycin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16A" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 16A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0020.jpeg" id="rightTab-GRAPHIC-d7e587-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16A. Anti-infective (anti-HIV) approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig16A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16B" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 16B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0021.jpeg" id="rightTab-GRAPHIC-d7e594-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16B. Anti-infective (antiviral) approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig16B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17A" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 17A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0022.jpeg" id="rightTab-GRAPHIC-d7e656-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17A. Anti-infective (nonviral) approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig17A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17B" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 17B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0023.jpeg" id="rightTab-GRAPHIC-d7e663-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17B. Anti-infective (nonviral) approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig17B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18A" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 18A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0024.jpeg" id="rightTab-GRAPHIC-d7e699-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18A. All alimentary tract and metabolism approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig18A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18B" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 18B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0025.jpeg" id="rightTab-GRAPHIC-d7e706-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18B. All alimentary tract and metabolism approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig18B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19A" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 19A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0026.jpeg" id="rightTab-GRAPHIC-d7e754-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19A. All cardiovascular approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig19A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19B" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 19B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0027.jpeg" id="rightTab-GRAPHIC-d7e761-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19B. All cardiovascular approved antihypertensive and secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig19B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0028.jpeg" id="rightTab-GRAPHIC-d7e799-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. All dermatological approved combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21A" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 21A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0029.jpeg" id="rightTab-GRAPHIC-d7e819-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21A. All endocrine system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig21A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21B" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 21B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0030.jpeg" id="rightTab-GRAPHIC-d7e826-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21B. All endocrine system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig21B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22A" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 22A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0031.jpeg" id="rightTab-GRAPHIC-d7e861-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22A. All genito-urinary and sex hormones system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig22A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22B" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 22B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0032.jpeg" id="rightTab-GRAPHIC-d7e868-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22B. All genito-urinary and sex hormones system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig22B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0033.jpeg" id="rightTab-GRAPHIC-d7e890-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. All musculo-skeletal approved combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24A" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 24A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0034.jpeg" id="rightTab-GRAPHIC-d7e953-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24A. All nervous system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig24A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24B" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 24B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0035.jpeg" id="rightTab-GRAPHIC-d7e960-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24B. All nervous system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig24B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25A" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 25A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0036.jpeg" id="rightTab-GRAPHIC-d7e1005-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25A. All respiratory system approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig25A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25B" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 25B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0037.jpeg" id="rightTab-GRAPHIC-d7e1012-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25B. All respiratory system approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig25B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26A" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 26A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0038.jpeg" id="rightTab-GRAPHIC-d7e1045-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26A. All sensory organ approved primary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig26A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26B" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 26B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0039.jpeg" id="rightTab-GRAPHIC-d7e1052-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26B. All sensory organ approved secondary combination structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig26B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27A" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 27A</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0040.jpeg" id="rightTab-GRAPHIC-d7e1125-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27A. Examples of primary cancer chemotherapeutic agents used in various combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig27A"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27B" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 27B</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0041.jpeg" id="rightTab-GRAPHIC-d7e1132-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27B. Examples of primary and secondary cancer chemotherapeutic agents used in various combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig27B"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/medium/jm-2018-01610t_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0042.jpeg" id="rightTab-GRAPHIC-d7e1155-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Examples of agents being used in immuno-oncological combinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01610/20190502/images/large/jm-2018-01610t_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01610&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 152 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brichacek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A graphical journey of innovative organic architectures that have improved our lives</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1348</span>– <span class="NLM_lpage">1349</span>, <span class="refDoi"> DOI: 10.1021/ed1003806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed1003806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=1348-1349&author=N.+A.+McGrathauthor=M.+Brichacekauthor=J.+T.+Njardarson&title=A+graphical+journey+of+innovative+organic+architectures+that+have+improved+our+lives&doi=10.1021%2Fed1003806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives</span></div><div class="casAuthors">McGrath, Nicholas A.; Brichacek, Matthew; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1348-1349</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">A new free graphical teaching tool that highlights the beautiful org. architectures of the top selling pharmaceuticals is detailed on two posters.  In addn. to the multitude of teaching and data-mining opportunities these posters offer, they were also created to emphasize the central role org. chemists play in the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPDa7XFu1jBLVg90H21EOLACvtfcHk0lhy3yscRs2J2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP&md5=abaab52626cc29b94b88389f39727513</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1021%2Fed1003806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed1003806%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DN.%2BA.%26aulast%3DBrichacek%26aufirst%3DM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520graphical%2520journey%2520of%2520innovative%2520organic%2520architectures%2520that%2520have%2520improved%2520our%2520lives%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2010%26volume%3D87%26spage%3D1348%26epage%3D1349%26doi%3D10.1021%2Fed1003806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">An in-pharm-ative educational poster anthology highlighting the therapeutic agents that chronicle our medicinal history</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1403</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1021/ed4002317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed4002317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCgt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2013&pages=1403-1405&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=An+in-pharm-ative+educational+poster+anthology+highlighting+the+therapeutic+agents+that+chronicle+our+medicinal+history&doi=10.1021%2Fed4002317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">An In-Pharm-ative Educational Poster Anthology Highlighting the Therapeutic Agents That Chronicle Our Medicinal History</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1403-1405</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">Disease Focused Posters is a new, free, and readily accessible collection of graphical timelines that arrange the vast no. of FDA approved pharmaceuticals according to a specific theme.  Capitalizing on the elegance of structural imagery and the innovative functions of org. compds., each poster (in its simplistic appearance) has the capacity to communicate a wealth of information that appeals to the educational desires of the public, from the non-scientist to the expert.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou7hPyEhlYGLVg90H21EOLACvtfcHk0lhy3yscRs2J2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCgt7nN&md5=ba2756db4be9554aef14e7ef64ac2983</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1021%2Fed4002317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed4002317%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAn%2520in-pharm-ative%2520educational%2520poster%2520anthology%2520highlighting%2520the%2520therapeutic%2520agents%2520that%2520chronicle%2520our%2520medicinal%2520history%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2013%26volume%3D90%26spage%3D1403%26epage%3D1405%26doi%3D10.1021%2Fed4002317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2842</span>, <span class="refDoi"> DOI: 10.1021/jm401375q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+design+and+discovery&doi=10.1021%2Fjm401375q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lg87kvKv-soZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842%26doi%3D10.1021%2Fjm401375q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Beyond C, H, O, and N! analysis of the elemental composition of U.S. FDA approved drug architectures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9764</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/jm501105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9764-9773&author=B.+R.+Smithauthor=C.+M.+Eastmanauthor=J.+T.+Njardarson&title=Beyond+C%2C+H%2C+O%2C+and+N%21+analysis+of+the+elemental+composition+of+U.S.+FDA+approved+drug+architectures&doi=10.1021%2Fjm501105n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond C, H, O, and N! Analysis of the Elemental Composition of U.S. FDA Approved Drug Architectures</span></div><div class="casAuthors">Smith, Brandon R.; Eastman, Candice M.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9764-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The diversity of elements among U.S.  Food and Drug Administration (FDA) approved pharmaceuticals is analyzed and reported, with a focus on atoms other than carbon, hydrogen, oxygen, and nitrogen.  Our anal. reveals that sulfur, chlorine, fluorine, and phosphorous represent about 90% of elemental substitutions, with sulfur being the fifth most used element followed closely by chlorine, then fluorine and finally phosphorous in the eighth place.  The remaining 10% of substitutions are represented by 16 other elements of which bromine, iodine, and iron occur most frequently.  The most detailed parts of our anal. are focused on chlorinated drugs as a function of approval date, disease condition, chlorine attachment, and structure.  To better aid our chlorine drug analyses, a new poster showcasing the structures of chlorinated pharmaceuticals was created specifically for this study.  Phosphorus, bromine, and iodine contg. drugs are analyzed closely as well, followed by a discussion about other elements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLwTieDN1HbVg90H21EOLACvtfcHk0lgfWMvcgkAKQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL&md5=95e1ab686ba41c63070059ad0987ff6c</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1021%2Fjm501105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501105n%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DEastman%26aufirst%3DC.%2BM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DBeyond%2520C%252C%2520H%252C%2520O%252C%2520and%2520N%2521%2520analysis%2520of%2520the%2520elemental%2520composition%2520of%2520U.S.%2520FDA%2520approved%2520drug%2520architectures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9764%26epage%3D9773%26doi%3D10.1021%2Fjm501105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+U.S.+FDA+approved+pharmaceuticals&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0lgfWMvcgkAKQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of US FDA drugs containing sulfur atoms</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1007/s41061-018-0184-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs41061-018-0184-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2018&pages=1-34&author=K.+A.+Scottauthor=J.+T.+Njardarson&title=Analysis+of+US+FDA+drugs+containing+sulfur+atoms&doi=10.1007%2Fs41061-018-0184-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.1007%2Fs41061-018-0184-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41061-018-0184-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520US%2520FDA%2520drugs%2520containing%2520sulfur%2520atoms%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2018%26volume%3D376%26spage%3D1%26epage%3D34%26doi%3D10.1007%2Fs41061-018-0184-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1g"><span>(<span class="NLM_label">(g) </span>) <span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span>; <span class="NLM_string-name">Smith, D. T.</span>; <span class="NLM_string-name">Anderson, B. J.</span>; <span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">From oxiranes to oligomers: architectures of US FDA approved pharmaceuticals containing oxygen heterocycles</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume">61</span> <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00876</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&author=M.+D.+Delost&author=D.+T.+Smith&author=B.+J.+Anderson&author=J.+T.+Njardarson&title=From+oxiranes+to+oligomers%3A+architectures+of+US+FDA+approved+pharmaceuticals+containing+oxygen+heterocycles&doi=10.1021%2Facs.jmedchem.8b00876"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1g&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26aulast%3DDelost%26aufirst%3DM.%2BD.%26atitle%3DFrom%2520oxiranes%2520to%2520oligomers%253A%2520architectures%2520of%2520US%2520FDA%2520approved%2520pharmaceuticals%2520containing%2520oxygen%2520heterocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26doi%3D10.1021%2Facs.jmedchem.8b00876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="note"><p class="first last">There are 25 approved combinations for which we were unable to find an approval year.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finland, M.</span></span> <span> </span><span class="NLM_article-title">Combinations of antimicrobial drugs: trimethoprim-sulfamethoxazole</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">624</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1056/NEJM197409192911209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJM197409192911209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=4851498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaE2czgtVGitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1974&pages=624-627&author=M.+Finland&title=Combinations+of+antimicrobial+drugs%3A+trimethoprim-sulfamethoxazole&doi=10.1056%2FNEJM197409192911209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: Combinations of antimicrobial drugs: trimethoprim-sulfamethoxazole</span></div><div class="casAuthors">Finland M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">624-7</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1P4-clnBof-IHSmpohpd0fW6udTcc2eZMb8ZaKDMA9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2czgtVGitw%253D%253D&md5=ebe3bf35b30ce9d3404ebc34b5499207</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM197409192911209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197409192911209%26sid%3Dliteratum%253Aachs%26aulast%3DFinland%26aufirst%3DM.%26atitle%3DCombinations%2520of%2520antimicrobial%2520drugs%253A%2520trimethoprim-sulfamethoxazole%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1974%26volume%3D291%26spage%3D624%26epage%3D627%26doi%3D10.1056%2FNEJM197409192911209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span> <span> </span><span class="NLM_article-title">Fluorination methods for drug discovery and development</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">999</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1223037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1080%2F17460441.2016.1223037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=27548817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyisL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=983-999&author=P.+Richardson&title=Fluorination+methods+for+drug+discovery+and+development&doi=10.1080%2F17460441.2016.1223037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorination methods for drug discovery and development</span></div><div class="casAuthors">Richardson, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">983-999</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The pivotal role that the element fluorine plays in modulating the properties of bioactive mols. is reflected by the growth of its presence in approved drugs.  In 1970, approx. 2% of drugs contained fluorine with this no. rising to 25% by 2011.  The synthetic chem. regarding incorporation of fluorine into org. mols. has also evolved over this time with a paradigm shift from harsh, toxic, hazardous reagents utilized primarily by specialist vendors to new deoxyfluorination reagents and metal-mediated techniques capable of the precise introduction of fluorine into complex org. substrates under relatively mild conditions.  This review highlights the importance of fluorinated compds. in drug discovery, and provides an overview on the synthetic strategies and methodologies developed to access them both in discovery and development.  The development of new reagents for the safe and precise regioselective fluorination of biol. relevant compds. particularly in drug discovery remains a contemporary challenge in org. chem.  However, significant strides have been made with the development of new deoxyfluorination reagents and the emergence of practical metal-mediated fluorination techniques have enabled the goal of efficient late-stage fluorination of drug-like compds. to be realized, and the extension of these methods for PET-labeling is being investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVKZBu8dlW7Vg90H21EOLACvtfcHk0liucjLU7IpgHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyisL7K&md5=a0f4772a1287ecef6afee01a0570b037</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1223037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1223037%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26atitle%3DFluorination%2520methods%2520for%2520drug%2520discovery%2520and%2520development%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D983%26epage%3D999%26doi%3D10.1080%2F17460441.2016.1223037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messerli, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangalore, S.</span></span> <span> </span><span class="NLM_article-title">Half a century of hydrochlorothiazide: facts, fads, fiction, and follies</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2011.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.amjmed.2011.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21962309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GgsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=896-899&author=F.+H.+Messerliauthor=S.+Bangalore&title=Half+a+century+of+hydrochlorothiazide%3A+facts%2C+fads%2C+fiction%2C+and+follies&doi=10.1016%2Fj.amjmed.2011.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies</span></div><div class="casAuthors">Messerli, Franz H.; Bangalore, Sripal</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">896-899</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Hydrochlorothiazide (HCTZ) has become by far the most commonly prescribed antihypertensive drug in the US.  In 2008, 47.8 million prescriptions were written for HCTZ alone and 87.1 million prescriptions for HCTZ combinations.  However, there is no evidence that HCTZ in its usual dose of 12.5-25 mg daily reduces myocardial infarction, stroke, or death.  In a meta-anal. of 19 randomized trials with over 1400 patients, the 24-h decrease in blood pressure with HCTZ was inferior to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and calcium channel blockers (P <.001 for all).  Even in combination with an angiotensin-converting enzyme inhibitor, HCTZ was found to reduce morbidity and mortality less well than a calcium channel blocker.  As measured by the adherence rate, thiazides are less well tolerated than any other drug class.  Because outcome data at the usual daily dose of 12.5-25 mg are lacking, antihypertensive efficacy is paltry, and adherence is poor, HCTZ is an inappropriate first-line drug in hypertension.  If a "thiazide-type" diuretic is indicated, either chlorthalidone or indapamide should be selected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCbUcMK7YtbVg90H21EOLACvtfcHk0liucjLU7IpgHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GgsbbM&md5=eb31f622dd490824638fa7369ec2abea</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2011.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2011.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMesserli%26aufirst%3DF.%2BH.%26aulast%3DBangalore%26aufirst%3DS.%26atitle%3DHalf%2520a%2520century%2520of%2520hydrochlorothiazide%253A%2520facts%252C%2520fads%252C%2520fiction%252C%2520and%2520follies%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2011%26volume%3D124%26spage%3D896%26epage%3D899%26doi%3D10.1016%2Fj.amjmed.2011.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, J.</span></span> <span> </span><span class="NLM_article-title">From snake venom to ACE inhibitor - The discovery and rise of captopril</span>. <i>Pharm. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2009&pages=455-456&author=J.+Bryan&title=From+snake+venom+to+ACE+inhibitor+-+The+discovery+and+rise+of+captopril"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DJ.%26atitle%3DFrom%2520snake%2520venom%2520to%2520ACE%2520inhibitor%2520-%2520The%2520discovery%2520and%2520rise%2520of%2520captopril%26jtitle%3DPharm.%2520J.%26date%3D2009%26volume%3D282%26spage%3D455%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span>; <span class="NLM_string-name">Maibaum, J.</span></span> In  <i>Aspartic Acid Proteases as Therapeutic Targets</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_year">2011</span>, Chapter  <span class="NLM_volume">10</span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">296</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=265-296&author=J.+M.+Wood&author=J.+Maibaum&title=Aspartic+Acid+Proteases+as+Therapeutic+Targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DJ.%2BM.%26btitle%3DAspartic%2520Acid%2520Proteases%2520as%2520Therapeutic%2520Targets%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2011%26volume%3D10%26spage%3D265%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, M.</span></span> <span> </span><span class="NLM_article-title">Rationale for combination therapy in the management of hypertension</span>. <i>J. Clin. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1111/j.1524-6175.2003.02668.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1524-6175.2003.02668.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3sngsFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=17-25&author=M.+Moser&title=Rationale+for+combination+therapy+in+the+management+of+hypertension&doi=10.1111%2Fj.1524-6175.2003.02668.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale for combination therapy in the management of hypertension</span></div><div class="casAuthors">Moser Marvin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical hypertension (Greenwich, Conn.)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6 Suppl 4</span>),
    <span class="NLM_cas:pages">17-25</span>
        ISSN:<span class="NLM_cas:issn">1524-6175</span>.
    </div><div class="casAbstract">Combination drug therapy in the management of hypertension has been used for many years.  Recent recommendations of the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the results of several new multiple-drug trials have focused on using the approach as initial therapy in many hypertensive patients.  Results of these long-term outcome trials, as well as short-term and smaller studies, indicate the advantage of multiple-drug therapy in the management of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNZNr0MLCap_69nzq6467DfW6udTcc2eZbobMCL7sO7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3sngsFymsg%253D%253D&md5=f6bc7f647e47b043c688027907ca45fb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1524-6175.2003.02668.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1524-6175.2003.02668.x%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DM.%26atitle%3DRationale%2520for%2520combination%2520therapy%2520in%2520the%2520management%2520of%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Hypertens.%26date%3D2003%26volume%3D5%26spage%3D17%26epage%3D25%26doi%3D10.1111%2Fj.1524-6175.2003.02668.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borghi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, A. F. G.</span></span> <span> </span><span class="NLM_article-title">Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data</span>. <i>Vasc. Health Risk. Manag.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.2147/vhrm.2006.2.4.341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2Fvhrm.2006.2.4.341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17323587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1ygtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=341-349&author=C.+Borghiauthor=A.+F.+G.+Cicero&title=Fixed+combination+of+zofenopril+plus+hydrochlorothiazide+in+the+management+of+hypertension%3A+a+review+of+available+data&doi=10.2147%2Fvhrm.2006.2.4.341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data</span></div><div class="casAuthors">Borghi, Claudio; Cicero, Arrigo F. G.</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Health and Risk Management</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-349</span>CODEN:
                <span class="NLM_cas:coden">VHRMAT</span>;
        ISSN:<span class="NLM_cas:issn">1176-6344</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiotensin-converting enzyme (ACE) inhibitors effectively interfere with the renin-angiotensin system and exert various beneficial actions on vascular structure and function beyond their blood pressure-lowering effects.  Zofenopril, a potent sulphydryl ACE inhibitor, is characterized by high lipophilicity, sustained cardiac ACE inhibition, and antioxidant and tissue protective activities.  Its ancillary properties, such as antioxidant activity and cardiovascular (CV) protection, make this drug potentially suitable for the treatment and prevention of certain CV diseases.  The Survival of Myocardial Infarction Long term Evaluation trials have demonstrated that the early administration of zofenopril to patients with acute myocardial infarction is assocd. with a significant redn. in the 6-wk occurrence of major CV events in high-risk patients with anterior non-thrombolyzed myocardial infarction.  The fixed combination of zofenopril-hydrochlorothiazide (HCTZ) 30/12.5 mg/day is approved for the management of mild-to-moderate hypertension in different European countries.  In clin. trials comparing zofenopril-HCTZ with each agent administered as monotherapy, combination therapy was clearly more effective in normalizing blood pressure (BP).  In addn., combination therapy provided sustained and consistent BP control over the entire 24 h dosing interval.  The efficacy and safety profile of zofenopril-HCTZ highlights that this combination is a potentially useful addn. to currently available therapy for patients with BP inadequately controlled by monotherapy, as well as for patients who require more rapid and intensive BP control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowU7Wlkcx-j7Vg90H21EOLACvtfcHk0liT7CAHW400OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1ygtLg%253D&md5=38abc639ce0054203a140b532eed5351</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2147%2Fvhrm.2006.2.4.341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fvhrm.2006.2.4.341%26sid%3Dliteratum%253Aachs%26aulast%3DBorghi%26aufirst%3DC.%26aulast%3DCicero%26aufirst%3DA.%2BF.%2BG.%26atitle%3DFixed%2520combination%2520of%2520zofenopril%2520plus%2520hydrochlorothiazide%2520in%2520the%2520management%2520of%2520hypertension%253A%2520a%2520review%2520of%2520available%2520data%26jtitle%3DVasc.%2520Health%2520Risk.%2520Manag.%26date%3D2006%26volume%3D2%26spage%3D341%26epage%3D349%26doi%3D10.2147%2Fvhrm.2006.2.4.341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, R.</span></span> <span> </span><span class="NLM_article-title">Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02833.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1365-2125.2006.02833.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17116124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsFWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=10-14&author=R.+Eccles&title=Substitution+of+phenylephrine+for+pseudoephedrine+as+a+nasal+decongeststant.+An+illogical+way+to+control+methamphetamine+abuse&doi=10.1111%2Fj.1365-2125.2006.02833.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse</span></div><div class="casAuthors">Eccles, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The aim of this review was to investigate the rationale for replacing the nasal decongestant pseudoephedrine (PDE) with phenylephrine (PE) as a means of controlling the illicit prodn. of methamphetamine.  A literature search was conducted in electronic databases and use of textbooks.  Restrictions have been placed on the sale of PDE in the USA in an attempt to control the illicit prodn. of methamphetamine.  This has caused a switch from PDE to PE in many common cold and cough medicines.  PE is a poor substitute for PDE as an orally administered decongestant as it is extensively metabolized in the gut and its efficacy as a decongestant is unproven.  Both PDE and PE have a good safety record, but the efficacy of PDE as a nasal decongestant is supported by clin. trials.  Studies in the USA indicate that restricting the sale of PDE to the public as a medicine has had little impact on the morbidity and no. of arrests assocd. with methamphetamine abuse.  Restricting the sale of PDE in order to control the illicit prodn. of methamphetamine will deprive the public of a safe and effective nasal decongestant and force the pharmaceutical industry to replace PDE with PE, which may be an ineffective decongestant.  Restrictions on sales of PDE to the public may not reduce the problems assocd. with methamphetamine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS7fSRNJzURLVg90H21EOLACvtfcHk0liT7CAHW400OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsFWqur0%253D&md5=d95e5f8c474c040a9b9043ec785a1a38</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02833.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02833.x%26sid%3Dliteratum%253Aachs%26aulast%3DEccles%26aufirst%3DR.%26atitle%3DSubstitution%2520of%2520phenylephrine%2520for%2520pseudoephedrine%2520as%2520a%2520nasal%2520decongeststant.%2520An%2520illogical%2520way%2520to%2520control%2520methamphetamine%2520abuse%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D63%26spage%3D10%26epage%3D14%26doi%3D10.1111%2Fj.1365-2125.2006.02833.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricard, N.</span></span> <span> </span><span class="NLM_article-title">The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. <i>J</i></span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/S0091-6749(99)70120-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0091-6749%2899%2970120-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10400846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK1MXltVKhtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=100-106&author=G.+L.+Sussmanauthor=J.+Masonauthor=D.+Comptonauthor=J.+Stewartauthor=N.+Ricard&title=The+efficacy+and+safety+of+fexofenadine+HCl+and+pseudoephedrine%2C+alone+and+in+combination%2C+in+seasonal+allergic+rhinitis.+J&doi=10.1016%2FS0091-6749%2899%2970120-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis</span></div><div class="casAuthors">Sussman, Gordon L.; Mason, Jolene; Compton, Diana; Stewart, John; Ricard, Nancy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-106</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Antihistamines effectively treat seasonal allergic rhinitis (SAR), although the ability of this drug class to reduce nasal congestion is limited.  Nasal decongestants effectively treat nasal congestion but not the histamine-related components of SAR.  Therefore antihistamine/nasal decongestant combinations are commonly used to maximize the treatment of SAR.  Fexofenadine HCl is a nonsedating, long-acting H1 receptor antagonist that provides fast and effective relief from SAR.  It is well tolerated, with no sedative or cardiotoxic effects.  We sought to compare the efficacy and safety of a fexofenadine HCl/pseudoephedrine HCl combination with that of each individual component in the treatment of ragweed allergy.  In this Canadian multicenter, double-blind, parallel-group study, 651 patients allergic to ragweed were randomized to receive 60 mg of fexofenadine HCl twice daily, 120 mg of sustained-release pseudoephedrine HCl twice daily, or a combination of the 2 drugs (60 mg of fexofenadine HCl/120 mg of sustained-release pseudoephedrine HCl) twice daily for 2 wk.  Efficacy analyses were based on symptom severity.  In addn., a health economic assessment was performed.  Combination therapy was significantly more effective than pseudoephedrine alone in improving primarily histaminemediated symptoms (sneezing; rhinorrhea; itchy nose, palate, and/or throat; and itchy, watery, red eyes) and significantly more effective than fexofenadine alone in reducing nasal congestion.  Combination therapy also produced greater improvements in daily activities and work productivity compared with the individual components.  No serious adverse events were reported in any of the treatment groups.  In addn., no clin. significant changes in 12-lead ECG parameters, vital signs, or clin. lab. values were obsd.  Combination therapy is more effective than fexofenadine alone or pseudoephedrine alone in relieving the full spectrum of SAR symptoms (ie, both the primarily histamine-related symptoms and nasal congestion).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJdolt3b7UULVg90H21EOLACvtfcHk0ljQnJFg76-RnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVKhtbw%253D&md5=1891918a27c7ea26ff34caded3d9c2ba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0091-6749%2899%2970120-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-6749%252899%252970120-X%26sid%3Dliteratum%253Aachs%26aulast%3DSussman%26aufirst%3DG.%2BL.%26aulast%3DMason%26aufirst%3DJ.%26aulast%3DCompton%26aufirst%3DD.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DRicard%26aufirst%3DN.%26atitle%3DThe%2520efficacy%2520and%2520safety%2520of%2520fexofenadine%2520HCl%2520and%2520pseudoephedrine%252C%2520alone%2520and%2520in%2520combination%252C%2520in%2520seasonal%2520allergic%2520rhinitis.%2520J%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1999%26volume%3D104%26spage%3D100%26epage%3D106%26doi%3D10.1016%2FS0091-6749%2899%2970120-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, D. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of antihistamines</span>. <i>Indian J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.4103/0019-5154.110832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4103%2F0019-5154.110832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23723474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=219-224&author=M.+K.+Churchauthor=D.+S.+Church&title=Pharmacology+of+antihistamines&doi=10.4103%2F0019-5154.110832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of antihistamines</span></div><div class="casAuthors">Church Martin K; Church Diana S</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">H1-antihistamines, the mainstay of treatment for urticaria, were developed from anticholinergic drugs more than 70 years ago.  They act as inverse agonists rather than antagonists of histamine H1-receptors which are members of the G-protein family.  The older first generation H1-antihistamines penetrate readily into the brain to cause sedation, drowsiness, fatigue and impaired concentration and memory causing detrimental effects on learning and examination performance in children and on impairment of the ability of adults to work and drive.  Their use should be discouraged.  The newer second-generation H1-antihistamines are safer, cause less sedation and are more efficacious.  Three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review.  Of these levocetirizine and fexofenadine are the most potent in humans in vivo.  However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection.  Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkA18dqept1EH3Rlp_k91zfW6udTcc2eYeR-S8UGljTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D&md5=867adc1094106d91708347063af8a9d9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4103%2F0019-5154.110832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0019-5154.110832%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26aulast%3DChurch%26aufirst%3DD.%2BS.%26atitle%3DPharmacology%2520of%2520antihistamines%26jtitle%3DIndian%2520J.%2520Dermatol.%26date%3D2013%26volume%3D58%26spage%3D219%26epage%3D224%26doi%3D10.4103%2F0019-5154.110832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, F. E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, K. J.</span></span> <span> </span><span class="NLM_article-title">H(1) Antihistamines: current status and future directions</span>. <i>World Allergy Organ. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1186/1939-4551-1-9-145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1186%2F1939-4551-1-9-145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23282578" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=145-155&author=F.+E.+R.+Simonauthor=K.+J.+Simons&title=H%281%29+Antihistamines%3A+current+status+and+future+directions&doi=10.1186%2F1939-4551-1-9-145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2F1939-4551-1-9-145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1939-4551-1-9-145%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DF.%2BE.%2BR.%26aulast%3DSimons%26aufirst%3DK.%2BJ.%26atitle%3DH%25281%2529%2520Antihistamines%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DWorld%2520Allergy%2520Organ.%2520J.%26date%3D2008%26volume%3D1%26spage%3D145%26epage%3D155%26doi%3D10.1186%2F1939-4551-1-9-145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brune, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiegs, G.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen/paracetamol: a history of errors, failures and false decisions</span>. <i>Eur. J. Pain.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1002/ejp.621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fejp.621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25429980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2Mzht1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=953-965&author=K.+Bruneauthor=B.+Rennerauthor=G.+Tiegs&title=Acetaminophen%2Fparacetamol%3A+a+history+of+errors%2C+failures+and+false+decisions&doi=10.1002%2Fejp.621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen/paracetamol: A history of errors, failures and false decisions</span></div><div class="casAuthors">Brune K; Renner B; Tiegs G</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pain (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acetaminophen/paracetamol is the most widely used drug of the world.  At the same time, it is probably one of the most dangerous compounds in medical use, causing hundreds of deaths in all industrialized countries due to acute liver failure (ALF).  Publications of the last 130 years found in the usual databases were analyzed.  Personal contacts existed to renowned researchers having contributed to the medical use of paracetamol and its precursors as H.U.  Zollinger, S.  Moeschlin, U.  Dubach, J.  Axelrod and others.  Further information is found in earlier reviews by Eichengrun, Rodnan and Benedek, Sneader, Brune; comp. references.  The history of the discovery of paracetamol starts with an error (active against worms), continues with a false assumption (paracetamol is safer than phenacetin), describes the first side-effect 'epidemy' (phenacetin nephropathy, drug-induced interstitial nephritis) and ends with the discovery of second-generation problems due to the unavoidable production of a highly toxic metabolite of paracetamol N-acetyl-p-benzoquinone imine (NAPQI) that may cause not only ALF and kidney damage but also impaired development of the fetus and the newborn child.  It appears timely to reassess the risk/benefit ratio of this compound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLoBa7zpMO7fh3YQQtAhNufW6udTcc2eYeR-S8UGljTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mzht1Wguw%253D%253D&md5=a7b6d396dcba593254c3325a52909412</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fejp.621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejp.621%26sid%3Dliteratum%253Aachs%26aulast%3DBrune%26aufirst%3DK.%26aulast%3DRenner%26aufirst%3DB.%26aulast%3DTiegs%26aufirst%3DG.%26atitle%3DAcetaminophen%252Fparacetamol%253A%2520a%2520history%2520of%2520errors%252C%2520failures%2520and%2520false%2520decisions%26jtitle%3DEur.%2520J.%2520Pain.%26date%3D2015%26volume%3D19%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fejp.621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grattan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beisel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, K.</span></span> <span> </span><span class="NLM_article-title">Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1177/0091270007299762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1177%2F0091270007299762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17442681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvF2jsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=715-726&author=B.+Rennerauthor=G.+Clarkeauthor=T.+Grattanauthor=A.+Beiselauthor=C.+Muellerauthor=U.+Wernerauthor=G.+Kobalauthor=K.+Brune&title=Caffeine+accelerates+absorption+and+enhances+the+analgesic+effect+of+acetaminophen&doi=10.1177%2F0091270007299762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen</span></div><div class="casAuthors">Renner, Bertold; Clarke, Geoff; Grattan, Tim; Beisel, Angelika; Mueller, Christian; Werner, Ulrike; Kobal, Gerd; Brune, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">715-726</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aim of this study was to det. the analgesic effect of acetaminophen compared to a combination of both caffeine and acetaminophen or caffeine alone using tonic and phasic pain stimulation.  Twenty-four subjects were treated orally with 1000 mg acetaminophen, 130 mg caffeine, and a combination of both in a 4-way crossover, double-blind, placebo-controlled study.  Pharmacokinetics and analgesic effects were assessed by means of an exptl. pain model based on pain-related cortical potentials after phasic stimulation of the nasal mucosa with CO2 and based on pain ratings after tonic stimulation with dry air.  Analgesic effects of acetaminophen and acetaminophen plus caffeine but not caffeine alone caused a significant redn. of pain-related cortical potentials beginning 30 min after medication.  The combination demonstrated an enhanced effect throughout the observation time up to 3 h.  Caffeine accelerated acetaminophen absorption, indicated by enhanced early AUCs.  Significant analgesic effects of the combination on tonic pain ratings were found throughout the observation time as compared to acetaminophen and placebo.  In this study, caffeine enhanced and prolonged the analgesic activity of acetaminophen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNq22p5Br5urVg90H21EOLACvtfcHk0lhZxSKoofvU7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvF2jsbY%253D&md5=11c70aa73ece72c30d3fe765adae3b13</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1177%2F0091270007299762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007299762%26sid%3Dliteratum%253Aachs%26aulast%3DRenner%26aufirst%3DB.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DGrattan%26aufirst%3DT.%26aulast%3DBeisel%26aufirst%3DA.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DWerner%26aufirst%3DU.%26aulast%3DKobal%26aufirst%3DG.%26aulast%3DBrune%26aufirst%3DK.%26atitle%3DCaffeine%2520accelerates%2520absorption%2520and%2520enhances%2520the%2520analgesic%2520effect%2520of%2520acetaminophen%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D47%26spage%3D715%26epage%3D726%26doi%3D10.1177%2F0091270007299762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberstein, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study</span>. <i>Headache</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1111/j.1526-4610.2006.00376.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1526-4610.2006.00376.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=16618262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD283ht1ynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=444-453&author=J.+Goldsteinauthor=S.+D.+Silbersteinauthor=J.+R.+Saperauthor=R.+E.+Ryanauthor=R.+B.+Lipton&title=Acetaminophen%2C+aspirin%2C+and+caffeine+in+combination+versus+ibuprofen+for+acute+migraine%3A+results+from+a+multicenter%2C+double-blind%2C+randomized%2C+parallel-group%2C+single-dose%2C+placebo-controlled+study&doi=10.1111%2Fj.1526-4610.2006.00376.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study</span></div><div class="casAuthors">Goldstein Jerome; Silberstein Stephen D; Saper Joel R; Ryan Robert E Jr; Lipton Richard B</div><div class="citationInfo"><span class="NLM_cas:title">Headache</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-53</span>
        ISSN:<span class="NLM_cas:issn">0017-8748</span>.
    </div><div class="casAbstract">OBJECTIVE:  Compare the effectiveness of a combination analgesic containing acetaminophen, aspirin, and caffeine to that of ibuprofen in the treatment of migraine.  METHODS:  Multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study.  A total of 1555 migraineurs were included in the analysis.  No patients were excluded solely because of severity of symptoms or degree of disability.  A single 2-tablet dose for each of the 3 treatment groups: a combination product containing acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg per tablet (AAC); ibuprofen 200 mg per tablet (IB); or matching placebo.  The primary efficacy endpoint was the weighted sum of pain relief (PAR) scores at 2 hours postdose (TOTPAR2) and an important secondary endpoint was the time to onset of meaningful relief.  RESULTS:  There were 669 patients in the AAC group, 666 patients in the IB group, and 220 patients in the placebo group.  The 3 treatment groups had similar demographic profiles, migraine histories, and baseline symptom profiles.  While both active treatments were significantly better than placebo in relieving the pain and associated symptoms of migraine, AAC was superior to IB for TOTPAR2, as well as for PAR, time to onset of meaningful PAR, pain intensity reduction, headache response, and pain free.  The mean TOTPAR2 scores for AAC, IB, and placebo were 2.7, 2.4, and 2.0, respectively (AAC vs.  IB, P < .03).  The median time to meaningful PAR for AAC was 20 minutes earlier than that of IB (P < .036).  CONCLUSION:  AAC and IB are safe, cost-effective treatments for migraine; AAC provides significantly superior efficacy and speed of onset compared with IB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93b6Dffuitxgd2Wuil24tfW6udTcc2eYWzm41Jen_QLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283ht1ynsw%253D%253D&md5=160b808d879dd573b7914ff497bcafbf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1526-4610.2006.00376.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1526-4610.2006.00376.x%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DJ.%26aulast%3DSilberstein%26aufirst%3DS.%2BD.%26aulast%3DSaper%26aufirst%3DJ.%2BR.%26aulast%3DRyan%26aufirst%3DR.%2BE.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26atitle%3DAcetaminophen%252C%2520aspirin%252C%2520and%2520caffeine%2520in%2520combination%2520versus%2520ibuprofen%2520for%2520acute%2520migraine%253A%2520results%2520from%2520a%2520multicenter%252C%2520double-blind%252C%2520randomized%252C%2520parallel-group%252C%2520single-dose%252C%2520placebo-controlled%2520study%26jtitle%3DHeadache%26date%3D2006%26volume%3D46%26spage%3D444%26epage%3D453%26doi%3D10.1111%2Fj.1526-4610.2006.00376.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawaddiruk, P.</span></span> <span> </span><span class="NLM_article-title">Tramadol hydrochloride/acetaminophen combination for the relief of acute pain</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1358/dot.2011.47.10.1608924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1358%2Fdot.2011.47.10.1608924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFClt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=763-772&author=P.+Sawaddiruk&title=Tramadol+hydrochloride%2Facetaminophen+combination+for+the+relief+of+acute+pain&doi=10.1358%2Fdot.2011.47.10.1608924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tramadol hydrochloride/acetaminophen combination for the relief of acute pain</span></div><div class="casAuthors">Sawaddiruk, P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">763-772</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Tramadol hydrochloride/acetaminophen is a combination drug contg. tramadol hydrochloride 37.5 mg and acetaminophen 325 mg.  The use of 25% less tramadol in the combination product reduces the incidence of tramadol-related adverse events, while the addn. of acetaminophen reduces the onset time of analgesia and improves the degree of analgesia.  However, there was no clin. significant difference in the pharmacokinetic parameters of tramadol or acetaminophen when the fixed-dose combination was compared with the individual agents after multiple-dose administration.  The onset time of tramadol hydrochloride/acetaminophen was the fastest at only 17 min compared 51 min for tramadol and 18 min for acetaminophen.  This combination has been found to be effective in the management of postoperative pain.  It improves pain relief and provides a faster onset and longer duration of action with fewer adverse events than either component sep.  It also reduces the severity of pain, photophobia and phonophobia assocd. with migraine headache.  Tramadol hydrochloride/acetaminophen has been shown to be most effective in patients with mild to moderate pain and has a lower risk of serious adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq08NoI_du2ubVg90H21EOLACvtfcHk0lhZxSKoofvU7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFClt70%253D&md5=83d5168a577aafd68556cce5bc2a26d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1358%2Fdot.2011.47.10.1608924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2011.47.10.1608924%26sid%3Dliteratum%253Aachs%26aulast%3DSawaddiruk%26aufirst%3DP.%26atitle%3DTramadol%2520hydrochloride%252Facetaminophen%2520combination%2520for%2520the%2520relief%2520of%2520acute%2520pain%26jtitle%3DDrugs%2520Today%26date%3D2011%26volume%3D47%26spage%3D763%26epage%3D772%26doi%3D10.1358%2Fdot.2011.47.10.1608924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rundgren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvison, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldeus, P.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1985&pages=306-311&author=E.+Albanoauthor=M.+Rundgrenauthor=P.+J.+Harvisonauthor=S.+D.+Nelsonauthor=P.+Moldeus&title=Mechanisms+of+N-acetyl-p-benzoquinone+imine+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlbano%26aufirst%3DE.%26aulast%3DRundgren%26aufirst%3DM.%26aulast%3DHarvison%26aufirst%3DP.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26aulast%3DMoldeus%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520N-acetyl-p-benzoquinone%2520imine%2520cytotoxicity%26jtitle%3DMol.%2520Pharmacol.%26date%3D1985%26volume%3D28%26spage%3D306%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rapoport, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutterman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cady, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, A. W.</span></span> <span> </span><span class="NLM_article-title">Analgesic rebound headache in clinical practice: data from a physician survey</span>. <i>Headache</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1046/j.1526-4610.1996.3601014.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1046%2Fj.1526-4610.1996.3601014.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=8666530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaK283nsVajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=14-19&author=A.+Rapoportauthor=P.+Stangauthor=D.+L.+Guttermanauthor=R.+Cadyauthor=H.+Markleyauthor=R.+Weeksauthor=J.+Saiersauthor=A.+W.+Fox&title=Analgesic+rebound+headache+in+clinical+practice%3A+data+from+a+physician+survey&doi=10.1046%2Fj.1526-4610.1996.3601014.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic rebound headache in clinical practice: data from a physician survey</span></div><div class="casAuthors">Rapoport A; Stang P; Gutterman D L; Cady R; Markley H; Weeks R; Saiers J; Fox A W</div><div class="citationInfo"><span class="NLM_cas:title">Headache</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-9</span>
        ISSN:<span class="NLM_cas:issn">0017-8748</span>.
    </div><div class="casAbstract">BACKGROUND:  Frequent, excessive use of over-the-counter or prescription analgesics may lead to analgesic rebound headache.  Little is known about the magnitude of the health problem posed by analgesic rebound headache, its epidemiology, the characteristics of analgesic rebound headache sufferers, or about physicians' approaches to treatment.  METHODS:  Four hundred seventy-three practitioners, who had previously expressed an interest in the treatment of headache, were mailed a questionnaire designed to capture information about the frequency and management of analgesic rebound headache and about the characteristics of analgesic rebound headache sufferers.  RESULTS:  Completed questionnaires were returned by 174 practitioners (37%) from 40 states, the District of Columbia, and Puerto Rico.  More than 40% of respondents indicated that analgesic rebound headache was present in at least 20% of their patients.  On average, the physicians reported that 73% of patients with analgesic rebound headache were women.  Analgesic rebound headache was most likely to occur in patients aged 31 to 40 years.  No one analgesic was consistently identified as causative, although acetaminophen, butalbital + aspirin + caffeine, and aspirin were commonly used by patients.  Eighty percent of respondents indicated that depression was commonly observed in analgesic rebound headache sufferers; 77% indicated that physical conditions (especially gastrointestinal symptoms) were commonly observed.  A variety of therapeutic strategies, including pharmacotherapy, were used in the management of analgesic rebound headache.  CONCLUSION:  Analgesic rebound headache was recognized as a distinct entity and a substantive component in more than 40% of the practices of 174 surveyed practitioners.  General practitioners, who see a wide variety of patient types with a spectrum of complaints, need to be able to diagnose analgesic rebound headache by taking a good history.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSHTXR87YQV1vAgqb2vdc5fW6udTcc2eYgh3H-dvypd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283nsVajtA%253D%253D&md5=719f41189a2bea678de465508eea0d2d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1046%2Fj.1526-4610.1996.3601014.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1526-4610.1996.3601014.x%26sid%3Dliteratum%253Aachs%26aulast%3DRapoport%26aufirst%3DA.%26aulast%3DStang%26aufirst%3DP.%26aulast%3DGutterman%26aufirst%3DD.%2BL.%26aulast%3DCady%26aufirst%3DR.%26aulast%3DMarkley%26aufirst%3DH.%26aulast%3DWeeks%26aufirst%3DR.%26aulast%3DSaiers%26aufirst%3DJ.%26aulast%3DFox%26aufirst%3DA.%2BW.%26atitle%3DAnalgesic%2520rebound%2520headache%2520in%2520clinical%2520practice%253A%2520data%2520from%2520a%2520physician%2520survey%26jtitle%3DHeadache%26date%3D1996%26volume%3D36%26spage%3D14%26epage%3D19%26doi%3D10.1046%2Fj.1526-4610.1996.3601014.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meek, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Laar, M. A. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonkeman, H. E.</span></span> <span> </span><span class="NLM_article-title">Non-steroidal anti-Inflammatory drugs: an overview of cardiovascular risks</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2162</span>, <span class="refDoi"> DOI: 10.3390/ph3072146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3390%2Fph3072146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=27713346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=2146-2162&author=I.+L.+Meekauthor=M.+A.+F.+J.+van+de+Laarauthor=H.+E.+Vonkeman&title=Non-steroidal+anti-Inflammatory+drugs%3A+an+overview+of+cardiovascular+risks&doi=10.3390%2Fph3072146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Non-steroidal anti-inflammatory drugs: an overview of cardiovascular risks</span></div><div class="casAuthors">Meek, Inger L.; van de Laar, Mart A. F. J.; Vonkeman, Harald E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2146-2162</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  While aspirin may offer protection, other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious cardiovascular side effects and complications.  This has led to a general "black box" warning for cardiovascular adverse events for NSAIDs.  This review explores the different mechanisms underlying the protective effects of aspirin, the NSAID assocd. renovascular effects causing hypertension, edema and heart failure, the cardiovascular effects causing myocardial infarction and stroke, and the possible deleterious interaction between NSAIDs and aspirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4J7x1BpQS3LVg90H21EOLACvtfcHk0liOZ4r5_d1Hzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFGlsro%253D&md5=edaefcbbb265662a468f56825d89abe1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fph3072146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph3072146%26sid%3Dliteratum%253Aachs%26aulast%3DMeek%26aufirst%3DI.%2BL.%26aulast%3Dvan%2Bde%2BLaar%26aufirst%3DM.%2BA.%2BF.%2BJ.%26aulast%3DVonkeman%26aufirst%3DH.%2BE.%26atitle%3DNon-steroidal%2520anti-Inflammatory%2520drugs%253A%2520an%2520overview%2520of%2520cardiovascular%2520risks%26jtitle%3DPharmaceuticals%26date%3D2010%26volume%3D3%26spage%3D2146%26epage%3D2162%26doi%3D10.3390%2Fph3072146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sneader, W.</span></span> <span> </span><span class="NLM_article-title">The discovery of aspirin: a reappraisal</span>. <i>BMJ. Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.1136/bmj.321.7276.1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1136%2Fbmj.321.7276.1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3M7jtFChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2000&pages=1591-1594&author=W.+Sneader&title=The+discovery+of+aspirin%3A+a+reappraisal&doi=10.1136%2Fbmj.321.7276.1591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of aspirin: a reappraisal</span></div><div class="casAuthors">Sneader W</div><div class="citationInfo"><span class="NLM_cas:title">BMJ (Clinical research ed.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1591-4</span>
        ISSN:<span class="NLM_cas:issn">0959-8138</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxJvJnuqC-nqj_yg7twvpfW6udTcc2eYgh3H-dvypd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7jtFChtA%253D%253D&md5=a150887be4eb42e2bfce310e57360782</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1136%2Fbmj.321.7276.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.321.7276.1591%26sid%3Dliteratum%253Aachs%26aulast%3DSneader%26aufirst%3DW.%26atitle%3DThe%2520discovery%2520of%2520aspirin%253A%2520a%2520reappraisal%26jtitle%3DBMJ.%2520Br.%2520Med.%2520J.%26date%3D2000%26volume%3D321%26spage%3D1591%26epage%3D1594%26doi%3D10.1136%2Fbmj.321.7276.1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Undas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel-Ziedins, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, K. G.</span></span> <span> </span><span class="NLM_article-title">Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2285</span>– <span class="NLM_lpage">2292</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-01-010645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1182%2Fblood-2006-01-010645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17148593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslyhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=2285-2292&author=A.+Undasauthor=K.+E.+Brummel-Ziedinsauthor=K.+G.+Mann&title=Antithrombotic+properties+of+aspirin+and+resistance+to+aspirin%3A+beyond+strictly+antiplatelet+actions&doi=10.1182%2Fblood-2006-01-010645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions</span></div><div class="casAuthors">Undas, Anetta; Brummel-Ziedins, Kathleen E.; Mann, Kenneth G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2285-2292</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Aspirin is effective in the prevention of cardiovascular events in high-risk patients.  The primary established effect of aspirin on hemostasis is to impair platelet aggregation via inhibition of platelet thromboxane A2 synthesis, thus reducing thrombus formation on the surface of the damaged arterial wall.  Growing evidence also indicates that aspirin exerts addnl. antithrombotic effects, which appear to some extent unrelated to platelet thromboxane A2 prodn.  Aspirin can reduce thrombin generation with the subsequent attenuation of thrombin-mediated coagulant reactions such as factor XIII activation.  Aspirin also acetylates lysine residues in fibrinogen resulting in increased fibrin clot permeability and enhanced clot lysis as well as directly promoting fibrinolysis with high-dose aspirin.  The variable effectiveness of aspirin in terms of clin. outcomes and lab. findings, which was termed aspirin resistance, may be related to these addnl. antithrombotic effects that are altered when assocd. with common genetic polymorphisms such as the Leu33Pro β3-integrin or VaI34Leu factor XIII mutations.  However, the clin. relevance of these observations is still unclear.  Elucidation of the actual impacts of aspirin other than antiaggregation effects could be important in view of the wide-spread use of this drug in the prevention of thrombotic manifestations of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9C5QN2LA027Vg90H21EOLACvtfcHk0liB0mcx32aKeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslyhu7c%253D&md5=e8baa9dde57ea3925d5bc3860894703f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-01-010645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-01-010645%26sid%3Dliteratum%253Aachs%26aulast%3DUndas%26aufirst%3DA.%26aulast%3DBrummel-Ziedins%26aufirst%3DK.%2BE.%26aulast%3DMann%26aufirst%3DK.%2BG.%26atitle%3DAntithrombotic%2520properties%2520of%2520aspirin%2520and%2520resistance%2520to%2520aspirin%253A%2520beyond%2520strictly%2520antiplatelet%2520actions%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D2285%26epage%3D2292%26doi%3D10.1182%2Fblood-2006-01-010645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veltri, K. T.</span></span> <span> </span><span class="NLM_article-title">Yosprala: a fixed dose combination of aspirin and omeprazole</span>. <i>Cardiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1097/CRD.0000000000000174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2FCRD.0000000000000174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29045287" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=50-53&author=K.+T.+Veltri&title=Yosprala%3A+a+fixed+dose+combination+of+aspirin+and+omeprazole&doi=10.1097%2FCRD.0000000000000174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2FCRD.0000000000000174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCRD.0000000000000174%26sid%3Dliteratum%253Aachs%26aulast%3DVeltri%26aufirst%3DK.%2BT.%26atitle%3DYosprala%253A%2520a%2520fixed%2520dose%2520combination%2520of%2520aspirin%2520and%2520omeprazole%26jtitle%3DCardiol.%2520Rev.%26date%3D2018%26volume%3D26%26spage%3D50%26epage%3D53%26doi%3D10.1097%2FCRD.0000000000000174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strack, T.</span></span> <span> </span><span class="NLM_article-title">Metformin: a review</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1358/dot.2008.44.4.1138124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1358%2Fdot.2008.44.4.1138124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotV2gsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=303-314&author=T.+Strack&title=Metformin%3A+a+review&doi=10.1358%2Fdot.2008.44.4.1138124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin: a review</span></div><div class="casAuthors">Strack, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-314</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today.  Despite low potency and a long list of contraindications, metformin has remained successful and even expanded exptl. use due to its well-established effects on glucose metab. and, as more recently demonstrated, its benefits on other cardiovascular risk factors.  Unlike insulin and secretagogues, metformin does not increase body wt. and when used as monotherapy does not likely cause hypoglycemia.  The most common adverse effects assocd. with metformin are mild, transient gastrointestinal symptoms, which are usually self-limiting.  These side effects can be minimized by initiating metformin therapy at a low dose and gradually titrating upward, and by taking metformin with meals.  Lactic acidosis caused by metformin is rare, and the risk of this complication may be diminished by the observance of prescribing precautions and contraindications that avoid accumulation of metformin or lactate in the body.  The many clin. benefits and the lack of safety risks when used with other antihyperglycemic agents have made metformin a preferred combination drug with other oral agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu4ddrOJ26k7Vg90H21EOLACvtfcHk0liB0mcx32aKeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotV2gsbo%253D&md5=008e82b672eb68a6f0e051a0f9b547de</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1358%2Fdot.2008.44.4.1138124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2008.44.4.1138124%26sid%3Dliteratum%253Aachs%26aulast%3DStrack%26aufirst%3DT.%26atitle%3DMetformin%253A%2520a%2520review%26jtitle%3DDrugs%2520Today%26date%3D2008%26volume%3D44%26spage%3D303%26epage%3D314%26doi%3D10.1358%2Fdot.2008.44.4.1138124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. J.</span></span> <span> </span><span class="NLM_article-title">Metformin: historical overview</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1576</span>, <span class="refDoi"> DOI: 10.1007/s00125-017-4318-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs00125-017-4318-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28776081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1566-1576&author=C.+J.+Bailey&title=Metformin%3A+historical+overview&doi=10.1007%2Fs00125-017-4318-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin: historical overview</span></div><div class="casAuthors">Bailey, Clifford J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1566-1576</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes.  Its history is linked to Galega officinalis (also known as goat's rue), a traditional herbal medicine in Europe, found to be rich in guanidine, which, in 1918, was shown to lower blood glucose.  Guanidine derivs., including metformin, were synthesized and some (not metformin) were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the increased availability of insulin.  Metformin was rediscovered in the search for antimalarial agents in the 1940s and, during clin. tests, proved useful to treat influenza when it sometimes lowered blood glucose.  This property was pursued by the French physician Jean Sterne, who first reported the use of metformin to treat diabetes in 1957.  However, metformin received limited attention as it was less potent than other glucose-lowering biguanides (phenformin and buformin), which were generally discontinued in the late 1970s due to high risk of lactic acidosis.  Metformin's future was precarious, its reputation tarnished by assocn. with other biguanides despite evident differences.  The ability of metformin to counter insulin resistance and address adult-onset hyperglycemia without wt. gain or increased risk of hypoglycemia gradually gathered credence in Europe, and after intensive scrutiny metformin was introduced into the USA in 1995.  Long-term cardiovascular benefits of metformin were identified by the UK Prospective Diabetes Study (UKPDS) in 1998, providing a new rationale to adopt metformin as initial therapy to manage hyperglycemia in type 2 diabetes.  Sixty years after its introduction in diabetes treatment, metformin has become the most prescribed glucose-lowering medicine worldwide with the potential for further therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMeoptV9GjCLVg90H21EOLACvtfcHk0liB0mcx32aKeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yiurvO&md5=dc84ba9bdc22e7d651cb383c9b24c6c5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4318-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4318-z%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DC.%2BJ.%26atitle%3DMetformin%253A%2520historical%2520overview%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26spage%3D1566%26epage%3D1576%26doi%3D10.1007%2Fs00125-017-4318-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Home, P. D.</span></span> <span> </span><span class="NLM_article-title">Impact of the UKPDS—an overview</span>. <i>Diabetic Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1111/j.1464-5491.2008.02501.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1464-5491.2008.02501.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18717971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1cros1ygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=2-8&author=P.+D.+Home&title=Impact+of+the+UKPDS%E2%80%94an+overview&doi=10.1111%2Fj.1464-5491.2008.02501.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of the UKPDS--an overview</span></div><div class="casAuthors">Home P D</div><div class="citationInfo"><span class="NLM_cas:title">Diabetic medicine : a journal of the British Diabetic Association</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">25 Suppl 2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The UK Prospective Diabetes Study (UKPDS) is a group of clinical trials, epidemiological analyses and health-modelling studies with an influence which can be assessed across a broad range of health domains.  Original publications (n = 85) are notable for being mainly published in the key weekly or diabetes journals (78%) and being mainly in the clinical arena (68%).  Notable reference to the publications can be found in UK National Institute for Clinical Excellence (NICE) guidelines, but also in evidence-based international guidelines, where UKPDS papers form a significant fraction of the citations.  In educational materials UKPDS-derived slides remain popular (10 and 30% of some international slide sets), again as much for the epidemiological findings as for the core trial results.  Slides of the deterioration in blood glucose control with time, and evidence that this is as a result of progressive decline of pancreatic islet B-cell function, are used particularly often.  The UKPDS enhanced the promotion of glycated haemoglobin to its core role in clinical monitoring, through understanding of the quantitative relationship of vascular complications to glucose control, and thus to target setting.  Notably, metformin therapy was promoted by the UKPDS findings on macrovascular disease in the overweight study, although controversy remains regarding the significance of the effect on macrovascular disease of the core glucose-lowering study, promoting the development of further studies reporting in 2008.  The effects of decreasing blood pressure on microvascular disease have had an important impact on guidelines and health economic analyses, together with other evidence on the value of rennin-angiotensin system blockers.  The UKPDS has evidently been unusually influential in the development of treatment guidelines, clinical education and the thinking of healthcare professionals.  By inference it must be responsible for a significant part of the improvement in health outcomes in people with Type 2 diabetes over the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSI61U0h7sOLq_dlEzl_fBafW6udTcc2eYYXCDS8vHd1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cros1ygug%253D%253D&md5=66438ba066af9443b8b141c3aa24508f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-5491.2008.02501.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-5491.2008.02501.x%26sid%3Dliteratum%253Aachs%26aulast%3DHome%26aufirst%3DP.%2BD.%26atitle%3DImpact%2520of%2520the%2520UKPDS%25E2%2580%2594an%2520overview%26jtitle%3DDiabetic%2520Med.%26date%3D2008%26volume%3D25%26spage%3D2%26epage%3D8%26doi%3D10.1111%2Fj.1464-5491.2008.02501.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvoor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy Dendi, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraleti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhawat, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montales, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriakose, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasapu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musham, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohani, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, W.</span></span> <span> </span><span class="NLM_article-title">Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.3389/fendo.2017.00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3389%2Ffendo.2017.00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28167928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jslyitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=6&author=A.+Chaudhuryauthor=C.+Duvoorauthor=V.+S.+Reddy+Dendiauthor=S.+Kraletiauthor=A.+Chadaauthor=R.+Ravillaauthor=A.+Marcoauthor=N.+S.+Shekhawatauthor=M.+T.+Montalesauthor=K.+Kuriakoseauthor=A.+Sasapuauthor=A.+Beebeauthor=N.+Patilauthor=C.+K.+Mushamauthor=G.+P.+Lohaniauthor=W.+Mirza&title=Clinical+review+of+antidiabetic+drugs%3A+implications+for+type+2+diabetes+mellitus+management&doi=10.3389%2Ffendo.2017.00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management</span></div><div class="casAuthors">Chaudhury Arun; Duvoor Chitharanjan; Chada Aditya; Ravilla Rahul; Reddy Dendi Vijaya Sena; Kraleti Shashank; Montales Maria Theresa; Sasapu Appalanaidu; Marco Asween; Shekhawat Nawal Singh; Kuriakose Kevin; Beebe Alexandria; Patil Naveen; Musham Chaitanya K; Lohani Govinda Prasad; Mirza Wasique</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/).  Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia.  Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas.  T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations.  In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR79GlNDVo7nOR_TJajKxJDfW6udTcc2eYoBo7lg9QXvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jslyitg%253D%253D&md5=018c81e9a18e754d2646bdbc5cfb22a9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2017.00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2017.00006%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhury%26aufirst%3DA.%26aulast%3DDuvoor%26aufirst%3DC.%26aulast%3DReddy%2BDendi%26aufirst%3DV.%2BS.%26aulast%3DKraleti%26aufirst%3DS.%26aulast%3DChada%26aufirst%3DA.%26aulast%3DRavilla%26aufirst%3DR.%26aulast%3DMarco%26aufirst%3DA.%26aulast%3DShekhawat%26aufirst%3DN.%2BS.%26aulast%3DMontales%26aufirst%3DM.%2BT.%26aulast%3DKuriakose%26aufirst%3DK.%26aulast%3DSasapu%26aufirst%3DA.%26aulast%3DBeebe%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DN.%26aulast%3DMusham%26aufirst%3DC.%2BK.%26aulast%3DLohani%26aufirst%3DG.%2BP.%26aulast%3DMirza%26aufirst%3DW.%26atitle%3DClinical%2520review%2520of%2520antidiabetic%2520drugs%253A%2520implications%2520for%2520type%25202%2520diabetes%2520mellitus%2520management%26jtitle%3DFront.%2520Endocrinol.%26date%3D2017%26volume%3D8%26spage%3D6%26doi%3D10.3389%2Ffendo.2017.00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavernia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubrook, J. H.</span></span> <span> </span><span class="NLM_article-title">Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals</span>. <i>Postgrad. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">808</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1080/00325481.2015.1085293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1080%2F00325481.2015.1085293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26439384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC283ptVKrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2015&pages=808-817&author=F.+Laverniaauthor=S.+E.+Adkinsauthor=J.+H.+Shubrook&title=Use+of+oral+combination+therapy+for+type+2+diabetes+in+primary+care%3A+Meeting+individualized+patient+goals&doi=10.1080%2F00325481.2015.1085293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals</span></div><div class="casAuthors">Lavernia Frank; Adkins Sarah E; Shubrook Jay H</div><div class="citationInfo"><span class="NLM_cas:title">Postgraduate medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">808-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The management of type 2 diabetes mellitus (T2DM) by primary care physicians (PCPs) has become increasingly complex due to limitations on consultation time, an increasing array of drug treatment options, and issues of comorbidities and polypharmacy.  Diabetes is a progressive condition and treatment with a single glucose-lowering agent can only address limited pathophysiologic targets and does not provide adequate glycemic control in many cases.  Consequently, most patients with T2DM will eventually require treatment with multiple glucose-lowering medications.  Oral combination therapy in T2DM may be given as multiple-pills, or as single-pill, fixed-dose combinations (FDCs), the latter of which offer convenience, ease of administration, and a reduction in the medication burden.  Therefore, FDCs can potentially improve patients' treatment adherence and optimize achievement and maintenance of glycemic targets.  However, cost factors also need to be considered.  An understanding of the issues associated with the use of combination therapy in T2DM will help PCPs to guide patient-centered decision making and promote the effective management of T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTg_TOBG-V72EcLvDNbOD4DfW6udTcc2eYoBo7lg9QXvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ptVKrsg%253D%253D&md5=d1a4a5a9787e66e7eacd47eef2dddc7a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F00325481.2015.1085293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00325481.2015.1085293%26sid%3Dliteratum%253Aachs%26aulast%3DLavernia%26aufirst%3DF.%26aulast%3DAdkins%26aufirst%3DS.%2BE.%26aulast%3DShubrook%26aufirst%3DJ.%2BH.%26atitle%3DUse%2520of%2520oral%2520combination%2520therapy%2520for%2520type%25202%2520diabetes%2520in%2520primary%2520care%253A%2520Meeting%2520individualized%2520patient%2520goals%26jtitle%3DPostgrad.%2520Med.%26date%3D2015%26volume%3D127%26spage%3D808%26epage%3D817%26doi%3D10.1080%2F00325481.2015.1085293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, V.</span></span> <span> </span><span class="NLM_article-title">Effect of thiazolidinediones on body weight in patients with diabetes mellitus</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2003.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.amjmed.2003.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=14678865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2003&pages=42-48&author=V.+Fonseca&title=Effect+of+thiazolidinediones+on+body+weight+in+patients+with+diabetes+mellitus&doi=10.1016%2Fj.amjmed.2003.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of thiazolidinediones on body weight in patients with diabetes mellitus</span></div><div class="casAuthors">Fonseca, Vivian</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8A</span>),
    <span class="NLM_cas:pages">42S-48S</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">Treatment of diabetes mellitus with medications, including insulin, sulfonylureas, and thiazolidinediones (TZDs), often leads to wt. gain through a variety of mechanisms.  Wt. gain can have adverse consequences for patients with type 2 diabetes, many of whom are overweight or obese, because obesity is linked to insulin resistance and other medical consequences such as cardiovascular disease.  TZDs improve glycemic control and insulin sensitivity in patients with type 2 diabetes, despite their potential to cause wt. gain.  Studies have attempted to elucidate the mechanisms behind the apparent paradox of TZDs improving insulin sensitivity while causing wt. gain.  Data indicate that with TZD treatment, there is a favorable shift in fat distribution from visceral to s.c. adipose depots that is assocd. with improvements in hepatic and peripheral tissue sensitivity to insulin.  Although wt. gain, may occur with TZD therapy, it is not inevitable.  A wt.-management program combining a low-calorie, low-sodium diet with education and behavior modification has been shown to be effective in, patients with type 2 diabetes being treated with TZDs.  Further research is needed to define the optimal dietary modifications that can be used universally in TZD-treated patients,to minimize wt. gain while effectively treating insulin resistance and hyperglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSccP971Zkz7Vg90H21EOLACvtfcHk0lhNZFTtLq9-KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlGkug%253D%253D&md5=66a58ac348b55121f2c29dbc516bc62a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2003.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2003.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DFonseca%26aufirst%3DV.%26atitle%3DEffect%2520of%2520thiazolidinediones%2520on%2520body%2520weight%2520in%2520patients%2520with%2520diabetes%2520mellitus%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2003%26volume%3D115%26spage%3D42%26epage%3D48%26doi%3D10.1016%2Fj.amjmed.2003.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ognibene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petracca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzatini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicembrini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messeri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotella, C. M.</span></span> <span> </span><span class="NLM_article-title">Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes</span>. <i>Diabetes Nutr. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15887627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlektL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=336-342&author=E.+Mannucciauthor=F.+Tesiauthor=G.+Bardiniauthor=A.+Ognibeneauthor=M.+G.+Petraccaauthor=S.+Cianiauthor=A.+Pezzatiniauthor=M.+Brogiauthor=I.+Dicembriniauthor=F.+Cremascoauthor=G.+Messeriauthor=C.+M.+Rotella&title=Effects+of+metformin+on+glucagon-like+peptide-1+levels+in+obese+patients+with+and+without+Type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes</span></div><div class="casAuthors">Mannucci, E.; Tesi, F.; Bardini, G.; Ognibene, A.; Petracca, M. G.; Ciani, S.; Pezzatini, A.; Brogi, M.; Dicembrini, I.; Cremasco, F.; Messeri, G.; Rotella, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Nutrition & Metabolism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">336-342</span>CODEN:
                <span class="NLM_cas:coden">DNMEEW</span>;
        ISSN:<span class="NLM_cas:issn">0394-3402</span>.
    
            (<span class="NLM_cas:orgname">Editrice Kurtis s.r.l.</span>)
        </div><div class="casAbstract">Metformin has been shown to increase glucagon-like peptide-1 (GLP-1) levels after an oral glucose load in obese non-diabetic subjects.  In order to verify if this effect of the drug was also present in obese Type 2 diabetic patients who have never been treated with hypoglycemic drugs, 22 Type 2 diabetic and 12 matched non-diabetic obese patients were studied.  GLP-1 was measured before and after a 100 g glucose load at baseline, after a single oral dose of 850 mg of metformin, and after 4 wk of treatment with metformin 850 mg three times daily.  Post-load GLP-1 levels were significantly lower in diabetic patients.  A single dose of metformin did not modify GLP-1 levels.  After 4 wk of treatment, fasting GLP-1 increased in diabetic patients (3.8 vs. 4.9 pmol/l; p<0.05), while the incremental area under the curve of GLP-1 significantly increased in both diabetic [93.6 (45.6-163.2) vs. 151.2 (36.0-300.5) pmol*min/l; p<0.05] and non-diabetic [187.2 (149.4-571.8) vs. 324.0 (238.2-744.0) pmol*min/l; p<0.05] subjects.  In conclusion, GLP-1 levels after an oral glucose load in obese type 2 diabetic patients were increased by 4 wk of metformin treatment in a similar fashion as in obese subjects with normal glucose tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotY7hCzQFL0bVg90H21EOLACvtfcHk0ljneVv_JB8AKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlektL8%253D&md5=57602645304e4da0190e36ac2b1ea675</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMannucci%26aufirst%3DE.%26aulast%3DTesi%26aufirst%3DF.%26aulast%3DBardini%26aufirst%3DG.%26aulast%3DOgnibene%26aufirst%3DA.%26aulast%3DPetracca%26aufirst%3DM.%2BG.%26aulast%3DCiani%26aufirst%3DS.%26aulast%3DPezzatini%26aufirst%3DA.%26aulast%3DBrogi%26aufirst%3DM.%26aulast%3DDicembrini%26aufirst%3DI.%26aulast%3DCremasco%26aufirst%3DF.%26aulast%3DMesseri%26aufirst%3DG.%26aulast%3DRotella%26aufirst%3DC.%2BM.%26atitle%3DEffects%2520of%2520metformin%2520on%2520glucagon-like%2520peptide-1%2520levels%2520in%2520obese%2520patients%2520with%2520and%2520without%2520Type%25202%2520diabetes%26jtitle%3DDiabetes%2520Nutr.%2520Metab.%26date%3D2004%26volume%3D17%26spage%3D336%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. H.</span></span> <span> </span><span class="NLM_article-title">Committee of clinical practice guidelines of the korean diabetes, A., combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus</span>. <i>Diabetes Metab. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.4093/dmj.2017.41.5.357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4093%2Fdmj.2017.41.5.357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29086533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtFSlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2017&pages=357-366&author=M.+K.+Moonauthor=K.+Y.+Hurauthor=S.+H.+Koauthor=S.+O.+Parkauthor=B.+W.+Leeauthor=J.+H.+Kimauthor=S.+Y.+Rheeauthor=H.+J.+Kimauthor=K.+M.+Choiauthor=N.+H.+Kim&title=Committee+of+clinical+practice+guidelines+of+the+korean+diabetes%2C+A.%2C+combination+therapy+of+oral+hypoglycemic+agents+in+patients+with+type+2+diabetes+mellitus&doi=10.4093%2Fdmj.2017.41.5.357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus</span></div><div class="casAuthors">Moon Min Kyong; Hur Kyu Yeon; Ko Seung Hyun; Park Seok O; Lee Byung Wan; Kim Jin Hwa; Rhee Sang Youl; Kim Hyun Jin; Choi Kyung Mook; Kim Nan Hee</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & metabolism journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-366</span>
        ISSN:<span class="NLM_cas:issn">2233-6079</span>.
    </div><div class="casAbstract">The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM).  In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines.  The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines.  All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different.  Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity.  In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs.  It will help to choose the appropriate drug for an individual patient with T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6t9k_XFN6cLGbPKh4T9eAfW6udTcc2eaneiRIi5O82bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtFSlsg%253D%253D&md5=1e61ce1c15edd2859f3e8d69447ce3dd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4093%2Fdmj.2017.41.5.357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4093%252Fdmj.2017.41.5.357%26sid%3Dliteratum%253Aachs%26aulast%3DMoon%26aufirst%3DM.%2BK.%26aulast%3DHur%26aufirst%3DK.%2BY.%26aulast%3DKo%26aufirst%3DS.%2BH.%26aulast%3DPark%26aufirst%3DS.%2BO.%26aulast%3DLee%26aufirst%3DB.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DN.%2BH.%26atitle%3DCommittee%2520of%2520clinical%2520practice%2520guidelines%2520of%2520the%2520korean%2520diabetes%252C%2520A.%252C%2520combination%2520therapy%2520of%2520oral%2520hypoglycemic%2520agents%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDiabetes%2520Metab.%2520J.%26date%3D2017%26volume%3D41%26spage%3D357%26epage%3D366%26doi%3D10.4093%2Fdmj.2017.41.5.357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pletzer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerschbaum, H. H.</span></span> <span> </span><span class="NLM_article-title">50 years of hormonal contraception—time to find out, what it does to our brain</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">256</span>, <span class="refDoi"> DOI: 10.3389/fnins.2014.00256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3389%2Ffnins.2014.00256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25191220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FosFWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=256&author=B.+A.+Pletzerauthor=H.+H.+Kerschbaum&title=50+years+of+hormonal+contraception%E2%80%94time+to+find+out%2C+what+it+does+to+our+brain&doi=10.3389%2Ffnins.2014.00256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">50 years of hormonal contraception-time to find out, what it does to our brain</span></div><div class="casAuthors">Pletzer Belinda A; Kerschbaum Hubert H</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Hormonal contraceptives are on the market for more than 50 years and used by 100 million women worldwide.  However, while endogenous steroids have been convincingly associated with change in brain structure, function and cognitive performance, the effects of synthetic steroids contained in hormonal contraceptives on brain and cognition have barely been investigated.  In this article we summarize the sparse findings, describing brain structural, functional and behavioral findings from the literature and suggest that synthetic steroids may contribute to masculinizing as well as feminizing effects on brain and behavior.  We try to identify methodological challenges, explain, how results on endogenous steroids may transfer into research on hormonal contraceptives and point out factors that need to be controlled in the study of hormonal contraceptive dependent effects.  We conclude that there is a strong need for more systematic studies, especially on brain structural, functional and cognitive changes due to hormonal contraceptive use.  The hormonal contraceptive pill is the major tool for population control.  Hence, such behavioral changes could cause a shift in society dynamics and should not stay unattended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQArY3Rx4ms8MSzjBFCN0BJfW6udTcc2eaneiRIi5O82bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FosFWisw%253D%253D&md5=d06bb2a1a0373f13ba494e992b110e75</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2014.00256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2014.00256%26sid%3Dliteratum%253Aachs%26aulast%3DPletzer%26aufirst%3DB.%2BA.%26aulast%3DKerschbaum%26aufirst%3DH.%2BH.%26atitle%3D50%2520years%2520of%2520hormonal%2520contraception%25E2%2580%2594time%2520to%2520find%2520out%252C%2520what%2520it%2520does%2520to%2520our%2520brain%26jtitle%3DFront.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D256%26doi%3D10.3389%2Ffnins.2014.00256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, A. J.</span></span> <span> </span><span class="NLM_article-title">Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive</span>. <i>Treat. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.2165/00024677-200302010-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00024677-200302010-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15871554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1eqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=49-70&author=S.+J.+Keamauthor=A.+J.+Wagstaff&title=Ethinylestradiol%2Fdrospirenone%3A+a+review+of+its+use+as+an+oral+contraceptive&doi=10.2165%2F00024677-200302010-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive</span></div><div class="casAuthors">Keam, Susan J.; Wagstaff, Antona J.</div><div class="citationInfo"><span class="NLM_cas:title">Treatments in Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-70</span>CODEN:
                <span class="NLM_cas:coden">TERNAN</span>;
        ISSN:<span class="NLM_cas:issn">1175-6349</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review which discusses the effectiveness of ethinylestradiol 30 μg/drospirenone 3 mg, a combined contraceptive pill for the prevention of pregnancy in women of reproductive age, as an oral contraceptive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPnFhRQDP8l7Vg90H21EOLACvtfcHk0li9PgRFNViMog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1eqs78%253D&md5=d9d8741664a9bf68d762cacf3a17019f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2165%2F00024677-200302010-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00024677-200302010-00005%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26aulast%3DWagstaff%26aufirst%3DA.%2BJ.%26atitle%3DEthinylestradiol%252Fdrospirenone%253A%2520a%2520review%2520of%2520its%2520use%2520as%2520an%2520oral%2520contraceptive%26jtitle%3DTreat.%2520Endocrinol.%26date%3D2003%26volume%3D2%26spage%3D49%26epage%3D70%26doi%3D10.2165%2F00024677-200302010-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> In  <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7th</span> ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">1393</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1393&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D1393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulds, D.</span></span> <span> </span><span class="NLM_article-title">Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.2165/00003495-199753040-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00003495-199753040-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=9098665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK2sXisFGgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=657-680&author=C.+M.+Perryauthor=D.+Faulds&title=Lamivudine.+A+review+of+its+antiviral+activity%2C+pharmacokinetic+properties+and+therapeutic+efficacy+in+the+management+of+HIV+infection&doi=10.2165%2F00003495-199753040-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Lamivudine A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection</span></div><div class="casAuthors">Perry, Caroline M.; Faulds, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-680</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 114 refs.  Lamivudine is a dideoxynucleoside analog which undergoes intracellular phosphorylation to the putative active metabolite, lamivudine triphosphate.  Lamivudine triphosphate prevents HIV replication by competitively inhibiting viral reverse transcriptase.  Lamivudine has a unique resistance profile and has the ability to delay resistance to zidovudine and restore zidovudine sensitivity in zidovudine-experienced patients.  Combination antiretroviral drug therapy is now generally considered preferable to monotherapy as first-line treatment for patients with HIV infection.  In double-blind trials in antiretroviral drug-experienced or-naive adults, improvements in surrogate markers of disease progression were significantly greater in patients receiving lamivudine plus zidovudine combination therapy than in patients who received either drug as monotherapy.  Preliminary results of CAESAR, a large multicenter trial in patients with moderately advanced HIV infection receiving zidovudine-based treatment regimens, show a 54% redn. in the rate of disease progression or death with the addn. of lamivudine, compared with the addn. of placebo.  Initial virol. data from studies of combination regimens including lamivudine and protease inhibitors are also promising, although the longer term efficacy of these regimens remains to be established.  Improvements in surrogate disease markers were also seen in children and adolescents with symptomatic HIV infection who received lamivudine monotherapy.  Studies of lamivudine-contg. combination therapy in children and adolescents are in progress, but few data have yet been published.  Lamivudine is generally well tolerated as monotherapy or in combination with other antiretroviral agents in HIV-infected adults with CD4+ counts ≥100 cells/μl.  Gastrointestinal disturbances were reported as the most common adverse events during lamivudine monotherapy or combination therapy.  Lamivudine appears to be less well tolerated in patients with advanced disease (CD4+ cell counts <100 cells/μl), but more data are required to clarify its tolerability in such patients.  Pancreatitis has been reported in children with advanced disease during treatment with the drug, but was not directly attributable to lamivudine therapy.  Thus, lamivudine, administered in combination with zidovudine, is now established as an effective agent for the treatment of antiretroviral drug-experienced or -naive individuals with asymptomatic or symptomatic HIV disease.  Moreover, encouraging preliminary data suggest that lamivudine is poised to become and important component of other regimens, in combination with drugs such as the protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNVyw67EImbVg90H21EOLACvtfcHk0li9PgRFNViMog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisFGgurg%253D&md5=0ca5dc09c2eecf4ac548bd9a1c87e8c2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2165%2F00003495-199753040-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199753040-00008%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DC.%2BM.%26aulast%3DFaulds%26aufirst%3DD.%26atitle%3DLamivudine.%2520A%2520review%2520of%2520its%2520antiviral%2520activity%252C%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%2520in%2520the%2520management%2520of%2520HIV%2520infection%26jtitle%3DDrugs%26date%3D1997%26volume%3D53%26spage%3D657%26epage%3D680%26doi%3D10.2165%2F00003495-199753040-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larson, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otofokun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, E. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic enhancers in HIV therapeutics</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1007/s40262-014-0167-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40262-014-0167-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25164142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=865-872&author=K.+B.+Larsonauthor=K.+Wangauthor=C.+Delilleauthor=I.+Otofokunauthor=E.+P.+Acosta&title=Pharmacokinetic+enhancers+in+HIV+therapeutics&doi=10.1007%2Fs40262-014-0167-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Enhancers in HIV Therapeutics</span></div><div class="casAuthors">Larson, Kajal B.; Wang, Kun; Delille, Cecile; Otofokun, Igho; Acosta, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">865-872</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Maximal and durable viral load suppression is one of the most important goals of HIV therapy and is directly related to adequate drug exposure.  Protease inhibitors (PIs), an important component of the antiretroviral armada, were historically assocd. with poor oral bioavailability and high pill burden.  However, because the PIs are metabolized by cytochrome P 450 (CYP) 3A enzymes, intentional inhibition of these enzymes leads to higher drug exposure, lower pill burden, and therefore simplified dosing schedules with this class of drug.  This is the basis of pharmacokinetic enhancement.  In HIV therapy, two pharmacokinetic enhancers or boosting agents are used: ritonavir and cobicistat.  Both agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than ritonavir.  Unlike ritonavir, cobicistat does not have antiretroviral activity.  Cobicistat has been evaluated in clin. trials and was recently approved in the USA as a fixed-dose combination with the integrase inhibitor, elvitegravir and two nucleos(t)ide analogs.  Addnl. studies are examg. cobicistat in fixed-dose combinations with various PIs.  In this review, we summarize current knowledge of these agents and clin. relevant drug regimens and ongoing trials.  Studies with elvitegravir and the novel PI TMC319011 are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgjPsIIAS3K7Vg90H21EOLACvtfcHk0li9PgRFNViMog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK&md5=b4fe83cebea17842fa9cda633e76ff2e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs40262-014-0167-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-014-0167-9%26sid%3Dliteratum%253Aachs%26aulast%3DLarson%26aufirst%3DK.%2BB.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DDelille%26aufirst%3DC.%26aulast%3DOtofokun%26aufirst%3DI.%26aulast%3DAcosta%26aufirst%3DE.%2BP.%26atitle%3DPharmacokinetic%2520enhancers%2520in%2520HIV%2520therapeutics%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2014%26volume%3D53%26spage%3D865%26epage%3D872%26doi%3D10.1007%2Fs40262-014-0167-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemsek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacArthur, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuritzkes, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M.</span></span> <span> </span><span class="NLM_article-title">Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">1662</span>– <span class="NLM_lpage">1669</span>, <span class="refDoi"> DOI: 10.1056/NEJM199512213332502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJM199512213332502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=7477218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK28XkvFyqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1995&pages=1662-1669&author=J.+J.+Eronauthor=S.+L.+Benoitauthor=J.+Jemsekauthor=R.+D.+MacArthurauthor=J.+Santanaauthor=J.+B.+Quinnauthor=D.+R.+Kuritzkesauthor=M.+A.+Fallonauthor=M.+Rubin&title=Treatment+with+lamivudine%2C+zidovudine%2C+or+both+in+HIV-positive+patients+with+200+to+500+CD4%2B+cells+per+cubic+millimeter&doi=10.1056%2FNEJM199512213332502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter</span></div><div class="casAuthors">Eron, Joseph J.; Benoit, Sharon L.; Jemsek, Joseph; MacArthur, Rodger D.; Santana, Jorge; Quinn, Joseph B.; Kuritzkes, Daniel R.; Fallon, Mary Ann; Rubin, Marc</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1662-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The reverse-transcriptase inhibitor lamivudine has in vitro synergy with zidovudine against the human immunodeficiency virus (HIV).  We studied the activity and safety of lamivudine plus zidovudine as compared with either drug alone as treatment for patients with HIV infection, most of whom had not previously received zidovudine.  Three hundred sixty-six patients with 200 to 500 CD4+ cells per cubic millimeter who had received zidovudine for four wk or less were randomly assigned to treatment with one of four regimens: 300 mg of lamivudine every 12 h; 200 mg of zidovudine every 8 h; 150 mg of lamivudine every 12 h plus zidovudine; or 300 mg of lamivudine every 12 h plus zidovudine.  The study was double-blind and lasted 24 wk, with an extension phase for another 28 wk.  Over the 24-wk period, the low-dose and high-dose regimens combining lamivudine and zidovudine were assocd. with greater increases in the CD4+ cell count (P=0.002 and P=0.015, resp.) and the percentage of CD4+ cells (P<0.001 for both) and with greater decreases in plasma levels of HIV type 1 (HIV-1) RNA (P<0.001 for both) than was treatment with zidovudine alone.  Combination therapy was also more effective than lamivudine alone in lowering plasma HIV-1 RNA levels and increasing the percentage of CD4+ cells (P<0.001 for all comparisons), and these advantages persisted through 52 wk.  Adverse events were not more frequent with combination therapy than with zidovudine along.  In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-yr period and produces more improvement in immunol. and virol. measures than does treatment with either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh794526E5MrVg90H21EOLACvtfcHk0li-gHbHy9cawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvFyqtA%253D%253D&md5=726048170b5d8114da881ba69654cab7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1056%2FNEJM199512213332502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199512213332502%26sid%3Dliteratum%253Aachs%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DBenoit%26aufirst%3DS.%2BL.%26aulast%3DJemsek%26aufirst%3DJ.%26aulast%3DMacArthur%26aufirst%3DR.%2BD.%26aulast%3DSantana%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DJ.%2BB.%26aulast%3DKuritzkes%26aufirst%3DD.%2BR.%26aulast%3DFallon%26aufirst%3DM.%2BA.%26aulast%3DRubin%26aufirst%3DM.%26atitle%3DTreatment%2520with%2520lamivudine%252C%2520zidovudine%252C%2520or%2520both%2520in%2520HIV-positive%2520patients%2520with%2520200%2520to%2520500%2520CD4%252B%2520cells%2520per%2520cubic%2520millimeter%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D333%26spage%3D1662%26epage%3D1669%26doi%3D10.1056%2FNEJM199512213332502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliardini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccarelli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiros Roldan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Ettorre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antinori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orofino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeddu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Pin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Avino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focà, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colafigli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giambenedetto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group">ATLAS-M Study Group</span> <span> </span><span class="NLM_article-title">Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96-week outcomes of a randomized trial</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1955</span>– <span class="NLM_lpage">1964</span>, <span class="refDoi"> DOI: 10.1093/jac/dky123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1093%2Fjac%2Fdky123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29668978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVahtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1955-1964&author=M.+Fabbianiauthor=R.+Gagliardiniauthor=N.+Ciccarelliauthor=E.+Quiros+Roldanauthor=A.+Latiniauthor=G.+d%E2%80%99Ettorreauthor=A.+Antinoriauthor=A.+Castagnaauthor=G.+Orofinoauthor=D.+Francisciauthor=P.+Chinelloauthor=G.+Madedduauthor=P.+Grimaauthor=S.+Rusconiauthor=B.+Del+Pinauthor=F.+Lombardiauthor=A.+D%E2%80%99Avinoauthor=E.+Foc%C3%A0author=M.+Colafigliauthor=R.+Caudaauthor=S.+Di+Giambenedettoauthor=A.+De+Lucaauthor=ATLAS-M+Study+Group&title=Atazanavir%2Fritonavir+with+lamivudine+as+maintenance+therapy+in+virologically+suppressed+HIV-infected+patients%3A+96-week+outcomes+of+a+randomized+trial&doi=10.1093%2Fjac%2Fdky123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial</span></div><div class="casAuthors">Fabbiani, Massimiliano; Gagliardini, Roberta; Ciccarelli, Nicoletta; Roldan, Eugenia Quiros; Latini, Alessandra; D'ettorre, Gabriella; Antinori, Andrea; Castagna, Antonella; Orofino, Giancarlo; Francisci, Daniela; Chinello, Pierangelo; Madeddu, Giordano; Grima, Pierfrancesco; Rusconi, Stefano; Del Pin, Barbara; Lombardi, Francesca; D'avino, Alessandro; Foca, Emanuele; Colafigli, Manuela; Cauda, Roberto; Di Giambenedetto, Simona; De Luca, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1955-1964</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ ritonavir + lamivudine vs. continuing a std. regimen with atazanavir/ritonavir + 2NRTI in virol. suppressed patients.  Methods: ATLAS-M is a 96 wk open-label, randomized, non-inferiority (margin #12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA,50 copies/mL and CD4 counts.200 cells/mm3.  At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir + lamivudine or to continue the previous regimen.  Here, we report the 96 wk efficacy and safety data.  The study was registered with ClinicalTrials.gov, no. NCT01599364.  Results: Overall, 266 subjects were enrolled (133 in each arm).  At 96 wk, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir + lamivudine and 87 (65.4%) with triple therapy (difference +12.0%, 95% CI +1.2/+22.8, P"0.030), demonstrating the superiority of dual therapy.  Two (1.5%) and 9 (6.8%) virol. failures occurred in the dual-therapy arm and the triple-therapy arm, resp., without development of resistance to any study drug.  Clin. adverse events occurred at similar rates in both arms.  A higher frequency of grade 3-4 hyperbilirubinemia (66.9% vs. 50.4%, P"0.006) and hypertriglyceridemia (6.8% vs. 1.5%, P"0.031) occurred with dual therapy, although this never led to treatment discontinuation.  A significant improvement in renal function and lumbar spine bone mineral d. occurred in the dual-therapy arm.  The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms.  Conclusions: In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virol. suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoD8TUq-An7Vg90H21EOLACvtfcHk0li-gHbHy9cawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVahtr4%253D&md5=6e4badb6563dd8e54a6d6c398a42568c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky123%26sid%3Dliteratum%253Aachs%26aulast%3DFabbiani%26aufirst%3DM.%26aulast%3DGagliardini%26aufirst%3DR.%26aulast%3DCiccarelli%26aufirst%3DN.%26aulast%3DQuiros%2BRoldan%26aufirst%3DE.%26aulast%3DLatini%26aufirst%3DA.%26aulast%3Dd%25E2%2580%2599Ettorre%26aufirst%3DG.%26aulast%3DAntinori%26aufirst%3DA.%26aulast%3DCastagna%26aufirst%3DA.%26aulast%3DOrofino%26aufirst%3DG.%26aulast%3DFrancisci%26aufirst%3DD.%26aulast%3DChinello%26aufirst%3DP.%26aulast%3DMadeddu%26aufirst%3DG.%26aulast%3DGrima%26aufirst%3DP.%26aulast%3DRusconi%26aufirst%3DS.%26aulast%3DDel%2BPin%26aufirst%3DB.%26aulast%3DLombardi%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Avino%26aufirst%3DA.%26aulast%3DFoc%25C3%25A0%26aufirst%3DE.%26aulast%3DColafigli%26aufirst%3DM.%26aulast%3DCauda%26aufirst%3DR.%26aulast%3DDi%2BGiambenedetto%26aufirst%3DS.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3D%26atitle%3DAtazanavir%252Fritonavir%2520with%2520lamivudine%2520as%2520maintenance%2520therapy%2520in%2520virologically%2520suppressed%2520HIV-infected%2520patients%253A%252096-week%2520outcomes%2520of%2520a%2520randomized%2520trial%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1955%26epage%3D1964%26doi%3D10.1093%2Fjac%2Fdky123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Emtricitabine: a review of its use in the management of HIV infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1448</span>, <span class="refDoi"> DOI: 10.2165/00003495-200565100-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00003495-200565100-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15977972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFWks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1427-1448&author=J.+E.+Framptonauthor=C.+M.+Perry&title=Emtricitabine%3A+a+review+of+its+use+in+the+management+of+HIV+infection&doi=10.2165%2F00003495-200565100-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Emtricitabine: a review of its use in the management of HIV infection</span></div><div class="casAuthors">Frampton, James E.; Perry, Caroline M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1427-1448</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Emtricitabine (Emtriva) is an orally administered nucleoside reverse transcriptase inhibitor (NRTI) that is indicated in combination with other antiretroviral agents in the treatment of HIV infection in adults.  As a component of antiretroviral therapy (ART), emtricitabine effectively reduces and/or maintains suppression of viral load in ART-naive adults or ART-experienced adults switching from stable combination regimens, and is generally well tolerated.  Emtricitabine is a component of preferred initial HIV combination therapy regimens; it can be used in place of lamivudine as part of the dual NRTI backbone in non-nucleoside reverse transcriptase inhibitor (NNRTI)- and protease inhibitor (PI)-based regimens.  Moreover, preliminary data from a randomized, open-label study suggest that emtricitabine plus tenofovir DF, a preferred dual-NRTI combination, is better tolerated than co-formulated lamivudine/zidovudine, another preferred dual-NRTI combination, resulting in a higher persistent virol. response rate, as analyzed using the US FDA time to loss of virol. response (TLOVR) algorithm.  With the convenience of once-daily (single pill) administration, no dietary restrictions and a favorable drug interaction and tolerability profile, emtricitabine should facilitate patient adherence to treatment, which, in turn, is central to the success of antiretroviral therapy.  Similarly, emtricitabine is attractive as an option for ART-experienced stable adults requiring regimen simplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqixOB__jI7W7Vg90H21EOLACvtfcHk0li-gHbHy9cawg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFWks7k%253D&md5=b70f30dc8cc5fa7f9ce7a10a9db0252d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2165%2F00003495-200565100-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200565100-00008%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DEmtricitabine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520HIV%2520infection%26jtitle%3DDrugs%26date%3D2005%26volume%3D65%26spage%3D1427%26epage%3D1448%26doi%3D10.2165%2F00003495-200565100-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masho, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, D. E.</span></span> <span> </span><span class="NLM_article-title">Review of tenofovir-emtricitabine</span>. <i>Ther. Clin. Risk Manag.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18516268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=1097-1104&author=S.+W.+Mashoauthor=C.-L.+Wangauthor=D.+E.+Nixon&title=Review+of+tenofovir-emtricitabine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Review of tenofovir-emtricitabine</span></div><div class="casAuthors">Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1097-1104</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality.  Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized.  Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations.  In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clin. trials, one-pill-a-day dosing convenience, and relatively low toxicity.  In addn., the drug is active against hepatitis B virus.  Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs.  This manuscript reviews the use of TDF-FTC in the treatment of HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb-BC_sxiqxrVg90H21EOLACvtfcHk0lie4qYxxlSfPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOks74%253D&md5=bcfad153d98a241a89b9d643d3ddbf37</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasho%26aufirst%3DS.%2BW.%26aulast%3DWang%26aufirst%3DC.-L.%26aulast%3DNixon%26aufirst%3DD.%2BE.%26atitle%3DReview%2520of%2520tenofovir-emtricitabine%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manag.%26date%3D2007%26volume%3D3%26spage%3D1097%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trustman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalong, A.</span></span> <span> </span><span class="NLM_article-title">HIV pharmacotherapy: A review of integrase inhibitors</span>. <i>JAAPA</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1097/01.JAA.0000475465.07971.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2F01.JAA.0000475465.07971.19" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=36-40&author=E.+Wongauthor=N.+Trustmanauthor=A.+Yalong&title=HIV+pharmacotherapy%3A+A+review+of+integrase+inhibitors&doi=10.1097%2F01.JAA.0000475465.07971.19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1097%2F01.JAA.0000475465.07971.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.JAA.0000475465.07971.19%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DE.%26aulast%3DTrustman%26aufirst%3DN.%26aulast%3DYalong%26aufirst%3DA.%26atitle%3DHIV%2520pharmacotherapy%253A%2520A%2520review%2520of%2520integrase%2520inhibitors%26jtitle%3DJAAPA%26date%3D2016%26volume%3D29%26spage%3D36%26epage%3D40%26doi%3D10.1097%2F01.JAA.0000475465.07971.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedziela-Majka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukolj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7086</span>– <span class="NLM_lpage">7097</span>, <span class="refDoi"> DOI: 10.1128/AAC.01474-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1128%2FAAC.01474-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=27645238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=7086-7097&author=M.+Tsiangauthor=G.+S.+Jonesauthor=J.+Goldsmithauthor=A.+Mulatoauthor=D.+Hansenauthor=E.+Kanauthor=L.+Tsaiauthor=R.+A.+Bamauthor=G.+Stepanauthor=K.+M.+Strayauthor=A.+Niedziela-Majkaauthor=S.+R.+Yantauthor=H.+Yuauthor=G.+Kukoljauthor=T.+Cihlarauthor=S.+E.+Lazerwithauthor=K.+L.+Whiteauthor=H.+Jin&title=Antiviral+activity+of+bictegravir+%28GS-9883%29%2C+a+novel+potent+HIV-1+integrase+strand+transfer+inhibitor+with+an+improved+resistance+profile&doi=10.1128%2FAAC.01474-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile</span></div><div class="casAuthors">Tsiang, Manuel; Jones, Gregg S.; Goldsmith, Joshua; Mulato, Andrew; Hansen, Derek; Kan, Elaine; Tsai, Luong; Bam, Rujuta A.; Stepan, George; Stray, Kirsten M.; Niedziela-Majka, Anita; Yant, Stephen R.; Yu, Helen; Kukolj, George; Cihlar, Tomas; Lazerwith, Scott E.; White, Kirsten L.; Jin, Haolun</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7086-7097</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concn. [IC50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells.  BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concns. ranging from 1.5 to 2.4 nM and selectivity indexes up to 8,700 relative to cytotoxicity.  BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals.  BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants.  BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with highlevel INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG.  In dose-escalation expts. conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, resp.  A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus.  All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals.  A high barrier to in vitro resistance emergence for both BIC and DTG was also obsd. in viral breakthrough studies in the presence of const. clin. relevant drug concns.  The overall virol. profile of BIC supports its ongoing clin. investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC24EKhD8sNbVg90H21EOLACvtfcHk0lie4qYxxlSfPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D&md5=87a180a313ffaa8b03201b06a8c875ff</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FAAC.01474-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01474-16%26sid%3Dliteratum%253Aachs%26aulast%3DTsiang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DG.%2BS.%26aulast%3DGoldsmith%26aufirst%3DJ.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DHansen%26aufirst%3DD.%26aulast%3DKan%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DJin%26aufirst%3DH.%26atitle%3DAntiviral%2520activity%2520of%2520bictegravir%2520%2528GS-9883%2529%252C%2520a%2520novel%2520potent%2520HIV-1%2520integrase%2520strand%2520transfer%2520inhibitor%2520with%2520an%2520improved%2520resistance%2520profile%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D7086%26epage%3D7097%26doi%3D10.1128%2FAAC.01474-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0160-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40265-013-0160-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24343782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=195-206&author=E.+D.+Deeks&title=Cobicistat%3A+a+review+of+its+use+as+a+pharmacokinetic+enhancer+of+atazanavir+and+darunavir+in+patients+with+HIV-1+infection&doi=10.1007%2Fs40265-013-0160-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Cobicistat (Tybost®) is a mechanism-based inhibitor of cytochrome P 450 (CYP) 3A enzymes that is indicated in the EU as a pharmacokinetic enhancer (i.e. booster) of the HIV-1 protease inhibitors (PIs) atazanavir and darunavir in adults.  Cobicistat has a lower potential for off-target drug interactions than the std. boosting agent ritonavir, due to its more selective inhibition of CYP3A and lower likelihood for enzymic induction, and is devoid of anti-HIV activity.  When used to boost darunavir or atazanavir in healthy volunteers, oral cobicistat 150 mg once daily provided bioequivalent PI exposure to that seen with oral ritonavir 100 mg once daily (i.e. low-dose ritonavir).  Moreover, in treatment-naive adults infected with HIV-1 participating in a large, double-blind, phase III trial, an atazanavir-based antiretroviral regimen boosted with cobicistat 150 mg once daily provided a high rate of virol. suppression after 48 wk of therapy that was noninferior to that seen with low-dose ritonavir boosting.  Cobicistat was generally well tolerated in this study, with a tolerability profile similar to that of ritonavir.  Cobicistat may increase serum creatinine levels (possibly via inhibition of proximal renal tubular cell transporters) and thus reduce estd. glomerular filtration rate (GFR), although it does not appear to affect actual GFR.  The drug is more sol. than ritonavir, making coformulation easier, and fixed-dose formulations combining cobicistat with darunavir and atazanavir are in development.  Thus, cobicistat is an emerging alternative to ritonavir for the pharmacokinetic enhancement of PIs in adults with HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk_LsSZwyKR7Vg90H21EOLACvtfcHk0lie4qYxxlSfPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7k%253D&md5=f121c1314a97499f723b7bc22642854d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0160-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0160-x%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DCobicistat%253A%2520a%2520review%2520of%2520its%2520use%2520as%2520a%2520pharmacokinetic%2520enhancer%2520of%2520atazanavir%2520and%2520darunavir%2520in%2520patients%2520with%2520HIV-1%2520infection%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D195%26epage%3D206%26doi%3D10.1007%2Fs40265-013-0160-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fares, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNicolantonio, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Keefe, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavie, C. J.</span></span> <span> </span><span class="NLM_article-title">Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes</span>. <i>Open Heart.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e000473</span> 1–7. <span class="refDoi"> DOI: 10.1136/openhrt-2016-000473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1136%2Fopenhrt-2016-000473" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&author=H.+Faresauthor=J.+J.+DiNicolantonioauthor=J.+H.+O%E2%80%99Keefeauthor=C.+J.+Lavie&title=Amlodipine+in+hypertension%3A+a+first-line+agent+with+efficacy+for+improving+blood+pressure+and+patient+outcomes&doi=10.1136%2Fopenhrt-2016-000473"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fopenhrt-2016-000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fopenhrt-2016-000473%26sid%3Dliteratum%253Aachs%26aulast%3DFares%26aufirst%3DH.%26aulast%3DDiNicolantonio%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DJ.%2BH.%26aulast%3DLavie%26aufirst%3DC.%2BJ.%26atitle%3DAmlodipine%2520in%2520hypertension%253A%2520a%2520first-line%2520agent%2520with%2520efficacy%2520for%2520improving%2520blood%2520pressure%2520and%2520patient%2520outcomes%26jtitle%3DOpen%2520Heart.%26date%3D2016%26volume%3D3%26doi%3D10.1136%2Fopenhrt-2016-000473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noji-Sakikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshigae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">11892</span>– <span class="NLM_lpage">11902</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.072629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1074%2Fjbc.M109.072629" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=11892-11902&author=T.+Ishizukaauthor=I.+Fujimoriauthor=M.+Katoauthor=C.+Noji-Sakikawaauthor=M.+Saitoauthor=Y.+Yoshigaeauthor=K.+Kubotaauthor=A.+Kuriharaauthor=T.+Izumiauthor=T.+Ikedaauthor=O.+Okazaki&title=Human+carboxymethylenebutenolidase+as+a+bioactivating+hydrolase+of+olmesartan+medoxomil+in+liver+and+intestine&doi=10.1074%2Fjbc.M109.072629"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.072629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.072629%26sid%3Dliteratum%253Aachs%26aulast%3DIshizuka%26aufirst%3DT.%26aulast%3DFujimori%26aufirst%3DI.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DNoji-Sakikawa%26aufirst%3DC.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DYoshigae%26aufirst%3DY.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DIzumi%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DHuman%2520carboxymethylenebutenolidase%2520as%2520a%2520bioactivating%2520hydrolase%2520of%2520olmesartan%2520medoxomil%2520in%2520liver%2520and%2520intestine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D11892%26epage%3D11902%26doi%3D10.1074%2Fjbc.M109.072629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zisaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskovic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzimanikatis, V.</span></span> <span> </span><span class="NLM_article-title">Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.2174/1381612820666141024151119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2174%2F1381612820666141024151119" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=806-822&author=A.+Zisakiauthor=L.+Miskovicauthor=V.+Hatzimanikatis&title=Antihypertensive+drugs+metabolism%3A+an+update+to+pharmacokinetic+profiles+and+computational+approaches&doi=10.2174%2F1381612820666141024151119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F1381612820666141024151119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612820666141024151119%26sid%3Dliteratum%253Aachs%26aulast%3DZisaki%26aufirst%3DA.%26aulast%3DMiskovic%26aufirst%3DL.%26aulast%3DHatzimanikatis%26aufirst%3DV.%26atitle%3DAntihypertensive%2520drugs%2520metabolism%253A%2520an%2520update%2520to%2520pharmacokinetic%2520profiles%2520and%2520computational%2520approaches%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D806%26epage%3D822%26doi%3D10.2174%2F1381612820666141024151119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waksman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechevalier, H. A.</span></span> <span> </span><span class="NLM_article-title">Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1126/science.109.2830.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1126%2Fscience.109.2830.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17782716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3czot1Siuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1949&pages=305-307&author=S.+A.+Waksmanauthor=H.+A.+Lechevalier&title=Neomycin%2C+a+new+antibiotic+active+against+streptomycin-resistant+bacteria%2C+including+tuberculosis+organisms&doi=10.1126%2Fscience.109.2830.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis Organisms</span></div><div class="casAuthors">Waksman S A; Lechevalier H A</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2830</span>),
    <span class="NLM_cas:pages">305-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyhgjk39aGkz69zv1FsJFMfW6udTcc2eZQJppnGc83cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czot1Siuw%253D%253D&md5=79ba78fd176e4ff2ce148b9198b2070d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1126%2Fscience.109.2830.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.109.2830.305%26sid%3Dliteratum%253Aachs%26aulast%3DWaksman%26aufirst%3DS.%2BA.%26aulast%3DLechevalier%26aufirst%3DH.%2BA.%26atitle%3DNeomycin%252C%2520a%2520new%2520antibiotic%2520active%2520against%2520streptomycin-resistant%2520bacteria%252C%2520including%2520tuberculosis%2520organisms%26jtitle%3DScience%26date%3D1949%26volume%3D109%26spage%3D305%26epage%3D307%26doi%3D10.1126%2Fscience.109.2830.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M.</span></span> <span> </span><span class="NLM_article-title">Neomycin: a review with particular reference to dermatological usage</span>. <i>Clin. Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2230.1983.tb01777.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1365-2230.1983.tb01777.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=6224608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaL3s3os1Siug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1983&pages=249-258&author=R.+H.+Macdonaldauthor=M.+Beck&title=Neomycin%3A+a+review+with+particular+reference+to+dermatological+usage&doi=10.1111%2Fj.1365-2230.1983.tb01777.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Neomycin: a review with particular reference to dermatological usage</span></div><div class="casAuthors">Macdonald R H; Beck M</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental dermatology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-58</span>
        ISSN:<span class="NLM_cas:issn">0307-6938</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFYJm8BeTjdXl8icjszYl0fW6udTcc2eZQJppnGc83cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s3os1Siug%253D%253D&md5=4f622e254683ed8dddc97352092f1b88</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2230.1983.tb01777.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2230.1983.tb01777.x%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DR.%2BH.%26aulast%3DBeck%26aufirst%3DM.%26atitle%3DNeomycin%253A%2520a%2520review%2520with%2520particular%2520reference%2520to%2520dermatological%2520usage%26jtitle%3DClin.%2520Exp.%2520Dermatol.%26date%3D1983%26volume%3D8%26spage%3D249%26epage%3D258%26doi%3D10.1111%2Fj.1365-2230.1983.tb01777.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, A.</span></span> <span> </span><span class="NLM_article-title">Colistin and polymyxin B: a re-emergence</span>. <i>Indian J. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.4103/0972-5229.56048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4103%2F0972-5229.56048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19881183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjtFCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=49-53&author=S.+Guptaauthor=D.+Govilauthor=P.+N.+Kakarauthor=O.+Prakashauthor=D.+Aroraauthor=S.+Dasauthor=P.+Govilauthor=A.+Malhotra&title=Colistin+and+polymyxin+B%3A+a+re-emergence&doi=10.4103%2F0972-5229.56048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Colistin and polymyxin B: a re-emergence</span></div><div class="casAuthors">Gupta Sachin; Govil Deepak; Kakar Prem N; Prakash Om; Arora Deep; Das Shibani; Govil Pradeep; Malhotra Ashima</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">49-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the greatest achievements of modern medicine is the development of antibiotics against life-threatening infections, but the emergence of multidrug-resistant (MDR) gram negative bacteria has drastically narrowed down the therapeutic options against them.  This limitation has led clinicians to reappraise the clinical application of polymyxins, an old class of cationic, cyclic polypeptide antibiotics.  Polymyxins are active against selected gram-negative bacteria, including the Acinetobacter species, Pseudomonas aeruginosa, Klebsiella species, and Enterobacter species.  In this article, we summarise the chemistry, pharmacokinetics, and pharmacodynamics of polymyxins and the latest understanding of their action against MDR pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfDfCQOJlejQaK-_ZudimnfW6udTcc2eaYImOsctHH_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjtFCmtQ%253D%253D&md5=0ba8fd42636548f144f967d13b6f1c66</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4103%2F0972-5229.56048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0972-5229.56048%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGovil%26aufirst%3DD.%26aulast%3DKakar%26aufirst%3DP.%2BN.%26aulast%3DPrakash%26aufirst%3DO.%26aulast%3DArora%26aufirst%3DD.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DGovil%26aufirst%3DP.%26aulast%3DMalhotra%26aufirst%3DA.%26atitle%3DColistin%2520and%2520polymyxin%2520B%253A%2520a%2520re-emergence%26jtitle%3DIndian%2520J.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D13%26spage%3D49%26epage%3D53%26doi%3D10.4103%2F0972-5229.56048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleney, F. L.</span></span> <span> </span><span class="NLM_article-title">Bacitracin: a new antibiotic produced by a member of the B. Subtilis group</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1945</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1126/science.102.2650.376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1126%2Fscience.102.2650.376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17770204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3czotFCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1945&pages=376-377&author=B.+A.+Johnsonauthor=H.+Ankerauthor=F.+L.+Meleney&title=Bacitracin%3A+a+new+antibiotic+produced+by+a+member+of+the+B.+Subtilis+group&doi=10.1126%2Fscience.102.2650.376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">BACITRACIN: A NEW ANTIBIOTIC PRODUCED BY A MEMBER OF THE B. SUBTILIS GROUP</span></div><div class="casAuthors">Johnson B A; Anker H; Meleney F L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1945</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2650</span>),
    <span class="NLM_cas:pages">376-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A new antibiotic "bacitracin" has been recovered from a strain of the B. subtilis group of organisms.  It is neutral, water-soluble, non-toxic and relatively heat stable.  In vitro it is active chiefly against Grampositive organisms, but the gonococcus and meningococcus are susceptible to its action.  It is also active in vivo against experimentally produced hemolytic streptococcal infections in mice and gas gangrene infections in guinea pigs.  Clinical use in hemolytic streptococcal and staphylococcal infections in man have given encouraging results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv92foddKM1uR_TJajKxJDfW6udTcc2eaYImOsctHH_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czotFCgsg%253D%253D&md5=eca1cdcf3accb83fc025be2cf446e3e0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.102.2650.376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.102.2650.376%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BA.%26aulast%3DAnker%26aufirst%3DH.%26aulast%3DMeleney%26aufirst%3DF.%2BL.%26atitle%3DBacitracin%253A%2520a%2520new%2520antibiotic%2520produced%2520by%2520a%2520member%2520of%2520the%2520B.%2520Subtilis%2520group%26jtitle%3DScience%26date%3D1945%26volume%3D102%26spage%3D376%26epage%3D377%26doi%3D10.1126%2Fscience.102.2650.376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenhouse, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryle, W. C.</span></span> <span> </span><span class="NLM_article-title">Combined bacitracin-neomycin ointment in treatment of pyogenic infections of the skin</span>. <i>Arch. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1954</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1001/archderm.1954.01540150112012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1001%2Farchderm.1954.01540150112012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaG2c%252FlslCqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1954&pages=366-367&author=J.+M.+Greenhouseauthor=W.+C.+Ryle&title=Combined+bacitracin-neomycin+ointment+in+treatment+of+pyogenic+infections+of+the+skin&doi=10.1001%2Farchderm.1954.01540150112012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Combined bacitracin-neomycin ointment in treatment of pyogenic infections of the skin</span></div><div class="casAuthors">GREENHOUSE J M; RYLE W C</div><div class="citationInfo"><span class="NLM_cas:title">A.M.A. archives of dermatology and syphilology</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-7</span>
        ISSN:<span class="NLM_cas:issn">0096-5979</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyVeE8YxaahVQKX3ooHxWjfW6udTcc2eaYImOsctHH_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG2c%252FlslCqtQ%253D%253D&md5=fc87c2b0bf724c481c16c398e7329baa</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1001%2Farchderm.1954.01540150112012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchderm.1954.01540150112012%26sid%3Dliteratum%253Aachs%26aulast%3DGreenhouse%26aufirst%3DJ.%2BM.%26aulast%3DRyle%26aufirst%3DW.%2BC.%26atitle%3DCombined%2520bacitracin-neomycin%2520ointment%2520in%2520treatment%2520of%2520pyogenic%2520infections%2520of%2520the%2520skin%26jtitle%3DArch.%2520Dermatol.%26date%3D1954%26volume%3D69%26spage%3D366%26epage%3D367%26doi%3D10.1001%2Farchderm.1954.01540150112012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubos, R. J.</span></span> <span> </span><span class="NLM_article-title">Studies on a bactericidal agent extracted from a soil bacillus: I. preparation of the agent. its activity in vitro</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1939</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1084/jem.70.1.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1084%2Fjem.70.1.1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1939&pages=1-10&author=R.+J.+Dubos&title=Studies+on+a+bactericidal+agent+extracted+from+a+soil+bacillus%3A+I.+preparation+of+the+agent.+its+activity+in+vitro&doi=10.1084%2Fjem.70.1.1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1084%2Fjem.70.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.70.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DDubos%26aufirst%3DR.%2BJ.%26atitle%3DStudies%2520on%2520a%2520bactericidal%2520agent%2520extracted%2520from%2520a%2520soil%2520bacillus%253A%2520I.%2520preparation%2520of%2520the%2520agent.%2520its%2520activity%2520in%2520vitro%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1939%26volume%3D70%26spage%3D1%26epage%3D10%26doi%3D10.1084%2Fjem.70.1.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubos, R. J.</span></span> <span> </span><span class="NLM_article-title">Studies on a bactericidal agent extracted from a soil bacillus: ii. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1939</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1084/jem.70.1.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1084%2Fjem.70.1.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19870886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaA1MXkvValsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1939&pages=11-17&author=R.+J.+Dubos&title=Studies+on+a+bactericidal+agent+extracted+from+a+soil+bacillus%3A+ii.+Protective+effect+of+the+bactericidal+agent+against+experimental+pneumococcus+infections+in+mice&doi=10.1084%2Fjem.70.1.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal agent extracted from a soil bacillus. II. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice</span></div><div class="casAuthors">Dubos, Rene J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1939</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-17</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">The above agent protects white mice against infection with large nos. of virulent pneumococci.  It is entirely ineffective against infection with virulent Friedl.ovrddot.ander bacilli (type B).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2oofuj2RNHLVg90H21EOLACvtfcHk0lgmfJYiQ4PygQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA1MXkvValsg%253D%253D&md5=cc1b9441299395a514268e2451957aaf</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1084%2Fjem.70.1.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.70.1.11%26sid%3Dliteratum%253Aachs%26aulast%3DDubos%26aufirst%3DR.%2BJ.%26atitle%3DStudies%2520on%2520a%2520bactericidal%2520agent%2520extracted%2520from%2520a%2520soil%2520bacillus%253A%2520ii.%2520Protective%2520effect%2520of%2520the%2520bactericidal%2520agent%2520against%2520experimental%2520pneumococcus%2520infections%2520in%2520mice%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1939%26volume%3D70%26spage%3D11%26epage%3D17%26doi%3D10.1084%2Fjem.70.1.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macander, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulitta, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, B. T.</span></span> <span> </span><span class="NLM_article-title">Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing</span>. <i>Pharmacotherapy.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1291</span>, <span class="refDoi"> DOI: 10.1592/phco.30.12.1279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1592%2Fphco.30.12.1279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21114395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1emsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=1279-1291&author=L.+M.+Limauthor=N.+Lyauthor=D.+Andersonauthor=J.+C.+Yangauthor=L.+Macanderauthor=A.+Jarkowskiauthor=A.+Forrestauthor=J.+B.+Bulittaauthor=B.+T.+Tsuji&title=Resurgence+of+colistin%3A+a+review+of+resistance%2C+toxicity%2C+pharmacodynamics%2C+and+dosing&doi=10.1592%2Fphco.30.12.1279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing</span></div><div class="casAuthors">Lim, Lauren M.; Ly, Neang; Anderson, Dana; Yang, Jenny C.; Macander, Laurie; Jarkowski, Anthony, III; Forrest, Alan; Bulitta, Jurgen B.; Tsuji, Brian T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1279-1291</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    
            (<span class="NLM_cas:orgname">Pharmacotherapy Publications</span>)
        </div><div class="casAbstract">A review.  Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of gram-neg. infections.  After several years of clin. use, its popularity diminished because of reports of significant nephrotoxicity and neurotoxicity.  Recently, the antibiotic has resurfaced as a last-line treatment option for multidrug-resistant organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.  The need for antibiotics with coverage of these gram-neg. pathogens is crit. because of their high morbidity and mortality, making colistin a very important treatment option.  Unfortunately, however, resistance to colistin has been documented among all three of these organisms in case reports.  Although the exact mechanism causing colistin resistance has not been defined, it is hypothesized that the PmrA-PmrB and PhoP-PhoQ genetic regulatory systems may play a role.  Colistin dosages must be optimized, as colistin is a last-line treatment option; in addn., suboptimal doses have been linked to the development of resistance.  The lack of pharmacokinetic and pharmacodynamic studies and no universal harmonization of dose units, however, have made it difficult to derive optimal dosing regimens and specific dosing guidelines for colistin.  In critically ill patients who may have multiorgan failure, renal insufficiency may alter colistin pharmacokinetics.  Therefore, dosage alterations in this patient population are imperative to achieve maximal efficacy and minimal toxicity With regard to colistin toxicity, most studies show that nephrotoxicity is reversible and less frequent than once thought, and neurotoxicity is rare.  Further research is needed to fully understand the impact that the two regulatory systems have on resistance, as well as the dosages of colistin needed to inhibit and overcome these developing patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopU7sumZvnMbVg90H21EOLACvtfcHk0lgmfJYiQ4PygQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1emsbrO&md5=8659470ab8d9c8d95c82faf5fb9e624d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1592%2Fphco.30.12.1279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1592%252Fphco.30.12.1279%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DL.%2BM.%26aulast%3DLy%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DMacander%26aufirst%3DL.%26aulast%3DJarkowski%26aufirst%3DA.%26aulast%3DForrest%26aufirst%3DA.%26aulast%3DBulitta%26aufirst%3DJ.%2BB.%26aulast%3DTsuji%26aufirst%3DB.%2BT.%26atitle%3DResurgence%2520of%2520colistin%253A%2520a%2520review%2520of%2520resistance%252C%2520toxicity%252C%2520pharmacodynamics%252C%2520and%2520dosing%26jtitle%3DPharmacotherapy.%26date%3D2010%26volume%3D30%26spage%3D1279%26epage%3D1291%26doi%3D10.1592%2Fphco.30.12.1279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podolsky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. A.</span></span> <span> </span><span class="NLM_article-title">Combination drugs — hype, harm, and hope</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1106161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMp1106161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21830965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVars7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=488-491&author=S.+H.+Podolskyauthor=J.+A.+Greene&title=Combination+drugs+%E2%80%94+hype%2C+harm%2C+and+hope&doi=10.1056%2FNEJMp1106161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: combination drugs - hype, Harm and hope</span></div><div class="casAuthors">Podolsky, Scott H.; Greene, Jeremy A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-491</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKfDYCjD5hPbVg90H21EOLACvtfcHk0lgmfJYiQ4PygQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVars7jL&md5=c6dd3d4479c1af1400675e9a9769d14b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1106161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1106161%26sid%3Dliteratum%253Aachs%26aulast%3DPodolsky%26aufirst%3DS.%2BH.%26aulast%3DGreene%26aufirst%3DJ.%2BA.%26atitle%3DCombination%2520drugs%2520%25E2%2580%2594%2520hype%252C%2520harm%252C%2520and%2520hope%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D488%26epage%3D491%26doi%3D10.1056%2FNEJMp1106161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clissold, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campoli-Richards, D. M.</span></span> <span> </span><span class="NLM_article-title">Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.2165/00003495-198733030-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00003495-198733030-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=3552595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaL2sXitVOjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1987&pages=183-241&author=S.+P.+Clissoldauthor=P.+A.+Toddauthor=D.+M.+Campoli-Richards&title=Imipenem%2Fcilastatin.+A+review+of+its+antibacterial+activity%2C+pharmacokinetic+properties+and+therapeutic+efficacy&doi=10.2165%2F00003495-198733030-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Imipenem/cilastatin.  A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy</span></div><div class="casAuthors">Clissold, Stephen P.; Todd, Peter A.; Campoli-Richards, Deborah M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-241</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with ∼360 refs. of the in vitro antibacterial activity and pharmacokinetics and therapeutic efficacy in humans and lab. animals of the imipenem-cilastatin mixt.  [85960-17-4].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9NRLX4pcDiLVg90H21EOLACvtfcHk0lgmfJYiQ4PygQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXitVOjsbs%253D&md5=0774ce138bf7c6791b3e88bd187c4113</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2165%2F00003495-198733030-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198733030-00001%26sid%3Dliteratum%253Aachs%26aulast%3DClissold%26aufirst%3DS.%2BP.%26aulast%3DTodd%26aufirst%3DP.%2BA.%26aulast%3DCampoli-Richards%26aufirst%3DD.%2BM.%26atitle%3DImipenem%252Fcilastatin.%2520A%2520review%2520of%2520its%2520antibacterial%2520activity%252C%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%26jtitle%3DDrugs%26date%3D1987%26volume%3D33%26spage%3D183%26epage%3D241%26doi%3D10.2165%2F00003495-198733030-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deretic, V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of action of isoniazid</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1220</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2958.2006.05467.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fj.1365-2958.2006.05467.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17074073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlenu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=1220-1227&author=G.+S.+Timminsauthor=V.+Deretic&title=Mechanisms+of+action+of+isoniazid&doi=10.1111%2Fj.1365-2958.2006.05467.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of action of isoniazid</span></div><div class="casAuthors">Timmins, Graham S.; Deretic, Vojo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1220-1227</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  For decades after its introduction, the mechanisms of action of the front-line antituberculosis therapeutic agent isoniazid (INH) remained unclear.  Recent developments have shown that peroxidative activation of isoniazid by the mycobacterial enzyme KatG generates reactive species that form adducts with NAD+ and NADP+ that are potent inhibitors of lipid and nucleic acid biosynthetic enzymes.  A direct role for some isoniazid-derived reactive species, such as nitric oxide, in inhibiting mycobacterial metabolic enzymes has also been shown.  The concerted effects of these activities - inhibition of cell wall lipid synthesis, depletion of nucleic acid pools and metabolic depression - drive the exquisite potency and selectivity of this agent.  To understand INH action and resistance fully, a synthesis of knowledge is required from multiple sep. lines of research - including mol. genetic approaches, in vitro biochem. studies and free radical chem. - which is the intent of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq9OybVddk-rVg90H21EOLACvtfcHk0lhhrGnaFmbRaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlenu7jE&md5=fbc095f0f79cd443b55d54c19b36f932</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2958.2006.05467.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2958.2006.05467.x%26sid%3Dliteratum%253Aachs%26aulast%3DTimmins%26aufirst%3DG.%2BS.%26aulast%3DDeretic%26aufirst%3DV.%26atitle%3DMechanisms%2520of%2520action%2520of%2520isoniazid%26jtitle%3DMol.%2520Microbiol.%26date%3D2006%26volume%3D62%26spage%3D1220%26epage%3D1227%26doi%3D10.1111%2Fj.1365-2958.2006.05467.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio-Aparicio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>, <span class="NLM_elocation-id">e01443-17</span> <span class="refDoi"> DOI: 10.1128/AAC.01443-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1128%2FAAC.01443-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28848018" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&author=O.+Lomovskayaauthor=D.+Sunauthor=D.+Rubio-Aparicioauthor=K.+Nelsonauthor=R.+Tsivkovskiauthor=D.+C.+Griffithauthor=M.+N.+Dudley&title=Vaborbactam%3A+spectrum+of+beta-lactamase+inhibition+and+impact+of+resistance+mechanisms+on+activity+in+enterobacteriaceae&doi=10.1128%2FAAC.01443-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.01443-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01443-17%26sid%3Dliteratum%253Aachs%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DRubio-Aparicio%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DK.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DVaborbactam%253A%2520spectrum%2520of%2520beta-lactamase%2520inhibition%2520and%2520impact%2520of%2520resistance%2520mechanisms%2520on%2520activity%2520in%2520enterobacteriaceae%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26doi%3D10.1128%2FAAC.01443-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denisuik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0013-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40265-013-0013-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23371303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWms7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=159-77&author=G.+G.+Zhanelauthor=C.+D.+Lawsonauthor=H.+Adamauthor=F.+Schweizerauthor=S.+Zelenitskyauthor=P.+R.+Lagace-Wiensauthor=A.+Denisuikauthor=E.+Rubinsteinauthor=A.+S.+Ginauthor=D.+J.+Hobanauthor=J.+P.+Lynchauthor=J.+A.+Karlowsky&title=Ceftazidime-avibactam%3A+a+novel+cephalosporin%2Fbeta-lactamase+inhibitor+combination&doi=10.1007%2Fs40265-013-0013-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination</span></div><div class="casAuthors">Zhanel, George G.; Lawson, Christopher D.; Adam, Heather; Schweizer, Frank; Zelenitsky, Sheryl; Lagace-Wiens, Philippe R. S.; Denisuik, Andrew; Rubinstein, Ethan; Gin, Alfred S.; Hoban, Daryl J.; Lynch, Joseph P., 3rd; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-177</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.  This review summarizes the existing data published for ceftazidime-avibactam, including relevant chem., mechanisms of action and resistance, microbiol., pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials.  Although not a β-lactam, the chem. structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to β-lactamases.  Very little is known about the potential for avibactam to select for resistance.  The addn. of avibactam greatly (4-1024-fold min. inhibitory concn. [MIC] redn.) improves the activity of ceftazidime vs. most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzyme(s).  Against Pseudomonas aeruginosa, the addn. of avibactam also improves the activity of ceftazidime (∼fourfold MIC redn.).  Limited data suggest that the addn. of avibactam does not improve the activity of ceftazidime vs. Acinetobacter species or most anaerobic bacteria (exceptions: Bacteroides fragilis, Clostridium perfringens, Prevotella spp. and Porphyromonas spp.).  The pharmacokinetics of avibactam follow a two-compartment model and do not appear to be altered by the co-administration of ceftazidime.  The max. plasma drug concn. (Cmax) and area under the plasma concn.-time curve (AUC) of avibactam increase linearly with doses ranging from 50 mg to 2,000 mg.  The mean vol. of distribution and half-life of 22 L (∼0.3 L/kg) and ∼2 h, resp., are similar to ceftazidime.  Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance.  Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal vs. β-lactamase-producing Gram-neg. bacilli that are not inhibited by ceftazidime alone.  Clin. trials to date have reported that ceftazidime-avibactam is as effective as std. carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-neg. isolates.  The safety and tolerability of ceftazidime-avibactam has been reported in three phase I pharmacokinetic studies and two phase II clin. studies.  Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.  In conclusion, avibactam serves to broaden the spectrum of ceftazidime vs. ss-lactamase-producing Gram-neg. bacilli.  The exact roles for ceftazidime-avibactam will be defined by efficacy and safety data from further clin. trials.  Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-neg.-bacilli producing extended-spectrum ss-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ss-lactamases.  In addn., ceftazidime-avibactam may be used in combination (with metronidazole) for suspected polymicrobial infections.  Finally, the increased activity of ceftazidime-avibactam vs. P. aeruginosa may be of clin. benefit in patients with suspected or documented P. aeruginosa infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6FoMOMncBbVg90H21EOLACvtfcHk0lhhrGnaFmbRaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWms7zO&md5=29776a4dd902a5e75f1971270fa545a5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0013-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0013-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DLawson%26aufirst%3DC.%2BD.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%26aulast%3DDenisuik%26aufirst%3DA.%26aulast%3DRubinstein%26aufirst%3DE.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DCeftazidime-avibactam%253A%2520a%2520novel%2520cephalosporin%252Fbeta-lactamase%2520inhibitor%2520combination%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D159%26epage%3D77%26doi%3D10.1007%2Fs40265-013-0013-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span> <span> </span><span class="NLM_article-title">Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors</span>. <i>Curr. Opin. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1016/j.mib.2011.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.mib.2011.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21840248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlCntrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=550-555&author=K.+Coleman&title=Diazabicyclooctanes+%28DBOs%29%3A+a+potent+new+class+of+non-%CE%B2-lactam+%CE%B2-lactamase+inhibitors&doi=10.1016%2Fj.mib.2011.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors</span></div><div class="casAuthors">Coleman, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-555</span>CODEN:
                <span class="NLM_cas:coden">COMIF7</span>;
        ISSN:<span class="NLM_cas:issn">1369-5274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The β-lactams have been among the most successful classes of antibacterial agents for the past half century.  However, a disturbing increase in resistance to β-lactams has been noted among Gram-neg. bacteria, which is attributable to β-lactamase enzymes not within the spectrum of currently marketed β-lactams or β-lactam/β-lactamase inhibitor combinations.  Diazabicyclooctanes (DBOs) were first investigated as β-lactam mimics in the mid-1990s by chemists at Hoechst Marion Roussel (now part of Sanofi-Aventis) and proved to be a rich source of β-lactamase inhibitors (BLI).  Two members of this novel series of highly potent, broad spectrum BLIs are now in clin. development and their properties are reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpneNkuutLgqrVg90H21EOLACvtfcHk0lhhrGnaFmbRaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlCntrjN&md5=0aafa5daac59fc737d464d7a7b637b2c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.mib.2011.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mib.2011.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DK.%26atitle%3DDiazabicyclooctanes%2520%2528DBOs%2529%253A%2520a%2520potent%2520new%2520class%2520of%2520non-%25CE%25B2-lactam%2520%25CE%25B2-lactamase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Microbiol.%26date%3D2011%26volume%3D14%26spage%3D550%26epage%3D555%26doi%3D10.1016%2Fj.mib.2011.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span> <span> </span><span class="NLM_article-title">Avibactam and class c β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5704</span>– <span class="NLM_lpage">5713</span>, <span class="refDoi"> DOI: 10.1128/AAC.03057-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1128%2FAAC.03057-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5704-5713&author=S.+D.+Lahiriauthor=M.+R.+Johnstoneauthor=P.+L.+Rossauthor=R.+E.+McLaughlinauthor=N.+B.+Olivierauthor=R.+A.+Alm&title=Avibactam+and+class+c+%CE%B2-lactamases%3A+mechanism+of+inhibition%2C+conservation+of+the+binding+pocket%2C+and+implications+for+resistance&doi=10.1128%2FAAC.03057-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FAAC.03057-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03057-14%26sid%3Dliteratum%253Aachs%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DJohnstone%26aufirst%3DM.%2BR.%26aulast%3DRoss%26aufirst%3DP.%2BL.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DOlivier%26aufirst%3DN.%2BB.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26atitle%3DAvibactam%2520and%2520class%2520c%2520%25CE%25B2-lactamases%253A%2520mechanism%2520of%2520inhibition%252C%2520conservation%2520of%2520the%2520binding%2520pocket%252C%2520and%2520implications%2520for%2520resistance%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5704%26epage%3D5713%26doi%3D10.1128%2FAAC.03057-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, P.</span></span> <span> </span><span class="NLM_article-title">Not boring at all. Boron is the new carbon in the quest for novel drug candidates</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1038/embor.2009.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fembor.2009.2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=125-128&author=P.+Hunter&title=Not+boring+at+all.+Boron+is+the+new+carbon+in+the+quest+for+novel+drug+candidates&doi=10.1038%2Fembor.2009.2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fembor.2009.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2009.2%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DP.%26atitle%3DNot%2520boring%2520at%2520all.%2520Boron%2520is%2520the%2520new%2520carbon%2520in%2520the%2520quest%2520for%2520novel%2520drug%2520candidates%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D125%26epage%3D128%26doi%3D10.1038%2Fembor.2009.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loutit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabetauthor=Z.+Taraziauthor=M.+C.+Cliftonauthor=K.+Atkinsauthor=A.+Raymondauthor=K.+T.+Pottsauthor=J.+Abendrothauthor=S.+H.+Boyerauthor=J.+S.+Loutitauthor=E.+E.+Morganauthor=S.+Dursoauthor=M.+N.+Dudley&title=Discovery+of+a+cyclic+boronic+acid+%CE%B2-lactamase+inhibitor+%28RPX7009%29+with+utility+vs+class+A+serine+carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0lh6URWh-x4x0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26aulast%3DTarazi%26aufirst%3DZ.%26aulast%3DClifton%26aufirst%3DM.%2BC.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DRaymond%26aufirst%3DA.%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BH.%26aulast%3DLoutit%26aufirst%3DJ.%2BS.%26aulast%3DMorgan%26aufirst%3DE.%2BE.%26aulast%3DDurso%26aufirst%3DS.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DDiscovery%2520of%2520a%2520cyclic%2520boronic%2520acid%2520%25CE%25B2-lactamase%2520inhibitor%2520%2528RPX7009%2529%2520with%2520utility%2520vs%2520class%2520A%2520serine%2520carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allington, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivey, M. P.</span></span> <span> </span><span class="NLM_article-title">Quinupristin/dalfopristin: A therapeutic review</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/S0149-2918(01)80028-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0149-2918%2801%2980028-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=11219478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVamsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=24-44&author=D.+R.+Allingtonauthor=M.+P.+Rivey&title=Quinupristin%2Fdalfopristin%3A+A+therapeutic+review&doi=10.1016%2FS0149-2918%2801%2980028-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Quinupristin/dalfopristin: a therapeutic review</span></div><div class="casAuthors">Allington, Douglas R.; Rivey, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-44</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review with 47 refs.  Background: The proliferation of multidrug-resistant gram-pos. bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium (VREF), has created a pressing need for effective alternative antibiotics.  Quinupristin/dalfopristin is a new combination streptogramin product with a selective spectrum of antibacterial activity, mainly against gram-pos. aerobic bacteria.  It has been assessed primarily in emergency-use protocols, in hospitalized patients with skin and skin-structure infections, and in patients with VREF bacteremia.  Objectives: The objectives of this review were to summarize important results of in vitro microbiol. studies; to provide information on relevant pharmacokinetic parameters, drug interactions, and Y-site compatibility; and to assess efficacy and safety data from clin. studies of quinupristin/dalfopristin.  Methods: Articles included in this review were identified by a MEDLINE search of the literature published between 1966 and Sept. 2000 using the terms Synercid, quinupristin, and dalfopristin.  Addnl. articles were retrieved from the ref. lists of articles identified in the MEDLINE search.  Results: In vitro anal. of the spectrum of activity of quinupristin/dalfopristin has confirmed its relatively selective coverage of gram-pos. aerobic bacteria.  Both quinupristin and dalfopristin undergo hepatic metab. and are extensively excreted in the feces.  Combination quinupristin/dalfopristin inhibits the cytochrome P 450 3A4 pathway, and caution is warranted with concomitant use of other medications eliminated via this pathway.  In trials in patients with VREF infections, treatment success with quinupristin/dalfopristin varied depending on the site of infection, ranging from 51.9% in bacteremia of unknown origin to 88.9% in urinary tract infections.  The results of comparative clin. trials suggest that quinupristin/dalfopristin has similar efficacy to that of commonly used antibiotics, including cefazolin, oxacillin, and vancomycin, in patients with skin and skin-structure infections or nosocomial pneumonia.  The most frequently reported adverse effects with administration of quinupristin/dalfopristin were infusion-site inflammation, pain, and edema; other infusion-site reactions; and thrombophlebitis.  Arthralgia, myalgia, nausea, diarrhea, vomiting, and rash occurred in 2.5% to 4.6% of patients and were the most frequently reported systemic adverse events.  Conclusions: Outcomes data from clin. trials indicate that quinupristin/dalfopristin has the potential to play an important role in the treatment of bacteremia, complicated skin and skin-structure infections, and nosocomial pneumonia caused by VREF.  Issues of bacterial resistance to quinupristin/dalfopristin and other appropriate uses of this combination agent remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnk7wTFdXDLVg90H21EOLACvtfcHk0lh6URWh-x4x0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVamsL8%253D&md5=15be911d7b3578e999ebd3178a5e3b9a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0149-2918%2801%2980028-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-2918%252801%252980028-X%26sid%3Dliteratum%253Aachs%26aulast%3DAllington%26aufirst%3DD.%2BR.%26aulast%3DRivey%26aufirst%3DM.%2BP.%26atitle%3DQuinupristin%252Fdalfopristin%253A%2520A%2520therapeutic%2520review%26jtitle%3DClin.%2520Ther.%26date%3D2001%26volume%3D23%26spage%3D24%26epage%3D44%26doi%3D10.1016%2FS0149-2918%2801%2980028-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prachayasittikul, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prachayasittikul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prachayasittikul, V.</span></span> <span> </span><span class="NLM_article-title">Prachayasittikul. V. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S49763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FDDDT.S49763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=1157-1178&author=V.+Prachayasittikulauthor=S.+Prachayasittikulauthor=S.+Ruchirawatauthor=V.+Prachayasittikul&title=Prachayasittikul.+V.+8-Hydroxyquinolines%3A+a+review+of+their+metal+chelating+properties+and+medicinal+applications&doi=10.2147%2FDDDT.S49763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S49763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S49763%26sid%3Dliteratum%253Aachs%26aulast%3DPrachayasittikul%26aufirst%3DV.%26aulast%3DPrachayasittikul%26aufirst%3DS.%26aulast%3DRuchirawat%26aufirst%3DS.%26aulast%3DPrachayasittikul%26aufirst%3DV.%26atitle%3DPrachayasittikul.%2520V.%25208-Hydroxyquinolines%253A%2520a%2520review%2520of%2520their%2520metal%2520chelating%2520properties%2520and%2520medicinal%2520applications%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D2013%26spage%3D1157%26epage%3D1178%26doi%3D10.2147%2FDDDT.S49763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, D.</span></span> <span> </span><span class="NLM_article-title">Lomotil (Diphenoxylate) dependence in India</span>. <i>Indian J. Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.4103/0253-7176.119474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.4103%2F0253-7176.119474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24249925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2c7osVCntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=248-250&author=A.+Mehraauthor=S.+Sarkarauthor=D.+Basu&title=Lomotil+%28Diphenoxylate%29+dependence+in+India&doi=10.4103%2F0253-7176.119474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Lomotil (diphenoxylate) dependence in India</span></div><div class="casAuthors">Mehra Aseem; Sarkar Siddharth; Basu Debasish</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of psychological medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-50</span>
        ISSN:<span class="NLM_cas:issn">0253-7176</span>.
    </div><div class="casAbstract">BACKGROUND:  Lomotil (diphenoxylate atropine combination) has been in use as an antidiarrhoeal agent.  Due to presence of opioid (diphenoxylate), there are chances of abuse.  The reports of abuse of lomotil have been few in published literature.  This chart review aimed to evaluate the characteristics of patients with dependence on lomotil coming to our centre.  MATERIALS AND METHODS:  This retrospective chart review was conducted at the Drug De-addiction and Treatment Centre of PGIMER, Chandigarh, India.  The records of patients who had presented to the centre with dependence on Lomotil in the last five years were identified, and clinical details were extracted from the records.  RESULTS:  We identified 41 patients who had presented to our centre with dependence upon lomotil as the primary substance of abuse.  The cases were typically married and employed males, educated up to 10(th) grade, belonging to a rural Sikh extended or joint family.  Most of the patients had taken other opioids too.  The number of tablets taken in a day varied from 3- to 250 (median 25).  The reasons of initiation were to relieve withdrawals, as a cheap substitute opioid, curiosity, and on suggestion of friends.  CONCLUSION:  Lomotil is a medication with a potential of abuse and regulatory controls are required to prevent escalation of misuse of this easily available prescription drug.  Lomotil (diphenoxylate and atropine combination) has been used since a long time as an anti-diarrheal agent.  Reports of abuse of diphenoxylate had surfaced.  We present a series of 41 cases of opioid dependence presenting with the use of the diphenoxylate as the primary substance.  The cases were typically married and employed males, educated up to 10(th) grade, belonging to a rural Sikh extended or joint family.  Most of the patients had taken other opioids too.  The number of tablets taken in a day varied from 3 to 250 (median 25).  The reasons of initiation of diphenoxylate were to relieve withdrawals, as a cheap substitute opioid, curiosity, and suggestion of friends.  Regulatory controls are needed to prevent escalation of use of this easily available prescription opioid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdwkSFKli2az0SWnHPWbmmfW6udTcc2ea832Wb_e2Pqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7osVCntw%253D%253D&md5=603b2ae4c429d149c8ac23ea9ab80300</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.4103%2F0253-7176.119474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0253-7176.119474%26sid%3Dliteratum%253Aachs%26aulast%3DMehra%26aufirst%3DA.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DBasu%26aufirst%3DD.%26atitle%3DLomotil%2520%2528Diphenoxylate%2529%2520dependence%2520in%2520India%26jtitle%3DIndian%2520J.%2520Psychol.%2520Med.%26date%3D2013%26volume%3D35%26spage%3D248%26epage%3D250%26doi%3D10.4103%2F0253-7176.119474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enns, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhead, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brusilow, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamosh, A.</span></span> <span> </span><span class="NLM_article-title">Survival after treatment with phenylacetate and benzoate for urea-cycle disorders</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">2282</span>– <span class="NLM_lpage">2292</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa066596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa066596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17538087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2282-2292&author=G.+M.+Ennsauthor=S.+A.+Berryauthor=G.+T.+Berryauthor=W.+J.+Rheadauthor=S.+W.+Brusilowauthor=A.+Hamosh&title=Survival+after+treatment+with+phenylacetate+and+benzoate+for+urea-cycle+disorders&doi=10.1056%2FNEJMoa066596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Survival after treatment with phenylacetate and benzoate for urea-cycle disorders</span></div><div class="casAuthors">Enns, Gregory M.; Berry, Susan A.; Berry, Gerard T.; Rhead, William J.; Brusilow, Saul W.; Hamosh, Ada</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2282-2292</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The combination of i.v. sodium phenylacetate and sodium benzoate has been shown to lower plasma ammonium levels and improve survival in small cohorts of patients with historically lethal urea-cycle enzyme defects.  We report the results of a 25-yr, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia.  Overall survival was 84% (250 of 299 patients).  Ninety-six percent of the patients survived episodes of hyperammonemia (1132 of 1181 episodes).  Patients over 30 days of age were more likely than neonates to survive an episode (98% vs. 73%, P < 0.001).  Patients 12 or more years of age (93 patients), who had 437 episodes, were more likely than all younger patients to survive (99%, P < 0.001).  Eighty-one percent of patients who were comatose at admission survived.  Patients less than 30 days of age with a peak ammonium level above 1000 μmol per L (1804 μg per dL) were least likely to survive a hyperammonemic episode (38%, P < 0.001).  Dialysis was also used in 56 neonates during 60% of episodes and in 80 patients 30 days of age or older during 7% of episodes.  Prompt recognition of a urea-cycle disorder and treatment with both sodium phenylacetate and sodium benzoate, in conjunction with other therapies, such as i.v. arginine hydrochloride and the provision of adequate calories to prevent catabolism, effectively lower plasma ammonium levels and result in survival in the majority of patients.  Hemodialysis may also be needed to control hyperammonemia, esp. in neonates and older patients who do not have a response to i.v. sodium phenylacetate and sodium benzoate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAtLnbNCW1PrVg90H21EOLACvtfcHk0lhf7p2XrcWYGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7o%253D&md5=e358df4111d1872f7c40e73b54f77f27</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa066596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa066596%26sid%3Dliteratum%253Aachs%26aulast%3DEnns%26aufirst%3DG.%2BM.%26aulast%3DBerry%26aufirst%3DS.%2BA.%26aulast%3DBerry%26aufirst%3DG.%2BT.%26aulast%3DRhead%26aufirst%3DW.%2BJ.%26aulast%3DBrusilow%26aufirst%3DS.%2BW.%26aulast%3DHamosh%26aufirst%3DA.%26atitle%3DSurvival%2520after%2520treatment%2520with%2520phenylacetate%2520and%2520benzoate%2520for%2520urea-cycle%2520disorders%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2282%26epage%3D2292%26doi%3D10.1056%2FNEJMoa066596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ornellas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, B.</span></span> <span> </span><span class="NLM_article-title">Naltrexone SR/Bupropion SR (Contrave): A new approach to weight loss in obese adults</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=255-262&author=T.+Ornellasauthor=B.+Chavez&title=Naltrexone+SR%2FBupropion+SR+%28Contrave%29%3A+A+new+approach+to+weight+loss+in+obese+adults"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrnellas%26aufirst%3DT.%26aulast%3DChavez%26aufirst%3DB.%26atitle%3DNaltrexone%2520SR%252FBupropion%2520SR%2520%2528Contrave%2529%253A%2520A%2520new%2520approach%2520to%2520weight%2520loss%2520in%2520obese%2520adults%26jtitle%3DPharm.%2520Ther.%26date%3D2011%26volume%3D36%26spage%3D255%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenstock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inzucchi, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seufert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekki, Q.</span></span> <span> </span><span class="NLM_article-title">Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2408</span>, <span class="refDoi"> DOI: 10.2337/dc10-0159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2337%2Fdc10-0159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=20724648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=2406-2408&author=J.+Rosenstockauthor=S.+E.+Inzucchiauthor=J.+Seufertauthor=P.+R.+Fleckauthor=C.+A.+Wilsonauthor=Q.+Mekki&title=Initial+combination+therapy+with+alogliptin+and+pioglitazone+in+drug-na%C3%AFve+patients+with+type+2+diabetes&doi=10.2337%2Fdc10-0159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes</span></div><div class="casAuthors">Rosenstock, Julio; Inzucchi, Silvio E.; Seufert, Jochen; Fleck, Penny R.; Wilson, Craig A.; Mekki, Qais</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2406-2408</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">OBJECTIVE: To assess the efficacy and tolerability of alogliptin plus pioglitazone for initial combination therapy in drug-naive type 2 diabetic patients.  RESEARCH DESIGN AND METHODS: This 26-wk, double-blind, parallel-group study randomized 655 patients with inadequately controlled type 2 diabetes to four arms: 25 mg alogliptin (A25) q.d. monotherapy, 30 mg pioglitazone (P30) q.d. monotherapy, or 12.5 (A12.5) or 25 mg alogliptin q.d. plus pioglitazone (P30) q.d. combination therapy.  Primary efficacy was A1C change from baseline with the high-dose combination (A25 + P30) vs. each monotherapy.  RESULTS: Combination therapy with A25 + P30 resulted in greater redns. in A1C (-1.7 ± 0.1% from an 8.8% mean baseline) vs. A25 (-1.0 ± 0.1%, P < 0.001) or P30 (-1.2 ± 0.1%, P < 0.001) and in fasting plasma glucose (-2.8 ± 0.2 mmol/l) vs. A25 (-1.4 ± 0.2 mmol/l, P < 0.001) or P30 (-2.1 ± 0.2 mmol/l, P = 0.006).  The A25 + P30 safety profile was consistent with those of its component monotherapies.  CONCLUSIONS: Alogliptin plus pioglitazone combination treatment appears to be an efficacious initial therapeutic option for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZj0Xht0o8v7Vg90H21EOLACvtfcHk0lgFntVBWKlHfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisrzP&md5=4d9506bfae4582dc9daa94b55351dac2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2337%2Fdc10-0159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc10-0159%26sid%3Dliteratum%253Aachs%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DInzucchi%26aufirst%3DS.%2BE.%26aulast%3DSeufert%26aufirst%3DJ.%26aulast%3DFleck%26aufirst%3DP.%2BR.%26aulast%3DWilson%26aufirst%3DC.%2BA.%26aulast%3DMekki%26aufirst%3DQ.%26atitle%3DInitial%2520combination%2520therapy%2520with%2520alogliptin%2520and%2520pioglitazone%2520in%2520drug-na%25C3%25AFve%2520patients%2520with%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2010%26volume%3D33%26spage%3D2406%26epage%3D2408%26doi%3D10.2337%2Fdc10-0159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neff, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawarskas, J. J.</span></span> <span> </span><span class="NLM_article-title">Hydrochlorothiazide versus chlorthalidone in the management of hypertension</span>. <i>Cardiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1097/CRD.0b013e3181c61b52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2FCRD.0b013e3181c61b52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=20010338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MfisFOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=51-56&author=K.+M.+Neffauthor=J.+J.+Nawarskas&title=Hydrochlorothiazide+versus+chlorthalidone+in+the+management+of+hypertension&doi=10.1097%2FCRD.0b013e3181c61b52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrochlorothiazide versus chlorthalidone in the management of hypertension</span></div><div class="casAuthors">Neff Kimberly M; Nawarskas James J</div><div class="citationInfo"><span class="NLM_cas:title">Cardiology in review</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thiazide diuretics are a mainstay for the treatment of hypertension.  Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure.  This is despite several clinical trials that have used and documented the benefits of chlorthalidone for hypertension management.  In terms of blood pressure lowering, both HCTZ and chlorthalidone appear to be very effective.  Head-to-head studies have shown trends favoring chlorthalidone as a more effective blood pressure lowering agent compared with HCTZ, but statistical significance in this regard has not been consistently demonstrated.  Also unclear is the relative benefits of these 2 drugs with regards to reducing clinical complications of hypertension, namely cardiovascular morbidity and mortality.  Whereas there is more aggregate clinical trial data documenting the benefits of chlorthalidone compared with HCTZ in terms of hard clinical outcomes, these trials are not direct comparisons and can only be used to fuel the debate as to which of the 2 thiazides are better.  From a safety perspective, hypokalemia is a risk with any of the thiazide diuretics and has been shown to be dose-related.  However, at equipotent dosages, the incidence of hypokalemia between chlorthalidone and HCTZ appears comparable.  The available evidence therefore supports both HCTZ and chlorthalidone as safe and effective drugs for treating hypertension.  Although there are favorable trends both in terms of antihypertensive efficacy as well as clinical outcomes data with chlorthalidone compared with HCTZ, the results are not conclusive, and as such may not be enough to shift the treatment paradigm in favor of chlorthalidone, given the comfort level that most prescribers have with HCTZ.  A head-to-head study looking at hard clinical outcomes, which may or may not ever be performed, may be the only way to resolve the ongoing debate as to which is the preferred thiazide for treating hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToajfqAoubLOWhZTslLrfffW6udTcc2ea5DfxBZWgpVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfisFOmsA%253D%253D&md5=1a2809be893c66c373e1b0485f36caa2</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1097%2FCRD.0b013e3181c61b52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCRD.0b013e3181c61b52%26sid%3Dliteratum%253Aachs%26aulast%3DNeff%26aufirst%3DK.%2BM.%26aulast%3DNawarskas%26aufirst%3DJ.%2BJ.%26atitle%3DHydrochlorothiazide%2520versus%2520chlorthalidone%2520in%2520the%2520management%2520of%2520hypertension%26jtitle%3DCardiol.%2520Rev.%26date%3D2010%26volume%3D18%26spage%3D51%26epage%3D56%26doi%3D10.1097%2FCRD.0b013e3181c61b52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. D.</span></span> <span> </span><span class="NLM_article-title">Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000103632.19915.0E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1161%2F01.HYP.0000103632.19915.0E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=14638621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3snht1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4-9&author=B.+L.+Carterauthor=M.+E.+Ernstauthor=J.+D.+Cohen&title=Hydrochlorothiazide+versus+chlorthalidone%3A+evidence+supporting+their+interchangeability&doi=10.1161%2F01.HYP.0000103632.19915.0E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability</span></div><div class="casAuthors">Carter Barry L; Ernst Michael E; Cohen Jerome D</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension (Dallas, Tex. : 1979)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thiazide diuretics are one of the preferred pharmacologic treatments for hypertension.  Hydrochlorothiazide and chlorthalidone have been the 2 most commonly used diuretics in major clinical trials.  Treatment guidelines and compendia often consider these 2 drugs interchangeable agents within the class of thiazide or thiazide-like diuretics.  Many sources list them as equipotent.  Despite these beliefs, there is some suggestion that cardiovascular outcomes are not necessarily the same with these 2 drugs.  We conducted a literature search from 1960 to 2003 to identify studies that evaluated the pharmacokinetic and blood pressure-lowering effects of these 2 agents.  There are significant pharmacokinetic and pharmacodynamic differences between these diuretics.  Chlorthalidone is approximately 1.5 to 2.0 times as potent as hydrochlorothiazide, and the former has a much longer duration of action.  Whether these pharmacokinetic and pharmacodynamic features cause differences in outcomes is not known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8_FIu9-6Enn6HPRus0rAafW6udTcc2ea5DfxBZWgpVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3snht1GjsQ%253D%253D&md5=bf91553c63d8f93351c8f41fa93a98e7</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000103632.19915.0E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000103632.19915.0E%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DB.%2BL.%26aulast%3DErnst%26aufirst%3DM.%2BE.%26aulast%3DCohen%26aufirst%3DJ.%2BD.%26atitle%3DHydrochlorothiazide%2520versus%2520chlorthalidone%253A%2520evidence%2520supporting%2520their%2520interchangeability%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26spage%3D4%26epage%3D9%26doi%3D10.1161%2F01.HYP.0000103632.19915.0E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vongpatanasin, W.</span></span> <span> </span><span class="NLM_article-title">Hydrochlorothiazide (HCTZ) is not the most useful nor versatile thiazide diuretic</span>. <i>Curr. Opin. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1097/HCO.0000000000000178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1097%2FHCO.0000000000000178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26049382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2MbhtlKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=361-365&author=W.+Vongpatanasin&title=Hydrochlorothiazide+%28HCTZ%29+is+not+the+most+useful+nor+versatile+thiazide+diuretic&doi=10.1097%2FHCO.0000000000000178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic</span></div><div class="casAuthors">Vongpatanasin Wanpen</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension.  RECENT FINDINGS:  HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide.  A recent meta-analysis also suggested HCTZ (12.5-25 mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists.  The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar.  Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD.  SUMMARY:  Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide.  Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics.  CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwwrmjUqMDQFVwdslNBF-tfW6udTcc2ea5DfxBZWgpVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbhtlKhtA%253D%253D&md5=bddaa2fdcedaeaa04fb5c0db1f4b14e5</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1097%2FHCO.0000000000000178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHCO.0000000000000178%26sid%3Dliteratum%253Aachs%26aulast%3DVongpatanasin%26aufirst%3DW.%26atitle%3DHydrochlorothiazide%2520%2528HCTZ%2529%2520is%2520not%2520the%2520most%2520useful%2520nor%2520versatile%2520thiazide%2520diuretic%26jtitle%3DCurr.%2520Opin.%2520Cardiol.%26date%3D2015%26volume%3D30%26spage%3D361%26epage%3D365%26doi%3D10.1097%2FHCO.0000000000000178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitka, M.</span></span> <span> </span><span class="NLM_article-title">Experts argue not all diuretics the same</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">31</span>, <span class="refDoi"> DOI: 10.1001/jama.298.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1001%2Fjama.298.1.31" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2007&pages=31&author=M.+Mitka&title=Experts+argue+not+all+diuretics+the+same&doi=10.1001%2Fjama.298.1.31"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1001%2Fjama.298.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.298.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DMitka%26aufirst%3DM.%26atitle%3DExperts%2520argue%2520not%2520all%2520diuretics%2520the%2520same%26jtitle%3DJAMA%26date%3D2007%26volume%3D298%26spage%3D31%26doi%3D10.1001%2Fjama.298.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vidt, D. G.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187s</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1981.tb02539.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fj.1875-9114.1981.tb02539.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=6927605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaL38Xmt1CjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1981&pages=179-187s&author=D.+G.+Vidt&title=Mechanism+of+action%2C+pharmacokinetics%2C+adverse+effects%2C+and+therapeutic+uses+of+amiloride+hydrochloride%2C+a+new+potassium-sparing+diuretic&doi=10.1002%2Fj.1875-9114.1981.tb02539.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic</span></div><div class="casAuthors">Vidt, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">179-87</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    </div><div class="casAbstract">A review with 57 refs. of amiloride (I)  [2609-46-3].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqchyX0LJ9yx7Vg90H21EOLACvtfcHk0lh7T-BMEB4CTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xmt1CjtA%253D%253D&md5=ba23cd636c8f17fcf072fed0c141745b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1981.tb02539.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1981.tb02539.x%26sid%3Dliteratum%253Aachs%26aulast%3DVidt%26aufirst%3DD.%2BG.%26atitle%3DMechanism%2520of%2520action%252C%2520pharmacokinetics%252C%2520adverse%2520effects%252C%2520and%2520therapeutic%2520uses%2520of%2520amiloride%2520hydrochloride%252C%2520a%2520new%2520potassium-sparing%2520diuretic%26jtitle%3DPharmacotherapy%26date%3D1981%26volume%3D1%26spage%3D179%26epage%3D187s%26doi%3D10.1002%2Fj.1875-9114.1981.tb02539.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Thabaiti, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiekh, R. A.</span></span> <span> </span><span class="NLM_article-title">Tetrazoles as carboxylic acid isosteres: chemistry and biology</span>. <i>J. Inclusion Phenom. Macrocyclic Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1007/s10847-013-0334-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs10847-013-0334-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1ekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2014&pages=15-37&author=M.+A.+Malikauthor=M.+Y.+Waniauthor=S.+A.+Al-Thabaitiauthor=R.+A.+Shiekh&title=Tetrazoles+as+carboxylic+acid+isosteres%3A+chemistry+and+biology&doi=10.1007%2Fs10847-013-0334-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrazoles as carboxylic acid isosteres: chemistry and biology</span></div><div class="casAuthors">Malik, Maqsood Ahmad; Wani, Mohmmad Younus; Al-Thabaiti, Shaeel Ahmed; Shiekh, Rayees Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inclusion Phenomena and Macrocyclic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">15-37</span>CODEN:
                <span class="NLM_cas:coden">JIPCF5</span>;
        ISSN:<span class="NLM_cas:issn">1388-3127</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tetrazoles are used as isosteric substituents of various functional groups in the development of biol. active substances.  The tetrazole motif has been used in various drug pharmacophores as a suitable replacement of carboxylic acid moiety and different methods have been used for the synthesis of tetrazoles using different reaction conditions.  The different synthetic methods, using catalysts or different reagents for the synthesis of tetrazoles were discussed.  The biol. importance of tetrazoles has also been highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-i6TX70KSH7Vg90H21EOLACvtfcHk0lh7T-BMEB4CTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1ekug%253D%253D&md5=b08182a12adbb5d68e2c5aadbe2e3621</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs10847-013-0334-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10847-013-0334-x%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DM.%2BA.%26aulast%3DWani%26aufirst%3DM.%2BY.%26aulast%3DAl-Thabaiti%26aufirst%3DS.%2BA.%26aulast%3DShiekh%26aufirst%3DR.%2BA.%26atitle%3DTetrazoles%2520as%2520carboxylic%2520acid%2520isosteres%253A%2520chemistry%2520and%2520biology%26jtitle%3DJ.%2520Inclusion%2520Phenom.%2520Macrocyclic%2520Chem.%26date%3D2014%26volume%3D78%26spage%3D15%26epage%3D37%26doi%3D10.1007%2Fs10847-013-0334-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleckenstein, A.</span></span> <span> </span><span class="NLM_article-title">History of calcium antagonists</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">I3</span>– <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1983&pages=I3-16&author=A.+Fleckenstein&title=History+of+calcium+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleckenstein%26aufirst%3DA.%26atitle%3DHistory%2520of%2520calcium%2520antagonists%26jtitle%3DCirc.%2520Res.%26date%3D1983%26volume%3D52%26spage%3DI3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frishman, W. H.</span></span> <span> </span><span class="NLM_article-title">Verapamil therapy for stable and unstable angina pectoris: Calcium channel antagonists in perspective</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1016/0002-9149(82)91249-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0002-9149%2882%2991249-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1982&pages=881-885&author=M.+Packerauthor=W.+H.+Frishman&title=Verapamil+therapy+for+stable+and+unstable+angina+pectoris%3A+Calcium+channel+antagonists+in+perspective&doi=10.1016%2F0002-9149%2882%2991249-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2882%2991249-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252882%252991249-8%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DFrishman%26aufirst%3DW.%2BH.%26atitle%3DVerapamil%2520therapy%2520for%2520stable%2520and%2520unstable%2520angina%2520pectoris%253A%2520Calcium%2520channel%2520antagonists%2520in%2520perspective%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1982%26volume%3D50%26spage%3D881%26epage%3D885%26doi%3D10.1016%2F0002-9149%2882%2991249-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roule, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milliez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, J.</span></span> <span> </span><span class="NLM_article-title">Verapamil and vasospastic angina: underuse in the elderly population</span>. <i>J. Geriatr. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.11909/j.issn.1671-5411.2017.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.11909%2Fj.issn.1671-5411.2017.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28868071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=430-435&author=X.+Humbertauthor=V.+Rouleauthor=P.+Milliezauthor=J.+Alexandre&title=Verapamil+and+vasospastic+angina%3A+underuse+in+the+elderly+population&doi=10.11909%2Fj.issn.1671-5411.2017.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Verapamil and vasospastic angina: underuse in the elderly population</span></div><div class="casAuthors">Humbert, Xavier; Roule, Vincent; Milliez, Paul; Alexandre, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Geriatric Cardiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">430-435</span>CODEN:
                <span class="NLM_cas:coden">JGCOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1671-5411</span>.
    
            (<span class="NLM_cas:orgname">Science Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLSfRJ3tW9k7Vg90H21EOLACvtfcHk0lh7T-BMEB4CTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVOisr8%253D&md5=9b75a418bea6be9cdece3d46f3204fb1</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.11909%2Fj.issn.1671-5411.2017.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.11909%252Fj.issn.1671-5411.2017.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DX.%26aulast%3DRoule%26aufirst%3DV.%26aulast%3DMilliez%26aufirst%3DP.%26aulast%3DAlexandre%26aufirst%3DJ.%26atitle%3DVerapamil%2520and%2520vasospastic%2520angina%253A%2520underuse%2520in%2520the%2520elderly%2520population%26jtitle%3DJ.%2520Geriatr.%2520Cardiol.%26date%3D2017%26volume%3D14%26spage%3D430%26epage%3D435%26doi%3D10.11909%2Fj.issn.1671-5411.2017.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H.</span>; <span class="NLM_string-name">Schnermann, J.</span></span> <span> </span><span class="NLM_article-title">Methylxanthines and the kidney</span>. In  <i>Methylxanthines</i>; <span class="NLM_publisher-name">Springer Berlin Heidelberg</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">412</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2F978-3-642-13443-2_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=391-412&author=H.+Osswald&author=J.+Schnermann&title=Methylxanthines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-13443-2_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-13443-2_15%26sid%3Dliteratum%253Aachs%26aulast%3DOsswald%26aufirst%3DH.%26atitle%3DMethylxanthines%2520and%2520the%2520kidney%26btitle%3DMethylxanthines%26pub%3DSpringer%2520Berlin%2520Heidelberg%26date%3D2011%26spage%3D391%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eichenfield, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paller, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzenberger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamlin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordoro, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanifin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmets, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begolka, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidbury, R.</span></span> <span> </span><span class="NLM_article-title">Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2014.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.jaad.2014.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24813302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2cjhtlKrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=116-132&author=L.+F.+Eichenfieldauthor=W.+L.+Tomauthor=T.+G.+Bergerauthor=A.+Krolauthor=A.+S.+Pallerauthor=K.+Schwarzenbergerauthor=J.+Bergmanauthor=S.+L.+Chamlinauthor=D.+E.+Cohenauthor=K.+D.+Cooperauthor=K.+M.+Cordoroauthor=D.+M.+Davisauthor=S.+R.+Feldmanauthor=J.+M.+Hanifinauthor=D.+J.+Margolisauthor=R.+A.+Silvermanauthor=E.+L.+Simpsonauthor=H.+C.+Williamsauthor=C.+A.+Elmetsauthor=J.+Blockauthor=C.+G.+Harrodauthor=W.+S.+Begolkaauthor=R.+Sidbury&title=Guidelines+of+care+for+the+management+of+atopic+dermatitis%3A+Section+2.+Management+and+treatment+of+atopic+dermatitis+with+topical+therapies&doi=10.1016%2Fj.jaad.2014.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies</span></div><div class="casAuthors">Eichenfield Lawrence F; Tom Wynnis L; Berger Timothy G; Cordoro Kelly M; Krol Alfons; Hanifin Jon M; Simpson Eric L; Paller Amy S; Schwarzenberger Kathryn; Bergman James N; Chamlin Sarah L; Cohen David E; Cooper Kevin D; Davis Dawn M; Feldman Steven R; Margolis David J; Silverman Robert A; Williams Hywel C; Elmets Craig A; Block Julie; Harrod Christopher G; Smith Begolka Wendy; Sidbury Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups.  This evidence-based guideline addresses important clinical questions that arise in its management.  In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed.  Where possible, suggestions on dosing and monitoring are given based on available evidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9pnzyTNi1Y75oR8RchjrrfW6udTcc2eZ41lDvk-LG7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjhtlKrsg%253D%253D&md5=71b0771572d704aa1d13485239bc6821</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2014.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2014.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DEichenfield%26aufirst%3DL.%2BF.%26aulast%3DTom%26aufirst%3DW.%2BL.%26aulast%3DBerger%26aufirst%3DT.%2BG.%26aulast%3DKrol%26aufirst%3DA.%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DSchwarzenberger%26aufirst%3DK.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DChamlin%26aufirst%3DS.%2BL.%26aulast%3DCohen%26aufirst%3DD.%2BE.%26aulast%3DCooper%26aufirst%3DK.%2BD.%26aulast%3DCordoro%26aufirst%3DK.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BM.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DHanifin%26aufirst%3DJ.%2BM.%26aulast%3DMargolis%26aufirst%3DD.%2BJ.%26aulast%3DSilverman%26aufirst%3DR.%2BA.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26aulast%3DWilliams%26aufirst%3DH.%2BC.%26aulast%3DElmets%26aufirst%3DC.%2BA.%26aulast%3DBlock%26aufirst%3DJ.%26aulast%3DHarrod%26aufirst%3DC.%2BG.%26aulast%3DBegolka%26aufirst%3DW.%2BS.%26aulast%3DSidbury%26aufirst%3DR.%26atitle%3DGuidelines%2520of%2520care%2520for%2520the%2520management%2520of%2520atopic%2520dermatitis%253A%2520Section%25202.%2520Management%2520and%2520treatment%2520of%2520atopic%2520dermatitis%2520with%2520topical%2520therapies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2014%26volume%3D71%26spage%3D116%26epage%3D132%26doi%3D10.1016%2Fj.jaad.2014.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treffel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapuis, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derancourt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agache, P.</span></span> <span> </span><span class="NLM_article-title">The tetracyclines in dermatology</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1016/0190-9622(91)70255-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0190-9622%2891%2970255-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1791227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaK387ms1SgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1991&pages=691-697&author=P.+Humbertauthor=P.+Treffelauthor=J.-F.+Chapuisauthor=S.+Buchetauthor=C.+Derancourtauthor=P.+Agache&title=The+tetracyclines+in+dermatology&doi=10.1016%2F0190-9622%2891%2970255-Z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The tetracyclines in dermatology</span></div><div class="casAuthors">Humbert P; Treffel P; Chapuis J F; Buchet S; Derancourt C; Agache P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">691-7</span>
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    </div><div class="casAbstract">Tetracycline is one of the most widely used antibiotics.  It may share some properties with conventional immunosuppressive drugs and act as an anti-inflammatory agent in the treatment of inflammatory disease.  This article reviews cutaneous diseases that have been treated with tetracyclines and their antiinflammatory and immunosuppressive properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7v7oJvqnQzBFwe7cAcrfPfW6udTcc2eZ41lDvk-LG7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387ms1SgtQ%253D%253D&md5=40f4522ba9579f22017fb3dabc74c46e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2F0190-9622%2891%2970255-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0190-9622%252891%252970255-Z%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DP.%26aulast%3DTreffel%26aufirst%3DP.%26aulast%3DChapuis%26aufirst%3DJ.-F.%26aulast%3DBuchet%26aufirst%3DS.%26aulast%3DDerancourt%26aufirst%3DC.%26aulast%3DAgache%26aufirst%3DP.%26atitle%3DThe%2520tetracyclines%2520in%2520dermatology%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1991%26volume%3D25%26spage%3D691%26epage%3D697%26doi%3D10.1016%2F0190-9622%2891%2970255-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, H. C.</span></span> <span> </span><span class="NLM_article-title">Clotrimazole as a pharmaceutical: past, present and future</span>. <i>J. Appl. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1111/jam.12554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fjam.12554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24863842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSrtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2014&pages=611-617&author=P.+D.+Crowleyauthor=H.+C.+Gallagher&title=Clotrimazole+as+a+pharmaceutical%3A+past%2C+present+and+future&doi=10.1111%2Fjam.12554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Clotrimazole as a pharmaceutical: past, present and future.</span></div><div class="casAuthors">Crowley, P. D.; Gallagher, H. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">611-617</span>CODEN:
                <span class="NLM_cas:coden">JAMIFK</span>;
        ISSN:<span class="NLM_cas:issn">1364-5072</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : Clotrimazole is a broad-spectrum antimycotic drug mainly used for the treatment of Candida albicans and other fungal infections.  A synthetic, azole antimycotic, clotrimazole is widely used as a topical treatment for tinea pedis (athlete's foot), as well as vulvovaginal and oropharyngeal candidiasis.  It displays fungistatic antimycotic activity by targeting the biosynthesis of ergosterol, thereby inhibiting fungal growth.  As well as its antimycotic activity, clotrimazole has become a drug of interest against several other diseases such as sickle cell disease, malaria and some cancers.  It has also been combined with other mols., such as the metals, to produce clotrimazole complexes that show improved pharmacol. efficacy.  Moreover, several new, modified-release pharmaceutical formulations are also undergoing development.  Clotrimazole is a very well-tolerated product with few side effects, although there is some drug resistance appearing among immunocompromised patients.  Here, we review the pharmaceutical chem., application and pharmacol. of clotrimazole and discuss future prospects for its further development as a chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8PAH-8cBX07Vg90H21EOLACvtfcHk0lgP0-uME8JQkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSrtbrN&md5=3323c4d5b684e3737422fc93e125f3e3</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1111%2Fjam.12554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjam.12554%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DP.%2BD.%26aulast%3DGallagher%26aufirst%3DH.%2BC.%26atitle%3DClotrimazole%2520as%2520a%2520pharmaceutical%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DJ.%2520Appl.%2520Microbiol.%26date%3D2014%26volume%3D117%26spage%3D611%26epage%3D617%26doi%3D10.1111%2Fjam.12554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Rosso, J. Q.</span></span> <span> </span><span class="NLM_article-title">What is the role of benzoyl peroxide cleansers in acne management?: Do they decrease propionibacterium acnes counts? Do they reduce acne lesions?</span>. <i>J. Clin. Aesthet. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=21218192" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=48-51&author=J.+Q.+Del%0ARosso&title=What+is+the+role+of+benzoyl+peroxide+cleansers+in+acne+management%3F%3A+Do+they+decrease+propionibacterium+acnes+counts%3F+Do+they+reduce+acne+lesions%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BRosso%26aufirst%3DJ.%2BQ.%26atitle%3DWhat%2520is%2520the%2520role%2520of%2520benzoyl%2520peroxide%2520cleansers%2520in%2520acne%2520management%253F%253A%2520Do%2520they%2520decrease%2520propionibacterium%2520acnes%2520counts%253F%2520Do%2520they%2520reduce%2520acne%2520lesions%253F%26jtitle%3DJ.%2520Clin.%2520Aesthet.%2520Dermatol.%26date%3D2008%26volume%3D1%26spage%3D48%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torok, H. M.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream</span>. <i>Am. J. Clin. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.2165/00128071-200607040-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2165%2F00128071-200607040-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=16901182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD28vnslarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=223-230&author=H.+M.+Torok&title=A+comprehensive+review+of+the+long-term+and+short-term+treatment+of+melasma+with+a+triple+combination+cream&doi=10.2165%2F00128071-200607040-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream</span></div><div class="casAuthors">Torok Helen M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of clinical dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">223-30</span>
        ISSN:<span class="NLM_cas:issn">1175-0561</span>.
    </div><div class="casAbstract">Melasma is a common disorder of hyperpigmentation and generally involves areas of the face and neck.  Hyperpigmentation is especially prevalent in darker complected patients and is often difficult to treat.  Hydroquinone, tretinoin, and topical corticosteroids are well established monotherapeutic agents for treating melasma and hyperpigmentation; however, a stable, once-daily formulation triple combination cream containing 0.05% tretinoin, 4.0% hydroquinone, and 0.01% fluocinolone acetonide (Tri-Luma) represents the only commercially available combination of all three agents.  This product is approved by the US FDA for the treatment of facial melasma.  A number of publications have described the safety and efficacy of triple combination cream in over 2000 patients with melasma, some of whom were treated for >12 months.  In the initial 8-week study, 29% of patients experienced complete clearing of melasma by week 8, and 77% were clear or almost clear by week 8.  Similarly, good results were seen in the two long-term studies, with the clear/mild rate ranging from 78% to 84% of patients at month 6 and from 81% to 94% of patients at month 12.  Adverse events were almost always mild in severity and typically occurred only at the application site.  The primary concern for most physicians using corticosteroid-containing products on the face is skin atrophy.  However, only two cases of skin atrophy were reported across the three published studies.  Overall, the results of these extensive studies indicate that triple combination cream is efficacious in treating melasma and exhibits a safe profile with low potential for adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW0r9d7c8iJwWRJ3OJdH_qfW6udTcc2eZ2Ex3vLfJjErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vnslarsw%253D%253D&md5=f7989c6b85908d7723976b3478ead402</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2165%2F00128071-200607040-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00128071-200607040-00003%26sid%3Dliteratum%253Aachs%26aulast%3DTorok%26aufirst%3DH.%2BM.%26atitle%3DA%2520comprehensive%2520review%2520of%2520the%2520long-term%2520and%2520short-term%2520treatment%2520of%2520melasma%2520with%2520a%2520triple%2520combination%2520cream%26jtitle%3DAm.%2520J.%2520Clin.%2520Dermatol.%26date%3D2006%26volume%3D7%26spage%3D223%26epage%3D230%26doi%3D10.2165%2F00128071-200607040-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmets, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfand, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhees, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, R.</span></span> <span> </span><span class="NLM_article-title">Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2008.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.jaad.2008.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19217694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=643-659&author=A.+Menterauthor=N.+J.+Kormanauthor=C.+A.+Elmetsauthor=S.+R.+Feldmanauthor=J.+M.+Gelfandauthor=K.+B.+Gordonauthor=A.+Gottliebauthor=J.+Y.+M.+Kooauthor=M.+Lebwohlauthor=H.+W.+Limauthor=A.+S.+Van+Voorheesauthor=K.+R.+Beutnerauthor=R.+Bhushan&title=Guidelines+of+care+for+the+management+of+psoriasis+and+psoriatic+arthritis%3A+section+3.+Guidelines+of+care+for+the+management+and+treatment+of+psoriasis+with+topical+therapies&doi=10.1016%2Fj.jaad.2008.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span></div><div class="casAuthors">Menter Alan; Korman Neil J; Elmets Craig A; Feldman Steven R; Gelfand Joel M; Gordon Kenneth B; Gottlieb Alice; Koo John Y M; Lebwohl Mark; Lim Henry W; Van Voorhees Abby S; Beutner Karl R; Bhushan Reva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the population.  In this third of 6 sections of the guidelines of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis.  The majority of patients with psoriasis have limited disease (<5% body surface area involvement) and can be treated with topical agents, which generally provide a high efficacy-to-safety ratio.  Topical agents may also be used adjunctively for patients with more extensive psoriasis undergoing therapy with either ultraviolet light, systemic or biologic medications.  However, the use of topical agents as monotherapy in the setting of extensive disease or in the setting of limited, but recalcitrant, disease is not routinely recommended.  Treatment should be tailored to meet individual patients' needs.  We will discuss the efficacy and safety of as well as offer recommendations for the use of topical corticosteroids, vitamin D analogues, tazarotene, tacrolimus, pimecrolimus, emollients, salicylic acid, anthralin, coal tar, as well as combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNrA_ozK6QJHy-c-E1v-fmfW6udTcc2eZ2Ex3vLfJjErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D&md5=c4975aee4050bd186fb5ff428a8f23bd</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2008.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2008.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DKorman%26aufirst%3DN.%2BJ.%26aulast%3DElmets%26aufirst%3DC.%2BA.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGelfand%26aufirst%3DJ.%2BM.%26aulast%3DGordon%26aufirst%3DK.%2BB.%26aulast%3DGottlieb%26aufirst%3DA.%26aulast%3DKoo%26aufirst%3DJ.%2BY.%2BM.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DVan%2BVoorhees%26aufirst%3DA.%2BS.%26aulast%3DBeutner%26aufirst%3DK.%2BR.%26aulast%3DBhushan%26aufirst%3DR.%26atitle%3DGuidelines%2520of%2520care%2520for%2520the%2520management%2520of%2520psoriasis%2520and%2520psoriatic%2520arthritis%253A%2520section%25203.%2520Guidelines%2520of%2520care%2520for%2520the%2520management%2520and%2520treatment%2520of%2520psoriasis%2520with%2520topical%2520therapies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2009%26volume%3D60%26spage%3D643%26epage%3D659%26doi%3D10.1016%2Fj.jaad.2008.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span> <span> </span><span class="NLM_article-title">Dutasteride for the treatment of benign prostatic hyperplasia</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1399</span>– <span class="NLM_lpage">1408</span>, <span class="refDoi"> DOI: 10.1517/14656566.2013.797965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1517%2F14656566.2013.797965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23750593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1CjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1399-1408&author=C.+Wuauthor=A.+Kapoor&title=Dutasteride+for+the+treatment+of+benign+prostatic+hyperplasia&doi=10.1517%2F14656566.2013.797965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dutasteride for the treatment of benign prostatic hyperplasia</span></div><div class="casAuthors">Wu, Christopher; Kapoor, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1399-1408</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Benign prostatic hyperplasia (BPH) is an age-related phenomenon assocd. with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms that greatly affect quality of life. is a selective inhibitor of type 1 and type 2 isoforms of 5-α-reductase, an enzyme responsible for the conversion of testosterone to 5-α-dihydrotestosterone, approved as a treatment for symptomatic BPH.  Areas covered: This article will cover the efficacy and safety of dutasteride in the treatment of BPH, with focus on landmark trials conducted on this drug.  Medical literature on the use of dutasteride in men with BPH were identified by searching databases since 1996 (including MEDLINE and EMBASE) as well as bibliogs. from published literature, clin. trial registries and manufacturer and federal drug regulatory websites.  Expert opinion: Dutasteride is an effective, safe and well-tolerated treatment either as monotherapy or in combination with an α-blocker, for the management of symptomatic BPH to improve symptoms, reduce the risk of acute urinary retention and risk for BPH-related surgery.  A new prostate-specific antigen baseline should be established after 6 mo of therapy for clin. decision making.  The relationship between dutasteride and high-grade prostate cancer is not clear, and dutasteride is not approved for prostate cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3DL5sS37_bVg90H21EOLACvtfcHk0ljRremlIO6mUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1CjsLg%253D&md5=eeb3716f00bd8f22cb0014c66058e07c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.797965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.797965%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DKapoor%26aufirst%3DA.%26atitle%3DDutasteride%2520for%2520the%2520treatment%2520of%2520benign%2520prostatic%2520hyperplasia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D1399%26epage%3D1408%26doi%3D10.1517%2F14656566.2013.797965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, F. C.</span></span> <span> </span><span class="NLM_article-title">Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia</span>. <i>Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">S13</span>– <span class="NLM_lpage">S21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=16986050" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=S13-S21&author=F.+C.+Lowe&title=Summary+of+clinical+experiences+with+tamsulosin+for+the+treatment+of+benign+prostatic+hyperplasia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DF.%2BC.%26atitle%3DSummary%2520of%2520clinical%2520experiences%2520with%2520tamsulosin%2520for%2520the%2520treatment%2520of%2520benign%2520prostatic%2520hyperplasia%26jtitle%3DRev.%2520Urol.%26date%3D2005%26volume%3D7%26spage%3DS13%26epage%3DS21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams-Frame, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, J. S.</span></span> <span> </span><span class="NLM_article-title">Costs of hormonal and nonhormonal prescription medications for hot flashes</span>. <i>Women's Health</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.2217/WHE.09.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2217%2FWHE.09.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MrnsF2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=497-502&author=A.+Williams-Frameauthor=J.+S.+Carpenter&title=Costs+of+hormonal+and+nonhormonal+prescription+medications+for+hot+flashes&doi=10.2217%2FWHE.09.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Costs of hormonal and nonhormonal prescription medications for hot flashes</span></div><div class="casAuthors">Williams-Frame Amie; Carpenter Janet S</div><div class="citationInfo"><span class="NLM_cas:title">Women's health (London, England)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-502</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hot flashes are the cardinal symptom of menopause and can be treated with hormonal and nonhormonal prescription medications.  However, considering that 6000 women enter menopause daily in the USA, and many of these women are symptomatic, the costs of these treatments can be a significant public health issue.  We evaluated annual individual and population costs of hormonal and nonhormonal prescription treatments for hot flashes.  Cost information may be helpful to clinicians and consumers in making treatment decisions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3AzUZDQsrd8ULxIEhxUjPfW6udTcc2eYtzaFFicN8Qrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrnsF2ltg%253D%253D&md5=f9bb444a26eff66b55263d5a57cddce8</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2217%2FWHE.09.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252FWHE.09.49%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams-Frame%26aufirst%3DA.%26aulast%3DCarpenter%26aufirst%3DJ.%2BS.%26atitle%3DCosts%2520of%2520hormonal%2520and%2520nonhormonal%2520prescription%2520medications%2520for%2520hot%2520flashes%26jtitle%3DWomen%2527s%2520Health%26date%3D2009%26volume%3D5%26spage%3D497%26epage%3D502%26doi%3D10.2217%2FWHE.09.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niebyl, J.</span></span> <span> </span><span class="NLM_article-title">Bendectin: how a safe and effective drug was removed from the market by our legal system</span>. <i>ACOG Clin. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=25-27&author=R.+W.+Haleauthor=J.+Niebyl&title=Bendectin%3A+how+a+safe+and+effective+drug+was+removed+from+the+market+by+our+legal+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DR.%2BW.%26aulast%3DNiebyl%26aufirst%3DJ.%26atitle%3DBendectin%253A%2520how%2520a%2520safe%2520and%2520effective%2520drug%2520was%2520removed%2520from%2520the%2520market%2520by%2520our%2520legal%2520system%26jtitle%3DACOG%2520Clin.%2520Rev.%26date%3D2012%26volume%3D17%26spage%3D25%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ornstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, G.</span></span> <span> </span><span class="NLM_article-title">Bendectin/Diclectin for morning sickness: A canadian follow-up of an American tragedy</span>. <i>Reprod. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/0890-6238(94)00050-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0890-6238%2894%2900050-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=8520127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK2MXktVOitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=1-6&author=M.+Ornsteinauthor=A.+Einarsonauthor=G.+Koren&title=Bendectin%2FDiclectin+for+morning+sickness%3A+A+canadian+follow-up+of+an+American+tragedy&doi=10.1016%2F0890-6238%2894%2900050-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Bendectin/dicletin for morning sickness: a Canadian follow-up of American tragedy</span></div><div class="casAuthors">Ornstein, Melanie; Einarson, Adrianne; Koren, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Reproductive Toxicology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">REPTED</span>;
        ISSN:<span class="NLM_cas:issn">0890-6238</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHy3VD3Bqc6LVg90H21EOLACvtfcHk0ljRremlIO6mUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktVOitbc%253D&md5=01a12649c78994038ebc20b39b70bee4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2F0890-6238%2894%2900050-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0890-6238%252894%252900050-7%26sid%3Dliteratum%253Aachs%26aulast%3DOrnstein%26aufirst%3DM.%26aulast%3DEinarson%26aufirst%3DA.%26aulast%3DKoren%26aufirst%3DG.%26atitle%3DBendectin%252FDiclectin%2520for%2520morning%2520sickness%253A%2520A%2520canadian%2520follow-up%2520of%2520an%2520American%2520tragedy%26jtitle%3DReprod.%2520Toxicol.%26date%3D1995%26volume%3D9%26spage%3D1%26epage%3D6%26doi%3D10.1016%2F0890-6238%2894%2900050-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuangchamnong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niebyl, J.</span></span> <span> </span><span class="NLM_article-title">Doxylamine succinate–pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview</span>. <i>Int. J. Women's Health</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.2147/IJWH.S46653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FIJWH.S46653" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=401-409&author=N.+Nuangchamnongauthor=J.+Niebyl&title=Doxylamine+succinate%E2%80%93pyridoxine+hydrochloride+%28Diclegis%29+for+the+management+of+nausea+and+vomiting+in+pregnancy%3A+an+overview&doi=10.2147%2FIJWH.S46653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2147%2FIJWH.S46653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJWH.S46653%26sid%3Dliteratum%253Aachs%26aulast%3DNuangchamnong%26aufirst%3DN.%26aulast%3DNiebyl%26aufirst%3DJ.%26atitle%3DDoxylamine%2520succinate%25E2%2580%2593pyridoxine%2520hydrochloride%2520%2528Diclegis%2529%2520for%2520the%2520management%2520of%2520nausea%2520and%2520vomiting%2520in%2520pregnancy%253A%2520an%2520overview%26jtitle%3DInt.%2520J.%2520Women%2527s%2520Health%26date%3D2014%26volume%3D2014%26spage%3D401%26epage%3D409%26doi%3D10.2147%2FIJWH.S46653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span> </span><span class="NLM_article-title">Lesinurad/allopurinol (Duzallo) for gout-associated
hyperuricemia</span>.  <i>Med. Lett. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>.  <span class="NLM_volume">59</span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">183</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29125593" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lesinurad%2Fallopurinol+%28Duzallo%29+for+gout-associated%0Ahyperuricemia.+Med.+Lett.+Drugs+Ther.+2017.+59%2C+182%E2%80%93183."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DLesinurad%252Fallopurinol%2520%2528Duzallo%2529%2520for%2520gout-associated%250Ahyperuricemia%26jtitle%3DMed.%2520Lett.%2520Drugs%2520Ther.%26date%3D2017%26volume%3D59%26spage%3D182%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komm, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chines, A. A.</span></span> <span> </span><span class="NLM_article-title">Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis</span>. <i>Ther. Adv. Musculoskeletal Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1177/1759720X11422602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1177%2F1759720X11422602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=22870492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsVSkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=21-34&author=B.+S.+Kommauthor=A.+A.+Chines&title=Bazedoxifene%3A+the+evolving+role+of+third-generation+selective+estrogen-receptor+modulators+in+the+management+of+postmenopausal+osteoporosis&doi=10.1177%2F1759720X11422602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis</span></div><div class="casAuthors">Komm, Barry S.; Chines, Arkadi A.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Musculoskeletal Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-34</span>CODEN:
                <span class="NLM_cas:coden">TAMDDB</span>;
        ISSN:<span class="NLM_cas:issn">1759-720X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Osteoporosis is a significant public health concern, particularly for postmenopausal women.  Current treatment options may not be appropriate for all women.  Selective estrogen-receptor modulators (SERMs) are a class of mols. with tissue-selective activity.  Bazedoxifene is currently in clin. development for the prevention and treatment of postmenopausal osteoporosis.  In a 2-yr, phase III, osteoporosis prevention study (N=1583), bazedoxifene 10, 20, and 40 mg was shown to preserve bone mineral d. and decrease biochem. markers of bone turnover compared with placebo in postmenopausal women at risk for osteoporosis.  In a pivotal 3-yr, phase III, osteoporosis treatment study (N=7492), bazedoxifene 20 and 40 mg significantly reduced the incidence of new vertebral fractures compared with placebo (p < 0.05 for both) in postmenopausal women with osteoporosis.  In a post hoc subgroup anal. of women at higher risk for fracture (n = 1772), bazedoxifene 20 mg significantly reduced the risk of nonvertebral fractures vs. placebo (p = 0.02) and raloxifene 60 mg (p = 0.05).  Bazedoxifene 20 mg has demonstrated sustained efficacy in reducing the risk of vertebral fractures over 5 and 7 years.  Overall, bazedoxifene was generally safe and well tolerated, with favorable endometrial and breast safety profiles.  As with other SERMs, the rate of deep vein thrombosis was higher in the bazedoxifene groups compared with placebo at 3 and 5 years.  Considering its demonstrated efficacy and safety, bazedoxifene may be an appropriate osteoporosis therapy for women who cannot take or are unwilling to take bisphosphonates because of safety or tolerability issues.  Bazedoxifene may also be appropriate for younger women at increased fracture risk who are concerned about the effects of long-term bisphosphonate therapy.  This article reviews the results of key clin. trials of bazedoxifene for the prevention and treatment of postmenopausal osteoporosis and describes its role in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU7eE7Fh2LN7Vg90H21EOLACvtfcHk0ljVVLyA-5z94g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsVSkuro%253D&md5=34fec43fb64cb96e4d432cf0bee5b4b3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1177%2F1759720X11422602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1759720X11422602%26sid%3Dliteratum%253Aachs%26aulast%3DKomm%26aufirst%3DB.%2BS.%26aulast%3DChines%26aufirst%3DA.%2BA.%26atitle%3DBazedoxifene%253A%2520the%2520evolving%2520role%2520of%2520third-generation%2520selective%2520estrogen-receptor%2520modulators%2520in%2520the%2520management%2520of%2520postmenopausal%2520osteoporosis%26jtitle%3DTher.%2520Adv.%2520Musculoskeletal%2520Dis.%26date%3D2012%26volume%3D4%26spage%3D21%26epage%3D34%26doi%3D10.1177%2F1759720X11422602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddleston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szinicz, L.</span></span> <span> </span><span class="NLM_article-title">Oximes for acute organophosphate pesticide poisoning</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD005085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2F14651858.CD005085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=1&author=N.+Buckleyauthor=M.+Eddlestonauthor=L.+Szinicz&title=Oximes+for+acute+organophosphate+pesticide+poisoning&doi=10.1002%2F14651858.CD005085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD005085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD005085%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DN.%26aulast%3DEddleston%26aufirst%3DM.%26aulast%3DSzinicz%26aufirst%3DL.%26atitle%3DOximes%2520for%2520acute%2520organophosphate%2520pesticide%2520poisoning%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2005%26spage%3D1%26doi%3D10.1002%2F14651858.CD005085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tfelt-Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlöf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Láinez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Ergotamine in the acute treatment of migraine: a review and European consensus</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1093/brain/123.1.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1093%2Fbrain%2F123.1.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10611116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FnvV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2000&pages=9-18&author=P.+Tfelt-Hansenauthor=P.+R.+Saxenaauthor=C.+Dahl%C3%B6fauthor=J.+Pascualauthor=M.+L%C3%A1inezauthor=P.+Henryauthor=H.+C.+Dienerauthor=J.+Schoenenauthor=M.+D.+Ferrariauthor=P.+J.+Goadsby&title=Ergotamine+in+the+acute+treatment+of+migraine%3A+a+review+and+European+consensus&doi=10.1093%2Fbrain%2F123.1.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Ergotamine in the acute treatment of migraine: a review and European consensus</span></div><div class="casAuthors">Tfelt-Hansen P; Saxena P R; Dahlof C; Pascual J; Lainez M; Henry P; Diener H; Schoenen J; Ferrari M D; Goadsby P J</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">123 ( Pt 1)</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-18</span>
        ISSN:<span class="NLM_cas:issn">0006-8950</span>.
    </div><div class="casAbstract">Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice.  An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine.  From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed.  In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions.  For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQow0IwdymLFX6CEoQgWY10fW6udTcc2eY_2e0afp-oerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FnvV2ktg%253D%253D&md5=54558d2207c9d2932bbb8bcbfc9f8ac1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2F123.1.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252F123.1.9%26sid%3Dliteratum%253Aachs%26aulast%3DTfelt-Hansen%26aufirst%3DP.%26aulast%3DSaxena%26aufirst%3DP.%2BR.%26aulast%3DDahl%25C3%25B6f%26aufirst%3DC.%26aulast%3DPascual%26aufirst%3DJ.%26aulast%3DL%25C3%25A1inez%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DP.%26aulast%3DDiener%26aufirst%3DH.%2BC.%26aulast%3DSchoenen%26aufirst%3DJ.%26aulast%3DFerrari%26aufirst%3DM.%2BD.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DErgotamine%2520in%2520the%2520acute%2520treatment%2520of%2520migraine%253A%2520a%2520review%2520and%2520European%2520consensus%26jtitle%3DBrain%26date%3D2000%26volume%3D123%26spage%3D9%26epage%3D18%26doi%3D10.1093%2Fbrain%2F123.1.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonaci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiotto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A.</span></span> <span> </span><span class="NLM_article-title">Recent advances in migraine therapy</span>. <i>SpringerPlus</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>, <span class="refDoi"> DOI: 10.1186/s40064-016-2211-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1186%2Fs40064-016-2211-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=637&author=F.+Antonaciauthor=N.+Ghiottoauthor=S.+Wuauthor=E.+Pucciauthor=A.+Costa&title=Recent+advances+in+migraine+therapy&doi=10.1186%2Fs40064-016-2211-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1186%2Fs40064-016-2211-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40064-016-2211-8%26sid%3Dliteratum%253Aachs%26aulast%3DAntonaci%26aufirst%3DF.%26aulast%3DGhiotto%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DPucci%26aufirst%3DE.%26aulast%3DCosta%26aufirst%3DA.%26atitle%3DRecent%2520advances%2520in%2520migraine%2520therapy%26jtitle%3DSpringerPlus%26date%3D2016%26volume%3D5%26spage%3D637%26doi%3D10.1186%2Fs40064-016-2211-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, P. R.</span></span> <span> </span><span class="NLM_article-title">Clinical effects and mechanism of action of sumatriptan in migraine</span>. <i>Clin. Neurol. Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/0303-8467(92)90028-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2F0303-8467%2892%2990028-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1321704" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1992&pages=73-77&author=M.+D.+Ferrariauthor=P.+R.+Saxena&title=Clinical+effects+and+mechanism+of+action+of+sumatriptan+in+migraine&doi=10.1016%2F0303-8467%2892%2990028-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0303-8467%2892%2990028-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-8467%252892%252990028-2%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DM.%2BD.%26aulast%3DSaxena%26aufirst%3DP.%2BR.%26atitle%3DClinical%2520effects%2520and%2520mechanism%2520of%2520action%2520of%2520sumatriptan%2520in%2520migraine%26jtitle%3DClin.%2520Neurol.%2520Neurosurg.%26date%3D1992%26volume%3D94%26spage%3D73%26epage%3D77%26doi%3D10.1016%2F0303-8467%2892%2990028-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaffenrath, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, T. J.</span></span> <span> </span><span class="NLM_article-title">Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1046/j.1468-2982.1995.1505337.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1046%2Fj.1468-2982.1995.1505337.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=8536293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaK287hsVWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=337-357&author=M.+Wilkinsonauthor=V.+Pfaffenrathauthor=J.+Schoenenauthor=H.+C.+Dienerauthor=T.+J.+Steiner&title=Migraine+and+cluster+headache%2D%2Dtheir+management+with+sumatriptan%3A+a+critical+review+of+the+current+clinical+experience&doi=10.1046%2Fj.1468-2982.1995.1505337.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience</span></div><div class="casAuthors">Wilkinson M; Pfaffenrath V; Schoenen J; Diener H C; Steiner T J</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-57</span>
        ISSN:<span class="NLM_cas:issn">0333-1024</span>.
    </div><div class="casAbstract">Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater following activation of the trigeminovascular system.  The mode of action of this drug in migraine and cluster headache is discussed.  On the basis of a detailed review of all published trials and available data from post-marketing studies, the efficacy, safety, tolerability and the place of oral and subcutaneous sumatriptan in the treatment of both conditions are assessed.  A number of double-blind clinical trials have demonstrated that sumatriptan 100 mg administered orally is clearly superior to placebo in the acute treatment of migraine headache and achieves significantly greater response rates than ergotamine or aspirin.  In other studies, 70 to 80% of patients receiving sumatriptan 6 mg sc experienced relief of migraine headaches by 1 or 2 h after administration, and patients consistently required less rescue medication for unresolved symptoms.  Sumatriptan was also effective in relieving associated migraine symptoms like nausea and vomiting.  Sumatriptan was equally effective regardless of migraine type or duration of migraine symptoms.  Overall, approximately 40% of patients who initially responded to oral or subcutaneous sumatriptan experienced recurrence of their headache usually within 24 h, effectively treated by a further dose of this drug.  In 75% of patients with cluster headache treated with sumatriptan 6 mg sc, relief was achieved within 15 min.  Based on pooled study data, sumatriptan is generally well tolerated and most adverse events are transient.  Adverse events following oral administration include nausea, vomiting, malaise, fatigue and dizziness.  With the subcutaneous injection, injection site reactions occur in approximately 30%.  Chest syumptoms are reported in 3 to 5% but have been associated with myocardial ischaemia only in rare isolated cases.  The recommended dosage of sumatriptan at the onset of migraine symptoms is 100 mg orally or 6 mg subcutaneously.  The recommended dosage for cluster headache is 6 mg sumatriptan sc.  Sumatriptan must not be given together with vasoconstrictive substances, e.g., ergotamines, or with migraine prophylactics with similar properties, e.g., methysergide.  Sumatriptan should not be given during the migraine aura.  It is contraindicated in patients with ischaemic heart disease, previous myocardial infarction, Prinzmetal (variant) angina and uncontrolled hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLJjCtJ_Y3iMjl5L8hwNX0fW6udTcc2eZaUYPFtBrO1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287hsVWhtg%253D%253D&md5=ca57418538a02c109fdaa5319eabdfbd</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1046%2Fj.1468-2982.1995.1505337.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1468-2982.1995.1505337.x%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DM.%26aulast%3DPfaffenrath%26aufirst%3DV.%26aulast%3DSchoenen%26aufirst%3DJ.%26aulast%3DDiener%26aufirst%3DH.%2BC.%26aulast%3DSteiner%26aufirst%3DT.%2BJ.%26atitle%3DMigraine%2520and%2520cluster%2520headache--their%2520management%2520with%2520sumatriptan%253A%2520a%2520critical%2520review%2520of%2520the%2520current%2520clinical%2520experience%26jtitle%3DCephalalgia%26date%3D1995%26volume%3D15%26spage%3D337%26epage%3D357%26doi%3D10.1046%2Fj.1468-2982.1995.1505337.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLure, H. A.</span></span> <span> </span><span class="NLM_article-title">Review of local anaesthetic agents</span>. <i>Curr. Anaesth. Crit. Care.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/j.cacc.2004.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.cacc.2004.08.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=247-254&author=G.+Laganauthor=H.+A.+McLure&title=Review+of+local+anaesthetic+agents&doi=10.1016%2Fj.cacc.2004.08.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.cacc.2004.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cacc.2004.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DLagan%26aufirst%3DG.%26aulast%3DMcLure%26aufirst%3DH.%2BA.%26atitle%3DReview%2520of%2520local%2520anaesthetic%2520agents%26jtitle%3DCurr.%2520Anaesth.%2520Crit.%2520Care.%26date%3D2004%26volume%3D15%26spage%3D247%26epage%3D254%26doi%3D10.1016%2Fj.cacc.2004.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuntokun, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2549</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1038/npp.2014.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fnpp.2014.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24801768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1ehsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=2549-2559&author=E.+Brunnerauthor=M.+Tohenauthor=O.+Osuntokunauthor=J.+Landryauthor=M.+E.+Thase&title=Efficacy+and+safety+of+olanzapine%2Ffluoxetine+combination+vs+fluoxetine+monotherapy+following+successful+combination+therapy+of+treatment-resistant+major+depressive+disorder&doi=10.1038%2Fnpp.2014.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder</span></div><div class="casAuthors">Brunner, Elizabeth; Tohen, Mauricio; Osuntokun, Olawale; Landry, John; Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2549-2559</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study assessed prevention of relapse in patients with treatment-resistant depression (TRD) taking olanzapine/fluoxetine combination (OFC).  Patients with major depressive disorder (MDD) who failed to satisfactorily respond to ≥2 different antidepressants for ≥6 wk within the current MDD episode were acutely treated for 6-8 wk, followed by stabilization (12 wk) on OFC.  Those who remained stable were randomized to OFC or fluoxetine for up to 27 wk.  Time-to-relapse was the primary efficacy outcome defined as 50% increase in Montgomery-Åsberg Depression Rating Scale score with Clin. Global Impressions-Severity of Depression score of ≥4; hospitalization for depression or suicidality; or discontinuation for lack of efficacy or worsening of depression or suicidality.  A total of 444 patients were randomized 1:1 to OFC (N=221) or fluoxetine (N=223).  Time-to-relapse was significantly longer in OFC-treated patients compared with fluoxetine-treated patients (p<0.001).  Treatment-emergent wt. gain and some mean and categorical fasting metabolic changes were significantly greater in OFC-treated patients.  Clin. significant wt. gain (≥7%) was obsd. in 55.7% of patients who remained on OFC throughout the study, including the relapse-prevention phase (up to 47 wk).  There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events.  We believe this is the first controlled relapse-prevention study in subjects with TRD that supports continued use of a second-generation antipsychotic beyond stabilization.  A thorough assessment of benefits and risks (in particular metabolic changes) assocd. with continuing treatment with OFC or fluoxetine must be done based on individual patient needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxeZo4ppELNrVg90H21EOLACvtfcHk0lisJVwY-RczJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1ehsb8%253D&md5=38dac2fd5deab2ebb35832aef9b8ad0b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2014.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2014.101%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DE.%26aulast%3DTohen%26aufirst%3DM.%26aulast%3DOsuntokun%26aufirst%3DO.%26aulast%3DLandry%26aufirst%3DJ.%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520olanzapine%252Ffluoxetine%2520combination%2520vs%2520fluoxetine%2520monotherapy%2520following%2520successful%2520combination%2520therapy%2520of%2520treatment-resistant%2520major%2520depressive%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D2549%26epage%3D2559%26doi%3D10.1038%2Fnpp.2014.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M. P.</span></span> <span> </span><span class="NLM_article-title">Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=325-328&author=M.+P.+Cruz&title=Nuedexta+for+the+treatment+of+pseudobulbar+affect%3A+a+condition+of+involuntary+crying+or+laughing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DM.%2BP.%26atitle%3DNuedexta%2520for%2520the%2520treatment%2520of%2520pseudobulbar%2520affect%253A%2520a%2520condition%2520of%2520involuntary%2520crying%2520or%2520laughing%26jtitle%3DPharm.%2520Ther.%26date%3D2013%26volume%3D38%26spage%3D325%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D.
J.</span></span> <span> </span><span class="NLM_article-title">Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective</span>. <i>Neuropsych. Dis. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.2147/NDT.S1660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FNDT.S1660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18728816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=39-47&author=D.%0AJ.+Brooks&title=Optimizing+levodopa+therapy+for+Parkinson%E2%80%99s+disease+with+levodopa%2Fcarbidopa%2Fentacapone%3A+implications+from+a+clinical+and+patient+perspective&doi=10.2147%2FNDT.S1660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacepone: implications from a clinical and patient perspective</span></div><div class="casAuthors">Brooks, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychiatric Disease and Treatment</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1A</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">NDTEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1176-6328</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  After 40 years of clin. experience, levodopa remains the gold std. treatment for Parkinson's disease (PD) despite the recent emergence of a host of new therapies.  Some physicians are cautious when prescribing levodopa because of its assocn. with motor complications.  Evidence now suggests that levodopa-assocd. complications are a result of deep troughs in delivery of levodopa to the brain caused by the short plasma half-life of conventional levodopa formulations (levodopa and a dopa decarboxylase inhibitor [DDCI]).  Dosing strategies, such as dose increases and dose fractionation, may be effective in the short term.  For the longer-term, levodopa/carbidopa/entacapone provides pharmacokinetically optimized levodopa therapy that significantly increases the plasma half-life and bioavailability of levodopa, providing more consistent plasma levodopa levels without deep troughs.  Evidence from clin. trials in PD patients experiencing re-emergence of symptoms due to wearing-off has consistently shown that levodopa/DDCI and entacapone significantly increases ON-time and affords greater functionality, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) with conventional levodopa.  These trials have also shown that levodopa/DDCI and entacapone is generally well tolerated, with notable adverse events including worsening dyskinesia, nausea and diarrhea.  Patients experiencing re-emergence of symptoms due to wearing-off may benefit from optimized levodopa therapy with levodopa/carbidopa/entacapone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmoeEowCYzFbVg90H21EOLACvtfcHk0liqRBNhWd7Wzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVeisL4%253D&md5=a59711859027f788c28576c2ceb4d1b8</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.2147%2FNDT.S1660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FNDT.S1660%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DOptimizing%2520levodopa%2520therapy%2520for%2520Parkinson%25E2%2580%2599s%2520disease%2520with%2520levodopa%252Fcarbidopa%252Fentacapone%253A%2520implications%2520from%2520a%2520clinical%2520and%2520patient%2520perspective%26jtitle%3DNeuropsych.%2520Dis.%2520Treat.%26date%3D2008%26volume%3D4%26spage%3D39%26epage%3D47%26doi%3D10.2147%2FNDT.S1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeberger, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, R. A.</span></span> <span> </span><span class="NLM_article-title">Levodopa/carbidopa/entacapone in Parkinson’s disease</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1586/ern.09.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1586%2Fern.09.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19589043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1egtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=929-940&author=L.+C.+Seebergerauthor=R.+A.+Hauser&title=Levodopa%2Fcarbidopa%2Fentacapone+in+Parkinson%E2%80%99s+disease&doi=10.1586%2Fern.09.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa/carbidopa/entacapone in Parkinson's disease</span></div><div class="casAuthors">Seeberger, Lauren C.; Hauser, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">929-940</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is assocd. with the development of motor complications.  Mounting evidence indicates the short half-life of levodopa and resultant pulsatile stimulation of striatal dopamine receptors leads to wearing off, motor fluctuations and dyskinesias.  Longer acting dopaminergic agents, such as dopamine agonists, are less likely to cause motor fluctuations and dyskinesias but are not as efficacious for control of motor symptoms.  Therefore, there is interest in exploring ways to deliver levodopa in a more continuous fashion, in an effort to maintain benefit through the day and reduce the development of motor fluctuations and dyskinesias.  A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central bioavailability.  When levodopa is administered with a DDCI, its main route of peripheral metab. is via catechol-O-Me transferase (COMT).  A COMT inhibitor can be added to the combination of levodopa and a DDCI to further extend the levodopa peripheral half-life and increase central bioavailability.  Stalevo is a combination tablet comprised of levodopa, carbidopa, and the COMT inhibitor entacapone.  It is available in fixed-dose combinations of levodopa/carbidopa/entacapone, 50/12.5/200, 75/18.75/200, 100/25/200, 125/31.25/200, 150/37.5/200 and 200/50/200 mg.  Stalevo is currently approved for use in Parkinson's disease patients with end-of-dose wearing off.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGVC48bEG7YrVg90H21EOLACvtfcHk0liqRBNhWd7Wzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1egtLs%253D&md5=e4fd4790ddf82f86134bde9dc17231ca</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1586%2Fern.09.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fern.09.64%26sid%3Dliteratum%253Aachs%26aulast%3DSeeberger%26aufirst%3DL.%2BC.%26aulast%3DHauser%26aufirst%3DR.%2BA.%26atitle%3DLevodopa%252Fcarbidopa%252Fentacapone%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2009%26volume%3D9%26spage%3D929%26epage%3D940%26doi%3D10.1586%2Fern.09.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Memantine ER/Donepezil: a review in alzheimer’s disease</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1007/s40263-015-0287-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1007%2Fs40263-015-0287-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26519339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=963-970&author=S.+L.+Greig&title=Memantine+ER%2FDonepezil%3A+a+review+in+alzheimer%E2%80%99s+disease&doi=10.1007%2Fs40263-015-0287-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Memantine ER/Donepezil: A Review in Alzheimer's Disease</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">963-970</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric) is available in the USA for patients with moderate to severe Alzheimer's disease (AD) on stable memantine and donepezil therapy.  The fixed-dose formulation is bioequivalent to coadministration of the individual drugs.  In a 24-wk, phase III trial in patients with moderate to severe AD, addn. of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clin. status, dementia behavior and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ.  In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behavior and semantic processing, although there were no significant between-group differences on measures of global clin. status and daily function.  Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients.  Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD.  The fixed-dose combination is potentially more convenient than coadministration of the individual agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJHr-ptRHLU7Vg90H21EOLACvtfcHk0liqRBNhWd7Wzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyks7vL&md5=875120e768f3f0343f23925e21909e2d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs40263-015-0287-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-015-0287-2%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DMemantine%2520ER%252FDonepezil%253A%2520a%2520review%2520in%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCNS%2520Drugs%26date%3D2015%26volume%3D29%26spage%3D963%26epage%3D970%26doi%3D10.1007%2Fs40263-015-0287-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Memantine hydrochloride</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1038/nrd1311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fnrd1311" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=109-110&author=A.+Wittauthor=N.+Macdonaldauthor=P.+Kirkpatrick&title=Memantine+hydrochloride&doi=10.1038%2Fnrd1311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fnrd1311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1311%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DA.%26aulast%3DMacdonald%26aufirst%3DN.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DMemantine%2520hydrochloride%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D109%26epage%3D110%26doi%3D10.1038%2Fnrd1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsu, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4821</span>– <span class="NLM_lpage">4829</span>, <span class="refDoi"> DOI: 10.1021/jm00024a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00024a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADyaK2MXptVGqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=4821-4829&author=H.+Sugimotoauthor=Y.+Iimuraauthor=Y.+Yamanishiauthor=K.+Yamatsu&title=Synthesis+and+structure-activity+relationships+of+acetylcholinesterase+inhibitors%3A+1-benzyl-4-%5B%285%2C6-dimethoxy-1-oxoindan-2-yl%29methyl%5Dpiperidine+hydrochloride+and+related+compounds&doi=10.1021%2Fjm00024a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds</span></div><div class="casAuthors">Sugimoto, Hachiro; Iimura, Youichi; Yamanishi, Yoshiharu; Yamatsu, Kiyomi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4821-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following the discovery of a new series of anti-acetylcholinesterase (anti-AChE) inhibitors such as 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine we reported that its rigid analog, 1-benzyl-4-(2-isoindolin-2-ylethyl)piperidine, had more potent activity.  The structure-activity relationship (SAR) study for the rigid analog was extended and it was found that the 2-isoindoline moiety in 1-benzyl-4-(2-isoindolin-2-ylethyl)piperidine can be replaced with a indanone moiety without a major loss in potency.  Among the indanone derivs., 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine [i.e., 2-[[1-(cyclohexylmethyl)-4-piperidinyl]methylene]-2,3-dihydro-5,6-dimetoxy-1H-inden-1-one] (E2020) (IC50 = 5.7 nM) was found to be one of the most potent anti-AChE inhibitors.  This compd. showed a selective affinity 1250 times greater for AChE than for butyrylcholinesterase.  In vivo studies demonstrated that 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine has a longer duration of action than physostigmine at a dose of 5 mg/kg (po) and produced a marked and significant increase in acetylcholine content in rat cerebral cortex.  The synthesis, SAR, and a proposed hypothetical binding site of 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine (E2020) were described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeF7RhU-sVW7Vg90H21EOLACvtfcHk0liblrNwLTCMtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptVGqtro%253D&md5=b2e5643010562e11d3015b86c6b6ecd1</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm00024a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00024a009%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DIimura%26aufirst%3DY.%26aulast%3DYamanishi%26aufirst%3DY.%26aulast%3DYamatsu%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520acetylcholinesterase%2520inhibitors%253A%25201-benzyl-4-%255B%25285%252C6-dimethoxy-1-oxoindan-2-yl%2529methyl%255Dpiperidine%2520hydrochloride%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D4821%26epage%3D4829%26doi%3D10.1021%2Fjm00024a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">The “cyclopropyl fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8712</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8712-8756&author=T.+T.+Talele&title=The+%E2%80%9Ccyclopropyl+fragment%E2%80%9D+is+a+versatile+player+that+frequently+appears+in+preclinical%2Fclinical+drug+molecules&doi=10.1021%2Facs.jmedchem.6b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8712-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclin. to clin. stage.  Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes.  The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs contg. it.  Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIJAG1XVRG7Vg90H21EOLACvtfcHk0liblrNwLTCMtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D&md5=b5586458ec4ab5e2d7586f5739663d1f</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DThe%2520%25E2%2580%259Ccyclopropyl%2520fragment%25E2%2580%259D%2520is%2520a%2520versatile%2520player%2520that%2520frequently%2520appears%2520in%2520preclinical%252Fclinical%2520drug%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8712%26epage%3D8756%26doi%3D10.1021%2Facs.jmedchem.6b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">In vitro Metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1021/tx7003085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7003085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=711-719&author=Q.+Sunauthor=R.+Zhuauthor=F.+W.+Fossauthor=T.+L.+Macdonald&title=In+vitro+Metabolism+of+a+model+cyclopropylamine+to+reactive+intermediate%3A+insights+into+trovafloxacin-induced+hepatotoxicity&doi=10.1021%2Ftx7003085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Metabolism of a Model Cyclopropylamine to Reactive Intermediate: Insights into Trovafloxacin-Induced Hepatotoxicity</span></div><div class="casAuthors">Sun, Qin; Zhu, Ran; Foss, Frank W.; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">711-719</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trovafloxacin (Trovan) is a fluoroquinolone antibiotic drug with a long half-life and broad-spectrum activity.  Since its entry into the market in 1998, trovafloxacin has been assocd. with numerous cases of hepatotoxicity, which has limited its clin. usefulness.  Trovafloxacin possesses two substructural elements that have the potential to generate reactive intermediates: a cyclopropylamine moiety and a difluoroanilino system.  The results presented here describe the in vitro metabolic activation of a synthetic drug model (DM) of trovafloxacin that contains the cyclopropylamine moiety.  Cyclopropylamine can be oxidized to reactive ring-opened products-a carbon-centered radical and a subsequently oxidized α,β-unsatd. aldehyde.  Expts. with monoamine oxygenases, horseradish peroxidase, flavin monooxygenase 3, and cDNA-expressed P 450 isoenzymes revealed that P 450 1A2 oxidizes DM to a reactive α,β-unsatd. aldehyde, M1.  Furthermore, myeloperoxidase (MPO) was also demonstrated to oxidize DM in the presence of chloride ion to produce M1.  DM proved to be a suicide inhibitor of MPO while showing no inhibition of P 450 1A2.  The structure of the reactive metabolite was confirmed by LC-MS/MS anal. by comparison with a synthetic std. M1 was further shown to react with glutathione and the related thiol nucleophile, 4-bromobenzyl mercaptan, suggesting the potential of this intermediate to react with protein nucleophiles.  In summary, these data provide evidence that trovafloxacin-induced hepatotoxicity may be mediated through the oxidn. of the cyclopropylamine substructure to reactive intermediates that may form covalent adducts to hepatic proteins, resulting in damage to liver tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr211JADO6oxbVg90H21EOLACvtfcHk0lhgpO1RHYJAVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D&md5=cb587b2776c7af787f6527a01765ebdb</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Ftx7003085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7003085%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DIn%2520vitro%2520Metabolism%2520of%2520a%2520model%2520cyclopropylamine%2520to%2520reactive%2520intermediate%253A%2520insights%2520into%2520trovafloxacin-induced%2520hepatotoxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D711%26epage%3D719%26doi%3D10.1021%2Ftx7003085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, T.</span></span> <span> </span><span class="NLM_article-title">Introduction of fluorine and fluorine-containing functional groups</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8214</span>– <span class="NLM_lpage">8264</span>, <span class="refDoi"> DOI: 10.1002/anie.201206566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fanie.201206566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8214-8264&author=T.+Liangauthor=C.+N.+Neumannauthor=T.+Ritter&title=Introduction+of+fluorine+and+fluorine-containing+functional+groups&doi=10.1002%2Fanie.201206566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Introduction of Fluorine and Fluorine-Containing Functional Groups</span></div><div class="casAuthors">Liang, Theresa; Neumann, Constanze N.; Ritter, Tobias</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8214-8264</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This Review gives a brief summary of conventional fluorination reactions, including those reactions that introduce fluorinated functional groups, and focuses on modern developments in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLdUas7duMW7Vg90H21EOLACvtfcHk0lhgpO1RHYJAVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7bI&md5=1dafdf60409a792e78d946731f6cc2b9</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fanie.201206566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201206566%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DNeumann%26aufirst%3DC.%2BN.%26aulast%3DRitter%26aufirst%3DT.%26atitle%3DIntroduction%2520of%2520fluorine%2520and%2520fluorine-containing%2520functional%2520groups%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8214%26epage%3D8264%26doi%3D10.1002%2Fanie.201206566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banks, W. A.</span></span> <span> </span><span class="NLM_article-title">Characteristics of compounds that cross the blood-brain barrier</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">S3</span>, <span class="refDoi"> DOI: 10.1186/1471-2377-9-S1-S3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1186%2F1471-2377-9-S1-S3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19534732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1MvktFyhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=S3&author=W.+A.+Banks&title=Characteristics+of+compounds+that+cross+the+blood-brain+barrier&doi=10.1186%2F1471-2377-9-S1-S3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Characteristics of compounds that cross the blood-brain barrier</span></div><div class="casAuthors">Banks William A</div><div class="citationInfo"><span class="NLM_cas:title">BMC neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Substances cross the blood-brain barrier (BBB) by a variety of mechanisms.  These include transmembrane diffusion, saturable transporters, adsorptive endocytosis, and the extracellular pathways.  Here, we focus on the chief characteristics of two mechanisms especially important in drug delivery: transmembrane diffusion and transporters.  Transmembrane diffusion is non-saturable and depends, on first analysis, on the physicochemical characteristics of the substance.  However, brain-to-blood efflux systems, enzymatic activity, plasma protein binding, and cerebral blood flow can greatly alter the amount of the substance crossing the BBB.  Transport systems increase uptake of ligands by roughly 10-fold and are modified by physiological events and disease states.  Most drugs in clinical use to date are small, lipid soluble molecules that cross the BBB by transmembrane diffusion.  However, many drug delivery strategies in development target peptides, regulatory proteins, oligonucleotides, glycoproteins, and enzymes for which transporters have been described in recent years.  We discuss two examples of drug delivery for newly discovered transporters: that for phosphorothioate oligonucleotides and for enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIZxs0Ddmv8a69lAbTj9rGfW6udTcc2eZWVZQpTi9DF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvktFyhtw%253D%253D&md5=8063f8a2a4184aac2d36a9a5c6f67d30</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1186%2F1471-2377-9-S1-S3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2377-9-S1-S3%26sid%3Dliteratum%253Aachs%26aulast%3DBanks%26aufirst%3DW.%2BA.%26atitle%3DCharacteristics%2520of%2520compounds%2520that%2520cross%2520the%2520blood-brain%2520barrier%26jtitle%3DBMC%2520Neurol.%26date%3D2009%26volume%3D9%26spage%3DS3%26doi%3D10.1186%2F1471-2377-9-S1-S3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alagha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofalvi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouitaa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanez, P.</span></span> <span> </span><span class="NLM_article-title">Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases</span>. <i>Ther. Adv. Chronic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1177/2040622313518227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1177%2F2040622313518227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24587893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=85-98&author=K.+Alaghaauthor=A.+Palotauthor=T.+Sofalviauthor=L.+Pahusauthor=M.+Gouitaaauthor=C.+Tumminoauthor=S.+Martinezauthor=D.+Charpinauthor=A.+Bourdinauthor=P.+Chanez&title=Long-acting+muscarinic+receptor+antagonists+for+the+treatment+of+chronic+airway+diseases&doi=10.1177%2F2040622313518227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases</span></div><div class="casAuthors">Alagha, Khuder; Palot, Alain; Sofalvi, Tunde; Pahus, Laurie; Gouitaa, Marion; Tummino, Celine; Martinez, Stephanie; Charpin, Denis; Bourdin, Arnaud; Chanez, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Chronic Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-98, 14</span>CODEN:
                <span class="NLM_cas:coden">TACDCS</span>;
        ISSN:<span class="NLM_cas:issn">2040-6223</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion.  It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells.  Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors.  Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide.  All have higher selectivity for M3 receptors than for M2 receptors, and dissoc. more slowly from the M3 receptors than they do from the M2 receptors.  Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-pos. goblet cell no., decrease in MUC5AC overexpression).  In the clinic, LAMAs showed a significant improvement of forced expiratory vol. in 1 s (FEV1), quality of life, dyspnea and reduced the no. of exacerbations in COPD and more recently in asthma.  This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVv9hvW4HRY7Vg90H21EOLACvtfcHk0lhboRdCG1yRjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF&md5=4f1bf29c29adced609e3c61c36cec938</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1177%2F2040622313518227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040622313518227%26sid%3Dliteratum%253Aachs%26aulast%3DAlagha%26aufirst%3DK.%26aulast%3DPalot%26aufirst%3DA.%26aulast%3DSofalvi%26aufirst%3DT.%26aulast%3DPahus%26aufirst%3DL.%26aulast%3DGouitaa%26aufirst%3DM.%26aulast%3DTummino%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DCharpin%26aufirst%3DD.%26aulast%3DBourdin%26aufirst%3DA.%26aulast%3DChanez%26aufirst%3DP.%26atitle%3DLong-acting%2520muscarinic%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520chronic%2520airway%2520diseases%26jtitle%3DTher.%2520Adv.%2520Chronic%2520Dis.%26date%3D2014%26volume%3D5%26spage%3D85%26epage%3D98%26doi%3D10.1177%2F2040622313518227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vankeerberghen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuppens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiman, J. J.</span></span> <span> </span><span class="NLM_article-title">The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions</span>. <i>J. Cystic Fibrosis</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/S1569-1993(01)00003-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS1569-1993%2801%2900003-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15463806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=13-29&author=A.+Vankeerberghenauthor=H.+Cuppensauthor=J.+J.+Cassiman&title=The+cystic+fibrosis+transmembrane+conductance+regulator%3A+an+intriguing+protein+with+pleiotropic+functions&doi=10.1016%2FS1569-1993%2801%2900003-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions</span></div><div class="casAuthors">Vankeerberghen, Anne; Cuppens, Harry; Cassiman, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-29</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Cystic fibrosis is a frequent autosomal recessive disorder that is caused by the malfunctioning of a small chloride channel, the cystic fibrosis transmembrane conductance regulator.  The protein is found in the apical membrane of epithelial cells lining exocrine glands.  Absence of this channel results in imbalance of ion concns. across the cell membrane.  As a result, fluids secreted through these glands become more viscous and, in the end, ducts become plugged and atrophic.  Little is known about the pathways that link the malfunctioning of the CFTR protein with the obsd. clin. phenotype.  Moreover, there is no strict correlation between specific CFTR mutations and the CF phenotype.  This might be explained by the fact that environmental and addnl. genetic factors may influence the phenotype.  The CFTR protein itself is regulated at the maturational level by chaperones and SNARE proteins and at the functional level by several protein kinases.  Moreover, CFTR functions also as a regulator of other ion channels and of intracellular membrane transport processes.  To be able to function as a protein with pleiotropic actions, CFTR seems to be linked with other proteins and with the cytoskeleton through interaction with PDZ-domain-contg. proteins at the apical pole of the cell.  Progress in cystic fibrosis research is substantial, but still leaves many questions unanswered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeb5SM-sSMUbVg90H21EOLACvtfcHk0lhboRdCG1yRjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslKmtbw%253D&md5=a7c0b3bcbf4c641fc90b8c1199c9deef</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS1569-1993%2801%2900003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1569-1993%252801%252900003-0%26sid%3Dliteratum%253Aachs%26aulast%3DVankeerberghen%26aufirst%3DA.%26aulast%3DCuppens%26aufirst%3DH.%26aulast%3DCassiman%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%253A%2520an%2520intriguing%2520protein%2520with%2520pleiotropic%2520functions%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2002%26volume%3D1%26spage%3D13%26epage%3D29%26doi%3D10.1016%2FS1569-1993%2801%2900003-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1992</span>– <span class="NLM_lpage">2001</span>, <span class="refDoi"> DOI: 10.1056/NEJMra043184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMra043184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15888700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFyrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1992-2001&author=S.+M.+Roweauthor=S.+Millerauthor=E.+J.+Sorscher&title=Cystic+Fibrosis&doi=10.1056%2FNEJMra043184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis</span></div><div class="casAuthors">Rowe, Steven M.; Miller, Stacey; Sorscher, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1992-2001</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Important advances have improved our understanding of the role of the CFTR protein in the progression of suppurative pulmonary failure in cystic fibrosis.  These discoveries are ushering in a new era of translational research that incorporates specific therapeutic targets and new cellular pathways.  Progress in research on cystic fibrosis will continue to rely on an improved understanding of CFTR function and its relationship to mucociliary clearance, airway secretion, and other ion channels.  Clin. advances directed at the correction of CFTR function predict an optimistic future for patients with cystic fibrosis and their families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKiiafli4tp7Vg90H21EOLACvtfcHk0lhboRdCG1yRjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFyrtLY%253D&md5=e6bc05b49d7b177d43dd7592ad63f0fb</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1056%2FNEJMra043184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra043184%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26atitle%3DCystic%2520Fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1992%26epage%3D2001%26doi%3D10.1056%2FNEJMra043184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marigowda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flume, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstan, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McColley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratjen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, M. P.</span></span> <span> </span><span class="NLM_article-title">Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1409547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa1409547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25981758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=220-231&author=C.+E.+Wainwrightauthor=J.+S.+Elbornauthor=B.+W.+Ramseyauthor=G.+Marigowdaauthor=X.+Huangauthor=M.+Cipolliauthor=C.+Colomboauthor=J.+C.+Daviesauthor=K.+De+Boeckauthor=P.+A.+Flumeauthor=M.+W.+Konstanauthor=S.+A.+McColleyauthor=K.+McCoyauthor=E.+F.+McKoneauthor=A.+Munckauthor=F.+Ratjenauthor=S.+M.+Roweauthor=D.+Waltzauthor=M.+P.+Boyle&title=Lumacaftor%E2%80%93ivacaftor+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del+CFTR&doi=10.1056%2FNEJMoa1409547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span></div><div class="casAuthors">Wainwright, C. E.; Elborn, J. S.; Ramsey, B. W.; Marigowda, G.; Huang, X.; Cipolli, M.; Colombo, C.; Davies, J. C.; De Boeck, K.; Flume, P. A.; Konstan, M. W.; McColley, S. A.; McCoy, K.; McKone, E. F.; Munck, A.; Ratjen, F.; Rowe, S. M.; Waltz, D.; Boyle, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-231</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity.  Phe508del is the most common CFTR mutation.  We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who had cystic fibrosis and were homozygous for the Phe508del CFTR mutation.  In both studies, patients were randomly assigned to receive either lumacaftor (600 mg once daily or 400 mg every 12 h) in combination with ivacaftor (250 mg every 12 h) or matched placebo for 24 wk.  The primary end point was the abs. change from baseline in the percentage of predicted forced expiratory vol. in 1 s (FEV1) at week 24.  A total of 1108 patients underwent randomization and received study drug.  The mean baseline FEV1 was 61% of the predicted value.  In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean abs. improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 percentage points (P<0.001), which corresponded to a mean relative treatment difference of 4.3 to 6.7% (P<0.001).  Pooled analyses showed that the rate of pulmonary exacerbations was 30 to 39% lower in the lumacaftor-ivacaftor groups than in the placebo group; the rate of events leading to hospitalization or the use of i.v. antibiotics was lower in the lumacaftor-ivacaftor groups as well.  The incidence of adverse events was generally similar in the lumacaftor-ivacaftor and placebo groups.  The rate of discontinuation due to an adverse event was 4.2% among patients who received lumacaftor-ivacaftor vs. 1.6% among those who received placebo.  These data show that lumacaftor in combination with ivacaftor provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZ6NBA6wsbbVg90H21EOLACvtfcHk0lj8nauXC1DwMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ&md5=223bb13c5c677a4db798be91ccedc665</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1409547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1409547%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCipolli%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BBoeck%26aufirst%3DK.%26aulast%3DFlume%26aufirst%3DP.%2BA.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DMcColley%26aufirst%3DS.%2BA.%26aulast%3DMcCoy%26aufirst%3DK.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DRatjen%26aufirst%3DF.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DBoyle%26aufirst%3DM.%2BP.%26atitle%3DLumacaftor%25E2%2580%2593ivacaftor%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%2520CFTR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D220%26epage%3D231%26doi%3D10.1056%2FNEJMoa1409547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor-Cousar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Ent, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingenito, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa1709846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=29099344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFyr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2013-2023&author=J.+L.+Taylor-Cousarauthor=A.+Munckauthor=E.+F.+McKoneauthor=C.+K.+van+der%0AEntauthor=A.+Moellerauthor=C.+Simardauthor=L.+T.+Wangauthor=E.+P.+Ingenitoauthor=C.+McKeeauthor=Y.+Luauthor=J.+Lekstrom-Himesauthor=J.+S.+Elborn&title=Tezacaftor%E2%80%93ivacaftor+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del&doi=10.1056%2FNEJMoa1709846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del</span></div><div class="casAuthors">Taylor-Cousar, Jennifer L.; Munck, Anne; McKone, Edward F.; van der Ent, Cornelis K.; Moeller, Alexander; Simard, Christopher; Wang, Linda T.; Ingenito, Edward P.; McKee, Charlotte; Lu, Yimeng; Lekstrom-Himes, Julie; Elborn, J. Stuart</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2013-2023</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis.  In this phase 3, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial, we evaluated combination therapy with tezacaftor and ivacaftor in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.  Patients were randomly assigned in a 1:1 ratio to receive either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily or matched placebo for 24 wk.  The primary end point was the abs. change in the percentage of the predicted forced expiratory vol. in 1 s (FEV1) through week 24 (calcd. in percentage points); relative change in the percentage of the predicted FEV1 through week 24 (calcd. as a percentage) was a key secondary end point.  Of the 510 patients who underwent randomization, 509 received tezacaftor-ivacaftor or placebo, and 475 completed 24 wk of the trial regimen.  The mean FEV1 at baseline was 60.0% of the predicted value.  The effects on the abs. and relative changes in the percentage of the predicted FEV1 in favor of tezacaftor-ivacaftor over placebo were 4.0 percentage points and 6.8%, resp. (P<0.001 for both comparisons).  The rate of pulmonary exacerbation was 35% lower in the tezacaftor-ivacaftor group than in the placebo group (P = 0.005).  The incidence of adverse events was similar in the two groups.  Most adverse events were of mild severity (in 41.8% of patients overall) or moderate severity (in 40.9% overall), and serious adverse events were less frequent with tezacaftor-ivacaftor (12.4%) than with placebo (18.2%).  A total of 2.9% of patients discontinued the assigned regimen owing to adverse events.  Fewer patients in the tezacaftor-ivacaftor group than in the placebo group had respiratory adverse events, none of which led to discontinuation. conclusions The combination of tezacaftor and ivacaftor was efficacious and safe in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry28bA5s2HMrVg90H21EOLACvtfcHk0lhjskWpKbeWfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFyr&md5=a8aec50415d3dec5202ce53b5176960d</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709846%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor-Cousar%26aufirst%3DJ.%2BL.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3Dvan%2Bder%2BEnt%26aufirst%3DC.%2BK.%26aulast%3DMoeller%26aufirst%3DA.%26aulast%3DSimard%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DIngenito%26aufirst%3DE.%2BP.%26aulast%3DMcKee%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26atitle%3DTezacaftor%25E2%2580%2593ivacaftor%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2013%26epage%3D2023%26doi%3D10.1056%2FNEJMoa1709846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichhpujani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, L. J.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension</span>. <i>Drug, Healthcare Patient Saf.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.2147/DHPS.S9757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FDHPS.S9757" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=73-83&author=P.+Ichhpujaniauthor=L.+J.+Katz&title=Efficacy%2C+safety+and+tolerability+of+combination+therapy+with+timolol+and+dorzolamide+in+glaucoma+and+ocular+hypertension&doi=10.2147%2FDHPS.S9757"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2147%2FDHPS.S9757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDHPS.S9757%26sid%3Dliteratum%253Aachs%26aulast%3DIchhpujani%26aufirst%3DP.%26aulast%3DKatz%26aufirst%3DL.%2BJ.%26atitle%3DEfficacy%252C%2520safety%2520and%2520tolerability%2520of%2520combination%2520therapy%2520with%2520timolol%2520and%2520dorzolamide%2520in%2520glaucoma%2520and%2520ocular%2520hypertension%26jtitle%3DDrug%252C%2520Healthcare%2520Patient%2520Saf.%26date%3D2010%26volume%3D2010%26spage%3D73%26epage%3D83%26doi%3D10.2147%2FDHPS.S9757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantor, L. B.</span></span> <span> </span><span class="NLM_article-title">Brimonidine in the treatment of glaucoma and ocular hypertension</span>. <i>Ther. Clin. Risk Manag.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.2147/tcrm.2006.2.4.337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2Ftcrm.2006.2.4.337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18360646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=337-346&author=L.+B.+Cantor&title=Brimonidine+in+the+treatment+of+glaucoma+and+ocular+hypertension&doi=10.2147%2Ftcrm.2006.2.4.337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Brimonidine in the treatment of glaucoma and ocular hypertension</span></div><div class="casAuthors">Cantor, Louis B.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-346</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression and vision loss.  The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle glaucoma and ocular hypertension.  A fixed combination of brimonidine and timolol, available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine and timolol and offers the convenience of 2 drugs in a single eyedrop.  Brimonidine is safe and well tolerated.  Its most common side-effects are conjunctival hyperemia, allergic conjunctivitis, and ocular pruritus.  The newest formulation of brimonidine, brimonidine-Purite 0.1%, has a higher pH to improve the ocular bioavailability of brimonidine.  This formulation contains the lowest effective concn. of brimonidine and is preserved with Purite'" to enhance ocular tolerability.  Brimonidine-Purite 0.1% is as effective in reducing IOP as the original brimonidine 0.2% soln. preserved with benzalkonium chloride.  Recent results from preclin. and clin. studies suggest that brimonidine may protect retinal ganglion cells and their projections from damage and death independently of its effects on IOP.  The potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and ocular hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkwBNY0ZB1U7Vg90H21EOLACvtfcHk0lhGjQw3jfis2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislOqtA%253D%253D&md5=507dd6199884e7e3d6b5015ae2b325de</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.2147%2Ftcrm.2006.2.4.337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Ftcrm.2006.2.4.337%26sid%3Dliteratum%253Aachs%26aulast%3DCantor%26aufirst%3DL.%2BB.%26atitle%3DBrimonidine%2520in%2520the%2520treatment%2520of%2520glaucoma%2520and%2520ocular%2520hypertension%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manag.%26date%3D2006%26volume%3D2%26spage%3D337%26epage%3D346%26doi%3D10.2147%2Ftcrm.2006.2.4.337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tǎtaru, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcǎrea, V. L.</span></span> <span> </span><span class="NLM_article-title">Antiglaucoma pharmacotherapy</span>. <i>J. Med. Life</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23049625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FjslSqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=247-251&author=C.+P.+T%C7%8Etaruauthor=V.+L.+Purc%C7%8Erea&title=Antiglaucoma+pharmacotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antiglaucoma pharmacotherapy</span></div><div class="casAuthors">Tataru C P; Purcarea V L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicine and life</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review presents the pharmacotherapeutic approaches available in the treatment of glaucomatous optic neuropathy.  Although its etiology is multi-factorial, currently, the main therapy is to decrease intraocular pressure.  New therapies are being developed; the current trend is a retinal ganglion cell neuroprotection.  Neuroprotection is achieved by combining antihypertensive agents with drugs that directly protect the optic nerve by promoting cell survival and inhibition of neuronal signals that initiate apoptosis.  The treatment should also preserve the ocular hemodynamics, ensure proper patient compliance and be free of side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMwJt9ij_06gqdek-gHSrIfW6udTcc2eaPf17WS9aJuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FjslSqtA%253D%253D&md5=c8d0d80408273737f97f14cc36b9748c</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DT%25C7%258Etaru%26aufirst%3DC.%2BP.%26aulast%3DPurc%25C7%258Erea%26aufirst%3DV.%2BL.%26atitle%3DAntiglaucoma%2520pharmacotherapy%26jtitle%3DJ.%2520Med.%2520Life%26date%3D2012%26volume%3D5%26spage%3D247%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawuyi, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbaxani, A.</span></span> <span> </span><span class="NLM_article-title">The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery</span>. <i>Clin. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.2147/OPTH.S72321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2FOPTH.S72321" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1249-1254&author=L.+E.+Lawuyiauthor=A.+Gurbaxani&title=The+clinical+utility+of+new+combination+phenylephrine%2Fketorolac+injection+in+cataract+surgery&doi=10.2147%2FOPTH.S72321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.2147%2FOPTH.S72321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOPTH.S72321%26sid%3Dliteratum%253Aachs%26aulast%3DLawuyi%26aufirst%3DL.%2BE.%26aulast%3DGurbaxani%26aufirst%3DA.%26atitle%3DThe%2520clinical%2520utility%2520of%2520new%2520combination%2520phenylephrine%252Fketorolac%2520injection%2520in%2520cataract%2520surgery%26jtitle%3DClin.%2520Ophthalmol.%26date%3D2015%26volume%3D2015%26spage%3D1249%26epage%3D1254%26doi%3D10.2147%2FOPTH.S72321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udell, I. J.</span></span> <span> </span><span class="NLM_article-title">A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.clinthera.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=15978305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=568-577&author=J.+V.+Greinerauthor=I.+J.+Udell&title=A+comparison+of+the+clinical+efficacy+of+pheniramine+maleate%2Fnaphazoline+hydrochloride+ophthalmic+solution+and+olopatadine+hydrochloride+ophthalmic+solution+in+the+conjunctival+allergen+challenge+model&doi=10.1016%2Fj.clinthera.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model</span></div><div class="casAuthors">Greiner, Jack V.; Udell, Ira J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-577</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">The signs and symptoms of allergic conjunctivitis include ocular redness and itching.  Two treatment options currently indicated for acute ocular allergic reaction are pheniramine maleate 0.3%/naphazoline hydrochloride 0.025% ophthalmic soln., an over-the-counter antihistamine/vasoconstrictor combination; and olopatadine hydrochloride 0.1% ophthalmic soln., a prescription antihistamine/mast cell stabilizer.  This study was designed to compare, at onset of action, the relative effectiveness of pheniramine/naphazoline and olopatadine, when administered before conjunctival allergen challenge (CAC), using the ocular allergy index (OAI) as the primary end point.  This was a prospective, randomized, double-masked, contralateral, active- and placebo-controlled, single-center study of the CAC model.  The first 2 study visits established and confirmed the subjects' ocular allergic reaction (no medication administered).  At visit 3, the subjects were randomly assigned to 1 of 3 contralateral (right eye vs left eye) treatment combinations: pheniramine/naphazoline + olopatadine, pheniramine/naphazoline + placebo, or olopatadine + placebo.  Medication was given 10 min before CAC.  The subjects' erythema in the ciliary, conjunctival, and episcleral vessel beds; eyelid swelling; chemosis; and itching were evaluated at 7, 12, and 20 min after CAC.  The OAI was calcd. as a composite score of 6 signs and symptoms of allergic conjunctivitis to assess global severity.  Between-treatment differences in OAI scores were used to evaluate efficacy.  Subjects were asked their eye drop preference at the conclusion of visit 3.  Subjects (n = 83) ranged in age from 20 to 70 years (mean, 42.5 years), 61.4% (n = 51) were female, and 94.0% (n = 78) were white.  Both pheniramine/naphazoline and olopatadine were assocd. with significantly lower OAI scores than placebo at all 3 time points (all, P < 0.001). OAI scores were significantly lower with pheniramine/naphazoline than with olopatadine at 12 and 20 min (P = 0.005 and P = 0.001, resp.).  In this patient sample, studied in a CAC model of onset of action, prophylactic pheniramine/naphazoline was more effective than olopatadine and placebo in alleviating the signs and symptoms of the acute ocular allergic reaction, as measured by the OAI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR97YSN3KHzrVg90H21EOLACvtfcHk0lga8CHBpYw2BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLzO&md5=e4c8b46cade177bd14d9a6f6df7ea86b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DGreiner%26aufirst%3DJ.%2BV.%26aulast%3DUdell%26aufirst%3DI.%2BJ.%26atitle%3DA%2520comparison%2520of%2520the%2520clinical%2520efficacy%2520of%2520pheniramine%2520maleate%252Fnaphazoline%2520hydrochloride%2520ophthalmic%2520solution%2520and%2520olopatadine%2520hydrochloride%2520ophthalmic%2520solution%2520in%2520the%2520conjunctival%2520allergen%2520challenge%2520model%26jtitle%3DClin.%2520Ther.%26date%3D2005%26volume%3D27%26spage%3D568%26epage%3D577%26doi%3D10.1016%2Fj.clinthera.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. J.</span></span> <span> </span><span class="NLM_article-title">The introduction of ‘chemotherapy’ using arsphenamine – the first magic bullet</span>. <i>J. R. Soc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1258/jrsm.2009.09k036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1258%2Fjrsm.2009.09k036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=19679737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1Mrltl2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2009&pages=343-348&author=K.+J.+Williams&title=The+introduction+of+%E2%80%98chemotherapy%E2%80%99+using+arsphenamine+%E2%80%93+the+first+magic+bullet&doi=10.1258%2Fjrsm.2009.09k036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The introduction of 'chemotherapy' using arsphenamine - the first magic bullet</span></div><div class="casAuthors">Williams K J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">343-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShc9t9tsOM4w20zIbnCCI3fW6udTcc2eZtMKLT5xoWRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mrltl2nsA%253D%253D&md5=dbb34b41116e73fb7e3395913c53ec13</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1258%2Fjrsm.2009.09k036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1258%252Fjrsm.2009.09k036%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520introduction%2520of%2520%25E2%2580%2598chemotherapy%25E2%2580%2599%2520using%2520arsphenamine%2520%25E2%2580%2593%2520the%2520first%2520magic%2520bullet%26jtitle%3DJ.%2520R.%2520Soc.%2520Med.%26date%3D2009%26volume%3D102%26spage%3D343%26epage%3D348%26doi%3D10.1258%2Fjrsm.2009.09k036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skipper, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schabel, F. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, W. S.</span></span> <span> </span><span class="NLM_article-title">Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with “curability” of experimental leukemia</span>. <i>Cancer Chemother. Rep.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=14117037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADyaF2c%252FnsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1964&pages=1-111&author=H.+E.+Skipperauthor=F.+R.+Schabelauthor=W.+S.+Wilcox&title=Experimental+evaluation+of+potential+anticancer+agents.+XII.+On+the+criteria+and+kinetics+associated+with+%E2%80%9Ccurability%E2%80%9D+of+experimental+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH   "CURABILITY" OF EXPERIMENTAL LEUKEMIA</span></div><div class="casAuthors">SKIPPER H E; SCHABEL F M Jr; WILCOX W S</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy reports</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-111</span>
        ISSN:<span class="NLM_cas:issn">0069-0112</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpEmGT4if7p_x2phytoz6_fW6udTcc2eZ9L_dS6Jy1fbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF2c%252FnsVOmtw%253D%253D&md5=6caccfebe1883b6606c8dcc7f8612bb9</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkipper%26aufirst%3DH.%2BE.%26aulast%3DSchabel%26aufirst%3DF.%2BR.%26aulast%3DWilcox%26aufirst%3DW.%2BS.%26atitle%3DExperimental%2520evaluation%2520of%2520potential%2520anticancer%2520agents.%2520XII.%2520On%2520the%2520criteria%2520and%2520kinetics%2520associated%2520with%2520%25E2%2580%259Ccurability%25E2%2580%259D%2520of%2520experimental%2520leukemia%26jtitle%3DCancer%2520Chemother.%2520Rep.%26date%3D1964%26volume%3D35%26spage%3D1%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, M. A.</span>; <span class="NLM_string-name">Spivak, J. L.</span>; <span class="NLM_string-name">Boxer, L. A.</span>; <span class="NLM_string-name">Shattil, S. J.</span>; <span class="NLM_string-name">Henderson, E. S.</span></span> <span> </span><span class="NLM_article-title">Commentary on and reprint of Freireich EJ, Karon M, Frei E III, Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood, in Proceedings of the American Association for Cancer Research (1964) 5:20</span>. In  <i>Hematology: Landmark Papers of the Twentieth Century</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2000</span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">657</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FB978-012448510-5%2F50152-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=655-657&author=M.+A.+Lichtman&author=J.+L.+Spivak&author=L.+A.+Boxer&author=S.+J.+Shattil&author=E.+S.+Henderson&title=Hematology%3A+Landmark+Papers+of+the+Twentieth+Century"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FB978-012448510-5%2F50152-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-012448510-5%252F50152-7%26sid%3Dliteratum%253Aachs%26aulast%3DLichtman%26aufirst%3DM.%2BA.%26atitle%3DCommentary%2520on%2520and%2520reprint%2520of%2520Freireich%2520EJ%252C%2520Karon%2520M%252C%2520Frei%2520E%2520III%252C%2520Quadruple%2520combination%2520therapy%2520%2528VAMP%2529%2520for%2520acute%2520lymphocytic%2520leukemia%2520of%2520childhood%252C%2520in%2520Proceedings%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%25281964%2529%25205%253A20%26btitle%3DHematology%253A%2520Landmark%2520Papers%2520of%2520the%2520Twentieth%2520Century%26pub%3DAcademic%2520Press%26date%3D2000%26spage%3D655%26epage%3D657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span> <span> </span><span class="NLM_article-title">A history of cancer chemotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">8643</span>– <span class="NLM_lpage">8653</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1158%2F0008-5472.CAN-07-6611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18974103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSktbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=8643-8653&author=V.+T.+DeVitaauthor=E.+Chu&title=A+history+of+cancer+chemotherapy&doi=10.1158%2F0008-5472.CAN-07-6611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A History of Cancer Chemotherapy</span></div><div class="casAuthors">DeVita, Vincent T., Jr.; Chu, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8643-8653</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The use of chemotherapy to treat cancer began at the start of the 20th century with attempts to narrow the universe of chems. that might affect the disease by developing methods to screen chems. using transplantable tumors in rodents.  It was, however, four World War II-related programs, and the effects of drugs that evolved from them, that provided the impetus to establish in 1955 the national drug development effort known as the Cancer Chemotherapy National Service Center.  The ability of combination chemotherapy to cure acute childhood leukemia and advanced Hodgkin's disease in the 1960s and early 1970s overcame the prevailing pessimism about the ability of drugs to cure advanced cancers, facilitated the study of adjuvant chemotherapy, and helped foster the national cancer program.  Today, chemotherapy has changed as important mol. abnormalities are being used to screen for potential new drugs as well as for targeted treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe683yjb5O2bVg90H21EOLACvtfcHk0lhiE_HvuF0wyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSktbbJ&md5=0b7460caa70c04f8421903b5b417e935</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6611%26sid%3Dliteratum%253Aachs%26aulast%3DDeVita%26aufirst%3DV.%2BT.%26aulast%3DChu%26aufirst%3DE.%26atitle%3DA%2520history%2520of%2520cancer%2520chemotherapy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D8643%26epage%3D8653%26doi%3D10.1158%2F0008-5472.CAN-07-6611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freireich, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frei, E.,  III.</span></span> <span> </span><span class="NLM_article-title">Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood</span>. <i>Proc. Am. Assoc. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">20</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1964&pages=20&author=E.+J.+Freireichauthor=M.+Karonauthor=E.+Frei&title=Quadruple+combination+therapy+%28VAMP%29+for+acute+lymphocytic+leukemia+of+childhood"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFreireich%26aufirst%3DE.%2BJ.%26aulast%3DKaron%26aufirst%3DM.%26aulast%3DFrei%26aufirst%3DE.%26atitle%3DQuadruple%2520combination%2520therapy%2520%2528VAMP%2529%2520for%2520acute%2520lymphocytic%2520leukemia%2520of%2520childhood%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D1964%26volume%3D5%26spage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppal, P.</span></span> <span> </span><span class="NLM_article-title">Trifluridine/Tipiracil (Lonsurf) for the treatment of metastatic colorectal cancer</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">325</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=314-325&author=T.+Kishauthor=P.+Uppal&title=Trifluridine%2FTipiracil+%28Lonsurf%29+for+the+treatment+of+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKish%26aufirst%3DT.%26aulast%3DUppal%26aufirst%3DP.%26atitle%3DTrifluridine%252FTipiracil%2520%2528Lonsurf%2529%2520for%2520the%2520treatment%2520of%2520metastatic%2520colorectal%2520cancer%26jtitle%3DPharm.%2520Ther.%26date%3D2016%26volume%3D41%26spage%3D314%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentikis, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A. C.</span></span> <span> </span><span class="NLM_article-title">CPX-351 ((Cytarabine:Daunorubicin) liposome injection, (Vyxeos)) does not prolong Qtcf intervals, requires no dose adjustment for impaired renal function and induces high rates of complete remission in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">2510</span>– <span class="NLM_lpage">2510</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=2510-2510&author=T.+L.+Linauthor=L.+F.+Newellauthor=R.+K.+Stuartauthor=L.+C.+Michaelisauthor=S.+E.+Rubensteinauthor=H.+S.+Pentikisauthor=T.+Callahanauthor=D.+Alvarezauthor=L.+D.+Mayerauthor=A.+C.+Louie&title=CPX-351+%28%28Cytarabine%3ADaunorubicin%29+liposome+injection%2C+%28Vyxeos%29%29+does+not+prolong+Qtcf+intervals%2C+requires+no+dose+adjustment+for+impaired+renal+function+and+induces+high+rates+of+complete+remission+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BL.%26aulast%3DNewell%26aufirst%3DL.%2BF.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DMichaelis%26aufirst%3DL.%2BC.%26aulast%3DRubenstein%26aufirst%3DS.%2BE.%26aulast%3DPentikis%26aufirst%3DH.%2BS.%26aulast%3DCallahan%26aufirst%3DT.%26aulast%3DAlvarez%26aufirst%3DD.%26aulast%3DMayer%26aufirst%3DL.%2BD.%26aulast%3DLouie%26aufirst%3DA.%2BC.%26atitle%3DCPX-351%2520%2528%2528Cytarabine%253ADaunorubicin%2529%2520liposome%2520injection%252C%2520%2528Vyxeos%2529%2529%2520does%2520not%2520prolong%2520Qtcf%2520intervals%252C%2520requires%2520no%2520dose%2520adjustment%2520for%2520impaired%2520renal%2520function%2520and%2520induces%2520high%2520rates%2520of%2520complete%2520remission%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D2510%26epage%3D2510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoering, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B.</span></span> <span> </span><span class="NLM_article-title">Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary) AML</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">7000</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.34.15_suppl.7000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1200%2FJCO.2016.34.15_suppl.7000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=7000&author=J.+Lancetauthor=G.+Uyauthor=J.+Cortesauthor=+Newellauthor=T.+Linauthor=E.+Ritchieauthor=R.+Stuartauthor=A.+Stricklandauthor=D.+Hoggeauthor=S.+Solomonauthor=R.+Stoneauthor=D.+Bixbyauthor=J.+Kolitzauthor=G.+Schillerauthor=J.+Wieduwiltauthor=D.+Ryanauthor=A.+Hoeringauthor=M.+Chiarellaauthor=A.+Louieauthor=B.+Medeiros&title=Final+results+of+a+phase+III+randomized+trial+of+CPX-351+versus+7+%2B+3+in+older+patients+with+newly+diagnosed+high+risk+%28secondary%29+AML&doi=10.1200%2FJCO.2016.34.15_suppl.7000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.7000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.7000%26sid%3Dliteratum%253Aachs%26aulast%3DLancet%26aufirst%3DJ.%26aulast%3DUy%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DNewell%26aulast%3DLin%26aufirst%3DT.%26aulast%3DRitchie%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DR.%26aulast%3DStrickland%26aufirst%3DA.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DSolomon%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DKolitz%26aufirst%3DJ.%26aulast%3DSchiller%26aufirst%3DG.%26aulast%3DWieduwilt%26aufirst%3DJ.%26aulast%3DRyan%26aufirst%3DD.%26aulast%3DHoering%26aufirst%3DA.%26aulast%3DChiarella%26aufirst%3DM.%26aulast%3DLouie%26aufirst%3DA.%26aulast%3DMedeiros%26aufirst%3DB.%26atitle%3DFinal%2520results%2520of%2520a%2520phase%2520III%2520randomized%2520trial%2520of%2520CPX-351%2520versus%25207%2520%252B%25203%2520in%2520older%2520patients%2520with%2520newly%2520diagnosed%2520high%2520risk%2520%2528secondary%2529%2520AML%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D7000%26doi%3D10.1200%2FJCO.2016.34.15_suppl.7000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzykson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenaux, P.</span></span> <span> </span><span class="NLM_article-title">Myelodysplastic syndromes</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">2239</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)61901-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0140-6736%2813%2961901-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24656536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2crmt1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=2239-2252&author=L.+Ad%C3%A8sauthor=R.+Itzyksonauthor=P.+Fenaux&title=Myelodysplastic+syndromes&doi=10.1016%2FS0140-6736%2813%2961901-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Myelodysplastic syndromes</span></div><div class="casAuthors">Ades Lionel; Itzykson Raphael; Fenaux Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9936</span>),
    <span class="NLM_cas:pages">2239-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people.  The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages.  Clinical manifestations result from cytopenias (anaemia, infection, and bleeding).  Diagnosis is based on examination of blood and bone marrow showing blood cytopenias and hypercellular marrow with dysplasia, with or without excess of blasts.  Prognosis depends largely on the marrow blast percentage, number and extent of cytopenias, and cytogenetic abnormalities.  Treatment of patients with lower-risk myelodysplastic syndromes, especially for anaemia, includes growth factors, lenalidomide, and transfusions.  Treatment of higher-risk patients is with hypomethylating agents and, whenever possible, allogeneic stem-cell transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5Er73mKiVSohLSh9fo81bfW6udTcc2eboL1JWi9_kl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmt1Shsw%253D%253D&md5=4d1f1ed2087f436803eac644355969ba</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2961901-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252961901-7%26sid%3Dliteratum%253Aachs%26aulast%3DAd%25C3%25A8s%26aufirst%3DL.%26aulast%3DItzykson%26aufirst%3DR.%26aulast%3DFenaux%26aufirst%3DP.%26atitle%3DMyelodysplastic%2520syndromes%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D2239%26epage%3D2252%26doi%3D10.1016%2FS0140-6736%2813%2961901-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. R.</span></span> <span> </span><span class="NLM_article-title">Nitrogen mustard inhibits transcription and translation in a cell free system</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3508</span>– <span class="NLM_lpage">3515</span>, <span class="refDoi"> DOI: 10.1093/nar/23.17.3508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1093%2Fnar%2F23.17.3508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=3508-3515&author=A.+Mastaauthor=P.+J.+Grayauthor=D.+R.+Phillips&title=Nitrogen+mustard+inhibits+transcription+and+translation+in+a+cell+free+system&doi=10.1093%2Fnar%2F23.17.3508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F23.17.3508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F23.17.3508%26sid%3Dliteratum%253Aachs%26aulast%3DMasta%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DP.%2BJ.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26atitle%3DNitrogen%2520mustard%2520inhibits%2520transcription%2520and%2520translation%2520in%2520a%2520cell%2520free%2520system%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1995%26volume%3D23%26spage%3D3508%26epage%3D3515%26doi%3D10.1093%2Fnar%2F23.17.3508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dasari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchounwou, P. B.</span></span> <span> </span><span class="NLM_article-title">Cisplatin in cancer therapy: molecular mechanisms of action</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>740</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.ejphar.2014.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25058905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GksbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=740&publication_year=2014&pages=364-378&author=S.+Dasariauthor=P.+B.+Tchounwou&title=Cisplatin+in+cancer+therapy%3A+molecular+mechanisms+of+action&doi=10.1016%2Fj.ejphar.2014.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin in cancer therapy: Molecular mechanisms of action</span></div><div class="casAuthors">Dasari, Shaloam; Bernard Tchounwou, Paul</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">740</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">364-378</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known chemotherapeutic drug.  It has been used for treatment of numerous human cancers including bladder, head and neck, lung, ovarian, and testicular cancers.  It is effective against various types of cancers, including carcinomas, germ cell tumors, lymphomas, and sarcomas.  Its mode of action has been linked to its ability to crosslink with the purine bases on the DNA; interfering with DNA repair mechanisms, causing DNA damage, and subsequently inducing apoptosis in cancer cells.  However, because of drug resistance and numerous undesirable side effects such as severe kidney problems, allergic reactions, decrease immunity to infections, gastrointestinal disorders, hemorrhage, and hearing loss esp. in younger patients, other platinum-contg. anti-cancer drugs such as carboplatin, oxaliplatin and others, have also been used.  Furthermore, combination therapies of cisplatin with other drugs have been highly considered to overcome drug-resistance and reduce toxicity.  This comprehensive review highlights the physicochem. properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various human cancers.  A special attention is paid to its mol. mechanisms of action, and its undesirable side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Hf3tjZX2tbVg90H21EOLACvtfcHk0liFlJpYvgdL4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GksbvL&md5=02206e68034a31198d1bf70d09920013</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DDasari%26aufirst%3DS.%26aulast%3DTchounwou%26aufirst%3DP.%2BB.%26atitle%3DCisplatin%2520in%2520cancer%2520therapy%253A%2520molecular%2520mechanisms%2520of%2520action%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D740%26spage%3D364%26epage%3D378%26doi%3D10.1016%2Fj.ejphar.2014.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrousseau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrey, L.</span></span> <span> </span><span class="NLM_article-title">Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors</span>. <i>Ther. Clin. Risk. Manag.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.2147/tcrm.2007.3.2.213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.2147%2Ftcrm.2007.3.2.213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18360630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1SrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=213-224&author=J.+P.+Armandauthor=V.+Ribragauthor=J.+L.+Harrousseauauthor=L.+Abrey&title=Reappraisal+of+the+use+of+procarbazine+in+the+treatment+of+lymphomas+and+brain+tumors&doi=10.2147%2Ftcrm.2007.3.2.213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors</span></div><div class="casAuthors">Armand, Jean-Pierre; Ribrag, Vincent; Harrousseau, Jean-Luc; Abrey, Lauren</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-224</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Procarbazine HCl is a 'nonclassical' oral alkylating anticancer agent that was first synthesized in the late 1950s.  It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin's lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin's lymphoma and primary central nervous system lymphoma.  Procarbazine is a prodrug that undergoes metabolic transformation into active intermediates that are thought to inhibit DNA, RNA, and protein synthesis.  Early use of procarbazine in combination with mechlorethamine, vincristine, and prednisone (MOPP) was effective in the treatment of advanced Hodgkin's lymphoma, but late toxic effects such as secondary cancer and infertility led to its replacement by other regimens.  However, its recent reintroduction in the dose-intensified BEACOPP (belomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has yielded very promising findings.  Procarbazine alone, or more commonly combined in the PCV (procarbazine, lomustine [CCNU], and vincristine) regimen, is also effective in treating gliomas comprising astrocytomas, glioblastomas, and oligodendrogliomas.  The most common side effects of procarbazine are gastrointestinal disturbances, myelosuppression, and central nervous system effects.  In conclusion, the use of procarbazine in combination with other drugs means that it remains a major anticancer drug in the management of Hodgkin's lymphoma and gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJcsgYzQnZaLVg90H21EOLACvtfcHk0lhtkA118EuupQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1SrtL8%253D&md5=29c8330dd166870de19e32055d7f3243</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2147%2Ftcrm.2007.3.2.213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Ftcrm.2007.3.2.213%26sid%3Dliteratum%253Aachs%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DRibrag%26aufirst%3DV.%26aulast%3DHarrousseau%26aufirst%3DJ.%2BL.%26aulast%3DAbrey%26aufirst%3DL.%26atitle%3DReappraisal%2520of%2520the%2520use%2520of%2520procarbazine%2520in%2520the%2520treatment%2520of%2520lymphomas%2520and%2520brain%2520tumors%26jtitle%3DTher.%2520Clin.%2520Risk.%2520Manag.%26date%3D2007%26volume%3D3%26spage%3D213%26epage%3D224%26doi%3D10.2147%2Ftcrm.2007.3.2.213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span> <span> </span><span class="NLM_article-title">Targeted therapies: a new generation of cancer treatments</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=18297955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BD1c7jvFyjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=311-319&author=D.+E.+Gerber&title=Targeted+therapies%3A+a+new+generation+of+cancer+treatments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapies: a new generation of cancer treatments</span></div><div class="casAuthors">Gerber David E</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-9</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, have significantly changed the treatment of cancer over the past 10 years.  These drugs are now a component of therapy for many common malignancies, including breast, colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma.  The mechanisms of action and toxicities of targeted therapies differ from those of traditional cytotoxic chemotherapy.  Targeted therapies are generally better tolerated than traditional chemotherapy, but they are associated with several adverse effects, such as acneiform rash, cardiac dysfunction, thrombosis, hypertension, and proteinuria.  Small molecule inhibitors are metabolized by cytochrome P450 enzymes and are subject to multiple drug interactions.  Targeted therapy has raised new questions about the tailoring of cancer treatment to an individual patient's tumor, the assessment of drug effectiveness and toxicity, and the economics of cancer care.  As more persons are diagnosed with cancer and as these patients live longer, primary care physicians will increasingly provide care for patients who have received targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfa1lMyMst9HWEEzDrymxmfW6udTcc2eahkL8ys_DPNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7jvFyjtw%253D%253D&md5=4d67592cced2e7ab64bf2218e1bcd821</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26atitle%3DTargeted%2520therapies%253A%2520a%2520new%2520generation%2520of%2520cancer%2520treatments%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2008%26volume%3D77%26spage%3D311%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raedler, L. A.</span></span> <span> </span><span class="NLM_article-title">Akynzeo (Netupitant and Palonosetron), a dual-acting oral agent, approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting</span>. <i>Am. Health Drug Benefits</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">48</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26629265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC28rgvVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=44-48&author=L.+A.+Raedler&title=Akynzeo+%28Netupitant+and+Palonosetron%29%2C+a+dual-acting+oral+agent%2C+approved+by+the+FDA+for+the+prevention+of+chemotherapy-induced+nausea+and+vomiting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting</span></div><div class="casAuthors">Raedler Lisa A</div><div class="citationInfo"><span class="NLM_cas:title">American health & drug benefits</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">Spec Feature</span>),
    <span class="NLM_cas:pages">44-8</span>
        ISSN:<span class="NLM_cas:issn">1942-2962</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGt-9WtWJAKpI8NvIb08rbfW6udTcc2eahkL8ys_DPNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgvVyhtg%253D%253D&md5=79fc1f18510503dce012faea2d52a08e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaedler%26aufirst%3DL.%2BA.%26atitle%3DAkynzeo%2520%2528Netupitant%2520and%2520Palonosetron%2529%252C%2520a%2520dual-acting%2520oral%2520agent%252C%2520approved%2520by%2520the%2520FDA%2520for%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DAm.%2520Health%2520Drug%2520Benefits%26date%3D2015%26volume%3D8%26spage%3D44%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joo, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visintin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, G.</span></span> <span> </span><span class="NLM_article-title">Targeted cancer therapy – Are the days of systemic chemotherapy numbered?</span>. <i>Maturitas</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.maturitas.2013.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.maturitas.2013.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24128673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Witr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=308-314&author=W.+D.+Jooauthor=I.+Visintinauthor=G.+Mor&title=Targeted+cancer+therapy+%E2%80%93+Are+the+days+of+systemic+chemotherapy+numbered%3F&doi=10.1016%2Fj.maturitas.2013.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy - Are the days of systemic chemotherapy numbered?</span></div><div class="casAuthors">Joo, Won Duk; Visintin, Irene; Mor, Gil</div><div class="citationInfo"><span class="NLM_cas:title">Maturitas</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-314</span>CODEN:
                <span class="NLM_cas:coden">MATUDK</span>;
        ISSN:<span class="NLM_cas:issn">0378-5122</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapy or mol. targeted therapy has been defined as a type of treatment that blocks the growth of cancer cells by interfering with specific cell mols. required for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells as with traditional chemotherapy.  There is a growing no. of FDA approved monoclonal antibodies and small mols. targeting specific types of cancer suggestive of the growing relevance of this therapeutic approach.  Targeted cancer therapies, also referred to as "Personalized Medicine", are being studied for use alone, in combination with other targeted therapies, and in combination with chemotherapy.  The objective of personalized medicine is the identification of patients that would benefit from a specific treatment based on the expression of mol. markers.  Examples of this approach include bevacizumab and olaparib, which have been designated as promising targeted therapies for ovarian cancer.  Combinations of trastuzumab with pertuzumab, or T-DM1 and mTOR inhibitors added to an aromatase inhibitor are new therapeutic strategies for breast cancer.  Although this approach has been seen as a major step in the expansion of personalized medicine, it has substantial limitations including its high cost and the presence of serious adverse effects.  The Cancer Genome Atlas is a useful resource to identify novel and more effective targets, which may help to overcome the present limitations.  In this review we will discuss the clin. outcome of some of these new therapies with a focus on ovarian and breast cancer.  We will also discuss novel concepts in targeted therapy, the target of cancer stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGwe46iKHWZ7Vg90H21EOLACvtfcHk0lhtkA118EuupQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Witr7O&md5=70a2650bea41a64585582255bcc43751</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.maturitas.2013.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.maturitas.2013.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DJoo%26aufirst%3DW.%2BD.%26aulast%3DVisintin%26aufirst%3DI.%26aulast%3DMor%26aufirst%3DG.%26atitle%3DTargeted%2520cancer%2520therapy%2520%25E2%2580%2593%2520Are%2520the%2520days%2520of%2520systemic%2520chemotherapy%2520numbered%253F%26jtitle%3DMaturitas%26date%3D2013%26volume%3D76%26spage%3D308%26epage%3D314%26doi%3D10.1016%2Fj.maturitas.2013.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilhot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gathmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousselot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiffers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saglio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratwohl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoef, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa022457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa022457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=12637609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvF2qsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=994-1004&author=S.+G.+O%E2%80%99Brienauthor=F.+Guilhotauthor=R.+A.+Larsonauthor=I.+Gathmannauthor=M.+Baccaraniauthor=F.+Cervantesauthor=J.+J.+Cornelissenauthor=T.+Fischerauthor=A.+Hochhausauthor=T.+Hughesauthor=K.+Lechnerauthor=J.+L.+Nielsenauthor=P.+Rousselotauthor=J.+Reiffersauthor=G.+Saglioauthor=J.+Shepherdauthor=B.+Simonssonauthor=A.+Gratwohlauthor=J.+M.+Goldmanauthor=H.+Kantarjianauthor=K.+Taylorauthor=G.+Verhoefauthor=A.+E.+Boltonauthor=R.+Capdevilleauthor=B.+J.+Druker&title=Imatinib+compared+with+interferon+and+low-dose+cytarabine+for+newly+diagnosed+chronic-phase+chronic+myeloid+leukemia&doi=10.1056%2FNEJMoa022457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</span></div><div class="casAuthors">O'Brien, Stephen G.; Guilhot, Francois; Larson, Richard A.; Gathmann, Insa; Baccarani, Michele; Cervantes, Francisco; Cornelissen, Jan J.; Fischer, Thomas; Hochhaus, Andreas; Hughes, Timothy; Lechner, Klaus; Nielsen, Johan L.; Rousselot, Philippe; Reiffers, Josy; Saglio, Giuseppe; Shepherd, John; Simonsson, Bengt; Gratwohl, Alois; Goldman, John M.; Kantarjian, D. M. Hagop; Taylor, Kerry; Verhoef, Gregor; Bolton, Ann E.; Capdeville, Renaud; Druker, Brian J.; Durrant, S.; Schwarer, A.; Joske, D.; Seymour, J.; Grigg, A.; Ma, D.; Arthur, C.; Bradstock, K.; Joshua, D.; Louwagie, A.; Martiat, P.; Straetmans, N.; Bosly, A.; Shustik, C.; Lipton, J.; Forrest, D.; Walker, I.; Roy, D.-C.; Rubinger, M.; Bence-Bruckler, I.; Stewart, D.; Kovacs, M.; Turner, A. R.; Birgens, H.; Bjerrum, O.; Facon, T.; Harousseau, J.-L.; Tulliez, M.; Guerci, A.; Blaise, D.; Maloisel, F.; Michallet, M.; Hossfeld, D.; Mertelsmann, R.; Andreesen, R.; Nerl, C.; Freund, M.; Gattermann, N.; Hoeffken, K.; Ehninger, G.; Deininger, M.; Ottmann, O.; Peschel, C.; Fruehauf, S.; Neubauer, A.; Le Coutre, P.; Aulitzky, W.; Fanin, R.; Rosti, G.; Mandelli, F.; Morra, E.; Carella, A.; Lazzarino, M.; Petrini, M.; Rossi Ferrini, P.; Nobile, F.; Liso, V.; Ferrara, F.; Rizzoli, V.; Fioritoni, G.; Martinelli, G.; Ossenkoppele, G.; Browett, P.; Gedde-Dahl, T.; Tangen, J.-M.; Dahl, I.; Odriozola, J.; Hernandez Boluda, J. C.; Steegmann, J. L.; Canizo, C.; Sureda, A.; Diaz, J.; Granena, A.; Fernandez, M. N.; Stenke, L.; Paul, C.; Bjoreman, M.; Malm, C.; Wadenvik, H.; Nilsson, P.-G.; Turesson, I.; Hess, U.; Solenthaler, M.; Russel, N.; Mufti, G.; Cavenagh, J.; Clark, R. E.; Green, A. R.; Holyoake, T. L.; Lucas, G. S.; Smith, G.; Milligan, D. W.; Rule, S. J.; Burnett, A. K.; Moroose, R.; Wetzler, M.; Bearden, J.; Brown, R.; Lobell, M.; Cataland, S.; Rabinowitz, I.; Meisenberg, B.; Gabrilove, J.; Thompson, K.; Graziano, S.; Emanuel, P.; Gross, H.; Cobb, P.; Bhatia, R.; Dakhil, S.; Irwin, D.; Issell, B.; Pavletic, S.; Kuebler, P.; Layhe, E.; Butera, P.; Glass, J.; Moore, J.; Grant, B.; Niell, H.; Herzig, R.; Burris, H.; Peterson, B.; Powell, B.; Kalaycio, M.; Stirewalt, D.; Samlowski, W.; Berman, E.; Limentani, S.; Seay, T.; Shea, T.; Akard, L.; Smith, G.; Becker, P.; DeVine, S.; Hart, R.; Veith, R.; Wade, J.; Brunvand, M.; Silver, R.; Kalman, L.; Strickland, D.; Shurafa, M.; Bashey, A.; Shadduck, R.; Cooper, S.; Safah, H.; Rubenstein, M.; Collins, R.; Keller, A.; Stone, R.; Tallman, M.; Stevens, D.; Pecora, A.; Agha, M.; Holmes, H.; Druker, B. J.; Guilhot, E.; Larson, R. A.; O'Brien, S. G.; Rowe, J.; Schiffer, C. A.; Buyse, M.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Kantarjian, H.; Lechner, K.; Nielsen, J. L.; Reiffers, J.; Rousselot, P.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J. M.; Taylor, K.; Verhoef, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">994-1004</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The efficacy of imatinib was compared with that of interferon-α combined with low-dose cytarabine in newly diagnosed chronic-phase chronic myeloid leukemia (CML).  After a median follow-up of 19 mo, the estd. rate of a major cytogenetic response (0-35% of cells in metaphase pos. for the Philadelphia chromosome) at 18 mo was 87.1% in the imatinib group and 34.7% in the group given interferon-α plus cytarabine. The estd. rates of complete cytogenetic response were 76.2% and 14.5%, resp. At 18 mo, the estd. rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7% in the imatinib group and 91.5% in the combination-therapy group. Imatinib was better tolerated than combination therapy.  Thus, in terms of hematol. and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon-α plus low-dose cytarabine as 1st-line therapy in newly diagnosed chronic-phase CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Klg6CHKdKrVg90H21EOLACvtfcHk0lgHUJ9f6m-_Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvF2qsL8%253D&md5=cab11b39f0131f03d12e97893526764d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa022457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa022457%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DGathmann%26aufirst%3DI.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DCornelissen%26aufirst%3DJ.%2BJ.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DLechner%26aufirst%3DK.%26aulast%3DNielsen%26aufirst%3DJ.%2BL.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DReiffers%26aufirst%3DJ.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DShepherd%26aufirst%3DJ.%26aulast%3DSimonsson%26aufirst%3DB.%26aulast%3DGratwohl%26aufirst%3DA.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DBolton%26aufirst%3DA.%2BE.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DImatinib%2520compared%2520with%2520interferon%2520and%2520low-dose%2520cytarabine%2520for%2520newly%2520diagnosed%2520chronic-phase%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D994%26epage%3D1004%26doi%3D10.1056%2FNEJMoa022457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib and trametinib, alone and in combination for <i>BRAF</i>-mutant metastatic melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2035</span>– <span class="NLM_lpage">2043</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1158%2F1078-0432.CCR-13-2054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24583796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2msro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2035-2043&author=A.+M.+Menziesauthor=G.+V.+Long&title=Dabrafenib+and+trametinib%2C+alone+and+in+combination+for+BRAF-mutant+metastatic+melanoma&doi=10.1158%2F1078-0432.CCR-13-2054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma</span></div><div class="casAuthors">Menzies, Alexander M.; Long, Georgina V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2035-2043</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant metastatic melanoma by the U.S. Food and Drug Administration (FDA) in 2013, and most recently, their use in combination has received accelerated FDA approval.  Both drugs target the mitogen-activated protein kinase (MAPK) pathway: dabrafenib selectively inhibits mutant BRAF that constitutively activates the pathway, and trametinib selectively inhibits MEK1 and MEK2 proteins activated by RAF kinases.  The phase III study of dabrafenib in BRAFV600E metastatic melanoma reported rapid tumor regression in most patients and a 59% objective RECIST response rate.  The median progression-free survival (PFS) and overall survival (OS) were improved compared with dacarbazine.  Toxicities were well tolerated and different from those reported for vemurafenib, the first FDA-approved BRAF inhibitor.  Efficacy has been demonstrated in other BRAF-mutant genotypes.  The phase III study of trametinib in BRAF inhibitor-naive patients with BRAFV600E or BRAFV600K also showed benefit with a prolonged median PFS and OS compared with chemotherapy.  Trametinib is ineffective in patients who have progressed on BRAF inhibitors.  A phase II trial of combined dabrafenib and trametinib demonstrated higher response rates and longer median PFS than dabrafenib monotherapy, with less cutaneous toxicity.  Here, we review the clin. development of both drugs as monotherapies and in combination, and discuss their role in the management of BRAF-mutant melanoma.  Clin Cancer Res; 20(8); 2035-43. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNH1htKPDY_rVg90H21EOLACvtfcHk0lgHUJ9f6m-_Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2msro%253D&md5=af0a14b04bef23de579b4745603bf27c</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2054%26sid%3Dliteratum%253Aachs%26aulast%3DMenzies%26aufirst%3DA.%2BM.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DDabrafenib%2520and%2520trametinib%252C%2520alone%2520and%2520in%2520combination%2520for%2520BRAF-mutant%2520metastatic%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2035%26epage%3D2043%26doi%3D10.1158%2F1078-0432.CCR-13-2054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraresi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probachai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarini, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irani, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mookerjee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)60898-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2FS0140-6736%2815%2960898-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26037941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVyrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=444-451&author=G.+V.+Longauthor=D.+Stroyakovskiyauthor=H.+Gogasauthor=E.+Levchenkoauthor=F.+de+Braudauthor=J.+Larkinauthor=C.+Garbeauthor=T.+Jouaryauthor=A.+Hauschildauthor=J.+J.+Grobauthor=V.+Chiarion-Sileniauthor=C.+Lebbeauthor=M.+Mandalaauthor=M.+Millwardauthor=A.+Aranceauthor=I.+Bondarenkoauthor=J.+B.+Haanenauthor=J.+Hanssonauthor=J.+Utikalauthor=V.+Ferraresiauthor=N.+Kovalenkoauthor=P.+Mohrauthor=V.+Probachaiauthor=D.+Schadendorfauthor=P.+Nathanauthor=C.+Robertauthor=A.+Ribasauthor=D.+J.+DeMariniauthor=J.+G.+Iraniauthor=S.+Swannauthor=J.+J.+Legosauthor=F.+Jinauthor=B.+Mookerjeeauthor=K.+Flaherty&title=Dabrafenib+and+trametinib+versus+dabrafenib+and+placebo+for+Val600+BRAF-mutant+melanoma%3A+a+multicentre%2C+double-blind%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2815%2960898-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial</span></div><div class="casAuthors">Long, Georgina V.; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandala, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B. A. G.; Hansson, Johan; Utikal, Jochen; Ferraresi, Virginia; Kovalenko, Nadezhda; Mohr, Peter; Probachai, Volodymr; Schadendorf, Dirk; Nathan, Paul; Robert, Caroline; Ribas, Antoni; De Marini, Douglas J.; Irani, Jhangir G.; Swann, Suzanne; Legos, Jeffrey J.; Jin, Fan; Mookerjee, Bijoyesh; Flaherty, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9992</span>),
    <span class="NLM_cas:pages">444-451</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with dabrafenib and placebo in patients with BRAF Val600Lys/Glu mutation-pos. metastatic melanoma.  The study was continued to assess the secondary endpoint of overall survival, which we report in this Article.  We did this double-blind phase 3 study at 113 sites in 14 countries.  We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-pos. unresectable stage IIIC or stage IV melanoma.  Participants were computer-randomised (1:1) to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily), or dabrafenib and placebo.  The primary endpoint was progression-free survival and overall survival was a secondary endpoint.  This study is registered with ClinicalTrials.gov, no. NCT01584648.  Between May 4, 2012, and Nov 30, 2012, we screened 947 patients for eligibility, of whom 423 were randomly assigned to receive dabrafenib and trametinib (n=211) or dabrafenib only (n=212).  The final data cutoff was Jan 12, 2015, at which time 222 patients had died.  Median overall survival was 25·1 mo (95% CI 19·2-not reached) in the dabrafenib and trametinib group vs. 18·7 mo (15·2-23·7) in the dabrafenib only group (hazard ratio [HR] 0·71, 95% CI 0·55-0·92; p=0·0107).  Overall survival was 74% at 1 yr and 51% at 2 years in the dabrafenib and trametinib group vs. 68% and 42%, resp., in the dabrafenib only group.  Based on 301 events, median progression-free survival was 11·0 mo (95% CI 8·0-13·9) in the dabrafenib and trametinib group and 8·8 mo (5·9-9·3) in the dabrafenib only group (HR 0·67, 95% CI 0·53-0·84; p=0·0004; unadjusted for multiple testing).  Treatment-related adverse events occurred in 181 (87%) of 209 patients in the dabrafenib and trametinib group and 189 (90%) of 211 patients in the dabrafenib only group; the most common was pyrexia (108 patients, 52%) in the dabrafenib and trametinib group, and hyperkeratosis (70 patients, 33%) in the dabrafenib only group.  Grade 3 or 4 adverse events occurred in 67 (32%) patients in the dabrafenib and trametinib group and 66 (31%) patients in the dabrafenib only group.  The improvement in overall survival establishes the combination of dabrafenib and trametinib as the std. targeted treatment for BRAF Val600 mutation-pos. melanoma.  Studies assessing dabrafenib and trametinib in combination with immunotherapies are ongoing.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeIg9L7TouB7Vg90H21EOLACvtfcHk0lgHUJ9f6m-_Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVyrt7k%253D&md5=3de7b0a659267f73299e8111ff2a09bb</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960898-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960898-4%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DFerraresi%26aufirst%3DV.%26aulast%3DKovalenko%26aufirst%3DN.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DProbachai%26aufirst%3DV.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDeMarini%26aufirst%3DD.%2BJ.%26aulast%3DIrani%26aufirst%3DJ.%2BG.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DLegos%26aufirst%3DJ.%2BJ.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DMookerjee%26aufirst%3DB.%26aulast%3DFlaherty%26aufirst%3DK.%26atitle%3DDabrafenib%2520and%2520trametinib%2520versus%2520dabrafenib%2520and%2520placebo%2520for%2520Val600%2520BRAF-mutant%2520melanoma%253A%2520a%2520multicentre%252C%2520double-blind%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D444%26epage%3D451%26doi%3D10.1016%2FS0140-6736%2815%2960898-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroiakovski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grange, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crist, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">Improved overall survival in melanoma with combined dabrafenib and trametinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1412690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMoa1412690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25399551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=30-39&author=C.+Robertauthor=B.+Karaszewskaauthor=J.+Schachterauthor=P.+Rutkowskiauthor=A.+Mackiewiczauthor=D.+Stroiakovskiauthor=M.+Lichinitserauthor=R.+Dummerauthor=F.+Grangeauthor=L.+Mortierauthor=V.+Chiarion-Sileniauthor=K.+Drucisauthor=I.+Krajsovaauthor=A.+Hauschildauthor=P.+Loriganauthor=P.+Wolterauthor=G.+V.+Longauthor=K.+Flahertyauthor=P.+Nathanauthor=A.+Ribasauthor=A.+M.+Martinauthor=P.+Sunauthor=W.+Cristauthor=J.+Legosauthor=S.+D.+Rubinauthor=S.+M.+Littleauthor=D.+Schadendorf&title=Improved+overall+survival+in+melanoma+with+combined+dabrafenib+and+trametinib&doi=10.1056%2FNEJMoa1412690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Improved overall survival in melanoma with combined dabrafenib and trametinib</span></div><div class="casAuthors">Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V.; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D.; Little, Shonda M.; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39/1-30-39/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.  Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.  Methods: In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy.  The primary end point was overall survival.  Results: At the preplanned interim overall survival anal., which was performed after 77% of the total no. of expected events occurred, the overall survival rate at 12 mo was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005).  The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014.  Median progression-free survival was 11.4 mo in the combination therapy group and 7.3 mo in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).  The objective response rate was 64% in the combination therapy group and 51% in the vemurafenib group (P<0.001).  Rates of severe adverse events and study-drug discontinuations were similar in the two groups.  Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group.  Conclusions: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov no., NCT01597908.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5of4j14YrP7Vg90H21EOLACvtfcHk0liIgCWA1rByBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D&md5=9d6a8f49bbd196f9463ec15958eb15d1</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1412690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1412690%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DStroiakovski%26aufirst%3DD.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGrange%26aufirst%3DF.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDrucis%26aufirst%3DK.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DCrist%26aufirst%3DW.%26aulast%3DLegos%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DS.%2BD.%26aulast%3DLittle%26aufirst%3DS.%2BM.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520overall%2520survival%2520in%2520melanoma%2520with%2520combined%2520dabrafenib%2520and%2520trametinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D30%26epage%3D39%26doi%3D10.1056%2FNEJMoa1412690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. K. H.</span></span> <span> </span><span class="NLM_article-title">The history of monoclonal antibody development – progress, remaining challenges and future innovations</span>. <i>Ann. Med. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.amsu.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.amsu.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25568796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2Mvks1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=113-116&author=J.+K.+H.+Liu&title=The+history+of+monoclonal+antibody+development+%E2%80%93+progress%2C+remaining+challenges+and+future+innovations&doi=10.1016%2Fj.amsu.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The history of monoclonal antibody development - Progress, remaining challenges and future innovations</span></div><div class="casAuthors">Liu Justin K H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of medicine and surgery (2012)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">113-6</span>
        ISSN:<span class="NLM_cas:issn">2049-0801</span>.
    </div><div class="casAbstract">As medicine progresses into a new era of personalised therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront.  Since the licencing of the first monoclonal antibody for clinical use 30 years ago, the monoclonal antibody industry has expanded exponentially and is now valued at billions of dollars.  With major advances in genetic sequencing and biomedical research, much research into monoclonal antibodies now focuses on identifying new targets for development and maximising their efficacy for use in clinical practice.  However, a balance has to be struck with regards to reducing numbers of side-effects and overall economic cost, which arguably somewhat blighted their early clinical and commercial successes.  Nowadays, there are approximately 30 monoclonal antibodies that have been approved for use in clinical practice with many more currently being tested in clinical trials.  Some of the current major limitations include: the use of inefficient models for generation, a lack of efficacy and issues of cost-effectiveness.  Some of the current research focuses on ways to improve the efficacy of existing monoclonal antibodies through optimising their effects and the addition of beneficial modifications.  This review will focus on the history of monoclonal antibody development - how it has increasingly moved away from using laborious animal models to a more effective phage display system, some of the major drawbacks from a clinical and economical point of view and future innovations that are currently being researched to maximise their effectiveness for future clinical use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2Zr12D3tJgOxsqfvU0ziafW6udTcc2eYIWTUm5Wp347ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mvks1GjsQ%253D%253D&md5=c00607a5afc71b2c1bc8bf1dd7491dae</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.amsu.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amsu.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BK.%2BH.%26atitle%3DThe%2520history%2520of%2520monoclonal%2520antibody%2520development%2520%25E2%2580%2593%2520progress%252C%2520remaining%2520challenges%2520and%2520future%2520innovations%26jtitle%3DAnn.%2520Med.%2520Surg.%26date%3D2014%26volume%3D3%26spage%3D113%26epage%3D116%26doi%3D10.1016%2Fj.amsu.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starlinger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlberger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weibrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitmayr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberger, T.</span></span> <span> </span><span class="NLM_article-title">5-FU based chemotherapy with bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">e23208</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.34.15_suppl.e23208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1200%2FJCO.2016.34.15_suppl.e23208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=e23208&author=B.+Gruenbergerauthor=P.+Starlingerauthor=E.+Messingerauthor=L.+Oehlbergerauthor=S.+Weibrechtauthor=J.+P.+Jonasauthor=B.+Weitmayrauthor=T.+Gruenberger&title=5-FU+based+chemotherapy+with+bevacizumab+in+synchronous+metastatic+colorectal+cancer+patients+with+bleeding+primary+tumor&doi=10.1200%2FJCO.2016.34.15_suppl.e23208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.e23208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.e23208%26sid%3Dliteratum%253Aachs%26aulast%3DGruenberger%26aufirst%3DB.%26aulast%3DStarlinger%26aufirst%3DP.%26aulast%3DMessinger%26aufirst%3DE.%26aulast%3DOehlberger%26aufirst%3DL.%26aulast%3DWeibrecht%26aufirst%3DS.%26aulast%3DJonas%26aufirst%3DJ.%2BP.%26aulast%3DWeitmayr%26aufirst%3DB.%26aulast%3DGruenberger%26aufirst%3DT.%26atitle%3D5-FU%2520based%2520chemotherapy%2520with%2520bevacizumab%2520in%2520synchronous%2520metastatic%2520colorectal%2520cancer%2520patients%2520with%2520bleeding%2520primary%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3De23208%26doi%3D10.1200%2FJCO.2016.34.15_suppl.e23208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gootenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-3-356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1634%2Ftheoncologist.12-3-356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=17405901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVSqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=356-361&author=M.+H.+Cohenauthor=J.+Gootenbergauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+bevacizumab+plus+FOLFOX4+as+second-line+treatment+of+colorectal+cancer&doi=10.1634%2Ftheoncologist.12-3-356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer</span></div><div class="casAuthors">Cohen, Martin H.; Gootenberg, Joe; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">356-361</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On June 20, 2006, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA), administered in combination with FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) for the second-line treatment of metastatic carcinoma of the colon or rectum.  Efficacy and safety were demonstrated in one Eastern Cooperative Oncol. Group (ECOG) open-label, multicenter, randomized, three-arm, active-controlled trial enrolling 829 adult patients.  Patients had received a fluoropyrimidine- and irinotecan-based regimen as initial therapy for metastatic disease; or they had received prior adjuvant irinotecan-based chemotherapy and had recurred within 6 mo of completing therapy.  Treatments included bevacizumab, 10 mg/kg, as a 90-min i.v. infusion on day 1, every 2 wk, either alone or in combination with FOLFOX4, or FOLFOX4 alone.  The bevacizumab monotherapy arm was closed to accrual after an interim efficacy anal. suggested a possibly shorter survival in that arm.  Overall survival (OS), the primary study endpoint, was significantly longer for patients receiving bevacizumab in combination with FOLFOX4 than for those receiving FOLFOX4 alone.  The objective response rate was significantly higher in the FOLFOX4 plus bevacizumab arm than in the FOLFOX4 alone arm.  The duration of response was approx. 6 mo for both treatment arms.  Patients treated with the bevacizumab combination were also reported, based on investigator assessment, to have significantly longer progression-free survival.  There were no new bevacizumab safety signals.  The most serious, and sometimes fatal, bevacizumab toxicities are gastrointestinal perforation, wound-healing complications, hemorrhage, arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, and congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUvJ7p7P5LrVg90H21EOLACvtfcHk0lhzxhOQjRS4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVSqur8%253D&md5=9d2d63712aec278adaa57e968dc4643c</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-3-356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-3-356%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DGootenberg%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520bevacizumab%2520plus%2520FOLFOX4%2520as%2520second-line%2520treatment%2520of%2520colorectal%2520cancer%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D356%26epage%3D361%26doi%3D10.1634%2Ftheoncologist.12-3-356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Summers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2009-0250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1634%2Ftheoncologist.2009-0250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=20061402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVaktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=104-111&author=J.+Summersauthor=M.+H.+Cohenauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+bevacizumab+plus+interferon+for+advanced+renal+cell+carcinoma&doi=10.1634%2Ftheoncologist.2009-0250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">FDA drug approval summary: bevacizumab plus interferon advanced renal cell carcinoma</span></div><div class="casAuthors">Summers, Jeff; Cohen, Martin H.; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-111</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-α2a for the treatment of patients with metastatic renal cell carcinoma.  The approval was primarily based on results from a randomized, double-blind, placebo-controlled clin. trial.  The primary efficacy endpoint, progression-free survival (PFS), was assessed by investigators and by an independent review committee (IRC) blinded to treatment assignment.  In total, 649 patients (bevacizumab plus IFN, 327; placebo plus IFN, 322) were enrolled.  The median PFS times, by investigator detn., were 10.2 mo for the bevacizumab plus IFN arm and 5.4 mo for the placebo plus IFN arm (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.49-0.72; p < .0001).  The IRC anal. of 569 patients with available radiographs yielded similar results (median PFS time, 10.4 mo vs. 5.5 mo; HR, 0.57; 95% CI, 0.45-0.72; p < .0001).  There was no survival advantage (HR, 0.86; 95% CI, 0.72-1.04; p = .13).  Support for the above results was provided by summarized results of a North American cooperative group study of bevacizumab plus IFN-α2b vs. IFN-α2b alone.  The median PFS times were 8.4 mo vs. 4.9 mo in favor of the bevacizumab combination.  There was no survival advantage.  In the reviewed trial, serious adverse events and National Cancer Institute Common Terminol. Criteria for Adverse Events grade ≥3 adverse events were reported more frequently in bevacizumab-treated patients (31% vs. 19% and 63% vs. 47%, resp.).  The most common bevacizumab-related toxicities were bleeding/hemorrhage, hypertension, proteinuria, and venous or arterial thromboembolic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVZWPBjxfhlbVg90H21EOLACvtfcHk0lhzxhOQjRS4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVaktbw%253D&md5=de8d0470fc9a9b11636ce23b6f846d39</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2009-0250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2009-0250%26sid%3Dliteratum%253Aachs%26aulast%3DSummers%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520bevacizumab%2520plus%2520interferon%2520for%2520advanced%2520renal%2520cell%2520carcinoma%26jtitle%3DOncologist%26date%3D2010%26volume%3D15%26spage%3D104%26epage%3D111%26doi%3D10.1634%2Ftheoncologist.2009-0250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormanik, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval: elotuzumab in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6759</span>– <span class="NLM_lpage">6763</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1158%2F1078-0432.CCR-16-2870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28249893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSnu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6759-6763&author=N.+J.+Gormleyauthor=C.+W.+Koauthor=A.+Deisserothauthor=L.+Nieauthor=E.+Kaminskasauthor=N.+Kormanikauthor=K.+B.+Goldbergauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+drug+approval%3A+elotuzumab+in+combination+with+lenalidomide+and+dexamethasone+for+the+treatment+of+relapsed+or+refractory+multiple+myeloma&doi=10.1158%2F1078-0432.CCR-16-2870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma</span></div><div class="casAuthors">Gormley, Nicole J.; Ko, Chia-Wen; Deisseroth, Albert; Nie, Lei; Kaminskas, Edvardas; Kormanik, Natasha; Goldberg, Kirsten B.; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6759-6763</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Nov. 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received one to three prior therapies.  FDA approval was based primarily on the results of a phase III, randomized, open-label, multicenter trial, CA204004, which evaluated elotuzumab in combination with lenalidomide and dexamethasone (E-Ld) compared with lenalidomide and dexamethasone (Ld) alone in patients with relapsed or refractory multiple myeloma.  Coprimary endpoints were progression-free survival (PFS) and overall response rate (ORR).  The key secondary endpoint was overall survival, but these data were not mature at the time of clin. database cutoff.  The trial demonstrated a statistically significant improvement in PFS, with an estd. HR of 0.70 for E-Ld over Ld [95% confidence interval (CI), 0.57-0.85; P = 0.0004. Estd. median PFS was 19.4 mo in the E-Ld arm and 14.9 mo in the Ld arm.  ORR was 75.8% in the E-Ld arm compared with 65.5% in the Ld arm.  Serious adverse reactions were reported in 65% of patients in the E-Ld arm compared with 57% in the Ld arm.  The FDA approved elotuzumab with the following warnings and precautions: infusion reactions, infections, second primary malignancies, hepatotoxicity, and interference with the detn. of complete response.  Clin Cancer Res; 23(22); 6759-63. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOVYhlp1UfTLVg90H21EOLACvtfcHk0lhzxhOQjRS4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSnu77M&md5=b910506811469b7c06816bad555a996d</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2870%26sid%3Dliteratum%253Aachs%26aulast%3DGormley%26aufirst%3DN.%2BJ.%26aulast%3DKo%26aufirst%3DC.%2BW.%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DKormanik%26aufirst%3DN.%26aulast%3DGoldberg%26aufirst%3DK.%2BB.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%253A%2520elotuzumab%2520in%2520combination%2520with%2520lenalidomide%2520and%2520dexamethasone%2520for%2520the%2520treatment%2520of%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D6759%26epage%3D6763%26doi%3D10.1158%2F1078-0432.CCR-16-2870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span> <span> </span><span class="NLM_article-title">What is the tryptophan kynurenine pathway and why is it important to neurotherapy?</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1586/14737175.2015.1049999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1586%2F14737175.2015.1049999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26004930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=719-721&author=I.+Davisauthor=A.+Liu&title=What+is+the+tryptophan+kynurenine+pathway+and+why+is+it+important+to+neurotherapy%3F&doi=10.1586%2F14737175.2015.1049999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?</span></div><div class="casAuthors">Davis, Ian; Liu, Aimin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">719-721</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The kynurenine pathway has received increasing attention as its connection to inflammation, the immune system and neurol. conditions has become more apparent.  It is the primary route for tryptophan catabolism in the liver and the starting point for the synthesis of NAD in mammals.  Dysregulation or overactivation of this pathway can lead to immune system activation and accumulation of potentially neurotoxic compds.  These aspects make the kynurenine pathway a promising target for therapeutic development to treat inflammation and disease with neurol. aspects, esp. in cancer patients undergoing chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_7WSU8_CGLVg90H21EOLACvtfcHk0ljUClu8i8SbHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfK&md5=9f4539d9101fbf39f6ebe4f20f027556</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.1049999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.1049999%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DA.%26atitle%3DWhat%2520is%2520the%2520tryptophan%2520kynurenine%2520pathway%2520and%2520why%2520is%2520it%2520important%2520to%2520neurotherapy%253F%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D719%26epage%3D721%26doi%3D10.1586%2F14737175.2015.1049999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity with combination of vemurafenib and ipilimumab</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1366</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1302338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1056%2FNEJMc1302338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23550685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1365-1366&author=A.+Ribasauthor=F.+S.+Hodiauthor=M.+Callahanauthor=C.+Kontoauthor=J.+Wolchok&title=Hepatotoxicity+with+combination+of+vemurafenib+and+ipilimumab&doi=10.1056%2FNEJMc1302338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity with combination of vemurafenib and ipilimumab</span></div><div class="casAuthors">Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1365-1366</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4C-d0ldXxG7Vg90H21EOLACvtfcHk0ljUClu8i8SbHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D&md5=e903ecac16e34bc5ee83d9d24338d950</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1302338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1302338%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DCallahan%26aufirst%3DM.%26aulast%3DKonto%26aufirst%3DC.%26aulast%3DWolchok%26aufirst%3DJ.%26atitle%3DHepatotoxicity%2520with%2520combination%2520of%2520vemurafenib%2520and%2520ipilimumab%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1365%26epage%3D1366%26doi%3D10.1056%2FNEJMc1302338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuraszeck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasichayanula, S.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1111/cts.12391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1111%2Fcts.12391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=26924066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC28jlt1Gmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=89-104&author=K.+M.+Morrisseyauthor=T.+M.+Yuraszeckauthor=C.+C.+Liauthor=Y.+Zhangauthor=S.+Kasichayanula&title=Immunotherapy+and+novel+combinations+in+oncology%3A+current+landscape%2C+challenges%2C+and+opportunities&doi=10.1111%2Fcts.12391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities</span></div><div class="casAuthors">Morrissey K M; Li C-C; Yuraszeck T M; Zhang Y; Kasichayanula S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ70p9dYFGYP9pSBfyDvp7fW6udTcc2eYzsDoHayO1t7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jlt1Gmug%253D%253D&md5=670ae50afa7e62835e3b4e50d32b177b</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1111%2Fcts.12391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12391%26sid%3Dliteratum%253Aachs%26aulast%3DMorrissey%26aufirst%3DK.%2BM.%26aulast%3DYuraszeck%26aufirst%3DT.%2BM.%26aulast%3DLi%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKasichayanula%26aufirst%3DS.%26atitle%3DImmunotherapy%2520and%2520novel%2520combinations%2520in%2520oncology%253A%2520current%2520landscape%252C%2520challenges%252C%2520and%2520opportunities%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2016%26volume%3D9%26spage%3D89%26epage%3D104%26doi%3D10.1111%2Fcts.12391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gyawali, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, V.</span></span> <span> </span><span class="NLM_article-title">Drugs that lack single-agent activity: are they worth pursuing in combination?</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">193</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1038%2Fnrclinonc.2017.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28266519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC1czjsFSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=193&author=B.+Gyawaliauthor=V.+Prasad&title=Drugs+that+lack+single-agent+activity%3A+are+they+worth+pursuing+in+combination%3F&doi=10.1038%2Fnrclinonc.2017.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that lack single-agent activity: are they worth pursuing in combination?</span></div><div class="casAuthors">Gyawali Bishal; Prasad Vinay; Prasad Vinay; Prasad Vinay</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-194</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_zBuwd5i4JVUIs6wFK5xJfW6udTcc2eYzsDoHayO1t7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czjsFSrsA%253D%253D&md5=0f2ef679b3e22301d5c41464b81b8051</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.27%26sid%3Dliteratum%253Aachs%26aulast%3DGyawali%26aufirst%3DB.%26aulast%3DPrasad%26aufirst%3DV.%26atitle%3DDrugs%2520that%2520lack%2520single-agent%2520activity%253A%2520are%2520they%2520worth%2520pursuing%2520in%2520combination%253F%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D193%26doi%3D10.1038%2Fnrclinonc.2017.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtari, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayouni, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgatskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeger, H.</span></span> <span> </span><span class="NLM_article-title">Combination therapy in combating cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">38022</span>– <span class="NLM_lpage">38043</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.16723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.18632%2Foncotarget.16723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=28410237" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=38022-38043&author=R.+B.+Mokhtariauthor=T.+S.+Homayouniauthor=N.+Baluchauthor=E.+Morgatskayaauthor=S.+Kumarauthor=B.+Dasauthor=H.+Yeger&title=Combination+therapy+in+combating+cancer&doi=10.18632%2Foncotarget.16723"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.16723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.16723%26sid%3Dliteratum%253Aachs%26aulast%3DMokhtari%26aufirst%3DR.%2BB.%26aulast%3DHomayouni%26aufirst%3DT.%2BS.%26aulast%3DBaluch%26aufirst%3DN.%26aulast%3DMorgatskaya%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DYeger%26aufirst%3DH.%26atitle%3DCombination%2520therapy%2520in%2520combating%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D38022%26epage%3D38043%26doi%3D10.18632%2Foncotarget.16723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gieling, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Costa, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.3109/14756366.2012.736979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.3109%2F14756366.2012.736979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=23163664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC3s7ksFGjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=360-369&author=R.+G.+Gielingauthor=C.+A.+Parkerauthor=L.+A.+De+Costaauthor=N.+Robertsonauthor=A.+L.+Harrisauthor=I.+J.+Stratfordauthor=K.+J.+Williams&title=Inhibition+of+carbonic+anhydrase+activity+modifies+the+toxicity+of+doxorubicin+and+melphalan+in+tumour+cells+in+vitro&doi=10.3109%2F14756366.2012.736979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro</span></div><div class="casAuthors">Gieling Roben G; Parker Catriona A; De Costa Lisa A; Robertson Naomi; Harris Adrian L; Stratford Ian J; Williams Kaye J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of enzyme inhibition and medicinal chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">360-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Carbonic anhydrase IX (CA IX) is a hypoxia-regulated enzyme, overexpressed in many types of human cancer.  CA IX is involved in pH homeostasis, contributing to extracellular acidification and tumourigenesis.  Acidification of the extracellular milieu can impact upon cellular uptake of chemotherapeutic drugs by favouring weak acids (e.g. melphalan), but limiting access of weak bases (e.g. doxorubicin).  We investigated whether alterations of CA IX activity affected anti-cancer drug uptake and toxicity.  CA inhibitor acetazolamide (AZM) enhanced doxorubicin toxicity but reduced melphalan toxicity in cell lines that highly expressed CA IX under anoxic conditions (HT29 and MDA435 CA9/18).  The toxicity changes reflected modification of passive drug uptake.  AZM did not alter toxicity or uptake in cells with low CA IX activity (HCT116 and MDA435 EV1).  AZM lowered intracellular pH in HT29 and MDA435 CA9/18 cells under anoxic conditions.  CA IX activity has chemomodulatory properties and is an attractive target for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAE0BYK_Myi2K_SFaaT9INfW6udTcc2eby1u75sgT5sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7ksFGjsQ%253D%253D&md5=5ca30aaff1e3a838b09055a8557d4854</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.3109%2F14756366.2012.736979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756366.2012.736979%26sid%3Dliteratum%253Aachs%26aulast%3DGieling%26aufirst%3DR.%2BG.%26aulast%3DParker%26aufirst%3DC.%2BA.%26aulast%3DDe%2BCosta%26aufirst%3DL.%2BA.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DStratford%26aufirst%3DI.%2BJ.%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26atitle%3DInhibition%2520of%2520carbonic%2520anhydrase%2520activity%2520modifies%2520the%2520toxicity%2520of%2520doxorubicin%2520and%2520melphalan%2520in%2520tumour%2520cells%2520in%2520vitro%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2013%26volume%3D28%26spage%3D360%26epage%3D369%26doi%3D10.3109%2F14756366.2012.736979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H. G.</span></span> <span> </span><span class="NLM_article-title">Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1016%2Fj.freeradbiomed.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=24970682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A280%3ADC%252BC2cfntV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=21-34&author=M.+T.+Doauthor=H.+G.+Kimauthor=J.+H.+Choiauthor=H.+G.+Jeong&title=Metformin+induces+microRNA-34a+to+downregulate+the+Sirt1%2FPgc-1alpha%2FNrf2+pathway%2C+leading+to+increased+susceptibility+of+wild-type+p53+cancer+cells+to+oxidative+stress+and+therapeutic+agents&doi=10.1016%2Fj.freeradbiomed.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents</span></div><div class="casAuthors">Do Minh Truong; Kim Hyung Gyun; Choi Jae Ho; Jeong Hye Gwang</div><div class="citationInfo"><span class="NLM_cas:title">Free radical biology & medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sirtuin 1 (Sirt1) plays an important role in cellular redox balance and resistance to oxidative stress.  Sirt1 exhibits oncogenic properties in wild-type p53 cancer cells, whereas it acts as a tumor suppressor in p53-mutated cancer cells.  Here, we investigated the effects of metformin on Sirt1 expression in several cancer cell lines.  Using human cancer cell lines that exhibit differential expression of p53, we found that metformin reduced Sirt1 protein levels in cancer cells bearing wild-type p53, but did not affect Sirt1 protein levels in cancer cell lines harboring mutant forms of p53.  Metformin-induced p53 protein levels in wild-type p53 cancer cells resulted in upregulation of microRNA (miR)-34a.  The use of a miR-34a inhibitor confirmed that metformin-induced miR-34a was required for Sirt1 downregulation.  Metformin suppressed peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (Pgc-1α) expression and its downstream target Nrf2 in MCF-7 cells.  Genetic tools demonstrated that the reduction of Sirt1 and Pgc-1α by metformin caused Nrf2 downregulation via suppression of PPARγ transcriptional activity.  Metformin reduced heme oxygenase-1 and superoxide dismutase 2 but upregulated catalase expression in MCF-7 cells.  Metformin-treated MCF-7 cells had no increase in basal levels of reactive oxygen species but were more susceptible to oxidative stress.  Furthermore, upregulation of death receptor 5 by metformin-mediated Sirt1 downregulation enhanced the sensitivity of wild-type p53 cancer cells to TRAIL-induced apoptosis.  Our results demonstrated that metformin induces miR-34a to suppress the Sirt1/Pgc-1α/Nrf2 pathway and increases susceptibility of wild-type p53 cancer cells to oxidative stress and TRAIL-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvPBEjXDiwaoNpW7w2tapOfW6udTcc2eby1u75sgT5sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfntV2ntg%253D%253D&md5=796479ce8d150e3fd36c3c26a7f0b6de</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DM.%2BT.%26aulast%3DKim%26aufirst%3DH.%2BG.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DJeong%26aufirst%3DH.%2BG.%26atitle%3DMetformin%2520induces%2520microRNA-34a%2520to%2520downregulate%2520the%2520Sirt1%252FPgc-1alpha%252FNrf2%2520pathway%252C%2520leading%2520to%2520increased%2520susceptibility%2520of%2520wild-type%2520p53%2520cancer%2520cells%2520to%2520oxidative%2520stress%2520and%2520therapeutic%2520agents%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2014%26volume%3D74%26spage%3D21%26epage%3D34%26doi%3D10.1016%2Fj.freeradbiomed.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span> <span> </span><span class="NLM_article-title">Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1002/cncr.29085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=10.1002%2Fcncr.29085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=25336333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit12lu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=556-561&author=J.+P.+Issaauthor=G.+Garcia-Maneroauthor=X.+Huangauthor=J.+Cortesauthor=F.+Ravandiauthor=E.+Jabbourauthor=G.+Borthakurauthor=M.+Brandtauthor=S.+Pierceauthor=H.+M.+Kantarjian&title=Results+of+phase+2+randomized+study+of+low-dose+decitabine+with+or+without+valproic+acid+in+patients+with+myelodysplastic+syndrome+and+acute+myelogenous+leukemia&doi=10.1002%2Fcncr.29085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia</span></div><div class="casAuthors">Issa, Jean-Pierre; Garcia-Manero, Guillermo; Huang, Xuelin; Cortes, Jorge; Ravandi, Farhad; Jabbour, Elias; Borthakur, Gautam; Brandt, Mark; Pierce, Sherry; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">556-561</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).  Preclin. and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results.  METHODS : The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML.  RESULTS : Patients with higher risk MDS or with AML aged ≥60 years were eligible.  Patients were randomized in a Bayesian response-adaptive design to receive i.v. decitabine 20 mg/m2 daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days.  Courses were repeated every 4 to 6 wk.  A max. of 150 patients were to be treated.  In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML.  The median patient age was 69 years (range, 20-89 years; 42% of patients were aged ≥70 years).  Overall, 34% of patients achieved complete remission, and 55% had an objective response.  The median survival was 11.9 mo, and the estd. 2-yr survival rate was 27%.  Outcome was not different with the addn. of valproic acid to decitabine vs. decitabine alone in relation to the rates of complete remission, overall response, or survival.  Subset analyses did not demonstrate a benefit within the MDS or AML categories.  Toxicities-particularly neurotoxicities-were higher with the combination arm.  CONCLUSIONS : Adding valproic acid to decitabine was not assocd. with improved outcome in the treatment of patients with MDS or elderly patients with AML.  Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.  Cancer 2015;121:556-561. © 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvZR8IxSwLrVg90H21EOLACvtfcHk0liMHZ46H7_7OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit12lu7g%253D&md5=94bda8d8fdfd9d327bc563204dba1846</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29085%26sid%3Dliteratum%253Aachs%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DResults%2520of%2520phase%25202%2520randomized%2520study%2520of%2520low-dose%2520decitabine%2520with%2520or%2520without%2520valproic%2520acid%2520in%2520patients%2520with%2520myelodysplastic%2520syndrome%2520and%2520acute%2520myelogenous%2520leukemia%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D556%26epage%3D561%26doi%3D10.1002%2Fcncr.29085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i28"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01610">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_82038"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01610">10.1021/acs.jmedchem.8b01610</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Combination drugs database tables (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_001.pdf">PDF</a>)</p></li><li><p class="inline">List of all molecules with SMILES strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_001.pdf">jm8b01610_si_001.pdf (1.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01610/suppl_file/jm8b01610_si_002.csv">jm8b01610_si_002.csv (32.3 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01610%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-9" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01610" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                15MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c771283ca13c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
